Induction	O
of	O
NF-KB	O
during	O
monocyte	O
differentiation	O
by	O
HIV	O
type	O
1	O
infection	O
.	O

The	O
production	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
progeny	O
was	O
followed	O
in	O
the	O
U937	O
promonocytic	O
cell	O
line	O
after	O
stimulation	O
either	O
with	O
retinoic	O
acid	O
or	O
PMA	O
,	O
and	O
in	O
purified	O
human	O
monocytes	O
and	O
macrophages	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
Southwestern	O
blotting	O
experiments	O
were	O
used	O
to	O
detect	O
the	O
binding	O
of	O
cellular	O
transactivation	O
factor	O
NF-KB	O
to	O
the	O
double	O
repeat-KB	O
enhancer	O
sequence	O
located	O
in	O
the	O
long	O
terminal	O
repeat	O
.	O

PMA	O
treatment	O
,	O
and	O
not	B-NEGATION
retinoic	I-NEGATION
acid	I-NEGATION
treatment	I-NEGATION
of	I-NEGATION
the	I-NEGATION
U937	I-NEGATION
cells	I-NEGATION
acts	O
in	O
inducing	O
NF-KB	O
expression	O
in	O
the	O
nuclei	O
.	O

In	O
nuclear	O
extracts	O
from	O
monocytes	O
or	O
macrophages	O
,	O
induction	O
of	O
NF-KB	O
occurred	O
only	O
if	O
the	O
cells	O
were	O
previously	O
infected	O
with	O
HIV-1	O
.	O

When	O
U937	O
cells	O
were	O
infected	O
with	O
HIV-1	O
,	O
no	B-NEGATION
induction	I-NEGATION
of	I-NEGATION
NF-KB	I-NEGATION
factor	I-NEGATION
was	I-NEGATION
detected	I-NEGATION
,	O
whereas	O
high	O
level	O
of	O
progeny	O
virions	O
was	O
produced	O
,	O
suggesting	B-SPECULATION
that	I-SPECULATION
this	I-SPECULATION
factor	I-SPECULATION
was	I-SPECULATION
not	B-NEGATION
required	I-NEGATION
for	I-NEGATION
viral	I-NEGATION
replication	I-NEGATION
.	O

These	O
results	O
indicate	B-SPECULATION
that	I-SPECULATION
in	I-SPECULATION
monocytic	I-SPECULATION
cell	I-SPECULATION
lineage	I-SPECULATION
,	I-SPECULATION
HIV-1	I-SPECULATION
could	B-SPECULATION
mimic	I-SPECULATION
some	I-SPECULATION
differentiation	I-SPECULATION
/	I-SPECULATION
activation	I-SPECULATION
stimuli	I-SPECULATION
allowing	I-SPECULATION
nuclear	I-SPECULATION
NF-KB	I-SPECULATION
expression	I-SPECULATION
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
immunoglobulin	O
gene	O
expression	O
by	O
a	O
novel	O
B-cell-specific	O
enhancer	O
element	O
.	O

A	O
new	O
B-cell-specific	O
enhancer	O
element	O
has	O
been	O
identified	O
3	O
'	O
of	O
E4	O
and	O
the	O
octamerlike	O
motifs	O
in	O
the	O
human	O
immunoglobulin	O
heavy-chain	O
gene	O
enhancer	O
.	O

Tandem	O
copies	O
of	O
this	O
67-bp	O
MnlI-AluI	O
fragment	O
,	O
when	O
fused	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
gene	O
driven	O
by	O
the	O
conalbumin	O
promoter	O
,	O
stimulated	O
transcription	O
in	O
B	O
cells	O
but	O
not	B-NEGATION
in	I-NEGATION
Jurkat	B-SPECULATION
T	I-SPECULATION
cells	I-SPECULATION
or	I-SPECULATION
HeLa	I-SPECULATION
cells	I-SPECULATION
.	O

Footprinting	O
analysis	O
revealed	O
that	O
the	O
identical	O
sequence	O
CCGAAACTGAAAAGG	O
,	O
designated	O
E6	O
,	O
was	O
protected	O
by	O
nuclear	O
extracts	O
from	O
B	B-SPECULATION
cells	I-SPECULATION
,	I-SPECULATION
T	I-SPECULATION
cells	I-SPECULATION
,	I-SPECULATION
or	I-SPECULATION
HeLa	I-SPECULATION
cells	I-SPECULATION
.	O

Gel	O
mobility	O
shift	O
assays	O
using	O
a	O
synthetic	O
E6	O
motif	O
detected	O
a	O
B-cell-specific	O
complex	O
in	O
addition	O
to	O
a	O
ubiquitous	O
band	O
found	O
also	O
in	O
T	O
cells	O
and	O
HeLa	O
cells	O
.	O

In	O
agreement	O
with	O
the	O
results	O
of	O
gel	O
retardation	O
assays	O
,	O
tandem	O
copies	O
of	O
the	O
E6	O
motif	O
stimulated	O
transcription	O
in	O
ARH77	O
and	O
Raji	O
cells	O
but	O
not	B-NEGATION
in	I-NEGATION
Jurkat	B-SPECULATION
or	I-SPECULATION
HeLa	I-SPECULATION
cells	O
.	O

Furthermore	O
,	O
a	O
mutant	O
E6	O
motif	O
lost	O
both	O
in	O
vitro	O
binding	O
activity	O
and	O
in	O
vivo	O
enhancer	O
activity	O
.	O

In	O
striking	O
contrast	O
to	O
the	O
mouse	O
Ig	O
heavy-chain	O
enhancer	O
,	O
in	O
which	O
the	O
octamer	O
motif	O
acts	O
as	O
a	O
B-cell-specific	O
enhancer	O
element	O
,	O
the	O
human	O
enhancer	O
contains	O
an	O
octamerlike	O
sequence	O
with	O
one	O
base	O
substitution	O
which	O
bound	O
octamer-binding	O
proteins	O
with	O
only	O
very	O
low	O
affinity	O
and	O
showed	O
no	B-NEGATION
enhancer	I-NEGATION
activity	I-NEGATION
of	I-NEGATION
its	I-NEGATION
own	I-NEGATION
.	O

Interestingly	O
,	O
the	O
MnlI-AluI	O
fragment	O
could	B-SPECULATION
suppress	I-SPECULATION
the	I-SPECULATION
basal-level	I-SPECULATION
activity	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
conalbumin	I-SPECULATION
promoter	I-SPECULATION
in	I-SPECULATION
both	I-SPECULATION
Jurkat	I-SPECULATION
and	I-SPECULATION
HeLa	I-SPECULATION
cells	I-SPECULATION
.	O

Moreover	O
,	O
simian	O
virus	O
40	O
enhancer	O
activity	O
was	O
blocked	O
by	O
the	O
MnlI-AluI	O
fragment	O
in	O
HeLa	O
cells	O
but	O
not	B-NEGATION
in	I-NEGATION
B	I-NEGATION
cells	I-NEGATION
.	O

Thus	O
,	O
the	O
novel	O
enhancer	O
element	O
identified	O
in	O
this	O
study	O
is	O
probably	B-SPECULATION
a	I-SPECULATION
target	I-SPECULATION
site	I-SPECULATION
for	I-SPECULATION
both	I-SPECULATION
positive	I-SPECULATION
and	I-SPECULATION
negative	I-SPECULATION
factors	I-SPECULATION
.	O

The	O
NF	O
kappa	O
B	O
independent	O
cis-acting	O
sequences	O
in	O
HIV-1	O
LTR	O
responsive	O
to	O
T-cell	O
activation	O
.	O

The	O
rate	O
of	O
transcription	O
initiation	O
directed	O
by	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV-1	O
increases	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
of	O
T	O
cells	O
.	O

Here	O
we	O
show	O
that	O
the	B-SPECULATION
response	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
HIV-1	I-SPECULATION
LTR	I-SPECULATION
may	I-SPECULATION
be	I-SPECULATION
governed	I-SPECULATION
by	I-SPECULATION
two	I-SPECULATION
independent	I-SPECULATION
sequences	I-SPECULATION
located	I-SPECULATION
5	I-SPECULATION
'	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
site	I-SPECULATION
of	I-SPECULATION
transcription	I-SPECULATION
initiation	I-SPECULATION
sequences	I-SPECULATION
that	I-SPECULATION
bind	I-SPECULATION
either	I-SPECULATION
NFAT-1	I-SPECULATION
or	I-SPECULATION
NF	I-SPECULATION
kappa	I-SPECULATION
B	I-SPECULATION
.	O

The	O
rate	O
of	O
LTR-directed	O
gene	O
expression	O
increased	O
in	O
response	O
to	O
treatment	O
with	O
either	O
a	O
phorbol	O
ester	O
or	O
tumor	O
necrosis	O
factor	O
alpha	O
if	O
either	O
the	O
NFAT-1	O
or	O
NF	O
kappa	O
B	O
binding	O
sites	O
were	O
deleted	O
,	O
but	O
failed	B-NEGATION
to	I-NEGATION
respond	I-NEGATION
to	I-NEGATION
these	I-NEGATION
mitogenic	I-NEGATION
stimuli	I-NEGATION
if	I-NEGATION
both	I-NEGATION
sequences	I-NEGATION
were	I-NEGATION
absent	I-NEGATION
.	O

The	O
HIV-1	O
mutant	O
virus	O
containing	O
both	O
NF	O
kappa	O
B	O
and	O
NFAT-1	O
deletion	O
was	O
able	O
to	O
replicate	O
although	O
at	O
a	O
much	O
decreased	O
growth	O
rate	O
,	O
while	O
the	O
deletion	O
of	O
NFAT-1	O
alone	O
increased	O
the	O
viral	O
growth	O
rate	O
in	O
Jurkat	O
cells	O
.	O

Neither	B-NEGATION
deletion	I-NEGATION
of	I-NEGATION
NF	I-NEGATION
kappa	I-NEGATION
B	I-NEGATION
.	O

Specific	O
depletion	O
of	O
the	O
B-cell	O
population	O
induced	O
by	O
aberrant	O
expression	O
of	O
human	O
interferon	O
regulatory	O
factor	O
1	O
gene	O
in	O
transgenic	O
mice	O
.	O

Interferons	O
(	O
IFNs	O
)	O
are	O
well	O
known	O
both	O
as	O
antiviral	O
proteins	O
and	O
as	O
potent	O
regulators	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
fact	O
,	O
IFNs	O
inhibit	O
growth	O
of	O
various	O
normal	O
and	O
transformed	O
cell	O
types	O
.	O

Previously	O
,	O
a	O
nuclear	O
factor	O
,	O
IRF-1	O
(	O
interferon	O
regulatory	O
factor	O
1	O
)	O
,	O
which	O
binds	O
to	O
type	O
I	O
IFN	O
and	O
some	O
IFN-inducible	O
gene	O
promoters	O
,	O
was	O
identified	O
and	O
cloned	O
.	O

Since	O
the	O
IRF-1	O
gene	O
is	O
both	O
virus	O
and	O
IFN	O
inducible	O
,	O
an	O
intriguing	O
issue	B-SPECULATION
is	I-SPECULATION
raised	I-SPECULATION
as	I-SPECULATION
to	I-SPECULATION
whether	B-SPECULATION
the	I-SPECULATION
IRF-1	I-SPECULATION
gene	I-SPECULATION
is	I-SPECULATION
functioning	I-SPECULATION
in	I-SPECULATION
IFN-mediated	I-SPECULATION
regulation	I-SPECULATION
of	I-SPECULATION
cell	I-SPECULATION
growth	I-SPECULATION
and	I-SPECULATION
differentiation	I-SPECULATION
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
transgenic	O
mice	O
carrying	O
the	O
human	O
IRF-1	O
gene	O
linked	O
to	O
the	O
human	O
immunoglobulin	O
heavy-chain	O
enhancer	O
.	O

In	O
the	O
transgenic	O
mice	O
,	O
all	O
the	O
lymphoid	O
tissues	O
examined	O
showed	O
a	O
dramatic	O
reduction	O
in	O
the	O
number	O
of	O
B	O
lymphocytes	O
(	O
B	O
cells	O
)	O
.	O

Preparation	O
and	O
analysis	O
of	O
bone	O
marrow	O
cells	O
from	O
the	O
chimeric	O
mice	O
indicated	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
bone	I-SPECULATION
marrow	I-SPECULATION
is	I-SPECULATION
the	I-SPECULATION
effective	I-SPECULATION
site	I-SPECULATION
for	I-SPECULATION
specific	I-SPECULATION
depletion	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
B-cell	I-SPECULATION
population	I-SPECULATION
.	O

In	O
fact	O
,	O
transgenic	O
bone	O
marrow	O
cells	O
cocultured	O
with	O
a	O
bone	O
marrow-derived	O
stromal	O
cell	O
line	O
revealed	O
an	O
altered	O
B-cell	O
maturation	O
pattern	O
.	O

Identification	O
and	O
cloning	O
of	O
TCF-1	O
,	O
a	O
T	O
lymphocyte-specific	O
transcription	O
factor	O
containing	O
a	O
sequence-specific	O
HMG	O
box	O
.	O

CD3-epsilon	O
expression	O
is	O
controlled	O
by	O
a	O
downstream	O
T	O
lymphocyte-specific	O
enhancer	O
element	O
.	O

We	O
report	O
the	O
identification	O
of	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
,	O
TCF-1	O
,	O
binding	O
to	O
this	O
element	O
.	O

The	O
multimerized	O
recognition	O
motif	O
of	O
TCF-1	O
constituted	O
a	O
T	O
cell-specific	O
enhancer	O
.	O

Subsequent	O
cloning	O
of	O
TCF-1	O
identified	O
three	O
splice	O
alternatives	O
.	O

TCF-1	O
contained	O
a	O
single	O
DNA-binding	O
HMG	O
box	O
most	O
closely	O
related	O
to	O
similar	O
boxes	O
in	O
the	O
putative	B-SPECULATION
mammalian	I-SPECULATION
sex-determining	I-SPECULATION
gene	I-SPECULATION
SRY	I-SPECULATION
and	O
in	O
the	O
Schizosaccharomyces	O
pombe	O
Mc	O
mating	O
type	O
gene	O
.	O

TCF-1	O
mRNA	O
was	O
expressed	O
uniquely	O
in	O
T	O
lymphocytes	O
.	O

Upon	O
cotransfection	O
into	O
non-T	O
cells	O
,	O
TCF-1	O
could	B-SPECULATION
transactivate	I-SPECULATION
through	I-SPECULATION
its	I-SPECULATION
cognate	I-SPECULATION
motif	I-SPECULATION
.	O

These	O
results	O
identify	O
TCF-1	O
as	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
,	O
which	O
might	B-SPECULATION
play	I-SPECULATION
a	I-SPECULATION
role	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
establishment	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
mature	I-SPECULATION
T	I-SPECULATION
cell	I-SPECULATION
phenotype	I-SPECULATION
.	O

Nuclear	O
factor	O
kappa	O
B	O
activates	O
proenkephalin	O
transcription	O
in	O
T	O
lymphocytes	O
.	O

Upon	O
activation	O
,	O
T	O
lymphocytes	O
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	O
mRNA	O
in	O
the	O
cells	O
.	O

Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O

The	O
proenkephalin	O
promoter	O
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	O
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	O
B	O
sequence	O
GGGGACTTTCC	O
,	O
the	O
binding	O
site	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
(	O
NF	O
)-	O
kappa	O
B	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
induces	O
an	O
NF-kappa	O
B-like	O
binding	O
activity	O
to	O
the	O
B2	O
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	O
promoter	O
.	O

Mutations	O
at	O
the	O
B2	O
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O

The	O
purified	O
homodimer	O
(	O
two	O
p50s	O
)	O
of	O
the	O
DNA-binding	O
subunit	O
of	O
NF-kappa	O
B	O
binds	O
the	O
B2	O
site	O
of	O
proenkephalin	O
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	O
(	O
two	O
p65s	O
plus	O
two	O
p50s	O
)	O
form	O
of	O
the	O
factor	O
.	O

Thus	O
,	O
it	O
appears	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
T-cell-specific	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
proenkephalin	I-SPECULATION
promoter	I-SPECULATION
is	I-SPECULATION
mediated	I-SPECULATION
by	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
.	O

However	O
,	O
as	O
NF-kappa	O
B	O
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	O
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	B-SPECULATION
another	I-SPECULATION
T-cell-specific	I-SPECULATION
factor	I-SPECULATION
which	I-SPECULATION
synergizes	I-SPECULATION
with	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
should	I-SPECULATION
be	I-SPECULATION
considered	I-SPECULATION
.	O

Expression	O
of	O
c-jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
proto-oncogenes	O
in	O
human	O
peripheral-blood	O
granulocytes	O
.	O

We	O
have	O
found	O
that	O
purified	O
human	O
peripheral-blood	O
granulocytes	O
express	O
constitutively	O
significant	O
levels	O
of	O
proto-oncogenes	O
c-jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
mRNA	O
.	O

Upon	O
functional	O
activation	O
of	O
granulocytes	O
by	O
4	O
beta-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
the	O
levels	O
of	O
c-jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
transcripts	O
were	O
increased	O
.	O

The	O
three	O
jun	O
genes	O
showed	O
a	O
similar	O
time	O
course	O
in	O
their	O
induction	O
by	O
PMA	O
,	O
maximal	O
mRNA	O
levels	O
being	O
reached	O
after	O
60	O
min	O
of	O
induction	O
.	O

These	O
results	O
suggest	B-SPECULATION
that	I-SPECULATION
expression	B-SPECULATION
of	I-SPECULATION
c-jun	I-SPECULATION
,	I-SPECULATION
jun	I-SPECULATION
B	I-SPECULATION
and	I-SPECULATION
jun	I-SPECULATION
D	I-SPECULATION
genes	I-SPECULATION
might	I-SPECULATION
be	I-SPECULATION
involved	I-SPECULATION
in	B-SPECULATION
terminal	I-SPECULATION
granulocyte	I-SPECULATION
differentiation	I-SPECULATION
or	I-SPECULATION
in	I-SPECULATION
regulating	I-SPECULATION
granulocyte	I-SPECULATION
functionality	I-SPECULATION
.	O

Platelet-activating	O
factor	O
induces	O
phospholipid	O
turnover	O
,	O
calcium	O
flux	O
,	O
arachidonic	O
acid	O
liberation	O
,	O
eicosanoid	O
generation	O
,	O
and	O
oncogene	O
expression	O
in	O
a	O
human	O
B	O
cell	O
line	O
.	O

Platelet-activating	O
factor	O
is	O
a	O
potent	O
mediator	O
of	O
the	O
inflammatory	O
response	O
.	O

Studies	O
of	O
the	O
actions	O
of	O
platelet-activating	O
factor	O
have	O
centered	O
mainly	O
around	O
neutrophils	O
,	O
monocytes	O
,	O
and	O
platelets	O
.	O

In	O
this	O
report	O
we	O
begin	O
to	O
uncover	O
the	O
influence	O
of	O
platelet-activating	O
factor	O
on	O
B	O
lymphocytes	O
.	O

Employing	O
the	O
EBV-transformed	O
human	O
B	O
cell	O
line	O
SKW6.4	O
,	O
we	O
demonstrate	O
that	O
platelet-activating	O
factor	O
significantly	O
alters	O
membrane	O
phospholipid	O
metabolism	O
indicated	O
by	O
the	O
incorporation	O
of	O
32P	O
into	O
phosphatidylcholine	O
,	O
phosphatidylinositol	O
,	O
and	O
phosphatidic	O
acid	O
but	O
not	O
significantly	O
into	O
phosphatidylethanolamine	O
at	O
concentrations	O
ranging	O
from	O
10	O
(-	O
9	O
)	O
to	O
10	O
(-	O
6	O
)	O
M	O
.	O

The	O
inactive	O
precursor	O
,	O
lyso-platelet-activating	O
factor	O
,	O
at	O
a	O
concentration	O
as	O
high	O
as	O
10	O
(-	O
7	O
)	O
M	O
had	O
no	B-NEGATION
effect	I-NEGATION
on	I-NEGATION
any	I-NEGATION
of	I-NEGATION
the	I-NEGATION
membrane	I-NEGATION
phospholipids	I-NEGATION
.	O

We	O
also	O
show	O
that	O
platelet-activating	O
factor	O
from	O
10	O
(-	O
12	O
)	O
to	O
10	O
(-	O
6	O
)	O
M	O
induced	O
rapid	O
and	O
significant	O
elevation	O
in	O
intracellular	O
calcium	O
levels	O
,	O
whereas	O
lyso-platelet-activating	O
factor	O
was	O
again	O
ineffective	O
.	O

We	O
further	O
demonstrate	O
the	O
impact	O
of	O
platelet-activating	O
factor	O
binding	O
to	O
B	O
cells	O
by	O
measuring	O
platelet-activating	O
factor	O
induced	O
arachidonic	O
acid	O
release	O
and	O
5-hydroxyeicosatetraenoic	O
acid	O
production	O
.	O

Moreover	O
,	O
platelet-activating	O
factor	O
was	O
capable	O
of	O
inducing	O
transcription	O
of	O
the	O
nuclear	O
proto-oncogenes	O
c-fos	O
and	O
c-jun	O
.	O

Finally	O
we	O
explored	O
the	O
possible	B-SPECULATION
role	I-SPECULATION
of	I-SPECULATION
5-hydroxyeicosatetraenoic	I-SPECULATION
acid	I-SPECULATION
as	I-SPECULATION
a	I-SPECULATION
regulator	I-SPECULATION
of	I-SPECULATION
arachidonic	I-SPECULATION
acid	I-SPECULATION
liberation	I-SPECULATION
demonstrating	O
that	O
endogenous	O
5-lipoxygenase	O
activity	O
modulates	O
platelet-activating	O
factor	O
induced	O
arachidonic	O
acid	O
release	O
perhaps	B-SPECULATION
acting	I-SPECULATION
at	I-SPECULATION
the	I-SPECULATION
level	I-SPECULATION
of	I-SPECULATION
phospholipase	I-SPECULATION
A2	I-SPECULATION
.	O

In	O
summary	O
,	O
platelet-activating	O
factor	O
is	O
shown	O
here	O
to	O
have	O
a	O
direct	O
and	O
profound	O
effect	O
on	O
a	O
pure	O
B	O
cell	O
line	O
.	O

A	O
novel	O
HIV-1	O
isolate	O
containing	O
alterations	O
affecting	O
the	O
NF-kappa	O
B	O
element	O
.	O

Three	O
molecular	O
clones	O
of	O
HIV-1	O
,	O
derived	O
from	O
a	O
single	O
isolate	O
(	O
AL1	O
)	O
,	O
exhibited	O
distinct	O
replicative	O
and	O
cytopathic	O
properties	O
during	O
propagation	O
in	O
a	O
human	O
T	O
cell	O
line	O
.	O

The	O
phenotypic	O
differences	O
observed	O
were	O
attributable	O
,	O
in	O
large	O
part	O
,	O
to	O
changes	O
affecting	O
the	O
viral	O
LTR	O
.	O

Nucleotide	O
sequence	O
and	O
PCR	O
analyses	O
demonstrated	O
the	O
presence	O
of	O
novel	B-SPECULATION
duplications	I-SPECULATION
or	I-SPECULATION
deletions	I-SPECULATION
involving	I-SPECULATION
the	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
motif	I-SPECULATION
.	O

These	O
changes	O
in	O
the	O
enhancer	O
element	O
were	O
identified	O
in	O
the	O
original	O
AL1	O
virus	O
stock	O
.	O

Subcloning	O
of	O
the	O
variant	O
NF-kappa	O
B	O
segments	O
into	O
LTR-driven	O
CAT	O
expression	O
vectors	O
confirmed	O
a	O
correlation	O
between	O
promoter	O
activity	O
and	O
replicative	O
/	O
cytopathic	O
capacity	O
.	O

1,25-Dihydroxyvitamin	O
D3	O
receptor	O
RNA	O
:	O
expression	O
in	O
hematopoietic	O
cells	O
.	O

1,25-Dihydroxyvitamin	O
D3	O
[	O
1,25	O
(	O
OH	O
)	O
2D3	O
]	O
induces	O
differentiation	O
and	O
inhibits	O
proliferation	O
of	O
myeloid	O
leukemic	O
cells	O
from	O
various	O
lines	O
and	O
patients	O
;	O

these	O
effects	O
are	O
probably	B-SPECULATION
mediated	I-SPECULATION
through	I-SPECULATION
the	I-SPECULATION
1,25	I-SPECULATION
(	I-SPECULATION
OH	I-SPECULATION
)	I-SPECULATION
2D3	I-SPECULATION
receptor	I-SPECULATION
.	O

Little	O
is	O
known	O
of	O
expression	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
in	O
hematopoietic	O
cells	O
.	O

We	O
examined	O
the	O
expression	O
and	O
modulation	O
of	O
expression	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
in	O
various	O
proliferating	O
and	O
nonproliferating	O
hematopoietic	O
cells	O
.	O

Constitutive	O
expression	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
was	O
detected	O
in	O
various	O
kinds	O
of	O
hematopoietic	O
cells	O
,	O
including	O
macrophages	O
and	O
activated	O
T	O
lymphocytes	O
,	O
as	O
well	O
as	O
in	O
cell	O
lines	O
KG-1	O
(	O
myeloblasts	O
)	O
,	O
HL-60	O
(	O
promyelocytes	O
)	O
,	O
ML-3	O
(	O
myelomonoblasts	O
)	O
,	O
U937	O
,	O
THP-1	O
(	O
monoblasts	O
)	O
,	O
K562	O
(	O
erythroblasts	O
)	O
,	O
and	O
S-LB1	O
(	O
HTLV-1-transfected	O
T	O
lymphocytes	O
)	O
.	O

Receptor	O
transcripts	O
were	O
4.6	O
kilobases	O
(	O
kb	O
)	O
,	O
and	O
no	B-NEGATION
variant	I-NEGATION
sizes	I-NEGATION
were	I-NEGATION
observed	I-NEGATION
.	O

All	O
cell	O
lines	O
examined	O
in	O
this	O
group	O
also	O
expressed	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
.	O

Most	O
B	O
lymphocyte	O
lines	O
expressed	O
negligible	O
levels	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
and	O
protein	O
;	O
however	O
;	O
analysis	O
of	O
a	O
lymphoid	O
/	O
myeloid	O
somatic	O
hybrid	O
suggested	B-SPECULATION
that	I-SPECULATION
suppression	I-SPECULATION
of	I-SPECULATION
expression	I-SPECULATION
of	I-SPECULATION
1,25	I-SPECULATION
(	I-SPECULATION
OH	I-SPECULATION
)	I-SPECULATION
2D3	I-SPECULATION
receptor	I-SPECULATION
RNA	I-SPECULATION
in	I-SPECULATION
B	I-SPECULATION
lymphocytes	I-SPECULATION
may	B-SPECULATION
be	I-SPECULATION
a	I-SPECULATION
dominant	I-SPECULATION
characteristic	I-SPECULATION
.	O

HL-60	O
cells	O
were	O
cultured	O
with	O
10	O
(-	O
7	O
)	O
mol	O
/	O
L	O
1,25	O
(	O
OH	O
)	O
2D3	O
for	O
24	O
to	O
72	O
hours	O
,	O
and	O
levels	O
of	O
expression	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
and	O
its	O
RNA	O
were	O
examined	O
.	O

Levels	B-NEGATION
of	I-NEGATION
RNA	I-NEGATION
coding	I-NEGATION
for	I-NEGATION
the	I-NEGATION
receptor	I-NEGATION
were	I-NEGATION
not	I-NEGATION
modulated	I-NEGATION
by	I-NEGATION
exposure	I-NEGATION
to	I-NEGATION
high	I-NEGATION
levels	I-NEGATION
of	I-NEGATION
ligand	I-NEGATION
.	O

Levels	O
of	O
occupied	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
protein	O
increased	O
in	O
these	O
HL-60	O
cells	O
;	O
but	O
the	O
total	O
number	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
decreased	O
about	O
50	O
%	O
at	O
24	O
hours	O
and	O
returned	O
toward	O
normal	O
at	O
72	O
hours	O
.	O

Steady-state	B-NEGATION
levels	I-NEGATION
of	I-NEGATION
1,25	I-NEGATION
(	I-NEGATION
OH	I-NEGATION
)	I-NEGATION
2D3	I-NEGATION
receptor	I-NEGATION
RNA	I-NEGATION
were	I-NEGATION
not	I-NEGATION
affected	I-NEGATION
by	I-NEGATION
terminal	I-NEGATION
differentiation	I-NEGATION
of	I-NEGATION
HL-60	I-NEGATION
toward	I-NEGATION
either	I-NEGATION
granulocytes	I-NEGATION
or	I-NEGATION
macrophages	I-NEGATION
.	O

Nondividing	O
macrophages	O
from	O
normal	O
individuals	O
also	O
expressed	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
.	O

In	O
contrast	O
,	O
nondividing	O
peripheral	O
blood	O
lymphocytes	O
from	O
normal	O
individuals	O
did	O
not	B-NEGATION
express	I-NEGATION
1,25	I-NEGATION
(	I-NEGATION
OH	I-NEGATION
)	I-NEGATION
2D3	I-NEGATION
receptor	I-NEGATION
RNA	I-NEGATION
;	O
.	O

with	O
stimulation	O
of	O
proliferation	O
of	O
these	O
cells	O
,	O
accumulation	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
increased	O
markedly	O
.	O

Half-life	O
(	O
t1	O
/	O
2	O
)	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
in	O
T	O
lymphocytes	O
was	O
short	O
(	O
1	O
hour	O
)	O
as	O
determined	O
by	O
measuring	O
decay	O
of	O
the	O
message	O
after	O
addition	O
of	O
actinomycin	O
D	O
.	O

Consistent	O
with	O
this	O
short	O
t1	O
/	O
2	O
,	O
accumulation	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
increased	O
in	O
cells	O
as	O
their	O
protein	O
synthesis	O
was	O
inhibited	O
.	O

Further	O
studies	O
are	O
required	O
to	O
understand	O
the	O
physiologic	O
role	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
in	O
myeloid	O
cells	O
and	O
proliferating	O
T	O
lymphocytes	O
.	O

Kappa	O
B	O
binding	O
proteins	O
are	O
constitutively	O
expressed	O
in	O
an	O
IL-2	O
autocrine	O
human	O
T	O
cell	O
line	O
.	O

The	O
IL-2	O
and	O
the	O
IL-2-R	O
alpha	O
genes	O
are	O
both	O
expressed	O
transiently	O
in	O
normal	O
T	O
lymphocytes	O
after	O
Ag	O
or	O
mitogen	O
activation	O
.	O

In	O
contrast	O
,	O
the	O
human	O
T	O
cell	O
line	O
,	O
IARC	O
301	O
,	O
expresses	O
these	O
two	O
genes	O
constitutively	O
and	O
we	O
have	O
previously	O
demonstrated	O
that	O
its	O
growth	O
depends	O
on	O
the	O
autocrine	O
production	O
of	O
this	O
T	O
cell	O
growth	O
factor	O
and	O
high	O
affinity	O
IL-2R	O
.	O

To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusual	O
persistent	O
expression	O
of	O
the	O
IL-2	O
and	O
IL-2-R	O
alpha	O
genes	O
in	O
these	O
IARC	O
301	O
T	O
cells	O
,	O
we	O
have	O
analyzed	O
the	O
interactions	O
of	O
constitutively	O
expressed	O
nuclear	O
proteins	O
with	O
the	O
5	O
'	O
flanking	O
regions	O
of	O
the	O
IL-2	O
and	O
IL-2-R	O
alpha	O
genes	O
using	O
both	O
DNase	O
I	O
footprinting	O
and	O
gel	O
retardation	O
techniques	O
.	O

We	O
have	O
found	O
that	O
a	O
region	O
in	O
both	O
genes	O
(-	O
276	O
to	O
-	O
250	O
for	O
IL-2-R	O
alpha	O
and	O
-	O
203	O
to	O
-	O
183	O
for	O
IL-2	O
)	O
,	O
which	O
corresponds	O
to	O
a	O
kappa	O
B	O
enhancer	O
element	O
,	O
is	O
specifically	O
protected	O
by	O
nuclear	O
proteins	O
from	O
IARC	O
301	O
.	O

In	O
agreement	O
with	O
this	O
finding	O
,	O
both	O
the	O
IL-2	O
and	O
IL-2-R	O
alpha	O
promoters	O
are	O
active	O
in	O
transient	O
transfection	O
assays	O
in	O
IARC	O
301	O
cells	O
.	O

In	O
contrast	O
,	O
mutation	O
of	O
the	O
kappa	O
B	O
enhancer	O
results	O
in	O
markedly	O
attenuated	O
activities	O
of	O
both	O
promoters	O
.	O

Two	O
proteins	O
binding	O
the	O
kappa	O
B	O
sequence	O
,	O
NF-kappa	O
B	O
and	O
KBF1	O
,	O
are	O
constitutively	O
expressed	O
in	O
IARC	O
301	O
nuclei	O
and	O
induced	O
by	O
PMA	O
and	O
PHA	O
in	O
Jurkat	O
.	O

They	O
bind	O
to	O
the	O
kappa	O
B	O
motifs	O
with	O
different	O
relative	O
affinities	O
that	O
may	B-SPECULATION
reflect	I-SPECULATION
their	I-SPECULATION
different	I-SPECULATION
contribution	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
expression	I-SPECULATION
of	I-SPECULATION
various	I-SPECULATION
promoters	I-SPECULATION
.	O

The	O
functional	O
domains	O
of	O
the	O
murine	O
Thy-1	O
gene	O
promoter	O
.	O

The	O
Thy-1	O
gene	O
promoter	O
resembles	O
a	O
"	O
housekeeping	O
"	O
promoter	O
in	O
that	O
it	O
is	O
located	O
within	O
a	O
methylation-free	O
island	O
,	O
lacks	B-NEGATION
a	I-NEGATION
canonical	I-NEGATION
TATA	I-NEGATION
box	I-NEGATION
,	O
and	O
displays	O
heterogeneity	O
in	O
the	O
5	O
'-	O
end	O
termini	O
of	O
the	O
mRNA	O
.	O

Using	O
transgenic	O
mice	O
,	O
we	O
show	O
that	O
this	O
promoter	O
does	O
not	B-NEGATION
confer	I-NEGATION
any	I-NEGATION
tissue	I-NEGATION
specificity	I-NEGATION
and	O
is	O
active	O
only	O
in	O
a	O
position-dependent	O
manner	O
.	O

It	O
can	O
only	O
be	O
activated	O
in	O
a	O
tissue-specific	O
manner	O
by	O
elements	O
that	O
lie	O
downstream	O
of	O
the	O
initiation	O
site	O
.	O

We	O
have	O
analyzed	O
the	O
functional	O
domains	O
of	O
the	O
minimal	O
Thy-1	O
promoter	O
and	O
show	O
that	O
the	O
dominant	O
promoter	O
elements	O
consist	O
of	O
multiple	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
Sp1	O
,	O
an	O
inverted	O
CCAAT	O
box	O
,	O
and	O
sequences	O
proximal	O
to	O
the	O
transcription	O
start	O
site	O
.	O

DNase	O
I	O
and	O
gel	O
mobility	O
shift	O
assays	O
show	O
the	O
binding	O
of	O
a	O
number	O
of	O
nuclear	O
factors	O
to	O
these	O
elements	O
,	O
including	O
Sp1	O
and	O
CP1	O
.	O

Our	O
results	O
show	O
that	O
the	O
structure	O
of	O
this	O
promoter	O
only	O
permits	O
productive	O
interactions	O
of	O
the	O
two	O
transcription	O
factors	O
Sp1	O
and	O
CP1	O
with	O
the	O
basal	O
transcription	O
machinery	O
in	O
the	O
presence	O
of	O
enhancer	O
sequences	O
.	O

Comparison	O
of	O
constitutive	O
and	O
inducible	O
transcriptional	O
enhancement	O
mediated	O
by	O
kappa	O
B-related	O
sequences	O
:	O
modulation	O
of	O
activity	O
in	O
B	O
cells	O
by	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
tax	O
gene	O
.	O

The	O
kappa	O
B	O
sequence	O
(	O
GGGACTTTCC	O
)	O
binds	O
a	O
factor	O
,	O
NF-kappa	O
B	O
,	O
that	O
is	O
constitutively	O
found	O
in	O
its	O
functional	O
,	O
DNA	O
binding	O
form	O
only	O
in	O
B	O
lymphocytes	O
.	O

A	O
factor	O
with	O
apparently	O
indistinguishable	O
sequence	O
specificity	O
can	O
be	O
induced	O
in	O
many	O
other	O
cell	O
types	O
,	O
where	O
it	O
is	O
used	O
to	O
regulate	O
inducible	O
gene	O
expression	O
.	O

For	O
example	O
,	O
kappa	O
B-related	O
sequences	O
have	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
transcription	O
of	O
a	O
few	O
inducible	O
genes	O
,	O
such	O
as	O
the	O
interleukin	O
2	O
receptor	O
alpha-chain	O
gene	O
and	O
the	O
beta-interferon	O
gene	O
.	O

However	O
,	O
these	O
genes	O
are	O
not	B-NEGATION
constitutively	I-NEGATION
active	I-NEGATION
in	I-NEGATION
B	I-NEGATION
lymphocytes	I-NEGATION
,	O
suggesting	B-SPECULATION
that	I-SPECULATION
other	I-SPECULATION
regulatory	I-SPECULATION
mechanisms	I-SPECULATION
must	I-SPECULATION
play	I-SPECULATION
a	I-SPECULATION
role	I-SPECULATION
in	I-SPECULATION
determining	I-SPECULATION
the	I-SPECULATION
patterns	I-SPECULATION
of	I-SPECULATION
expression	I-SPECULATION
.	O

We	O
have	O
investigated	O
the	O
constitutive	O
and	O
inducible	O
transcriptional	O
activity	O
mediated	O
by	O
five	O
kappa	O
B-related	O
sequence	O
elements	O
in	O
two	O
different	O
cell	O
types	O
.	O

We	O
show	O
that	O
in	O
S194	O
plasma	O
cells	O
the	O
activity	O
of	O
each	O
element	O
correlates	O
well	O
with	O
the	O
relative	O
affinity	O
of	O
B-cell-derived	O
NF-kappa	O
B	O
for	O
that	O
element	O
.	O

This	O
leads	O
to	O
significantly	O
lower	O
transcription	O
enhancement	O
by	O
sites	O
derived	O
from	O
the	O
interleukin	O
2	O
receptor	O
or	O
T-cell	O
receptor	O
genes	O
in	O
S194	O
cells	O
.	O

However	O
,	O
in	O
either	O
EL-4	O
(	O
T	O
)	O
cells	O
or	O
S194	O
cells	O
,	O
both	O
lower-affinity	O
sites	O
can	O
be	O
significantly	O
induced	O
by	O
the	O
tax	O
gene	O
product	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
,	O
showing	O
that	O
NF-kappa	O
B	O
activity	O
can	O
be	O
modulated	O
even	O
in	O
a	O
B-cell	O
line	O
that	O
constitutively	O
expresses	O
this	O
factor	O
.	O

Isolation	O
of	O
a	O
rel-related	O
human	O
cDNA	O
that	O
potentially	B-SPECULATION
encodes	I-SPECULATION
the	I-SPECULATION
65-kD	I-SPECULATION
subunit	I-SPECULATION
of	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1991	O
Oct	O
4	O
;	O
254	O
(	O
5028	O
)	O
:	O
11	O
]	O
.	O

A	O
DNA	O
probe	O
that	O
spanned	O
a	O
domain	O
conserved	O
among	O
the	O
proto-oncogene	O
c-rel	O
,	O
the	O
Drosophila	O
morphogen	O
dorsal	O
,	O
and	O
the	O
p50	O
DNA	O
binding	O
subunit	O
of	O
NF-kappa	O
B	O
was	O
generated	O
from	O
Jurkat	O
T	O
cell	O
complementary	O
DNA	O
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
degenerate	O
oligonucleotides	O
.	O

This	O
probe	O
was	O
used	O
to	O
identify	O
a	O
rel-related	O
complementary	O
DNA	O
that	O
hybridized	O
to	O
a	O
2.6-kilobase	O
messenger	O
RNA	O
present	O
in	O
human	O
T	O
and	O
B	O
lymphocytes	O
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
complementary	O
DNA	O
resulted	O
in	O
the	O
synthesis	O
of	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
size	O
of	O
65	O
kilodaltons	O
(	O
kD	O
)	O
.	O

The	O
translated	O
protein	O
showed	O
weak	O
DNA	O
binding	O
with	O
a	O
specificity	O
for	O
the	O
kappa	O
B	O
binding	O
motif	O
.	O

This	O
protein-DNA	O
complex	O
comigrated	O
with	O
the	O
complex	O
obtained	O
with	O
the	O
purified	O
human	O
p65	O
NF-kappa	O
B	O
subunit	O
and	O
binding	O
was	O
inhibited	O
by	O
I	O
kappa	O
B-alpha	O
and	O
-	O
beta	O
proteins	O
.	O

In	O
addition	O
,	O
the	O
65-kD	O
protein	O
associated	O
with	O
the	O
p50	O
subunit	O
of	O
NF-kappa	O
B	O
and	O
the	O
kappa	O
B	O
probe	O
to	O
form	O
a	O
complex	O
with	O
the	O
same	O
electrophoretic	O
mobility	O
as	O
the	O
NF-kappa	O
B-DNA	O
complex	O
.	O

Therefore	O
the	O
rel-related	O
65-kD	O
protein	O
may	B-SPECULATION
represent	I-SPECULATION
the	I-SPECULATION
p65	I-SPECULATION
subunit	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
active	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
transcription	I-SPECULATION
factor	I-SPECULATION
complex	I-SPECULATION
.	O

Lymphocyte	O
glucocorticoid	O
receptor	O
number	O
in	O
posttraumatic	O
stress	O
disorder	O
.	O

OBJECTIVE	O
:	O
The	O
authors	O
'	O
objective	O
was	O
to	O
investigate	O
the	O
possibility	B-SPECULATION
that	I-SPECULATION
glucocorticoid	B-SPECULATION
receptor	I-SPECULATION
changes	I-SPECULATION
may	I-SPECULATION
be	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
dysregulation	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
hypothalamic-pituitary-adrenal	I-SPECULATION
(	I-SPECULATION
HPA	I-SPECULATION
)	I-SPECULATION
axis	I-SPECULATION
in	I-SPECULATION
posttraumatic	I-SPECULATION
stress	I-SPECULATION
disorder	I-SPECULATION
(	I-SPECULATION
PTSD	I-SPECULATION
)	I-SPECULATION
.	O

METHOD	O
:	O
They	O
measured	O
the	O
number	O
of	O
lymphocyte	O
cytosolic	O
glucocorticoid	O
receptors	O
and	O
plasma	O
cortisol	O
concentrations	O
in	O
15	O
consecutively	O
admitted	O
male	O
combat	O
Vietnam	O
veterans	O
with	O
PTSD	O
and	O
in	O
a	O
normal	O
comparison	O
group	O
of	O
11	O
subjects	O
.	O

RESULTS	O
:	O
Both	O
the	O
patients	O
and	O
the	O
normal	O
comparison	O
subjects	O
showed	O
a	O
morning-to-afternoon	O
decline	O
in	O
glucocorticoid	O
receptor	O
concentrations	O
,	O
paralleling	O
the	O
normal	O
diurnal	O
decline	O
in	O
cortisol	O
levels	O
.	O

The	O
number	O
of	O
glucocorticoid	O
receptors	O
was	O
63	O
%	O
greater	O
in	O
the	O
morning	O
and	O
26	O
%	O
greater	O
in	O
the	O
afternoon	O
in	O
the	O
patients	O
with	O
PTSD	O
than	O
in	O
the	O
normal	O
subjects	O
.	O

No	B-NEGATION
group	I-NEGATION
differences	I-NEGATION
in	I-NEGATION
cortisol	I-NEGATION
levels	I-NEGATION
were	I-NEGATION
observed	I-NEGATION
,	O
nor	B-NEGATION
were	I-NEGATION
glucocorticoid	I-NEGATION
receptor	I-NEGATION
number	I-NEGATION
and	I-NEGATION
cortisol	I-NEGATION
levels	I-NEGATION
correlated	I-NEGATION
.	O

The	O
number	O
of	O
morning	O
glucocorticoid	O
receptors	O
was	O
positively	O
correlated	O
with	O
symptoms	O
of	O
PTSD	O
and	O
anxiety	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
provide	O
further	O
evidence	O
for	O
a	O
dysregulation	O
of	O
the	O
HPA	O
axis	O
in	O
PTSD	O
.	O

The	O
finding	O
that	O
patients	O
with	O
PTSD	O
had	O
a	O
substantially	O
greater	O
number	O
of	O
lymphocyte	O
glucocorticoid	O
receptors	O
than	O
normal	O
comparison	O
subjects	O
is	O
consistent	O
with	O
the	O
authors	O
'	O
previous	O
observations	O
of	O
low	O
24-hour	O
urinary	O
cortisol	O
excretion	O
in	O
subjects	O
with	O
PTSD	O
.	O

Furthermore	O
,	O
the	O
receptor	O
changes	O
observed	O
are	O
opposite	O
of	O
those	O
reported	O
in	O
major	O
depressive	O
disorder	O
.	O

The	O
present	O
data	O
,	O
along	O
with	O
other	O
findings	O
of	O
HPA	O
abnormalities	O
in	O
PTSD	O
,	O
support	O
the	O
possibility	B-SPECULATION
of	I-SPECULATION
a	I-SPECULATION
greater	I-SPECULATION
negative	I-SPECULATION
feedback	I-SPECULATION
sensitivity	I-SPECULATION
at	I-SPECULATION
one	I-SPECULATION
or	I-SPECULATION
more	I-SPECULATION
levels	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
HPA	I-SPECULATION
axis	I-SPECULATION
.	O

A	O
thymus-specific	O
member	O
of	O
the	O
HMG	O
protein	O
family	O
regulates	O
the	O
human	O
T	O
cell	O
receptor	O
C	O
alpha	O
enhancer	O
.	O

The	O
human	O
T	O
cell-specific	O
transcription	O
factor	O
TCF-1	O
alpha	O
plays	O
a	O
key	O
role	O
in	O
the	O
tissue-specific	O
activation	O
of	O
the	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
C	O
alpha	O
enhancer	O
and	O
binds	O
to	O
pyrimidine-rich	O
elements	O
(	O
5	O
'-	O
PyCTTTG-3	O
')	O
present	O
in	O
a	O
variety	O
of	O
other	O
T	O
cell-specific	O
control	O
regions	O
.	O

Using	O
amino	O
acid	O
sequence	O
information	O
derived	O
from	O
the	O
DNA	O
affinity-purified	O
protein	O
,	O
we	O
have	O
now	O
isolated	O
cDNA	O
clones	O
encoding	O
TCF-1	O
alpha	O
.	O

The	O
TCF-1	O
alpha	O
cDNA	O
contains	O
a	O
single	O
68-amino-acid	O
domain	O
that	O
is	O
homologous	O
to	O
a	O
region	O
conserved	O
among	O
high-mobility	O
group	O
(	O
HMG	O
)	O
and	O
nonhistone	O
chromosomal	O
proteins	O
.	O

Expression	O
of	O
full-length	O
and	O
mutant	O
cDNA	O
clones	O
in	O
bacteria	O
reveal	O
that	O
the	O
single	O
HMG	O
motif	O
,	O
which	B-SPECULATION
is	I-SPECULATION
predicted	I-SPECULATION
to	I-SPECULATION
contain	I-SPECULATION
two	I-SPECULATION
extended	I-SPECULATION
alpha-helical	I-SPECULATION
segments	I-SPECULATION
,	O
is	O
sufficient	O
to	O
direct	O
the	O
sequence-specific	O
binding	O
of	O
TCF-1	O
alpha	O
to	O
DNA	O
.	O

Northern	O
blot	O
experiments	O
demonstrate	O
further	O
that	O
TCF-1	O
alpha	O
mRNA	O
is	O
highly	O
tissue	O
specific	O
,	O
found	O
primarily	O
in	O
the	O
thymus	O
or	O
T	O
cell	O
lines	O
.	O

The	O
immature	O
CEM	O
T	O
cell	O
line	O
expresses	O
relatively	O
low	O
levels	O
of	O
TCF-1	O
alpha	O
mRNA	O
,	O
which	O
are	O
increased	O
upon	O
activation	O
of	O
these	O
cells	O
by	O
phorbol	O
esters	O
.	O

Interestingly	O
,	O
the	O
cloned	O
TCF-1	O
alpha	O
protein	O
is	O
a	O
potent	O
transcriptional	O
activator	O
of	O
the	O
human	O
TCR	O
alpha	O
enhancer	O
in	O
nonlymphoid	O
cell	O
lines	O
,	O
whereas	O
the	O
activity	O
of	O
the	O
endogenous	O
protein	O
in	O
T	O
cell	O
lines	O
is	O
strongly	O
dependent	O
on	O
an	O
additional	O
T	O
cell-specific	O
protein	O
that	O
interacts	O
with	O
the	O
core	O
enhancer	O
.	O

TCF-1	O
alpha	O
is	O
currently	O
unique	O
among	O
the	O
newly	O
emerging	O
family	O
of	O
DNA-binding	O
regulatory	O
proteins	O
that	O
share	O
the	O
HMG	O
motif	O
in	O
that	O
it	O
is	O
a	O
highly	O
tissue-specific	O
RNA	O
polymerase	O
II	O
transcription	O
factor	O
.	O

Immune	O
response	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
to	O
HBx-antigen	O
of	O
hepatitis	O
B	O
virus	O
.	O

The	O
hepatitis	O
B	O
virus	O
genome	O
encodes	O
a	O
transcriptional	O
transactivator	O
protein	O
designated	O
HBxAg	O
.	O

We	O
have	O
investigated	O
whether	B-SPECULATION
this	I-SPECULATION
antigen	I-SPECULATION
is	I-SPECULATION
a	I-SPECULATION
target	I-SPECULATION
structure	I-SPECULATION
for	I-SPECULATION
human	I-SPECULATION
T-lymphocytes	I-SPECULATION
.	O

Using	O
recombinant	O
HBxAg	O
protein	O
,	O
we	O
found	O
HBxAg-specific	O
stimulation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
in	O
patients	O
with	O
acute	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
6	O
)	O
and	O
chronic	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
17	O
)	O
but	O
not	B-NEGATION
in	I-NEGATION
healthy	I-NEGATION
individuals	I-NEGATION
.	O

With	O
HBxAg-specific	O
synthetic	O
polypeptides	O
,	O
several	O
T-cell	O
epitopes	O
were	O
identified	O
.	O

Most	O
were	O
located	O
in	O
the	O
carboxyterminal	O
half	O
of	O
the	O
HBxAg	O
protein	O
.	O

Five	O
T-cell	O
clones	O
specific	O
for	O
a	O
T-cell	O
epitope	O
located	O
at	O
the	O
carboxyterminal	O
region	O
of	O
HBxAg	O
were	O
established	O
and	O
found	O
to	O
belong	O
to	O
the	O
CD2	O
/	O
CD4-positive	O
,	O
CD8-negative	O
subtype	O
.	O

These	O
data	O
establish	O
for	O
the	O
first	O
time	O
HBxAg	O
as	O
an	O
antigen	O
in	O
the	O
cellular	O
immune	O
response	O
.	O

A	O
study	O
on	O
the	O
circadian	O
rhythm	O
of	O
glucocorticoid	O
receptor	O
.	O

Circadian	O
rhythm	O
in	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
was	O
studied	O
in	O
the	O
rat	O
liver	O
and	O
human	O
peripheral	O
leukocytes	O
.	O

For	O
rats	O
exposed	O
to	O
a	O
natural	O
environmental	O
photic	O
cycle	O
or	O
a	O
12L	O
:	O
12D	O
artificial	O
light	O
regime	O
,	O
peak	O
values	O
of	O
hepatic	O
GR	O
were	O
detected	O
between	O
23:00	O
and	O
02:00	O
h	O
.	O

Except	O
for	O
a	O
4-hour	O
advancement	O
of	O
the	O
peak	O
,	O
a	O
similar	O
circadian	O
rhythm	O
of	O
hepatic	O
GR	O
was	O
detected	O
in	O
rats	O
reared	O
under	O
a	O
reversed	O
lighting	O
regimen	O
(	O
12D	O
:	O
12L	O
;	O
lights	O
on	O
between	O
18:30	O
and	O
06:30	O
h	O
)	O
.	O

In	O
human	O
leukocytes	O
,	O
the	O
peak	O
value	O
of	O
GR	O
was	O
found	O
to	O
parallel	O
that	O
of	O
plasma	O
cortisol	O
with	O
high	O
and	O
low	O
values	O
detected	O
at	O
04:00-08:00	O
h	O
and	O
23:00-24:00	O
h	O
,	O
respectively	O
.	O

In	O
patients	O
suffering	O
from	O
Cushing	O
'	O
s	O
syndrome	O
,	O
the	O
circadian	O
rhythm	O
of	O
plasma	O
cortisol	O
either	B-SPECULATION
disappeared	I-SPECULATION
while	O
that	O
of	O
GR	O
did	O
not	O
significantly	O
deviate	O
from	O
the	O
normal	O
subjects	O
.	O

For	O
apoplexic	O
patients	O
with	O
lesions	O
localized	O
to	O
the	O
base	O
of	O
the	O
brain	O
as	O
indicated	O
by	O
computerized	O
tomography	O
,	O
the	O
diurnal	O
variation	O
of	O
GR	O
was	O
abolished	O
.	O

Conversely	O
,	O
diurnal	O
rhythmicity	O
persisted	O
in	O
apoplexy	O
patients	O
whose	O
lesions	O
were	O
in	O
the	O
cerebral	O
cortex	O
.	O

Thus	O
,	O
we	O
postulated	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
circadian	I-SPECULATION
modification	I-SPECULATION
of	I-SPECULATION
GR	I-SPECULATION
was	I-SPECULATION
independent	I-SPECULATION
of	I-SPECULATION
the	B-SPECULATION
diurnal	I-SPECULATION
fluctuations	I-SPECULATION
in	I-SPECULATION
plasma	I-SPECULATION
cortisol	I-SPECULATION
level	I-SPECULATION
or	I-SPECULATION
the	I-SPECULATION
circadian	I-SPECULATION
variations	I-SPECULATION
in	I-SPECULATION
environmental	I-SPECULATION
lighting	I-SPECULATION
and	O
that	O
the	B-SPECULATION
rhythmicity	I-SPECULATION
might	I-SPECULATION
be	I-SPECULATION
regulated	I-SPECULATION
by	I-SPECULATION
the	I-SPECULATION
'	I-SPECULATION
circadian	I-SPECULATION
pacemaker	I-SPECULATION
'	I-SPECULATION
located	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
human	I-SPECULATION
basal	I-SPECULATION
brain	I-SPECULATION
.	O

These	O
diurnal	O
variations	O
in	O
GR	O
might	B-SPECULATION
serve	I-SPECULATION
to	I-SPECULATION
coordinate	I-SPECULATION
the	I-SPECULATION
reactivity	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
target	I-SPECULATION
cells	I-SPECULATION
to	I-SPECULATION
cortisol	I-SPECULATION
because	O
the	O
diurnal	O
rhythms	O
of	O
a	O
GR-mediated	O
response	O
,	O
the	O
fractional	O
inhibition	O
of	O
chemotactic	O
migration	O
rate	O
of	O
polymorphonuclear	O
leukocytes	O
by	O
cortisol	O
,	O
were	O
found	O
to	O
be	O
synchronous	O
with	O
those	O
of	O
GR	O
.	O

Multiple	O
Oct2	O
isoforms	O
are	O
generated	O
by	O
alternative	O
splicing	O
.	O

The	O
interaction	O
of	O
the	O
Oct2	O
transcription	O
factor	O
with	O
the	O
cognate	O
octamer	O
motif	O
ATGCAAAT	O
is	O
a	O
critical	O
determinant	O
of	O
the	O
lymphoid-specific	O
expression	O
of	O
immunoglobulin	O
genes	O
.	O

Ectopic	O
expression	O
of	O
cloned	O
Oct2	O
cDNA	O
was	O
shown	O
to	O
be	O
sufficient	O
to	O
reconstitute	O
at	O
least	O
some	O
aspects	O
of	O
this	O
regulation	O
in	O
non-lymphoid	O
cells	O
.	O

We	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
multiple	O
cDNAs	O
encoding	O
mouse	O
Oct2	O
from	O
a	O
mature	O
B-cell	O
line	O
and	O
we	O
show	O
that	O
a	O
variety	O
of	O
isoforms	O
of	O
this	O
transcription	O
factor	O
is	O
generated	O
from	O
a	O
single	O
gene	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

All	O
the	O
isoforms	O
retain	O
the	O
previously	O
characterized	O
POU-domain	O
and	O
are	O
therefore	O
able	O
to	O
bind	O
to	O
the	O
octamer	O
motif	O
.	O

Different	O
amounts	O
of	O
the	O
various	O
isoforms	O
are	O
present	O
within	O
the	O
same	O
B-cell	O
regardless	O
of	O
the	O
developmental	O
stage	O
of	O
B-cell	O
differentiation	O
and	O
at	O
least	O
some	O
of	O
the	O
isoforms	O
are	O
conserved	O
between	O
mouse	O
and	O
humans	O
.	O

In	O
cotransfection	O
experiments	O
we	O
show	O
that	O
all	O
the	O
isoforms	O
are	O
able	O
to	O
activate	O
an	O
octamer	O
containing	O
promoter	O
element	O
in	O
fibroblasts	O
revealing	O
an	O
unexpected	O
functional	O
redundancy	O
.	O

Finally	O
,	O
we	O
show	O
that	O
one	O
of	O
the	O
isoforms	O
encodes	O
the	O
previously	O
described	O
lymphoid-specific	O
Oct2B	O
protein	O
which	B-SPECULATION
has	I-SPECULATION
been	I-SPECULATION
suggested	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
function	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
octamer	I-SPECULATION
motif	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
context	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
immunoglobulin	I-SPECULATION
heavy-chain	I-SPECULATION
(	I-SPECULATION
IgH	I-SPECULATION
)	I-SPECULATION
enhancer	I-SPECULATION
.	O

Murine	O
and	O
human	O
T-lymphocyte	O
GATA-3	O
factors	O
mediate	O
transcription	O
through	O
a	O
cis-regulatory	O
element	O
within	O
the	O
human	O
T-cell	O
receptor	O
delta	O
gene	O
enhancer	O
.	O

A	O
family	O
of	O
transcriptional	O
activators	O
has	O
recently	O
been	O
identified	O
in	O
chickens	O
;	O

these	O
transcriptional	O
activators	O
recognize	O
a	O
common	O
consensus	O
motif	O
(	O
WGATAR	O
)	O
through	O
a	O
conserved	O
C4	O
zinc	O
finger	O
DNA-binding	O
domain	O
.	O

One	O
of	O
the	O
members	O
of	O
this	O
multigene	O
family	O
,	O
cGATA-3	O
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
the	O
T-lymphocyte	O
cell	O
lineage	O
.	O

Analysis	O
of	O
human	O
and	O
murine	O
GATA-3	O
factors	O
shows	O
a	O
striking	O
degree	O
of	O
amino	O
acid	O
sequence	O
identity	O
and	O
similar	O
patterns	O
of	O
tissue	O
specificity	O
of	O
expression	O
in	O
these	O
three	O
organisms	O
.	O

The	O
murine	O
and	O
human	O
factors	O
are	O
abundantly	O
expressed	O
in	O
a	O
variety	O
of	O
human	O
and	O
murine	O
T-cell	O
lines	O
and	O
can	O
activate	O
transcription	O
through	O
a	O
tissue-specific	O
GATA-binding	O
site	O
identified	O
within	O
the	O
human	O
T-cell	O
receptor	O
delta	O
gene	O
enhancer	O
.	O

We	O
infer	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
murine	I-SPECULATION
and	I-SPECULATION
human	I-SPECULATION
GATA-3	I-SPECULATION
proteins	I-SPECULATION
play	I-SPECULATION
a	I-SPECULATION
central	I-SPECULATION
and	I-SPECULATION
highly	I-SPECULATION
conserved	I-SPECULATION
role	I-SPECULATION
in	I-SPECULATION
vertebrate	I-SPECULATION
T-cell-specific	I-SPECULATION
transcriptional	I-SPECULATION
regulation	I-SPECULATION
.	O

Processing	O
of	O
the	O
precursor	O
of	O
NF-kappa	O
B	O
by	O
the	O
HIV-1	O
protease	O
during	O
acute	O
infection	O
.	O

Transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
genome	O
is	O
regulated	O
in	O
part	O
by	O
cellular	O
factors	O
and	O
is	O
stimulated	O
by	O
activation	O
of	O
latently	O
infected	O
T	O
cells	O
.	O

T-cell	O
activation	O
also	O
correlates	O
with	O
the	O
induction	O
of	O
the	O
factor	O
NF-kappa	O
B	O
which	O
binds	O
to	O
two	O
adjacent	O
sites	O
in	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
.	O

This	O
factor	O
consists	O
of	O
two	O
DNA-binding	O
subunits	O
of	O
relative	O
molecular	O
mass	O
50,000	O
(	O
50K	O
)	O
associated	O
with	O
two	O
65K	O
subunits	O
.	O

It	O
is	O
located	O
in	O
the	O
nucleus	O
in	O
mature	O
B	O
cells	O
,	O
but	O
is	O
present	O
in	O
other	O
cell	O
types	O
as	O
an	O
inactive	O
cytoplasmic	O
complex	O
.	O

External	O
stimuli	O
,	O
including	O
those	O
that	O
activate	O
T	O
cells	O
,	O
result	O
in	O
nuclear	O
translocation	O
of	O
active	O
NF-kappa	O
B	O
.	O

The	O
cloning	O
of	O
the	O
complementary	O
DNA	O
for	O
the	O
50K	O
subunit	O
helped	O
to	O
identify	O
an	O
exclusively	O
cytoplasmic	O
105K	O
precursor	O
(	O
p105	O
)	O
(	O
V.B.	O
,	O
P.K.	O
and	O
A.I.	O
,	O
manuscript	O
submitted	O
)	O
.	O

The	B-SPECULATION
expression	I-SPECULATION
of	I-SPECULATION
active	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
might	I-SPECULATION
therefore	I-SPECULATION
also	I-SPECULATION
be	I-SPECULATION
regulated	I-SPECULATION
by	I-SPECULATION
the	I-SPECULATION
extent	I-SPECULATION
of	I-SPECULATION
processing	I-SPECULATION
of	I-SPECULATION
p105	I-SPECULATION
.	O

Because	O
HIV-1	O
requires	O
active	O
NF-kappa	O
B	O
for	O
efficient	O
transcription	O
,	O
we	O
tested	O
the	O
effect	O
of	O
HIV-1	O
infection	O
on	O
the	O
processing	O
of	O
the	O
human	O
105K	O
precursor	O
.	O

We	O
show	O
here	O
that	O
the	O
HIV-1	O
protease	O
can	O
process	O
p105	O
and	O
increases	O
levels	O
of	O
active	O
nuclear	O
NF-kappa	O
B	O
complex	O
.	O

Vitamin	O
D	O
receptor	O
expression	O
in	O
human	O
lymphocytes	O
.	O

Signal	O
requirements	O
and	O
characterization	O
by	O
western	O
blots	O
and	O
DNA	O
sequencing	O
.	O

The	O
signals	O
controlling	O
the	O
expression	O
of	O
the	O
receptor	O
protein	O
for	O
1	O
alpha,25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	O
lymphocytes	O
and	O
the	O
relationship	O
of	O
this	O
protein	O
to	O
the	O
classical	O
vitamin	O
D	O
receptor	O
were	O
examined	O
.	O

Lymphocytes	O
activated	O
with	O
the	O
OKT3	O
antibody	O
to	O
the	O
T-cell	O
antigen	O
receptor	O
expressed	O
fewer	O
binding	O
sites	O
as	O
compared	O
to	O
lymphocytes	O
that	O
were	O
activated	O
by	O
the	O
polyclonal	O
activator	O
phytohemagglutinin	O
(	O
PHA	O
)	O
.	O

However	O
,	O
combination	O
of	O
OKT3	O
and	O
phorbol	O
myristate	O
acetate	O
produced	O
a	O
concentration	O
of	O
binding	O
sites	O
similar	O
to	O
the	O
PHA-activated	O
cells	O
.	O

The	O
receptor	O
from	O
OKT3	O
and	O
OKT3	O
+	O
phorbol	O
myristate	O
acetate-activated	O
lymphocytes	O
exhibited	O
decreased	O
binding	O
to	O
DNA-cellulose	O
compared	O
to	O
PHA-activated	O
lymphocytes	O
.	O

In	O
lymphocytes	O
activated	O
either	O
by	O
PHA	O
or	O
OKT3	O
(	O
but	O
not	B-NEGATION
in	I-NEGATION
resting	I-NEGATION
cells	I-NEGATION
)	O
,	O
a	O
50-kDa	O
species	O
cross-reacting	O
with	O
a	O
monoclonal	O
antibody	O
against	O
the	O
intestinal	O
vitamin	O
D	O
receptor	O
was	O
detected	O
.	O

Finally	O
,	O
RNA	O
from	O
activated	O
lymphocytes	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
using	O
oligonucleotide	O
primers	O
flanking	O
the	O
196	O
base	O
pair	O
long	O
region	O
encoding	O
the	O
DNA-binding	O
domain	O
of	O
the	O
human	O
intestinal	O
receptor	O
.	O

The	O
amplified	O
product	O
showed	O
an	O
identical	O
nucleotide	O
sequence	O
to	O
the	O
DNA-binding	O
domain	O
of	O
the	O
human	O
intestinal	O
receptor	O
.	O

These	O
findings	O
suggest	B-SPECULATION
that	I-SPECULATION
expression	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
1,25	I-SPECULATION
-(	I-SPECULATION
OH	I-SPECULATION
)	I-SPECULATION
2D3	I-SPECULATION
receptor	I-SPECULATION
in	I-SPECULATION
lymphocytes	I-SPECULATION
is	I-SPECULATION
triggered	I-SPECULATION
by	I-SPECULATION
distinct	I-SPECULATION
and	I-SPECULATION
contingent	I-SPECULATION
signals	I-SPECULATION
,	I-SPECULATION
and	I-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
protein	I-SPECULATION
and	I-SPECULATION
the	I-SPECULATION
mRNA	I-SPECULATION
encoding	I-SPECULATION
it	I-SPECULATION
are	I-SPECULATION
identical	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
classical	I-SPECULATION
vitamin	I-SPECULATION
D	I-SPECULATION
receptor	I-SPECULATION
.	O

Cloning	O
of	O
murine	O
TCF-1	O
,	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
interacting	O
with	O
functional	O
motifs	O
in	O
the	O
CD3-epsilon	O
and	O
T	O
cell	O
receptor	O
alpha	O
enhancers	O
.	O

CD3-epsilon	O
gene	O
expression	O
is	O
confined	O
to	O
the	O
T	O
cell	O
lineage	O
.	O

We	O
have	O
recently	O
identified	O
and	O
cloned	O
a	O
human	O
transcription	O
factor	O
,	O
TCF-1	O
,	O
that	O
binds	O
to	O
a	O
functional	O
element	O
in	O
the	O
T	O
lymphocyte-specific	O
enhancer	O
of	O
CD3-epsilon	O
.	O

In	O
a	O
panel	O
of	O
human	O
cell	O
lines	O
,	O
TCF-1	O
expression	O
was	O
restricted	O
to	O
T	O
lineage	O
cells	O
.	O

TCF-1	O
belonged	O
to	O
a	O
novel	O
family	O
of	O
genes	O
that	O
contain	O
the	O
so-called	O
high	O
mobility	O
group	O
1	O
(	O
HMG	O
)	O
box	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
of	O
murine	O
TCF-1	O
.	O

Two	O
splice	O
alternatives	O
were	O
identified	O
that	B-NEGATION
were	I-NEGATION
not	I-NEGATION
previously	I-NEGATION
observed	I-NEGATION
in	I-NEGATION
human	I-NEGATION
TCF-1	I-NEGATION
.	O

Murine	O
and	O
human	O
TCF-1	O
displayed	O
a	O
95.5	O
%	O
overall	O
amino	O
acid	O
homology	O
.	O

Recombinant	O
murine	O
and	O
human	O
TCF-1	O
recognized	O
the	O
same	O
sequence	O
motif	O
in	O
the	O
CD3-epsilon	O
enhancer	O
as	O
judged	O
by	O
gel	O
retardation	O
and	O
methylation	O
interference	O
assays	O
.	O

With	O
the	O
murine	O
cDNA	O
clones	O
several	O
aspects	O
of	O
TCF-1	O
were	O
analyzed	O
.	O

First	O
,	O
deletion	O
analysis	O
revealed	O
that	O
a	O
region	O
of	O
TCF-1	O
containing	O
the	O
HMG	O
box	O
was	O
sufficient	O
for	O
sequence-specific	O
binding	O
.	O

Second	O
,	O
by	O
high	O
stringency	O
Northern	O
blotting	O
and	O
in	O
situ	O
hybridization	O
,	O
TCF-1	O
expression	O
was	O
shown	O
to	O
be	O
confined	O
to	O
the	O
thymus	O
and	O
to	O
the	O
T	O
cell	O
areas	O
of	O
the	O
spleen	O
.	O

Third	O
,	O
TCF-1	O
bound	O
specifically	O
to	O
a	O
functional	O
T	O
cell-specific	O
element	O
in	O
the	O
T	O
cell	O
receptor	O
alpha	O
(	O
TCR-alpha	O
)	O
enhancer	O
.	O

The	O
T	O
lineage-specific	O
expression	O
and	O
the	O
affinity	O
for	O
functional	O
motifs	O
in	O
the	O
TCR-alpha	O
and	O
CD3-epsilon	O
enhancers	O
imply	B-SPECULATION
an	I-SPECULATION
important	I-SPECULATION
role	I-SPECULATION
for	I-SPECULATION
TCF-1	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
establishment	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
mature	I-SPECULATION
T	I-SPECULATION
cell	I-SPECULATION
phenotype	I-SPECULATION
.	O

HIV	O
enhancer	O
activity	O
perpetuated	O
by	O
NF-kappa	O
B	O
induction	O
on	O
infection	O
of	O
monocytes	O
[	O
see	O
comments	O
]	O

Permissiveness	O
to	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
differs	O
in	O
T	O
lymphocytes	O
and	O
macrophages	O
.	O

In	O
T	O
cells	O
,	O
HIV	O
transcription	O
is	O
poorly	O
detected	O
in	O
vivo	O
.	O

Cloned	O
,	O
normal	O
T	O
lymphocytes	O
show	O
very	O
little	O
,	O
if	O
any	O
,	O
basal	O
activity	O
of	O
the	O
HIV	O
enhancer	O
and	O
low	O
nuclear	O
expression	O
of	O
NF-kappa	O
B	O
,	O
a	O
potent	O
transcriptional	O
activator	O
of	O
the	O
HIV	O
enhancer	O
.	O

In	O
contrast	O
,	O
fixed	O
tissue	O
macrophages	O
express	O
detectable	O
HIV	O
proteins	O
,	O
indicating	O
permanent	O
virus	O
transcription	O
.	O

One	B-SPECULATION
explanation	I-SPECULATION
for	I-SPECULATION
the	I-SPECULATION
perpetuation	I-SPECULATION
of	I-SPECULATION
virus	I-SPECULATION
infection	I-SPECULATION
in	I-SPECULATION
macrophages	I-SPECULATION
could	I-SPECULATION
be	I-SPECULATION
sustained	I-SPECULATION
nuclear	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
expression	I-SPECULATION
.	O

However	O
,	O
the	O
U937	O
monocytic	O
cell	O
line	O
,	O
which	O
is	O
fully	O
permissive	O
to	O
HIV	O
replication	O
,	O
is	O
known	O
to	O
express	O
only	O
low	O
levels	O
of	O
nuclear	O
NF-kappa	O
B	O
.	O

We	O
show	O
here	O
that	O
chronic	O
HIV	O
infection	O
results	O
in	O
both	O
induction	O
of	O
a	O
nuclear	O
factor	O
with	O
antigenic	O
properties	O
indistinguishable	O
from	O
those	O
of	O
NF-kappa	O
B	O
and	O
permanently	O
increased	O
HIV	O
enhancer	O
activity	O
.	O

This	O
phenomenon	O
,	O
which	O
is	O
independent	O
of	O
tumour	O
necrosis	O
factor	O
,	O
is	O
associated	O
with	O
HIV	O
replication	O
,	O
and	O
is	B-SPECULATION
thus	I-SPECULATION
likely	I-SPECULATION
to	I-SPECULATION
explain	I-SPECULATION
at	I-SPECULATION
least	I-SPECULATION
in	I-SPECULATION
part	I-SPECULATION
the	I-SPECULATION
perpetuation	I-SPECULATION
of	I-SPECULATION
HIV	I-SPECULATION
infection	I-SPECULATION
in	I-SPECULATION
monocytes	I-SPECULATION
.	O

Role	O
for	O
the	O
Epstein-Barr	O
virus	O
nuclear	O
antigen	O
2	O
in	O
viral	O
promoter	O
switching	O
during	O
initial	O
stages	O
of	O
infection	O
.	O

During	O
latent	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
human	O
B	O
lymphocytes	O
,	O
six	O
viral	O
nuclear	O
antigen	O
(	O
EBNAs	O
)	O
are	O
expressed	O
from	O
long	O
primary	O
transcripts	O
by	O
means	O
of	O
alternative	O
splicing	O
and	O
alternative	O
polyadenylylation	O
sites	O
.	O

These	O
transcripts	O
initiate	O
from	O
one	O
of	O
two	O
promoters	O
,	O
Cp	O
or	O
Wp	O
,	O
that	O
function	O
in	O
a	O
mutually	O
exclusive	O
fashion	O
.	O

Wp	O
is	O
exclusively	O
utilized	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
of	O
primary	O
B	O
lymphocytes	O
,	O
followed	O
by	O
a	O
switch	O
to	O
Cp	O
usage	O
.	O

These	O
studies	O
have	O
been	O
extended	O
to	O
show	O
that	O
(	O
i	O
)	O
a	O
mutant	O
EBV	O
strain	O
lacking	B-NEGATION
the	I-NEGATION
gene	I-NEGATION
encoding	I-NEGATION
EBNA	I-NEGATION
2	I-NEGATION
fails	O
to	O
switch	O
from	O
Wp	O
to	O
Cp	O
usage	O
in	O
primary	O
B	O
lymphocytes	O
,	O
although	O
the	O
virus	O
contains	O
a	O
functional	O
Cp	O
;	O
(	O
ii	O
)	O
a	O
region	O
from	O
-	O
429	O
to	O
-	O
245	O
base	O
pairs	O
upstream	O
of	O
Cp	O
is	O
essential	O
for	O
Cp	O
activity	O
in	O
B	O
lymphocytes	O
,	O
but	O
only	O
in	O
the	O
context	O
of	O
upstream	O
and	O
downstream	O
sequences	O
;	O
(	O
iii	O
)	O
this	O
region	O
contains	O
an	O
EBNA	O
2-dependent	O
enhancer	O
;	O
and	O
(	O
iv	O
)	O
DNase	O
I	O
protection	O
employing	O
nuclear	O
extracts	O
from	O
B	O
and	O
T	O
lymphocytes	O
revealed	O
a	O
B-cell-specific	O
footprint	O
in	O
the	O
region	O
of	O
the	O
EBNA	O
2-dependent	O
enhancer	O
.	O

These	O
results	O
support	O
a	O
model	O
for	O
viral	O
promoter	O
switching	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
in	O
which	O
Wp	O
activity	O
leads	O
to	O
the	O
expression	O
of	O
EBNA	O
2	O
,	O
followed	O
by	O
activation	O
of	O
Cp	O
through	O
the	O
EBNA	O
2-dependent	O
enhancer	O
.	O

Glucocorticoid	O
receptor	O
characteristics	O
in	O
monocytes	O
of	O
patients	O
with	O
corticosteroid-resistant	O
bronchial	O
asthma	O
.	O

The	O
mechanism	O
of	O
corticosteroid	O
resistance	O
in	O
bronchial	O
asthma	O
has	O
been	O
studied	O
by	O
determining	O
the	O
rank	O
order	O
of	O
potency	O
for	O
different	O
corticosteroids	O
in	O
inhibiting	O
the	O
generation	O
of	O
a	O
3	O
kD	O
molecule	O
from	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
corticosteroid-sensitive	O
(	O
CS	O
)	O
and	O
corticosteroid-resistant	O
(	O
CR	O
)	O
asthmatic	O
subjects	O
,	O
which	O
augments	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
generation	O
by	O
human	O
neutrophils	O
(	O
PMN	O
)	O
stimulated	O
by	O
calcium	O
ionophore	O
.	O

In	O
addition	O
,	O
binding	O
studies	O
with	O
(	O
3H	O
)	O
dexamethasone	O
have	O
been	O
performed	O
to	O
determine	O
the	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
receptor	O
numbers	O
(	O
Ro	O
)	O
in	O
the	O
monocytes	O
of	O
these	O
two	O
groups	O
of	O
subjects	O
.	O

The	O
concentration	O
of	O
corticosteroid	O
producing	O
50	O
%	O
inhibition	O
(	O
IC50	O
)	O
was	O
600	O
nM	O
,	O
70	O
nM	O
,	O
and	O
0.5	O
nM	O
for	O
hydrocortisone	O
,	O
methylprednisolone	O
,	O
and	O
dexamethasone	O
,	O
respectively	O
,	O
in	O
monocytes	O
from	O
CS	O
individuals	O
.	O

There	O
was	O
only	O
weak	O
inhibition	O
of	O
the	O
generation	O
of	O
enhancing	O
activity	O
by	O
the	O
corticosteroids	O
in	O
the	O
CR	O
asthmatic	O
individuals	O
.	O

The	O
dexamethasone	O
Kd	O
was	O
2.45	O
	O
0.58	O
nM	O
(	O
mean	O
	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CS	O
group	O
and	O
1.6	O
	O
0.35	O
nM	O
(	O
mean	O
	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CR	O
group	O
of	O
patients	O
(	O
p	O
=	O
0.14	O
)	O
.	O

The	O
Ro	O
in	O
the	O
CS	O
group	O
was	O
3,605	O
	O
984	O
binding	O
sites	O
per	O
nucleus	O
(	O
mean	O
	O
SEM	O
,	O
n	O
=	O
6	O
)	O
and	O
4,757	O
	O
692	O
binding	O
sites	O
per	O
nucleus	O
(	O
mean	O
	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CR	O
group	O
(	O
p	O
=	O
0.23	O
)	O
.	O

These	O
findings	O
indicate	B-SPECULATION
that	I-SPECULATION
corticosteroid	B-NEGATION
resistance	I-NEGATION
in	I-NEGATION
bronchial	I-NEGATION
asthma	I-NEGATION
can	I-NEGATION
not	I-NEGATION
be	I-NEGATION
explained	I-NEGATION
by	I-NEGATION
abnormalities	I-NEGATION
in	I-NEGATION
corticosteroid	I-NEGATION
receptor	I-NEGATION
characteristics	I-NEGATION
.	O

Tissue-specific	O
expression	O
of	O
the	O
platelet	O
GPIIb	O
gene	O
.	O

One	O
of	O
the	O
major	O
objectives	O
in	O
the	O
study	O
of	O
thrombogenesis	O
is	O
to	O
determine	O
the	O
mechanisms	O
by	O
which	O
a	O
hematopoietic	O
progenitor	O
is	O
activated	O
and	O
committed	O
to	O
the	O
megakaryocytic	O
lineage	O
.	O

Recent	O
development	O
of	O
primary	O
cultures	O
of	O
human	O
megakaryocytes	O
and	O
the	O
molecular	O
cloning	O
of	O
genes	O
that	O
are	O
specific	O
to	O
this	O
lineage	O
offer	O
the	O
possibility	O
of	O
getting	O
some	O
insights	O
into	O
the	O
genetic	O
mechanisms	O
that	O
control	O
megakaryocytopoiesis	O
.	O

One	O
gene	O
of	O
interest	O
is	O
the	O
glycoprotein	O
IIb	O
(	O
GPIIb	O
)	O
gene	O
;	O

GPIIb	O
,	O
the	O
alpha	O
subunit	O
of	O
the	O
platelet	O
cytoadhesin	O
GPIIb-IIIa	O
,	O
is	O
produced	O
in	O
megakaryocytes	O
at	O
an	O
early	O
stage	O
of	O
the	O
differentiation	O
,	O
whereas	O
the	O
other	O
subunit	O
of	O
this	O
complex	O
,	O
GPIIIa	O
,	O
is	O
expressed	O
in	O
other	O
cells	O
.	O

For	O
these	O
reasons	O
,	O
the	O
5	O
'-	O
flanking	O
region	O
of	O
the	O
GPIIb	O
gene	O
was	O
used	O
to	O
identify	O
the	O
regions	O
that	O
interact	O
with	O
DNA-binding	O
nuclear	O
factors	O
.	O

A	O
fragment	O
extending	O
from	O
-	O
643	O
to	O
+	O
33	O
is	O
capable	O
of	O
controlling	O
the	O
tissue-specific	O
expression	O
of	O
the	O
CAT	O
gene	O
in	O
transfection	O
experiments	O
.	O

Within	O
this	O
region	O
,	O
we	O
have	O
identified	O
several	O
sequences	O
that	O
are	O
implicated	O
in	O
DNA	O
protein	O
interactions	O
as	O
shown	O
in	O
DNAse	O
I	O
footprints	O
and	O
gel	O
mobility	O
shift	O
assays	O
.	O

One	O
region	O
,	O
centered	O
at	O
-	O
54	O
,	O
is	O
similar	O
to	O
a	O
nuclear	O
factor	O
E1-binding	O
site	O
,	O
and	O
a	O
region	O
located	O
at	O
position	O
-	O
233	O
contains	O
a	O
CCAAT	O
motif	O
.	O

Two	O
domains	O
centered	O
at	O
positions	O
-	O
345	O
and	O
-	O
540	O
,	O
respectively	O
,	O
bind	O
proteins	O
that	O
are	O
present	O
in	O
megakaryocytic	O
cells	O
and	O
nonrelated	O
cells	O
as	O
well	O
.	O

Finally	O
,	O
two	O
other	O
domains	O
,	O
located	O
at	O
positions	O
-	O
460	O
and	O
-	O
510	O
,	O
interact	O
with	O
proteins	O
that	O
are	O
only	O
present	O
in	O
megakaryocytic	O
cells	O
.	O

In	O
addition	O
,	O
deletion	O
of	O
the	O
region	O
containing	O
these	O
two	O
domains	O
results	O
in	O
a	O
significant	O
decrease	O
of	O
the	O
promoter	O
activity	O
.	O

It	O
is	O
very	O
likely	B-SPECULATION
that	I-SPECULATION
these	I-SPECULATION
domains	I-SPECULATION
bind	I-SPECULATION
megakaryocyte-specific	I-SPECULATION
nuclear	I-SPECULATION
proteins	I-SPECULATION
acting	I-SPECULATION
as	I-SPECULATION
positive	I-SPECULATION
transcription	I-SPECULATION
factors	I-SPECULATION
.	O

Inhibition	O
of	O
protein	O
phosphatases	O
by	O
okadaic	O
acid	O
induces	O
AP1	O
in	O
human	O
T	O
cells	O
.	O

To	O
examine	O
the	O
role	O
of	O
protein	O
phosphatases	O
in	O
T	O
cell	O
activation	O
,	O
Jurkat	O
cells	O
were	O
treated	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	O
1	O
and	O
2A	O
phosphatases	O
,	O
and	O
nuclear	O
extracts	O
were	O
examined	O
for	O
the	O
presence	O
of	O
AP1	O
as	O
a	O
measure	O
of	O
early	O
T	O
cell	O
activation	O
.	O

Okadaic	O
acid	O
was	O
found	O
to	O
be	O
a	O
potent	O
inducer	O
of	O
AP1	O
.	O

In	O
contrast	O
to	O
phorbol	O
esters	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
the	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
occurs	O
predominantly	O
by	O
transcriptional	O
activation	O
of	O
the	O
jun	O
and	O
fos	O
family	O
of	O
proto-oncogenes	O
.	O

Surprisingly	O
,	O
while	O
the	O
addition	O
of	O
phytohemagglutinin	O
further	O
enhanced	O
the	O
induction	O
of	O
AP1	O
,	O
the	O
addition	O
of	O
PMA	O
inhibited	O
it	O
.	O

Okadaic	O
acid	O
treatment	O
was	O
found	O
to	O
dramatically	O
increase	O
mRNA	O
transcripts	O
of	O
the	O
jun	O
family	O
of	O
proto-oncogenes	O
including	O
c-jun	O
,	O
junD	O
,	O
and	O
junB	O
and	O
to	O
a	O
lesser	O
extent	O
the	O
fos	O
family	O
including	O
c-fos	O
and	O
fra-1	O
.	O

By	O
comparison	O
,	O
PMA	O
is	O
a	O
very	O
inefficient	O
inducer	O
of	O
the	O
jun	O
gene	O
family	O
in	O
Jurkat	O
cells	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
the	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
,	O
PMA	O
inhibits	O
the	O
induction	O
of	O
c-jun	O
mRNA	O
by	O
okadaic	O
acid	O
.	O

Transfection	O
of	O
c-jun	O
promoter	O
constructs	O
confirmed	O
the	O
marked	O
difference	O
between	O
PMA	O
and	O
okadaic	O
acid	O
in	O
inducing	O
c-jun	O
transcription	O
.	O

The	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
suggests	B-SPECULATION
that	I-SPECULATION
protein	I-SPECULATION
phosphatases	I-SPECULATION
1	I-SPECULATION
and	I-SPECULATION
2A	I-SPECULATION
(	I-SPECULATION
PP1	I-SPECULATION
and	I-SPECULATION
PP2A	I-SPECULATION
)	I-SPECULATION
may	B-SPECULATION
be	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
T	I-SPECULATION
cell	I-SPECULATION
activation	I-SPECULATION
as	I-SPECULATION
important	I-SPECULATION
negative	I-SPECULATION
regulators	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
transcription	I-SPECULATION
factor	I-SPECULATION
AP1	I-SPECULATION
.	O

Demonstration	O
of	O
estrogen	O
and	O
progesterone	O
receptors	O
as	O
well	O
as	O
Ki-67	O
and	O
p-145	O
antigens	O
in	O
single	O
tumor	O
cells	O
from	O
blood	O
and	O
pleural	O
effusions	O
using	O
a	O
slide	O
assay	O
.	O

We	O
describe	O
a	O
slide	O
assay	O
that	O
allows	O
the	O
demonstration	O
of	O
antigens	O
localized	O
in	O
the	O
nucleus	O
from	O
isolated	O
white	O
blood	O
cells	O
as	O
well	O
as	O
from	O
single	O
tumor	O
cells	O
derived	O
from	O
malignant	O
effusions	O
.	O

With	O
the	O
antibodies	O
Ki-67	O
and	O
anti-p-145	O
an	O
increased	O
rate	O
of	O
nuclear	O
and	O
nucleolar	O
staining	O
resulted	O
in	O
cells	O
from	O
highly	O
malignant	O
lymphomas	O
.	O

An	O
almost	O
identical	O
reaction	O
was	O
obtained	O
when	O
tumor	O
cells	O
from	O
malignant	O
effusions	O
were	O
tested	O
.	O

Cells	O
isolated	O
from	O
the	O
blood	O
of	O
patients	O
with	O
leukemic	O
spread	O
of	O
lymphomas	O
of	O
low	O
malignancy	O
yielded	O
a	O
weak	O
staining	O
comparable	O
to	O
that	O
of	O
normal	O
mesothelial	O
cells	O
from	O
non-tumorous	O
cavity	O
fluids	O
.	O

The	O
detection	O
of	O
estrogen	O
and	O
progesterone	O
receptors	O
(	O
ER	O
and	O
PR	O
)	O
localized	O
in	O
the	O
cell	O
nucleus	O
can	O
be	O
achieved	O
by	O
the	O
same	O
assay	O
.	O

The	O
reaction	O
is	O
enhanced	O
by	O
incubation	O
of	O
the	O
tumor	O
cells	O
for	O
30	O
min	O
at	O
37	O
degrees	O
C	O
prior	O
to	O
fixation	O
.	O

Pleural	O
effusions	O
from	O
20	O
patients	O
with	O
breast	O
cancer	O
were	O
tested	O
.	O

ER	O
was	O
positive	O
in	O
13	O
and	O
PR	O
was	O
positive	O
in	O
12	O
of	O
the	O
20	O
samples	O
.	O

In	O
5	O
cases	O
there	O
was	O
a	O
divergent	O
reaction	O
with	O
ER	O
and	O
PR	O
antibody	O
.	O

The	O
hormone	O
receptors	O
of	O
the	O
primary	O
tumor	O
were	O
known	O
in	O
15	O
(	O
ER	O
)	O
and	O
14	O
(	O
PR	O
)	O
patients	O
,	O
respectively	O
.	O

In	O
each	O
cohort	O
there	O
was	O
only	O
one	O
case	O
with	O
a	O
negative	O
reaction	O
of	O
the	O
primary	O
tumor	O
and	O
a	O
positive	O
reaction	O
with	O
the	O
isolated	O
tumor	O
cells	O
from	O
the	O
pleural	O
effusions	O
.	O

These	O
results	O
indicate	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
demonstration	I-SPECULATION
of	I-SPECULATION
hormone	I-SPECULATION
receptor	I-SPECULATION
proteins	I-SPECULATION
in	I-SPECULATION
cells	I-SPECULATION
from	I-SPECULATION
malignant	I-SPECULATION
effusions	I-SPECULATION
is	I-SPECULATION
possible	I-SPECULATION
and	O
that	O
there	O
is	O
a	O
correlation	O
with	O
the	O
status	O
of	O
the	O
primary	O
site	O
of	O
cancer	O
.	O

Transforming	O
growth	O
factor-beta	O
suppresses	O
human	O
B	O
lymphocyte	O
Ig	O
production	O
by	O
inhibiting	O
synthesis	O
and	O
the	O
switch	O
from	O
the	O
membrane	O
form	O
to	O
the	O
secreted	O
form	O
of	O
Ig	O
mRNA	O
.	O

Transforming	O
growth	O
factor-beta	O
(	O
TGF-beta	O
)	O
inhibits	O
B	O
cell	O
Ig	O
secretion	O
and	O
reduces	O
B	O
cell	O
membrane	O
Ig	O
expression	O
.	O

The	O
addition	O
of	O
TGF-beta	O
to	O
human	O
B	O
lymphocyte	O
cultures	O
stimulated	O
with	O
Staphylococcus	O
aureus	O
Cowan	O
strain	O
I	O
and	O
IL-2	O
completely	O
inhibited	O
B	O
cell	O
Ig	O
secretion	O
(	O
greater	O
than	O
90	O
%)	O
and	O
decreased	O
B	O
cell	O
surface	O
IgM	O
,	O
IgD	O
,	O
kappa	O
L	O
chain	O
,	O
and	O
lambda	O
L	O
chain	O
expression	O
.	O

In	O
contrast	O
,	O
TGF-beta	O
had	O
only	O
minimal	O
effects	O
on	O
two	O
other	O
B	O
cell	O
membrane	O
proteins	O
,	O
HLA-DR	O
and	O
CD20	O
.	O

Internal	O
labeling	O
with	O
[	O
35S	O
]	O
methionine	O
and	O
immunoprecipitation	O
with	O
anti-IgM	O
,	O
anti-kappa	O
,	O
and	O
anti-lambda	O
antibodies	O
revealed	O
a	O
striking	O
reduction	O
in	O
kappa	O
L	O
chain	O
in	O
the	O
presence	O
of	O
TGF-beta	O
.	O

A	O
less	O
pronounced	O
reduction	O
in	O
lambda	O
L	O
chain	O
and	O
microH	O
chain	O
was	O
also	O
noted	O
.	O

Northern	O
blot	O
analysis	O
of	O
RNA	O
purified	O
from	O
B	O
cells	O
treated	O
with	O
TGF-beta	O
for	O
varying	O
time	O
intervals	O
revealed	O
a	O
significant	O
decrease	O
in	O
steady	O
state	O
kappa	O
and	O
lambda	O
L	O
chain	O
mRNA	O
levels	O
.	O

Furthermore	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
switch	O
from	O
the	O
membrane	O
forms	O
of	O
mu	O
and	O
gamma	O
to	O
their	O
respective	O
secreted	O
forms	O
was	O
noted	O
in	O
the	O
presence	O
of	O
TGF-beta	O
.	O

Nuclear	O
run-on	O
experiments	O
demonstrated	O
decreased	O
transcription	O
of	O
kappa	O
L	O
chain	O
.	O

The	O
effects	O
of	O
TGF-beta	O
on	O
two	O
transcriptional	O
regulatory	O
factors	O
,	O
Oct-2	O
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
kappa	O
B	O
,	O
known	O
to	O
be	O
important	O
in	O
Ig	O
gene	O
transcription	O
were	O
examined	O
.	O

Oct-2	B-NEGATION
mRNA	I-NEGATION
levels	I-NEGATION
and	I-NEGATION
both	I-NEGATION
Oct-2	I-NEGATION
and	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
proteins	I-NEGATION
in	I-NEGATION
nuclear	I-NEGATION
extracts	I-NEGATION
were	I-NEGATION
not	I-NEGATION
altered	I-NEGATION
by	I-NEGATION
treatment	I-NEGATION
with	I-NEGATION
TGF-beta	I-NEGATION
.	O

In	O
contrast	O
,	O
levels	O
of	O
the	O
transcriptional	O
factor	O
AP-1	O
,	O
which	B-NEGATION
is	I-NEGATION
not	I-NEGATION
known	I-NEGATION
to	I-NEGATION
be	I-NEGATION
important	I-NEGATION
in	I-NEGATION
B	I-NEGATION
cell	I-NEGATION
Ig	I-NEGATION
production	I-NEGATION
,	O
were	O
reduced	O
by	O
TGF-beta	O
.	O

These	O
findings	O
demonstrate	O
that	O
TGF-beta	O
decreases	O
B	O
lymphocyte	O
Ig	O
secretion	O
by	O
inhibiting	O
the	O
synthesis	O
of	O
Ig	O
mRNA	O
and	O
inhibiting	O
the	O
switch	O
from	O
the	O
membrane	O
form	O
to	O
the	O
secreted	O
forms	O
of	O
mu	O
and	O
gamma	O
mRNA	O
.	O

The	B-SPECULATION
mechanism	I-SPECULATION
by	I-SPECULATION
which	I-SPECULATION
TGF-beta	I-SPECULATION
inhibits	I-SPECULATION
Ig	I-SPECULATION
chain	I-SPECULATION
synthesis	I-SPECULATION
is	I-SPECULATION
unclear	I-SPECULATION
although	O
it	O
does	O
not	B-NEGATION
involve	I-NEGATION
inhibition	I-NEGATION
of	I-NEGATION
the	I-NEGATION
binding	I-NEGATION
of	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
or	I-NEGATION
Oct-2	I-NEGATION
to	I-NEGATION
their	I-NEGATION
respective	I-NEGATION
target	I-NEGATION
sequences	I-NEGATION
.	O

Differentiation-associated	O
expression	O
of	O
the	O
Epstein-Barr	O
virus	O
BZLF1	O
transactivator	O
protein	O
in	O
oral	O
hairy	O
leukoplakia	O
.	O

The	O
BZLF1	O
protein	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
key	O
immediate-early	O
protein	O
which	O
has	O
been	O
shown	O
to	O
disrupt	O
virus	O
latency	O
in	O
EBV-infected	O
B	O
cells	O
.	O

We	O
have	O
generated	O
a	O
monoclonal	O
antibody	O
,	O
BZ1	O
,	O
to	O
BZLF1	O
which	O
reacts	O
in	O
immunohistology	O
,	O
immunoblotting	O
,	O
and	O
immunoprecipitation	O
and	O
which	O
recognizes	O
both	O
the	O
active	O
,	O
dimeric	O
form	O
and	O
the	O
inactive	O
,	O
monomeric	O
form	O
of	O
the	O
protein	O
.	O

Biopsies	O
of	O
oral	O
hairy	O
leukoplakia	O
,	O
an	O
AIDS-associated	O
lesion	O
characterized	O
by	O
high-level	O
EBV	O
replication	O
,	O
were	O
examined	O
by	O
immunohistochemistry	O
using	O
the	O
BZ1	O
monoclonal	O
antibody	O
.	O

A	O
differentiation-associated	O
pattern	O
of	O
BZLF1	O
expression	O
was	O
observed	O
,	O
BZ1	O
reacting	O
with	O
nuclei	O
of	O
the	O
upper	O
spinous	O
layer	O
of	O
the	O
lesion	O
.	O

This	O
finding	O
suggests	B-SPECULATION
that	I-SPECULATION
the	B-SPECULATION
BZLF1	I-SPECULATION
promoter	I-SPECULATION
may	I-SPECULATION
be	I-SPECULATION
regulated	I-SPECULATION
by	I-SPECULATION
the	I-SPECULATION
degree	I-SPECULATION
of	I-SPECULATION
squamous	I-SPECULATION
differentiation	I-SPECULATION
.	O

A	O
comparison	O
of	O
in	O
situ	O
hybridization	O
to	O
EBV	O
DNA	O
and	O
viral	O
capsid	O
antigen	O
staining	O
with	O
BZ1	O
reactivity	O
suggested	B-SPECULATION
that	I-SPECULATION
BZLF1	I-SPECULATION
expression	I-SPECULATION
precedes	I-SPECULATION
rampant	I-SPECULATION
virus	I-SPECULATION
replication	I-SPECULATION
.	O

The	O
inability	O
to	O
detect	O
EBV	O
in	O
the	O
lower	O
epithelial	O
layers	O
of	O
oral	O
hairy	O
leukoplakia	O
raises	B-SPECULATION
questions	I-SPECULATION
concerning	I-SPECULATION
the	I-SPECULATION
nature	I-SPECULATION
of	I-SPECULATION
EBV	I-SPECULATION
latency	I-SPECULATION
and	I-SPECULATION
persistence	I-SPECULATION
in	I-SPECULATION
stratified	I-SPECULATION
squamous	I-SPECULATION
epithelium	I-SPECULATION
.	O

Transactivation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
promoter	O
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
strains	O
GS	O
and	O
Z-29	O
in	O
primary	O
human	O
T	O
lymphocytes	O
and	O
identification	O
of	O
transactivating	O
HHV-6	O
(	O
GS	O
)	O
gene	O
fragments	O
.	O

Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
can	O
activate	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	O
and	O
accelerate	O
cytopathic	O
effects	O
in	O
HIV-infected	O
human	O
T	O
cells	O
.	O

This	O
study	O
examines	O
the	O
regions	O
of	O
the	O
HIV	O
promoter	O
required	O
for	O
HHV-6	O
transactivation	O
in	O
a	O
heterogeneous	O
population	O
of	O
primary	O
human	O
T	O
lymphocytes	O
with	O
or	O
without	B-NEGATION
antigenic	I-NEGATION
stimulation	I-NEGATION
.	O

Two	O
different	O
strains	O
of	O
HHV-6	O
,	O
GS	O
and	O
Z29	O
,	O
transactivated	O
the	O
HIV	O
promoter	O
.	O

The	O
GS	O
strain	O
transactivated	O
the	O
promoter	O
in	O
both	O
stimulated	O
and	O
resting	O
T	O
cells	O
,	O
while	O
the	O
Z29	O
strain	O
increased	O
HIV	O
promoter	O
activity	O
only	O
in	O
stimulated	O
T	O
cells	O
.	O

Three	O
DNA	O
clones	O
containing	O
HHV-6	O
(	O
GS	O
)	O
genomic	O
fragments	O
transactivated	O
the	O
HIV	O
promoter	O
in	O
cotransfected	O
T	O
cells	O
.	O

A	O
21.4-kb	O
DNA	O
clone	O
,	O
pZVB70	O
,	O
showed	O
the	O
highest	O
transactivating	O
ability	O
,	O
while	O
two	O
other	O
DNA	O
fragments	O
,	O
pZVB10	O
(	O
6.2	O
kb	O
)	O
and	O
pZVH14	O
(	O
8.7	O
kb	O
)	O
,	O
showed	O
lower	O
activity	O
.	O

One	O
of	O
these	O
clones	O
,	O
pZVH14	O
,	O
activated	O
the	O
HIV	O
promoter	O
construct	O
containing	O
a	O
mutation	O
in	O
the	O
NF	O
kappa	O
B	O
site	O
.	O

However	O
,	O
this	B-NEGATION
mutated	I-NEGATION
NF	I-NEGATION
kappa	I-NEGATION
B	I-NEGATION
promoter	I-NEGATION
was	I-NEGATION
not	I-NEGATION
transactivated	I-NEGATION
during	I-NEGATION
HHV-6	I-NEGATION
(	I-NEGATION
GS	I-NEGATION
)	I-NEGATION
infection	I-NEGATION
or	I-NEGATION
after	I-NEGATION
cotransfection	I-NEGATION
with	I-NEGATION
pZVB70	I-NEGATION
or	I-NEGATION
pZVB10	I-NEGATION
.	O

These	O
data	O
indicate	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
NF	I-SPECULATION
kappa	I-SPECULATION
B	I-SPECULATION
sites	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
HIV	I-SPECULATION
promoter	I-SPECULATION
are	I-SPECULATION
essential	I-SPECULATION
for	I-SPECULATION
its	I-SPECULATION
transactivation	I-SPECULATION
during	I-SPECULATION
HHV-6	I-SPECULATION
(	I-SPECULATION
GS	I-SPECULATION
)	I-SPECULATION
infection	I-SPECULATION
.	O

By	O
increasing	O
HIV	O
promoter	O
activity	O
in	O
primary	O
T	O
lymphocytes	O
,	O
HHV-6	O
may	B-SPECULATION
consequently	I-SPECULATION
increase	I-SPECULATION
HIV	I-SPECULATION
replication	I-SPECULATION
,	I-SPECULATION
leading	I-SPECULATION
to	I-SPECULATION
an	I-SPECULATION
increase	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
cytopathic	I-SPECULATION
effect	I-SPECULATION
on	I-SPECULATION
coinfected	I-SPECULATION
human	I-SPECULATION
T	I-SPECULATION
cells	I-SPECULATION
.	O

The	O
rhombotin	O
family	O
of	O
cysteine-rich	O
LIM-domain	O
oncogenes	O
:	O
distinct	O
members	O
are	O
involved	O
in	O
T-cell	O
translocations	O
to	O
human	O
chromosomes	O
11p15	O
and	O
11p13	O
.	O

A	O
chromosomal	O
translocation	O
in	O
a	O
T-cell	O
leukemia	O
involving	O
the	O
short	O
arm	O
of	O
human	O
chromosome	O
11	O
at	O
band	O
11p15	O
disrupts	O
the	O
rhombotin	O
gene	O
.	O

This	O
gene	O
encodes	O
a	O
protein	O
with	O
duplicated	O
cysteine-rich	O
regions	O
called	O
LIM	O
domains	O
,	O
which	O
show	O
homology	O
to	O
zinc-binding	O
proteins	O
and	O
to	O
iron-sulfur	O
centers	O
of	O
ferredoxins	O
.	O

Two	O
homologues	O
of	O
the	O
rhombotin	O
gene	O
have	O
now	O
been	O
isolated	O
.	O

One	O
of	O
these	O
,	O
designated	O
Rhom-2	O
,	O
is	O
located	O
on	O
human	O
chromosome	O
11	O
at	O
band	O
11p13	O
,	O
where	O
a	O
cluster	O
of	O
T-cell	O
leukemia-specific	O
translocations	O
occur	O
;	O

all	O
translocation	O
breakpoints	O
at	O
11p13	O
are	O
upstream	O
of	O
the	O
Rhom-2	O
gene	O
.	O

Human	O
and	O
mouse	O
Rhom-2	O
are	O
highly	O
conserved	O
and	O
,	O
like	O
rhombotin	O
,	O
encode	O
two	O
tandem	O
cysteine-rich	O
LIM	O
domains	O
.	O

Rhom-2	O
mRNA	O
is	O
expressed	O
in	O
early	O
mouse	O
development	O
in	O
central	O
nervous	O
system	O
,	O
lung	O
,	O
kidney	O
,	O
liver	O
,	O
and	O
spleen	O
but	O
only	O
very	O
low	O
levels	O
occur	O
in	O
thymus	O
.	O

The	O
other	O
gene	O
,	O
designated	O
Rhom-3	O
,	O
is	O
not	B-NEGATION
on	I-NEGATION
chromosome	I-NEGATION
11	I-NEGATION
but	O
also	O
retains	O
homology	O
to	O
the	O
LIM	O
domain	O
of	O
rhombotin	O
.	O

Since	O
the	O
Rhom-2	O
gene	O
is	O
such	O
a	O
common	O
site	O
of	O
chromosomal	O
damage	O
in	O
T-cell	O
tumors	O
,	O
the	O
consistency	O
of	O
translocations	O
near	O
the	O
rhombotin	O
gene	O
was	O
further	O
examined	O
.	O

A	O
second	O
translocation	O
adjacent	O
to	O
rhombotin	O
was	O
found	O
and	O
at	O
the	O
same	O
position	O
as	O
in	O
the	O
previous	O
example	O
.	O

Therefore	O
,	O
chromosome	O
bands	O
11p15	O
(	O
rhombotin	O
)	O
and	O
11p13	O
(	O
Rhom-2	O
)	O
are	O
consistent	O
sites	O
of	O
chromosome	O
translocation	O
in	O
T-cell	O
leukemia	O
,	O
with	O
the	O
11p15	O
target	O
more	O
rarely	O
involved	O
.	O

The	O
results	O
define	O
the	O
rhombotin	O
gene	O
family	O
as	O
a	O
class	O
of	O
T-cell	O
oncogenes	O
with	O
duplicated	O
cysteine-rich	O
LIM	O
domains	O
.	O

The	O
human	O
myelomonocytic	O
cell	O
line	O
U-937	O
as	O
a	O
model	O
for	O
studying	O
alterations	O
in	O
steroid-induced	O
monokine	O
gene	O
expression	O
:	O
marked	O
enhancement	O
of	O
lipopolysaccharide-stimulated	O
interleukin-1	O
beta	O
messenger	O
RNA	O
levels	O
by	O
1,25-dihydroxyvitamin	O
D3	O
.	O

The	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
1,25-dihydroxyvitamin	O
D3	O
[	O
1,25	O
-(	O
OH	O
)	O
2D3	O
]	O
,	O
is	O
a	O
potent	O
regulator	O
of	O
human	O
monocyte	O
/	O
macrophage	O
function	O
in	O
vitro	O
.	O

To	O
establish	O
a	O
model	O
for	O
1,25	O
-(	O
OH	O
)	O
2D3	O
regulation	O
of	O
human	O
monocyte	O
monokine	O
synthesis	O
,	O
three	O
human	O
cell	O
lines	O
(	O
U-937	O
,	O
THP-1	O
,	O
and	O
HL-60	O
)	O
were	O
examined	O
for	O
:	O
1	O
)	O
the	O
presence	O
of	O
functional	O
1,25	O
-(	O
OH	O
)	O
2D3	O
receptors	O
;	O
2	O
)	O
the	O
accumulation	O
of	O
interleukin-1	O
beta	O
(	O
IL-1	O
beta	O
)	O
mRNA	O
and	O
IL-1	O
beta	O
protein	O
in	O
response	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
;	O
and	O
3	O
)	O
the	O
regulation	O
of	O
this	O
response	O
by	O
1,25	O
-(	O
OH	O
)	O
2D3	O
.	O

All	O
three	O
cell	O
lines	O
expressed	O
vitamin	O
D	O
receptor	O
and	O
had	O
increased	O
levels	O
of	O
IL-1	O
beta	O
mRNA	O
in	O
response	O
to	O
LPS	O
.	O

Preincubation	O
of	O
cells	O
with	O
1,25	O
-(	O
OH	O
)	O
2D3	O
augmented	O
IL-1	O
beta	O
mRNA	O
levels	O
only	O
in	O
U-937	O
and	O
HL-60	O
cells	O
.	O

From	O
these	O
data	O
,	O
and	O
taking	O
into	O
consideration	O
their	O
state	O
of	O
differentiation	O
and	O
relative	O
ease	O
of	O
culture	O
,	O
U-937	O
was	O
chosen	O
over	O
HL-60	O
and	O
THP-1	O
as	O
the	O
cell	O
line	O
we	O
further	O
characterized	O
.	O

In	O
U-937	O
cells	O
,	O
optimum	O
time	O
and	O
dose	O
of	O
pretreatment	O
with	O
1,25	O
-(	O
OH	O
)	O
2D3	O
were	O
determined	O
to	O
be	O
12-24	O
h	O
at	O
a	O
receptor	O
saturating	O
concentration	O
of	O
1,25	O
-(	O
OH	O
)	O
2D3	O
(	O
10	O
nM	O
)	O
.	O

Preincubation	O
of	O
cells	O
with	O
1,25	O
-(	O
OH	O
)	O
2D3	O
had	O
no	B-NEGATION
effect	I-NEGATION
on	I-NEGATION
the	I-NEGATION
time	I-NEGATION
course	I-NEGATION
of	I-NEGATION
IL-1	I-NEGATION
beta	I-NEGATION
mRNA	I-NEGATION
appearance	I-NEGATION
in	I-NEGATION
response	I-NEGATION
to	I-NEGATION
LPS	I-NEGATION
.	O

However	O
,	O
exposure	O
of	O
U-937	O
cells	O
to	O
1,25	O
-(	O
OH	O
)	O
2D3	O
increased	O
by	O
200	O
%	O
the	O
level	O
of	O
IL-1	O
beta	O
mRNA	O
detected	O
and	O
decreased	O
by	O
three	O
orders	O
of	O
magnitude	O
the	O
concentration	O
of	O
LPS	O
required	O
to	O
achieve	O
steady	O
state	O
mRNA	O
levels	O
equivalent	O
to	O
those	O
observed	O
in	O
U-937	O
cells	O
not	B-NEGATION
preincubated	I-NEGATION
with	I-NEGATION
the	I-NEGATION
hormone.2	I-NEGATION
+	I-NEGATION
o	I-NEGATION
.	O

Cortivazol	O
mediated	O
induction	O
of	O
glucocorticoid	O
receptor	O
messenger	O
ribonucleic	O
acid	O
in	O
wild-type	O
and	O
dexamethasone-resistant	O
human	O
leukemic	O
(	O
CEM	O
)	O
cells	O
.	O

Cortivazol	O
is	O
a	O
phenylpyrazolo	O
glucocorticoid	O
of	O
high	O
potency	O
and	O
unusual	O
structure	O
.	O

In	O
both	O
wild-type	O
and	O
highly	O
dexamethasone	O
(	O
dex	O
)-	O
resistant	O
clones	O
of	O
the	O
human	O
leukemic	O
cell	O
line	O
CEM	O
,	O
exposure	O
to	O
cortivazol	O
leads	O
to	O
cell	O
death	O
.	O

It	O
has	O
been	O
shown	O
recently	O
that	O
in	O
wild-type	O
CEM	O
cells	O
but	O
not	B-NEGATION
in	I-NEGATION
a	I-NEGATION
dex-resistant	I-NEGATION
,	I-NEGATION
glucocorticoid	I-NEGATION
receptor	I-NEGATION
(	I-NEGATION
GR	I-NEGATION
)	I-NEGATION
-	O
defective	O
clone	O
ICR-27	O
TK-3	O
,	O
dex	O
induces	O
GR	O
mRNA	O
.	O

To	O
test	O
the	O
hypothesis	B-SPECULATION
that	I-SPECULATION
cortivazol	I-SPECULATION
acts	I-SPECULATION
in	I-SPECULATION
dex-resistant	I-SPECULATION
cells	I-SPECULATION
by	I-SPECULATION
making	I-SPECULATION
use	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
residual	I-SPECULATION
GR	I-SPECULATION
found	I-SPECULATION
there	I-SPECULATION
,	O
wild-type	O
and	O
dex-resistant	O
clones	O
were	O
treated	O
with	O
various	O
concentrations	O
of	O
cortivazol	O
and	O
induction	O
of	O
GR	O
mRNA	O
was	O
studied	O
.	O

Cortivazol	O
significantly	O
induced	O
GR	O
mRNA	O
in	O
the	O
normal	O
CEM-C7	O
as	O
well	O
as	O
in	O
two	O
classes	O
of	O
dex-resistant	O
clones	O
,	O
although	O
the	O
dex-resistant	O
clones	O
needed	O
at	O
least	O
10	O
times	O
more	O
cortivazol	O
than	O
the	O
normal	O
cells	O
for	O
significant	O
GR	O
mRNA	O
induction	O
.	O

Increased	O
levels	O
of	O
GR	O
mRNA	O
were	O
noticed	O
as	O
early	O
as	O
3	O
h	O
after	O
treatment	O
.	O

A	O
general	O
correlation	O
between	O
induction	O
of	O
GR	O
mRNA	O
and	O
lysis	O
of	O
the	O
normal	O
and	O
dex-resistant	O
cells	O
was	O
found	O
.	O

Positive	O
induction	O
of	O
GR	O
mRNA	O
or	B-SPECULATION
might	B-SPECULATION
be	I-SPECULATION
one	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
earliest	I-SPECULATION
crucial	I-SPECULATION
steps	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
lysis	I-SPECULATION
of	I-SPECULATION
normal	I-SPECULATION
and	I-SPECULATION
dex-resistant	I-SPECULATION
CEM	I-SPECULATION
cells	I-SPECULATION
,	O
might	B-SPECULATION
serve	I-SPECULATION
as	I-SPECULATION
a	I-SPECULATION
marker	I-SPECULATION
for	I-SPECULATION
the	I-SPECULATION
process	I-SPECULATION
.	O

However	O
,	O
the	O
lysis	O
pathway	O
in	O
the	O
dex-resistant	O
cells	O
is	O
defective	O
in	O
that	O
dex-resistant	O
clones	O
needed	O
significantly	O
more	O
cortivazol	O
than	O
the	O
normal	O
cells	O
for	O
lysis	O
of	O
the	O
cells	O
.	O

Expression	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
on	O
alveolar	O
lymphocytes	O
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
.	O

1,25	O
(	O
OH	O
)	O
2D3	O
is	O
known	O
to	O
be	O
produced	O
at	O
sites	O
of	O
granulomatous	O
reactions	O
.	O

In	O
order	O
to	O
characterize	O
the	O
cell	O
types	O
that	O
are	O
targets	O
for	O
this	O
immunoregulatory	O
hormone	O
,	O
we	O
have	O
evaluated	O
the	O
expression	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
on	O
peripheral	O
blood	O
T-lymphocytes	O
and	O
those	O
recovered	O
from	O
the	O
lung	O
by	O
bronchoalveolar	O
lavage	O
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
(	O
tuberculosis	O
and	O
sarcoidosis	O
)	O
and	O
from	O
normal	O
control	O
subjects	O
using	O
combined	O
autoradiographic	O
and	O
immunohistochemical	O
techniques	O
.	O

Lavage	O
T-lymphocytes	O
from	O
patients	O
with	O
tuberculosis	O
or	O
with	O
sarcoidosis	O
,	O
but	O
not	B-NEGATION
those	I-NEGATION
from	I-NEGATION
normal	I-NEGATION
control	I-NEGATION
subjects	I-NEGATION
,	O
expressed	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
as	O
demonstrated	O
by	O
binding	O
of	O
[	O
3H	O
]	O
1,25	O
(	O
OH	O
)	O
2D3	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
presence	O
of	O
excess	O
unlabeled	O
1,25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
not	B-NEGATION
by	I-NEGATION
the	I-NEGATION
presence	I-NEGATION
of	I-NEGATION
unlabeled	I-NEGATION
25	I-NEGATION
(	I-NEGATION
OH	I-NEGATION
)	I-NEGATION
D3	I-NEGATION
(	I-NEGATION
receptor-positive	I-NEGATION
lymphocytes	I-NEGATION
:	O
sarcoidosis	O
,	O
20	O
	O
12	O
%	O
;	O
tuberculosis	O
,	O
31	O
	O
17	O
%)	O
.	O

In	O
contrast	O
,	O
blood	O
lymphocytes	O
from	O
patients	O
with	O
granulomatous	O
diseases	O
did	O
not	B-NEGATION
express	I-NEGATION
detectable	I-NEGATION
1,25	I-NEGATION
(	I-NEGATION
OH	I-NEGATION
)	I-NEGATION
2D3	I-NEGATION
receptors	I-NEGATION
.	O

The	O
percentage	O
of	O
lavage	O
T-lymphocytes	O
expressing	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
was	O
significantly	O
greater	O
for	O
patients	O
with	O
tuberculosis	O
presenting	O
with	O
isolated	O
hilar	O
adenopathy	O
than	O
for	O
patients	O
with	O
pulmonary	O
infiltrates	O
and	O
/	O
or	O
cavities	O
.	O

1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
were	O
expressed	O
to	O
a	O
greater	O
extent	O
on	O
CD8	O
+	O
T-lymphocytes	O
than	O
on	O
CD4	O
+	O
T-lymphocytes	O
in	O
sarcoidosis	O
,	O
whereas	O
a	O
greater	O
proportion	O
of	O
CD4	O
+	O
than	O
of	O
CD8	O
+	O
T-lymphocytes	O
from	O
patients	O
with	O
tuberculosis	O
were	O
receptor-positive	O
.	O

These	O
findings	O
support	O
the	O
conclusion	O
that	O
the	O
interaction	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
with	O
its	O
receptor	O
on	O
T-lymphocytes	O
may	B-SPECULATION
play	I-SPECULATION
an	I-SPECULATION
important	I-SPECULATION
role	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
regulation	I-SPECULATION
of	I-SPECULATION
granulomatous	I-SPECULATION
reactions	I-SPECULATION
,	O
but	O
because	O
these	O
receptors	O
are	O
expressed	O
on	O
different	O
lymphocyte	O
populations	O
,	O
the	O
net	O
effect	O
of	O
this	O
potent	O
immunoregulatory	O
molecule	O
is	O
likely	B-SPECULATION
different	I-SPECULATION
in	I-SPECULATION
sarcoidosis	I-SPECULATION
and	I-SPECULATION
tuberculosis	I-SPECULATION
.	O

Inhibition	O
of	O
transcription	O
factors	O
belonging	O
to	O
the	O
rel	O
/	O
NF-kappa	O
B	O
family	O
by	O
a	O
transdominant	O
negative	O
mutant	O
.	O

The	O
KBF1	O
factor	O
,	O
which	O
binds	O
to	O
the	O
enhancer	O
A	O
located	O
in	O
the	O
promoter	O
of	O
the	O
mouse	O
MHC	O
class	O
I	O
gene	O
H-2Kb	O
,	O
is	O
indistinguishable	O
from	O
the	O
p50	O
DNA	O
binding	O
subunit	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
,	O
which	O
regulates	O
a	O
series	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

The	O
KBF1	O
/	O
p50	O
factor	O
binds	O
as	O
a	O
homodimer	O
but	O
can	O
also	O
form	O
heterodimers	O
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c-rel	O
and	O
v-rel	O
(	O
proto	O
)	O
oncogenes	O
.	O

The	O
dimerization	O
domain	O
of	O
KBF1	O
/	O
p50	O
is	O
contained	O
between	O
amino	O
acids	O
201	O
and	O
367	O
.	O

A	O
mutant	O
of	O
KBF1	O
/	O
p50	O
(	O
delta	O
SP	O
)	O
,	O
unable	B-NEGATION
to	I-NEGATION
bind	I-NEGATION
to	I-NEGATION
DNA	I-NEGATION
but	O
able	O
to	O
form	O
homo	O
-	O
or	O
heterodimers	O
,	O
has	O
been	O
constructed	O
.	O

This	O
protein	O
reduces	O
or	O
abolishes	O
in	O
vitro	O
the	O
DNA	O
binding	O
activity	O
of	O
wild-type	O
proteins	O
of	O
the	O
same	O
family	O
(	O
KBF1	O
/	O
p50	O
,	O
c	O
-	O
and	O
v-rel	O
)	O
.	O

This	O
mutant	O
also	O
functions	O
in	O
vivo	O
as	O
a	O
trans-acting	O
dominant	O
negative	O
regulator	O
:	O

the	O
transcriptional	O
inducibility	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
which	O
contains	O
two	O
potential	O
NF-kappa	O
B	O
binding	O
sites	O
)	O
by	O
phorbol	O
ester	O
(	O
PMA	O
)	O
is	O
inhibited	O
when	O
it	O
is	O
co-transfected	O
into	O
CD4	O
+	O
T	O
cells	O
with	O
the	O
delta	O
SP	O
mutant	O
.	O

Similarly	O
the	O
basal	O
as	O
well	O
as	O
TNF	O
or	O
IL1-induced	O
activity	O
of	O
the	O
MHC	O
class	O
I	O
H-2Kb	O
promoter	O
can	O
be	O
inhibited	O
by	O
this	O
mutant	O
in	O
two	O
different	O
cell	O
lines	O
.	O

These	O
results	O
constitute	O
the	O
first	O
formal	O
demonstration	O
that	O
these	O
genes	O
are	O
regulated	O
by	O
members	O
of	O
the	O
rel	O
/	O
NF-kappa	O
B	O
family	O
.	O

Human	O
erythroid	O
5-aminolevulinate	O
synthase	O
:	O
promoter	O
analysis	O
and	O
identification	O
of	O
an	O
iron-responsive	O
element	O
in	O
the	O
mRNA	O
.	O

5-Aminolevulinate	O
synthase	O
(	O
ALAS	O
)	O
catalyzes	O
the	O
first	O
step	O
of	O
the	O
heme	O
biosynthetic	O
pathway	O
.	O

cDNA	O
clones	O
for	O
the	O
human	O
erythroid	O
ALAS	O
isozyme	O
were	O
isolated	O
from	O
a	O
fetal	O
liver	O
library	O
.	O

It	B-SPECULATION
can	I-SPECULATION
be	I-SPECULATION
deduced	I-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
erythroid	I-SPECULATION
ALAS	I-SPECULATION
precursor	I-SPECULATION
protein	I-SPECULATION
has	I-SPECULATION
a	I-SPECULATION
molecular	I-SPECULATION
weight	I-SPECULATION
of	I-SPECULATION
64.6	I-SPECULATION
kd	I-SPECULATION
,	I-SPECULATION
and	I-SPECULATION
is	I-SPECULATION
similar	I-SPECULATION
in	I-SPECULATION
size	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
previously	I-SPECULATION
isolated	I-SPECULATION
human	I-SPECULATION
housekeeping	I-SPECULATION
ALAS	I-SPECULATION
precursor	I-SPECULATION
of	I-SPECULATION
molecular	I-SPECULATION
weight	I-SPECULATION
70.6	I-SPECULATION
kd	I-SPECULATION
.	O

The	B-SPECULATION
mature	I-SPECULATION
mitochondrial	I-SPECULATION
forms	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
erythroid	I-SPECULATION
and	I-SPECULATION
housekeeping	I-SPECULATION
ALAS	I-SPECULATION
isozymes	I-SPECULATION
are	I-SPECULATION
predicted	I-SPECULATION
to	I-SPECULATION
have	I-SPECULATION
molecular	I-SPECULATION
weights	I-SPECULATION
of	I-SPECULATION
59.5	I-SPECULATION
kd	I-SPECULATION
and	I-SPECULATION
64.6	I-SPECULATION
kd	I-SPECULATION
,	I-SPECULATION
respectively	I-SPECULATION
.	O

The	O
two	O
isozymes	O
show	O
little	O
amino	O
acid	O
identity	O
in	O
their	O
N-terminal	O
signal	O
sequences	O
but	O
have	O
considerable	O
sequence	O
identity	O
in	O
the	O
C-terminal	O
two-thirds	O
of	O
their	O
proteins	O
.	O

An	O
analysis	O
of	O
the	O
immediate	O
promoter	O
of	O
the	O
human	O
erythroid	O
ALAS	O
gene	O
revealed	O
several	O
putative	B-SPECULATION
erythroid-specific	I-SPECULATION
cis-acting	I-SPECULATION
elements	I-SPECULATION
including	O
both	O
a	O
GATA-1	O
and	O
an	O
NF-E2	O
binding	O
site	O
.	O

An	O
iron-responsive	O
element	O
(	O
IRE	O
)	O
motif	O
has	O
been	O
identified	O
in	O
the	O
5	O
'-	O
untranslated	O
region	O
of	O
the	O
human	O
erythroid	O
ALAS	O
mRNA	O
,	O
but	O
is	O
not	B-NEGATION
present	I-NEGATION
in	I-NEGATION
the	I-NEGATION
housekeeping	I-NEGATION
ALAS	I-NEGATION
mRNA	I-NEGATION
.	O

Gel	O
retardation	O
experiments	O
established	O
that	O
this	O
IRE	O
motif	O
formed	O
a	O
protein-RNA	O
complex	O
with	O
cytosolic	O
extracts	O
from	O
human	O
K562	O
cells	O
and	O
this	O
binding	O
was	O
strongly	O
competed	O
with	O
IRE	O
transcripts	O
from	O
ferritin	O
or	O
transferrin	O
receptor	O
mRNAs	O
.	O

A	O
transcript	O
of	O
the	O
ALAS	O
IRE	O
,	O
mutated	O
in	O
the	O
conserved	O
loop	O
of	O
the	O
IRE	O
,	O
did	O
not	B-NEGATION
readily	I-NEGATION
form	I-NEGATION
this	I-NEGATION
protein-RNA	I-NEGATION
complex	I-NEGATION
.	O

These	O
results	O
suggest	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
IRE	I-SPECULATION
motif	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
ALAS	I-SPECULATION
mRNA	I-SPECULATION
is	I-SPECULATION
functional	I-SPECULATION
and	O
imply	B-SPECULATION
that	I-SPECULATION
translation	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
mRNA	I-SPECULATION
is	I-SPECULATION
controlled	I-SPECULATION
by	I-SPECULATION
cellular	I-SPECULATION
iron	I-SPECULATION
availability	I-SPECULATION
during	I-SPECULATION
erythropoiesis	I-SPECULATION
.	O

Human	O
tumor	O
necrosis	O
factor	O
alpha	O
gene	O
regulation	O
in	O
phorbol	O
ester	O
stimulated	O
T	O
and	O
B	O
cell	O
lines	O
.	O

The	O
minimal	O
region	O
of	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
gene	O
promoter	O
necessary	O
for	O
its	O
transcriptional	O
induction	O
by	O
phorbol	O
esters	O
(	O
PMA	O
)	O
in	O
human	O
T	O
and	O
B	O
lymphocyte	O
cell	O
lines	O
has	O
been	O
localized	O
between	O
-	O
52	O
and	O
+	O
89	O
nucleotides	O
(	O
nt	O
)	O
relative	O
to	O
the	O
gene	O
'	O
s	O
transcriptional	O
start	O
site	O
.	O

Comparison	O
of	O
these	O
sequences	O
to	O
those	O
required	O
to	O
mediate	O
virus	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
the	O
gene	O
reveal	O
significant	O
differences	O
,	O
and	O
thus	O
,	O
the	O
sequence	O
requirements	O
for	O
PMA	O
induction	O
are	O
distinct	O
from	O
those	O
that	O
mediate	O
induction	O
by	O
virus	O
or	O
LPS	O
.	O

Although	O
three	O
sites	O
in	O
the	O
TNF-alpha	O
promoter	O
(	O
kappa	O
1	O
,	O
kappa	O
2	O
,	O
and	O
kappa	O
3	O
)	O
specifically	O
bind	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
in	O
lymphoid	O
nuclear	O
extracts	O
,	O
TNF-alpha	O
mRNA	O
induction	O
by	O
PMA	O
does	O
not	B-NEGATION
correlate	I-NEGATION
with	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
binding	I-NEGATION
activities	I-NEGATION
displayed	I-NEGATION
by	I-NEGATION
different	I-NEGATION
T	I-NEGATION
and	I-NEGATION
B	I-NEGATION
cell	I-NEGATION
lines	I-NEGATION
.	O

Moreover	O
,	O
kappa	O
1-kappa	O
3	O
can	O
each	O
be	O
deleted	O
from	O
the	O
TNF-alpha	O
promoter	O
with	O
little	O
effect	O
on	O
the	O
gene	O
'	O
s	O
inducibility	O
by	O
PMA	O
.	O

Therefore	O
,	O
TNF-alpha	O
mRNA	O
induction	O
by	O
PMA	O
,	O
like	O
its	O
induction	O
by	O
virus	O
and	O
LPS	O
,	O
is	B-NEGATION
not	I-NEGATION
primarily	I-NEGATION
mediated	I-NEGATION
by	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
,	O
but	O
rather	O
is	O
mediated	O
through	O
other	O
sequences	O
and	O
protein	O
factors	O
.	O

Surprisingly	O
,	O
multimers	O
of	O
kappa	O
1-kappa	O
3	O
can	O
confer	O
PMA	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
in	O
a	O
B	O
(	O
Raji	O
)	O
,	O
but	O
not	B-NEGATION
a	I-NEGATION
T	I-NEGATION
(	I-NEGATION
HUT78	I-NEGATION
)	I-NEGATION
cell	I-NEGATION
line	I-NEGATION
.	O

However	O
they	O
are	O
not	B-NEGATION
functional	I-NEGATION
on	I-NEGATION
a	I-NEGATION
truncated	I-NEGATION
TNF-alpha	I-NEGATION
promoter	I-NEGATION
,	O
indicating	B-SPECULATION
that	I-SPECULATION
promoter	I-SPECULATION
context	I-SPECULATION
and	I-SPECULATION
cell	I-SPECULATION
type	I-SPECULATION
specificity	I-SPECULATION
influence	I-SPECULATION
the	I-SPECULATION
PMA	I-SPECULATION
inducible	I-SPECULATION
function	I-SPECULATION
of	I-SPECULATION
these	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
binding	I-SPECULATION
sites	I-SPECULATION
.	O

Towards	O
a	O
molecular	O
understanding	O
of	O
T-cell	O
differentiation	O
.	O

Lymphoid	O
differentiation	O
is	O
one	O
of	O
the	O
best	O
studied	O
examples	O
of	O
mammalian	O
development	O
.	O

Here	O
Hans	O
Clevers	O
and	O
Michael	O
Owen	O
describe	O
how	O
the	O
cloning	O
of	O
the	O
genes	O
that	O
encode	O
T-cell-specific	O
membrane	O
proteins	O
allows	O
the	O
identification	O
of	O
transcription	O
factors	O
that	O
control	O
the	O
expression	O
of	O
these	O
T-cell	O
genes	O
.	O

Such	O
transcription	O
factors	O
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
the	O
mature	O
T-cell	O
phenotype	O
by	O
functioning	O
as	O
'	O
master	O
regulators	O
of	O
T-cell	O
differentiation	O
'	O
.	O

Regulation	O
of	O
jun	O
and	O
fos	O
gene	O
expression	O
in	O
human	O
monocytes	O
by	O
the	O
macrophage	O
colony-stimulating	O
factor	O
.	O

The	O
macrophage	O
colony-stimulating	O
factor	O
(	O
M-CSF	O
)	O
is	O
required	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
mononuclear	O
phagocytes	O
.	O

However	O
,	O
the	O
signaling	O
events	O
responsible	O
for	O
these	O
effects	O
remain	O
unclear	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
M-CSF	O
on	O
potential	O
signaling	O
pathways	O
involving	O
expression	O
of	O
the	O
jun	O
and	O
fos	O
early	O
response	O
genes	O
.	O

Low	O
levels	O
of	O
c-jun	O
transcripts	O
were	O
detectable	O
in	O
resting	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

Treatment	O
of	O
these	O
cells	O
with	O
10	O
(	O
3	O
)	O
units	O
/	O
ml	O
human	O
recombinant	O
M-CSF	O
was	O
associated	O
with	O
rapid	O
and	O
transient	O
increases	O
in	O
c-jun	O
mRNA	O
levels	O
.	O

Nuclear	O
run-on	O
assays	O
and	O
mRNA	O
stability	O
studies	O
demonstrated	O
that	O
M-CSF	O
regulates	O
c-jun	O
expression	O
by	O
both	O
an	O
increase	O
in	O
transcription	O
rate	O
and	O
a	O
prolongation	O
in	O
the	O
half-life	O
of	O
c-jun	O
transcripts	O
.	O

M-CSF	O
treatment	O
was	O
also	O
associated	O
with	O
a	O
rapid	O
induction	O
of	O
the	O
jun-B	O
gene	O
,	O
although	O
expression	O
of	O
this	O
gene	O
was	O
prolonged	O
compared	O
to	O
that	O
of	O
c-jun	O
.	O

We	O
further	O
demonstrate	O
that	O
M-CSF	O
increases	O
c-fos	O
mRNA	O
levels	O
in	O
human	O
monocytes	O
through	O
control	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Maximal	O
induction	O
of	O
the	O
c-fos	O
gene	O
was	O
followed	O
by	O
that	O
for	O
the	O
fos-B	O
gene	O
.	O

Moreover	O
,	O
M-CSF-induced	O
expression	O
of	O
the	O
fos-related	O
gene	O
,	O
fra-1	O
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c-fos	O
and	O
fos-B	O
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	B-SPECULATION
that	I-SPECULATION
M-CSF	I-SPECULATION
treatment	I-SPECULATION
is	I-SPECULATION
associated	I-SPECULATION
with	I-SPECULATION
differential	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
multiple	I-SPECULATION
members	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
jun	I-SPECULATION
/	I-SPECULATION
fos	I-SPECULATION
family	I-SPECULATION
and	I-SPECULATION
that	I-SPECULATION
expression	I-SPECULATION
of	I-SPECULATION
these	I-SPECULATION
genes	I-SPECULATION
could	B-SPECULATION
contribute	I-SPECULATION
to	I-SPECULATION
nuclear	I-SPECULATION
signaling	I-SPECULATION
mechanisms	I-SPECULATION
that	I-SPECULATION
regulate	I-SPECULATION
a	I-SPECULATION
specific	I-SPECULATION
program	I-SPECULATION
of	I-SPECULATION
monocyte	I-SPECULATION
differentiation	I-SPECULATION
.	O

Cloning	O
of	O
a	O
human	O
homeobox	O
gene	O
that	O
resembles	O
a	O
diverged	O
Drosophila	O
homeobox	O
gene	O
and	O
is	O
expressed	O
in	O
activated	O
lymphocytes	O
.	O

A	O
new	O
homeobox	O
gene	O
,	O
HB24	O
,	O
has	O
been	O
isolated	O
from	O
a	O
human	O
B-lymphocyte	O
cDNA	O
library	O
.	O

Northern	O
blot	O
analysis	O
of	O
polyadenylated	O
RNA	O
purified	O
from	O
activated	O
human	O
B	O
cells	O
revealed	O
a	O
single	O
mRNA	O
transcript	O
of	O
approximately	O
2.3	O
kb	O
.	O

Two	O
cDNA	O
clones	O
were	O
sequenced	O
and	O
provided	O
2,250	O
nucleotides	O
(	O
nt	O
)	O
of	O
DNA	O
sequence	O
information	O
.	O

There	O
is	O
a	O
single	O
methionine	O
codon-initiated	O
open	O
reading	O
frame	O
of	O
1,458	O
nt	O
in	O
frame	O
with	O
a	O
homeobox	O
and	O
a	O
CAX	O
repeat	O
,	O
and	O
the	B-SPECULATION
open	I-SPECULATION
reading	I-SPECULATION
frame	I-SPECULATION
is	I-SPECULATION
predicted	I-SPECULATION
to	I-SPECULATION
encode	I-SPECULATION
a	I-SPECULATION
protein	I-SPECULATION
of	I-SPECULATION
51,659	I-SPECULATION
daltons	I-SPECULATION
.	O

When	O
the	O
homeodomain	O
from	O
HB24	O
was	O
compared	O
to	O
known	O
mammalian	O
and	O
Drosophila	O
homeodomains	O
it	O
was	O
found	O
to	O
be	O
only	O
moderately	O
conserved	O
,	O
but	O
when	O
it	O
was	O
compared	O
to	O
a	O
highly	O
diverged	O
Drosophila	O
homeodomain	O
,	O
H2.0	O
,	O
it	O
was	O
found	O
to	O
be	O
80	O
%	O
identical	O
.	O

The	O
HB24	O
mRNA	O
was	O
absent	B-SPECULATION
or	I-SPECULATION
present	I-SPECULATION
at	O
low	O
levels	O
in	O
normal	O
B	O
and	O
T	O
lymphocytes	O
;	O
.	O

however	O
,	O
with	O
the	O
appropriate	O
activation	O
signal	O
HB24	O
mRNA	O
was	O
induced	O
within	O
several	O
hours	O
even	O
in	O
the	O
presence	O
of	O
cycloheximide	O
.	O

Characterization	O
of	O
HB24	O
expression	O
in	O
lymphoid	O
and	O
select	O
developing	O
tissues	O
was	O
performed	O
by	O
in	O
situ	O
hybridization	O
.	O

Positive	O
hybridization	O
was	O
found	O
in	O
thymus	O
,	O
tonsil	O
,	O
bone	O
marrow	O
,	O
developing	O
vessels	O
,	O
and	O
in	O
fetal	O
brain	O
.	O

HB24	B-SPECULATION
is	I-SPECULATION
likely	I-SPECULATION
to	I-SPECULATION
have	I-SPECULATION
an	I-SPECULATION
important	I-SPECULATION
role	I-SPECULATION
in	I-SPECULATION
lymphocytes	I-SPECULATION
as	I-SPECULATION
well	I-SPECULATION
as	I-SPECULATION
in	I-SPECULATION
certain	I-SPECULATION
developing	I-SPECULATION
tissues	I-SPECULATION
.	O

Severe	O
5-fluorouracil	O
toxicity	O
secondary	O
to	O
dihydropyrimidine	O
dehydrogenase	O
deficiency	O
.	O

A	O
potentially	B-SPECULATION
more	I-SPECULATION
common	I-SPECULATION
pharmacogenetic	I-SPECULATION
syndrome	I-SPECULATION
.	O

This	O
study	O
describes	O
the	O
inheritance	O
of	O
a	O
defect	O
in	O
pyrimidine	O
catabolism	O
and	O
its	O
association	O
with	O
drug-induced	O
toxicity	O
in	O
a	O
patient	O
receiving	O
5-fluorouracil	O
(	O
FUra	O
)	O
as	O
adjuvant	O
chemotherapy	O
for	O
breast	O
carcinoma	O
.	O

The	O
study	O
population	O
included	O
the	O
affected	O
patient	O
(	O
proband	O
)	O
,	O
nine	O
of	O
her	O
blood	O
relatives	O
,	O
and	O
seven	O
healthy	O
volunteers	O
.	O

The	O
activity	O
of	O
dihydropyrimidine	O
dehydrogenase	O
(	O
DPD	O
)	O
,	O
the	O
initial	O
enzyme	O
of	O
pyrimidine	O
(	O
and	O
FUra	O
)	O
catabolism	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
was	O
measured	O
in	O
each	O
subject	O
by	O
a	O
specific	O
radiometric	O
assay	O
using	O
FUra	O
as	O
the	O
substrate	O
.	O

The	O
proband	O
had	O
no	B-NEGATION
detectable	I-NEGATION
DPD	I-NEGATION
activity	I-NEGATION
.	O

When	O
enzyme	O
levels	O
in	O
the	O
proband	O
and	O
relatives	O
were	O
compared	O
with	O
that	O
in	O
controls	O
,	O
an	O
autosomal	O
recessive	O
pattern	O
of	O
inheritance	O
was	O
demonstrated	O
.	O

This	O
is	O
the	O
third	O
patient	O
with	O
severe	O
FUra	O
toxicity	O
secondary	O
to	O
an	O
alteration	O
in	O
pyrimidine	O
catabolism	O
and	O
the	O
second	O
from	O
our	O
clinic	O
population	O
suggesting	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
frequency	I-SPECULATION
of	I-SPECULATION
this	I-SPECULATION
genetic	I-SPECULATION
defect	I-SPECULATION
may	B-SPECULATION
be	I-SPECULATION
greater	I-SPECULATION
than	I-SPECULATION
previously	I-SPECULATION
thought	I-SPECULATION
.	O

Monitoring	O
DPD	O
activity	O
may	B-SPECULATION
be	I-SPECULATION
important	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
management	I-SPECULATION
of	I-SPECULATION
patients	I-SPECULATION
experiencing	I-SPECULATION
severe	I-SPECULATION
toxicity	I-SPECULATION
secondary	I-SPECULATION
to	I-SPECULATION
FUra	I-SPECULATION
chemotherapy	I-SPECULATION
.	O

Characterization	O
of	O
an	O
immediate-early	O
gene	O
induced	O
in	O
adherent	O
monocytes	O
that	O
encodes	O
I	O
kappa	O
B-like	O
activity	O
.	O

We	O
have	O
cloned	O
a	O
group	O
of	O
cDNAs	O
representing	O
mRNAs	O
that	O
are	O
rapidly	O
induced	O
following	O
adherence	O
of	O
human	O
monocytes	O
.	O

One	O
of	O
the	O
induced	O
transcripts	O
(	O
MAD-3	O
)	O
encodes	O
a	O
protein	O
of	O
317	O
amino	O
acids	O
with	O
one	O
domain	O
containing	O
five	O
tandem	O
repeats	O
of	O
the	O
cdc10	O
/	O
ankyrin	O
motif	O
,	O
which	O
is	O
60	O
%	O
similar	O
(	O
46	O
%	O
identical	O
)	O
to	O
the	O
ankyrin	O
repeat	O
region	O
of	O
the	O
precursor	O
of	O
NF-kappa	O
B	O
/	O
KBF1	O
p50	O
.	O

The	O
C-terminus	O
has	O
a	O
putative	B-SPECULATION
protein	I-SPECULATION
kinase	I-SPECULATION
C	I-SPECULATION
phosphorylation	I-SPECULATION
site	I-SPECULATION
.	O

In	O
vitro	O
translated	O
MAD-3	O
protein	O
was	O
found	O
to	O
specifically	O
inhibit	O
the	O
DNA-binding	O
activity	O
of	O
the	O
p50	O
/	O
p65	O
NF-kappa	O
B	O
complex	O
but	O
not	B-NEGATION
that	I-NEGATION
of	I-NEGATION
the	I-NEGATION
p50	I-NEGATION
/	I-NEGATION
p50	I-NEGATION
KBF1	I-NEGATION
factor	I-NEGATION
or	I-NEGATION
of	I-NEGATION
other	I-NEGATION
DNA-binding	I-NEGATION
proteins	I-NEGATION
.	O

The	O
MAD-3	O
cDNA	O
encodes	O
an	O
I	O
kappa	O
B-like	O
protein	O
that	B-SPECULATION
is	I-SPECULATION
likely	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
regulation	I-SPECULATION
of	I-SPECULATION
transcriptional	I-SPECULATION
responses	I-SPECULATION
to	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
,	I-SPECULATION
including	I-SPECULATION
adhesion-dependent	I-SPECULATION
pathways	I-SPECULATION
of	I-SPECULATION
monocyte	I-SPECULATION
activation	I-SPECULATION
.	O

Reactive	O
oxygen	O
intermediates	O
as	O
apparently	O
widely	O
used	O
messengers	O
in	O
the	O
activation	O
of	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
and	O
HIV-1	O
.	O

Hydrogen	O
peroxide	O
and	O
oxygen	O
radicals	O
are	O
agents	O
commonly	O
produced	O
during	O
inflammatory	O
processes	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
micromolar	O
concentrations	O
of	O
H2O2	O
can	O
induce	O
the	O
expression	O
and	O
replication	O
of	O
HIV-1	O
in	O
a	O
human	O
T	O
cell	O
line	O
.	O

The	O
effect	O
is	O
mediated	O
by	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
which	O
is	O
potently	O
and	O
rapidly	O
activated	O
by	O
an	O
H2O2	O
treatment	O
of	O
cells	O
from	O
its	O
inactive	O
cytoplasmic	O
form	O
.	O

N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
well	O
characterized	O
antioxidant	O
which	O
counteracts	O
the	O
effects	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
in	O
living	O
cells	O
,	O
prevented	O
the	O
activation	O
of	O
NF-kappa	O
B	O
by	O
H2O2	O
.	O

NAC	O
and	O
other	O
thiol	O
compounds	O
also	O
blocked	O
the	O
activation	O
of	O
NF-kappa	O
B	O
by	O
cycloheximide	O
,	O
double-stranded	O
RNA	O
,	O
calcium	O
ionophore	O
,	O
TNF-alpha	O
,	O
active	O
phorbol	O
ester	O
,	O
interleukin-1	O
,	O
lipopolysaccharide	O
and	O
lectin	O
.	O

This	O
suggests	B-SPECULATION
that	I-SPECULATION
diverse	I-SPECULATION
agents	I-SPECULATION
thought	B-SPECULATION
to	I-SPECULATION
activate	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
by	I-SPECULATION
distinct	I-SPECULATION
intracellular	I-SPECULATION
pathways	I-SPECULATION
might	B-SPECULATION
all	I-SPECULATION
act	I-SPECULATION
through	I-SPECULATION
a	I-SPECULATION
common	I-SPECULATION
mechanism	I-SPECULATION
involving	I-SPECULATION
the	I-SPECULATION
synthesis	I-SPECULATION
of	I-SPECULATION
ROI	I-SPECULATION
.	O

ROI	B-SPECULATION
appear	I-SPECULATION
to	I-SPECULATION
serve	I-SPECULATION
as	I-SPECULATION
messengers	I-SPECULATION
mediating	I-SPECULATION
directly	B-SPECULATION
or	I-SPECULATION
indirectly	I-SPECULATION
the	O
release	O
of	O
the	O
inhibitory	O
subunit	O
I	O
kappa	O
B	O
from	O
NF-kappa	O
B	O
.	O

HTLV-1	O
Tax	O
induces	O
expression	O
of	O
various	O
immediate	O
early	O
serum	O
responsive	O
genes	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

We	O
showed	O
here	O
by	O
mobility-shift	O
assay	O
that	O
T-cell	O
lines	O
transformed	O
with	O
the	O
virus	O
contained	O
high	O
levels	O
of	O
AP-1	O
activities	O
.	O

Consistent	O
with	O
this	O
result	O
,	O
these	O
cell	O
lines	O
expressed	O
increased	O
levels	O
of	O
mRNAs	O
encoding	O
the	O
AP-1	O
proteins	O
,	O
c-Fos	O
,	O
Fra-1	O
,	O
c-Jun	O
,	O
JunB	O
,	O
and	O
JunD	O
.	O

Previously	O
,	O
transcription	O
of	O
the	O
c-fos	O
gene	O
has	O
been	O
reported	O
to	O
be	O
transactivated	O
by	O
the	O
viral	O
transcription	O
factor	O
,	O
Tax1	O
.	O

By	O
using	O
the	O
human	O
T-cell	O
line	O
(	O
JPX-9	O
)	O
,	O
in	O
which	O
expression	O
of	O
the	O
Tax1	O
is	O
inducible	O
,	O
we	O
showed	O
that	O
expression	O
of	O
mRNAs	O
for	O
Fra-1	O
,	O
c-Jun	O
,	O
and	O
JunD	O
was	O
also	O
transactivated	O
by	O
Tax1	O
.	O

Moreover	O
,	O
Tax1	O
activated	O
expression	O
of	O
two	O
other	O
transcription	O
factors	O
having	O
zinc	O
finger	O
motifs	O
,	O
Egr-1	O
and	O
Egr-2	O
,	O
in	O
the	O
same	O
cells	O
.	O

The	O
Tax1-inducible	O
transcription	O
factors	O
identified	O
here	O
are	O
encoded	O
by	O
the	O
members	O
of	O
immediate	O
early	O
genes	O
under	O
the	O
control	O
of	O
growth	O
signals	O
.	O

Thus	O
,	O
Tax1	B-SPECULATION
was	I-SPECULATION
suggested	I-SPECULATION
to	I-SPECULATION
replace	I-SPECULATION
growth	I-SPECULATION
signals	I-SPECULATION
,	I-SPECULATION
at	I-SPECULATION
least	I-SPECULATION
in	I-SPECULATION
part	I-SPECULATION
,	I-SPECULATION
by	I-SPECULATION
this	I-SPECULATION
mechanism	I-SPECULATION
.	O

Contribution	O
of	O
NF-kappa	O
B	O
and	O
Sp1	O
binding	O
motifs	O
to	O
the	O
replicative	O
capacity	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
:	O
distinct	O
patterns	O
of	O
viral	O
growth	O
are	O
determined	O
by	O
T-cell	O
types	O
.	O

Starting	O
with	O
a	O
replication-incompetent	O
molecular	O
clone	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
lacking	B-NEGATION
all	I-NEGATION
the	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
and	I-NEGATION
Sp1	I-NEGATION
binding	I-NEGATION
sites	I-NEGATION
present	I-NEGATION
in	I-NEGATION
the	I-NEGATION
native	I-NEGATION
long	I-NEGATION
terminal	I-NEGATION
repeat	I-NEGATION
(	I-NEGATION
LTR	I-NEGATION
)	I-NEGATION
,	O
proviruses	O
containing	O
reconstructed	O
LTRs	O
with	O
individual	O
or	O
combinations	O
of	O
NF-kappa	O
B	O
and	O
Sp1	O
elements	O
were	O
generated	O
and	O
evaluated	B-SPECULATION
for	I-SPECULATION
their	I-SPECULATION
capacity	I-SPECULATION
to	I-SPECULATION
produce	I-SPECULATION
virus	I-SPECULATION
progeny	I-SPECULATION
following	I-SPECULATION
transfection-cocultivation	I-SPECULATION
.	O

Virus	O
stocks	O
obtained	O
from	O
these	O
experiments	O
exhibited	O
a	O
continuum	O
of	O
replicative	O
capacities	O
in	O
different	O
human	O
T-cell	O
types	O
depending	O
on	O
which	O
element	O
(	O
s	O
)	O
was	O
present	O
in	O
the	O
LTR	O
.	O

For	O
example	O
,	O
in	O
experiments	O
involving	O
proviral	O
clones	O
with	O
LTRs	O
containing	O
one	O
or	O
two	O
NF-kappa	O
B	O
elements	O
(	O
and	O
no	B-NEGATION
Sp1	I-NEGATION
binding	I-NEGATION
sites	I-NEGATION
)	O
,	O
a	O
hierarchy	O
of	O
cellular	O
permissivity	O
to	O
virus	O
replication	O
(	O
peripheral	O
blood	O
lymphocytes	O
=	O
MT4	O
greater	O
than	O
H9	O
greater	O
than	O
CEM	O
greater	O
than	O
Jurkat	O
)	O
was	O
observed	O
.	O

Of	O
note	O
was	O
the	O
associated	O
emergence	O
of	O
second-site	O
LTR	O
revertants	O
which	O
involved	O
an	O
alteration	O
of	O
the	O
TATA	O
box	O
.	O

These	O
results	O
suggest	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
human	I-SPECULATION
immunodeficiency	I-SPECULATION
virus	I-SPECULATION
type	I-SPECULATION
1	I-SPECULATION
LTR	I-SPECULATION
possesses	I-SPECULATION
functional	I-SPECULATION
redundancy	I-SPECULATION
which	I-SPECULATION
ensures	I-SPECULATION
virus	I-SPECULATION
replication	I-SPECULATION
in	I-SPECULATION
different	I-SPECULATION
T-cell	I-SPECULATION
types	I-SPECULATION
and	I-SPECULATION
is	I-SPECULATION
capable	I-SPECULATION
of	I-SPECULATION
changing	I-SPECULATION
depending	I-SPECULATION
on	I-SPECULATION
the	I-SPECULATION
particular	I-SPECULATION
combination	I-SPECULATION
of	I-SPECULATION
transcriptional	I-SPECULATION
factors	I-SPECULATION
present	I-SPECULATION
.	O

Enhancement	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
replication	O
in	O
monocytes	O
by	O
1,25-dihydroxycholecalciferol	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
expression	O
and	O
replication	O
are	O
under	O
tight	O
regulatory	O
control	O
.	O

We	O
demonstrate	O
that	O
1,25-dihydroxycholecalciferol	O
[	O
1,25	O
-(	O
OH	O
)	O
2D3	O
]	O
enhances	O
the	O
replication	O
of	O
monocyte	O
-	O
and	O
lymphocyte-tropic	O
strains	O
of	O
HIV-1	O
up	O
to	O
10,000-fold	O
in	O
monocyte	O
cell	O
lines	O
,	O
peripheral	O
blood	O
monocytes	O
,	O
and	O
unfractionated	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

1,25	O
(	O
OH	O
)	O
2D3	O
is	O
therefore	O
one	O
of	O
the	O
most	O
potent	O
regulators	O
of	O
HIV-1	O
replication	O
described	O
to	O
date	O
.	O

Precursors	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
enhance	O
HIV-1	O
replication	O
in	O
proportion	O
to	O
their	O
affinity	O
for	O
the	O
1,25	O
(	O
OH	O
)	O
2D3	O
intracellular	O
receptor	O
,	O
suggesting	B-SPECULATION
that	I-SPECULATION
1,25	I-SPECULATION
(	I-SPECULATION
OH	I-SPECULATION
)	I-SPECULATION
2D3	I-SPECULATION
influences	I-SPECULATION
HIV-1	I-SPECULATION
replication	I-SPECULATION
by	I-SPECULATION
mechanisms	I-SPECULATION
involving	I-SPECULATION
this	I-SPECULATION
receptor	I-SPECULATION
.	O

These	O
studies	O
may	B-SPECULATION
have	I-SPECULATION
important	I-SPECULATION
implications	I-SPECULATION
for	I-SPECULATION
the	I-SPECULATION
design	I-SPECULATION
of	I-SPECULATION
effective	I-SPECULATION
therapy	I-SPECULATION
of	I-SPECULATION
HIV-1	I-SPECULATION
infection	I-SPECULATION
.	O

Inhibition	O
of	O
HIV-1	O
replication	O
and	O
NF-kappa	O
B	O
activity	O
by	O
cysteine	O
and	O
cysteine	O
derivatives	O
.	O

HIV-1	O
proviral	O
DNA	O
contains	O
two	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
.	O

HIV-1-infected	O
individuals	O
have	O
,	O
on	O
average	O
,	O
abnormally	O
high	O
levels	O
of	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
and	O
abnormally	O
low	O
plasma	O
cysteine	O
levels	O
.	O

We	O
therefore	O
investigated	O
the	O
effects	O
of	O
cysteine	O
and	O
related	O
thiols	O
on	O
HIV-1	O
replication	O
and	O
NF-kappa	O
B	O
expression	O
.	O

The	O
experiments	O
in	O
this	O
report	O
show	O
that	O
cysteine	O
or	O
N-acetylcysteine	O
(	O
NAC	O
)	O
raise	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
level	O
and	O
inhibit	O
HIV-1	O
replication	O
in	O
persistently	O
infected	O
Molt-4	O
and	O
U937	O
cells	O
.	O

However	O
,	O
inhibition	B-SPECULATION
of	I-SPECULATION
HIV-1	I-SPECULATION
replication	I-SPECULATION
appears	I-SPECULATION
not	B-NEGATION
to	I-NEGATION
be	I-NEGATION
directly	I-NEGATION
correlated	I-NEGATION
with	I-NEGATION
GSH	I-NEGATION
levels	I-NEGATION
.	O

Cysteine	O
and	O
NAC	O
also	O
inhibit	O
NF-kappa	O
B	O
activity	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
chloramphenicol	O
acetyl-transferase	O
(	O
CAT	O
)	O
gene	O
expression	O
under	O
control	O
of	O
NF-kappa	O
B	O
binding	O
sites	O
in	O
uninfected	O
cells	O
.	O

This	O
suggests	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
cysteine	I-SPECULATION
deficiency	I-SPECULATION
in	I-SPECULATION
HIV-1-infected	I-SPECULATION
individuals	I-SPECULATION
may	B-SPECULATION
cause	I-SPECULATION
an	I-SPECULATION
over-expression	I-SPECULATION
of	I-SPECULATION
NF-kappa	I-SPECULATION
B-dependent	I-SPECULATION
genes	I-SPECULATION
and	I-SPECULATION
enhance	I-SPECULATION
HIV-1	I-SPECULATION
replication	I-SPECULATION
.	O

NAC	B-SPECULATION
may	I-SPECULATION
be	I-SPECULATION
considered	I-SPECULATION
for	I-SPECULATION
the	I-SPECULATION
treatment	I-SPECULATION
of	I-SPECULATION
HIV-1-infected	I-SPECULATION
individuals	I-SPECULATION
.	O

Glucocorticoid	O
receptors	O
in	O
systemic	O
lupus	O
erythematosus	O
.	O

Glucocorticosteroids	O
remain	O
the	O
major	O
treatment	O
modality	O
for	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
but	O
their	O
mechanism	O
of	O
action	O
is	O
unclear	O
.	O

Over	O
the	O
past	O
decade	O
it	O
has	O
become	O
clear	O
that	O
glucocorticosteroid	O
receptors	O
play	O
a	O
significant	O
role	O
in	O
the	O
mechanism	O
of	O
glucocorticosteroid	O
action	O
.	O

We	O
studied	O
glucocorticosteroid	O
receptor	O
density	O
and	O
affinity	O
on	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
the	O
glucocorticosteroid	O
binding	O
assay	O
in	O
33	O
patients	O
with	O
SLE	O
who	O
had	O
taken	O
no	B-NEGATION
glucocorticosteroid	I-NEGATION
for	I-NEGATION
the	I-NEGATION
previous	I-NEGATION
6	I-NEGATION
months	I-NEGATION
and	I-NEGATION
in	I-NEGATION
32	I-NEGATION
healthy	I-NEGATION
controls	I-NEGATION
.	O

Patients	O
'	O
disease	O
activity	O
was	O
measured	O
by	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
(	O
SLEDAI	O
)	O
.	O

Glucocorticosteroid	O
receptors	O
on	O
leukocytes	O
of	O
patients	O
with	O
SLE	O
were	O
significantly	O
higher	O
than	O
in	O
healthy	O
controls	O
(	O
4419	O
	O
306	O
vs	O
3369	O
	O
196	O
,	O
p	O
less	O
than	O
0.005	O
)	O
.	O

The	O
binding	O
affinity	O
was	O
not	B-NEGATION
different	I-NEGATION
between	I-NEGATION
patients	I-NEGATION
and	I-NEGATION
controls	I-NEGATION
.	O

There	O
was	O
no	B-NEGATION
correlation	I-NEGATION
between	I-NEGATION
glucocorticosteroid	I-NEGATION
receptor	I-NEGATION
number	I-NEGATION
and	I-NEGATION
SLE	I-NEGATION
disease	I-NEGATION
activity	I-NEGATION
.	O

[	O
Changes	O
in	O
leucocytic	O
estrogen	O
receptor	O
levels	O
in	O
patients	O
with	O
gynecomastia	O
]	O

The	O
number	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
13	O
men	O
with	O
gynecomastia	O
were	O
measured	O
by	O
radioligand	O
binding	O
method	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
of	O
13	O
sex	O
-	O
and	O
age-matched	O
healthy	O
subjects	O
.	O

It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	O
in	O
leucocytes	O
was	O
significantly	O
increased	O
in	O
gynecomastia	O
(	O
Rs	O
of	O
leucocytes	O
were	O
1054	O
	O
254	O
sites	O
/	O
cell	O
)	O
.	O

It	O
suggested	B-SPECULATION
that	I-SPECULATION
increase	I-SPECULATION
of	I-SPECULATION
ER	I-SPECULATION
levels	I-SPECULATION
play	I-SPECULATION
an	I-SPECULATION
important	I-SPECULATION
role	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
pathogenesis	I-SPECULATION
of	I-SPECULATION
gynecomastia	I-SPECULATION
.	O

[	O
Changes	O
in	O
levels	O
of	O
leucocytic	O
estrogen	O
receptor	O
in	O
patients	O
with	O
menopausal	O
type	O
II	O
diabetes	O
and	O
its	O
significance	O
]	O

The	O
number	O
of	O
estrogen	O
receptors	O
(	O
ER	O
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
12	O
women	O
with	O
menopausal	O
type	O
II	O
diabetes	O
was	O
measured	O
with	O
radio-ligand	O
binding	O
method	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
of	O
12	O
menopausal	O
women	O
without	B-NEGATION
diabetes	I-NEGATION
and	O
12	O
normal	O
women	O
of	O
childbearing	O
age	O
.	O

It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	O
in	O
the	O
patients	O
was	O
significantly	O
decreased	O
.	O

Our	O
data	O
indicate	B-SPECULATION
that	I-SPECULATION
decrease	I-SPECULATION
of	I-SPECULATION
ER	I-SPECULATION
level	I-SPECULATION
in	I-SPECULATION
leukocytes	I-SPECULATION
may	B-SPECULATION
be	I-SPECULATION
related	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
pathogenesis	I-SPECULATION
of	I-SPECULATION
type	I-SPECULATION
II	I-SPECULATION
diabetes	I-SPECULATION
in	I-SPECULATION
menopausal	I-SPECULATION
period	I-SPECULATION
.	O

Lymphocyte	O
glucocorticoid	O
receptor	O
binding	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
.	O

Lymphocyte	O
glucocorticoid	O
receptor	O
binding	O
parameters	O
were	O
studied	O
in	O
15	O
severely	O
depressed	O
patients	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
,	O
and	O
in	O
15	O
healthy	O
controls	O
.	O

There	O
was	O
no	B-NEGATION
difference	I-NEGATION
in	I-NEGATION
glucocorticoid	B-SPECULATION
receptor	I-SPECULATION
number	I-SPECULATION
or	I-SPECULATION
affinity	I-SPECULATION
between	O
depressed	O
patients	O
and	O
recovered	O
or	O
control	O
subjects	O
.	O

Afternoon	O
ACTH	O
and	O
cortisol	O
concentrations	O
did	O
not	B-NEGATION
differ	I-NEGATION
significantly	I-NEGATION
between	I-NEGATION
the	I-NEGATION
three	I-NEGATION
groups	I-NEGATION
.	O

No	B-NEGATION
relationship	I-NEGATION
could	I-NEGATION
be	I-NEGATION
established	I-NEGATION
between	I-NEGATION
glucocorticoid	I-NEGATION
receptor	I-NEGATION
binding	I-NEGATION
and	I-NEGATION
antidepressant	I-NEGATION
medication	I-NEGATION
.	O

These	O
data	O
support	B-SPECULATION
the	I-SPECULATION
view	I-SPECULATION
of	I-SPECULATION
an	I-SPECULATION
impaired	I-SPECULATION
ligand-induced	I-SPECULATION
plasticity	I-SPECULATION
of	I-SPECULATION
glucocorticoid	I-SPECULATION
receptor	I-SPECULATION
regulation	I-SPECULATION
rather	B-NEGATION
than	I-NEGATION
the	I-NEGATION
hypothesis	I-NEGATION
of	I-NEGATION
decreased	I-NEGATION
glucocorticoid	I-NEGATION
receptor	I-NEGATION
numbers	I-NEGATION
during	I-NEGATION
depression	I-NEGATION
.	O

Nuclear	O
association	O
of	O
a	O
T-cell	O
transcription	O
factor	O
blocked	O
by	O
FK-506	O
and	O
cyclosporin	O
A	O
[	O
see	O
comments	O
]	O

Cyclosporin	O
A	O
and	O
FK506	O
inhibit	O
T	O
-	O
and	O
B-cell	O
activation	O
and	O
other	O
processes	O
essential	O
to	O
an	O
effective	O
immune	O
response	O
.	O

In	O
T	O
lymphocytes	O
these	O
drugs	O
disrupt	O
an	O
unknown	O
step	O
in	O
the	O
transmission	O
of	O
signals	O
from	O
the	O
T-cell	O
antigen	O
receptor	O
to	O
cytokine	O
genes	O
that	O
coordinate	O
the	O
immune	O
response	O
.	O

The	O
putative	B-SPECULATION
intracellular	I-SPECULATION
receptors	I-SPECULATION
for	I-SPECULATION
FK506	I-SPECULATION
and	I-SPECULATION
cyclosporin	I-SPECULATION
are	O
cis-trans	O
prolyl	O
isomerases	O
.	O

Binding	O
of	O
the	O
drug	O
inhibits	O
isomerase	O
activity	O
,	O
but	O
studies	O
with	O
other	O
prolyl	O
isomerase	O
inhibitors	O
and	O
analysis	O
of	O
cyclosporin-resistant	O
mutants	O
in	O
yeast	O
suggest	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
effects	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
drug	I-SPECULATION
result	I-SPECULATION
from	I-SPECULATION
the	I-SPECULATION
formation	I-SPECULATION
of	I-SPECULATION
an	I-SPECULATION
inhibitory	I-SPECULATION
complex	I-SPECULATION
between	I-SPECULATION
the	I-SPECULATION
drug	I-SPECULATION
and	I-SPECULATION
isomerase	I-SPECULATION
,	I-SPECULATION
and	I-SPECULATION
not	B-NEGATION
from	I-NEGATION
inhibition	I-NEGATION
of	I-NEGATION
isomerase	I-NEGATION
activity	I-NEGATION
.	O

A	B-SPECULATION
transcription	I-SPECULATION
factor	I-SPECULATION
,	I-SPECULATION
NF-AT	I-SPECULATION
,	I-SPECULATION
which	I-SPECULATION
is	I-SPECULATION
essential	I-SPECULATION
for	I-SPECULATION
early	I-SPECULATION
T-cell	I-SPECULATION
gene	I-SPECULATION
activation	I-SPECULATION
,	I-SPECULATION
seems	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
a	I-SPECULATION
specific	I-SPECULATION
target	I-SPECULATION
of	I-SPECULATION
cyclosporin	I-SPECULATION
A	I-SPECULATION
and	I-SPECULATION
FK506	I-SPECULATION
action	I-SPECULATION
because	O
transcription	O
directed	O
by	O
this	O
protein	O
is	O
blocked	O
in	O
T	O
cells	O
treated	O
with	O
these	O
drugs	O
,	O
with	O
little	B-SPECULATION
or	I-SPECULATION
on	O
other	O
transcription	O
factors	O
such	O
as	O
AP-1	O
and	O
NF-kappa	O
B	O
.	O
no	B-NEGATION
effect	I-NEGATION
.	O

Here	O
we	O
demonstrate	O
that	O
NF-AT	O
is	O
formed	O
when	O
a	O
signal	O
from	O
the	O
antigen	O
receptor	O
induces	O
a	O
pre-existing	O
cytoplasmic	O
subunit	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
combine	O
with	O
a	O
newly	O
synthesized	O
nuclear	O
subunit	O
of	O
NF-AT	O
.	O

FK506	O
and	O
cyclosporin	O
A	O
block	O
translocation	O
of	O
the	O
cytoplasmic	O
component	O
without	B-NEGATION
affecting	I-NEGATION
synthesis	I-NEGATION
of	I-NEGATION
the	I-NEGATION
nuclear	I-NEGATION
subunit	I-NEGATION
.	O

Regulation	O
of	O
M-CSF	O
expression	O
by	O
M-CSF	O
:	O
role	O
of	O
protein	O
kinase	O
C	O
and	O
transcription	O
factor	O
NF	O
kappa	O
B	O
.	O

Macrophage-colony-stimulating	O
factor	O
(	O
M-CSF	O
)	O
,	O
also	O
referred	O
to	O
as	O
CSF-1	O
,	O
regulates	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
and	O
functional	O
activity	O
of	O
monocytes	O
by	O
binding	O
to	O
a	O
single	O
class	O
of	O
high-affinity	O
cell	O
surface	O
receptors	O
,	O
known	O
to	O
be	O
the	O
product	O
of	O
the	O
c-fms	O
protooncogene	O
.	O

The	O
detection	O
of	O
both	O
M-CSF	O
and	O
c-fms	O
expression	O
by	O
cells	O
of	O
the	O
monocyte	O
lineage	O
has	O
suggested	B-SPECULATION
that	I-SPECULATION
M-CSF	I-SPECULATION
may	B-SPECULATION
act	I-SPECULATION
by	I-SPECULATION
an	I-SPECULATION
autocrine	I-SPECULATION
mechanism	I-SPECULATION
.	O

Interestingly	O
,	O
it	O
has	O
been	O
shown	O
that	O
M-CSF	O
can	O
induce	O
the	O
expression	O
of	O
its	O
own	O
gene	O
.	O

Although	O
sensitivity	O
to	O
M-CSF	O
can	O
be	O
modulated	O
by	O
regulation	O
of	O
receptor	O
expression	O
and	O
function	O
,	O
M-CSF	O
responsiveness	O
is	O
largely	O
determined	O
at	O
a	O
postreceptor	O
level	O
.	O

To	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
intracellular	O
pathway	O
of	O
M-CSF	O
signal	O
transduction	O
.	O

We	O
have	O
therefore	O
investigated	O
the	O
changes	O
in	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activity	O
upon	O
exposure	O
of	O
monocytes	O
to	O
M-CSF	O
.	O

We	O
show	O
that	O
M-CSF	O
activates	O
and	O
translocates	O
PKC	O
.	O

Inhibition	O
of	O
PKC	O
by	O
the	O
isoquinoline	O
derivative	O
H7	O
abolishes	O
induction	O
of	O
M-CSF	O
by	O
M-CSF	O
.	O

Furthermore	O
,	O
activation	O
of	O
PKC	O
was	O
pertussis-toxin-sensitive	O
and	O
was	O
associated	O
with	O
the	O
detection	O
of	O
an	O
NF	O
kappa	O
B	O
protein	O
in	O
nuclear	O
extracts	O
of	O
M-CSF-induced	O
blood	O
monocytes	O
but	O
not	B-NEGATION
in	I-NEGATION
monocytes	I-NEGATION
exposed	I-NEGATION
to	I-NEGATION
medium	I-NEGATION
treatment	I-NEGATION
only	I-NEGATION
.	O

The	O
results	O
suggest	B-SPECULATION
that	I-SPECULATION
M-CSF	I-SPECULATION
induction	I-SPECULATION
of	I-SPECULATION
M-CSF	I-SPECULATION
involves	I-SPECULATION
G	I-SPECULATION
proteins	I-SPECULATION
,	I-SPECULATION
PKC	I-SPECULATION
and	I-SPECULATION
NF	I-SPECULATION
kappa	I-SPECULATION
B	I-SPECULATION
.	O

NF-kappa	O
B	O
activation	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
is	O
independent	O
of	O
protein	O
kinase	O
A	O
,	O
protein	O
kinase	O
C	O
,	O
and	O
Ca	O
(	O
2	O
+)-	O
regulated	O
kinases	O
.	O

NF-kappa	O
B	O
is	O
a	O
DNA-binding	O
regulatory	O
factor	O
able	O
to	O
control	O
transcription	O
of	O
a	O
number	O
of	O
genes	O
,	O
including	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
genes	O
.	O

In	O
T	O
cells	O
,	O
NF-kappa	O
B	O
is	O
activated	O
upon	O
cellular	O
treatment	O
by	O
phorbol	O
esters	O
and	O
the	O
cytokine	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
the	O
molecular	O
events	O
leading	O
to	O
NF-kappa	O
B	O
activation	O
by	O
TNF	O
alpha	O
in	O
a	O
human	O
T	O
cell	O
line	O
(	O
Jurkat	O
)	O
and	O
its	O
subclone	O
JCT6	O
,	O
which	O
presents	O
a	O
deficiency	O
in	O
the	O
PKA	O
transduction	O
pathway	O
.	O

We	O
found	O
that	O
in	O
both	O
cell	O
lines	O
,	O
both	O
phorbol	O
ester	O
and	O
TNF	O
alpha	O
were	O
able	O
to	O
activate	O
NF-kappa	O
B	O
.	O

Phorbol	O
activation	O
was	O
positively	O
modulated	O
by	O
Ca2	O
+	O
influx	O
while	O
TNF	B-NEGATION
alpha	I-NEGATION
activation	I-NEGATION
was	I-NEGATION
not	I-NEGATION
.	O

Furthermore	O
,	O
while	O
PMA	O
activation	O
was	O
inhibited	O
by	O
the	O
PKC	O
inhibitor	O
staurosporin	O
,	O
the	O
TNF	O
alpha	O
effect	O
was	O
unchanged	O
.	O

TNF	O
alpha	O
did	O
not	B-NEGATION
activate	I-NEGATION
cAMP	I-NEGATION
production	I-NEGATION
and	O
its	B-NEGATION
signal	I-NEGATION
was	I-NEGATION
not	I-NEGATION
modulated	I-NEGATION
by	I-NEGATION
cAMP	I-NEGATION
activators	I-NEGATION
.	O

Moreover	O
,	O
cAMP	O
activators	O
did	O
not	B-NEGATION
activate	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
in	I-NEGATION
Jurkat	I-NEGATION
cells	I-NEGATION
.	O

Thus	O
,	O
TNF	B-NEGATION
alpha-induced	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
activation	I-NEGATION
was	I-NEGATION
found	I-NEGATION
to	I-NEGATION
be	I-NEGATION
mediated	I-NEGATION
by	I-NEGATION
none	I-NEGATION
of	I-NEGATION
the	I-NEGATION
major	I-NEGATION
signal-mediating	I-NEGATION
kinases	I-NEGATION
such	I-NEGATION
as	I-NEGATION
protein	I-NEGATION
kinase	I-NEGATION
C	I-NEGATION
(	I-NEGATION
PKC	I-NEGATION
)	I-NEGATION
,	I-NEGATION
protein	I-NEGATION
kinase	I-NEGATION
A	I-NEGATION
,	I-NEGATION
or	I-NEGATION
Ca	I-NEGATION
(	I-NEGATION
2	I-NEGATION
+)-	I-NEGATION
regulated	I-NEGATION
kinases	I-NEGATION
.	O

Furthermore	O
,	O
we	O
found	O
that	O
cytoplasmic	O
acidification	O
facilitated	O
NF-kappa	O
B	O
activation	O
by	O
both	O
TNF	O
alpha	O
and	O
PKC	O
,	O
by	O
a	O
mechanism	O
that	O
increases	O
NF-kappa	O
B	O
/	O
I	O
kappa	O
B	O
dissociation	O
without	B-NEGATION
affecting	I-NEGATION
the	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
translocation	I-NEGATION
step	I-NEGATION
.	O

NF-kappa	O
B	O
activity	O
in	O
T	O
cells	O
stably	O
expressing	O
the	O
Tax	O
protein	O
of	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
.	O

The	O
effect	O
of	O
constitutive	O
Tax	O
expression	O
on	O
the	O
interaction	O
of	O
NF-kappa	O
B	O
with	O
its	O
recognition	O
sequence	O
and	O
on	O
NF-kappa	O
B-dependent	O
gene	O
expression	O
was	O
examined	O
in	O
T	O
lymphoid	O
Jurkat	O
cell	O
lines	O
(	O
19D	O
and	O
9J	O
)	O
stably	O
transformed	O
with	O
a	O
Tax	O
expression	O
vector	O
.	O

Tax	O
expressing	O
T	O
cell	O
lines	O
contained	O
a	O
constitutive	O
level	O
of	O
NF-kappa	O
B	O
binding	O
activity	O
,	O
detectable	O
by	O
mobility	O
shift	O
assay	O
and	O
uv	O
cross-linking	O
using	O
a	O
palindromic	O
NF-kappa	O
B	O
probe	O
homologous	O
to	O
the	O
interferon	O
beta	O
PRDII	O
site	O
.	O

In	O
Jurkat	O
and	O
NC2.10	O
induction	O
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
appearance	O
of	O
new	O
DNA	O
binding	O
proteins	O
of	O
85	O
,	O
75	O
,	O
and	O
54	O
kDa	O
,	O
whereas	O
in	O
Tax	O
expressing	O
cells	O
the	O
85-kDa	O
protein	O
and	O
a	O
92-kDa	O
DNA	O
binding	O
protein	O
were	O
constitutively	O
induced	O
.	O

Expression	O
of	O
Tax	O
protein	O
in	O
19D	O
and	O
9J	O
resulted	O
in	O
transcription	O
of	O
the	O
endogenous	O
NF-kappa	O
B-dependent	O
granulocyte-macrophage	O
colony	O
stimulating	O
factor	O
gene	O
and	O
increased	O
basal	O
level	O
expression	O
of	O
transfected	O
NF-kappa	O
B-regulated	O
promoters	O
.	O

Nonetheless	O
transcription	O
of	O
both	O
the	O
endogenous	O
and	O
the	O
transfected	O
gene	O
was	O
inducible	O
by	O
PMA	O
treatment	O
.	O

Tax	O
expression	O
in	O
Jurkat	O
T	O
cells	O
may	B-SPECULATION
alter	I-SPECULATION
the	I-SPECULATION
stoichiometry	I-SPECULATION
of	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
DNA	I-SPECULATION
binding	I-SPECULATION
proteins	I-SPECULATION
and	I-SPECULATION
thus	I-SPECULATION
change	I-SPECULATION
the	I-SPECULATION
expression	I-SPECULATION
of	I-SPECULATION
NF-kappa	I-SPECULATION
B-regulated	I-SPECULATION
promoters	I-SPECULATION
.	O

Regulation	O
of	O
glucocorticoid	O
receptors	O
in	O
human	O
mononuclear	O
cells	O
:	O
effects	O
of	O
glucocorticoid	O
treatment	O
,	O
Cushing	O
'	O
s	O
disease	O
and	O
ketoconazole	O
.	O

Glucocorticoid	O
receptors	O
(	O
GcR	O
)	O
were	O
determined	O
by	O
a	O
whole	O
cell	O
assay	O
in	O
human	O
mononulear	O
leukocytes	O
(	O
hMNL	O
)	O
from	O
control	O
subjects	O
,	O
patients	O
receiving	O
glucocorticoid	O
therapy	O
for	O
systemic	O
diseases	O
and	O
Cushing	O
'	O
s	O
disease	O
patients	O
with	O
or	O
without	B-NEGATION
ketoconazole	I-NEGATION
therapy	I-NEGATION
.	O

Prolonged	O
corticosteroid	O
treatment	O
resulted	O
in	O
down-regulation	O
of	O
GcR	O
,	O
while	O
the	O
mean	O
level	O
of	O
GcR	O
in	O
Cushing	O
'	O
s	O
disease	O
was	O
normal	O
.	O

In	O
this	O
group	O
,	O
however	O
,	O
receptor	O
levels	O
and	O
morning	O
plasma	O
cortisol	O
values	O
showed	O
a	O
negative	O
correlation	O
,	O
indicating	B-SPECULATION
a	I-SPECULATION
subtle	I-SPECULATION
down-regulatory	I-SPECULATION
effect	I-SPECULATION
.	O

Furthermore	O
,	O
GcR	O
were	O
unaltered	O
after	O
these	O
patients	O
received	O
ketoconazole	O
,	O
in	O
spite	O
of	O
a	O
marked	O
reduction	O
in	O
morning	O
plasma	O
cortisol	O
and	O
urinary	O
free	O
cortisol	O
.	O

We	O
also	O
observed	O
that	O
ketoconazole	O
was	O
a	O
weak	O
competitor	O
of	O
GcR	O
in	O
intact	O
cells	O
,	O
although	O
it	O
significantly	O
inhibited	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosolic	O
preparations	O
from	O
rat	O
tissues	O
.	O

The	O
results	O
suggested	B-SPECULATION
that	I-SPECULATION
GcR	I-SPECULATION
in	I-SPECULATION
hMNL	I-SPECULATION
are	I-SPECULATION
down-regulated	I-SPECULATION
by	I-SPECULATION
synthetic	I-SPECULATION
steroids	I-SPECULATION
given	I-SPECULATION
in	I-SPECULATION
vivo	I-SPECULATION
,	O
but	O
they	O
showed	O
very	O
mild	O
down-regulation	O
in	O
hypercortisolemic	O
patients	O
suffering	O
from	O
Cushing	O
'	O
s	O
disease	O
.	O

Finally	O
,	O
we	O
did	O
not	B-NEGATION
observed	I-NEGATION
either	I-NEGATION
up-regulation	I-NEGATION
or	I-NEGATION
antagonism	I-NEGATION
of	I-NEGATION
GcR	I-NEGATION
by	I-NEGATION
ketoconazole	I-NEGATION
treatment	I-NEGATION
,	I-NEGATION
at	I-NEGATION
the	I-NEGATION
time	I-NEGATION
that	I-NEGATION
cortisol	I-NEGATION
levels	I-NEGATION
of	I-NEGATION
patients	I-NEGATION
with	I-NEGATION
Cushing	I-NEGATION
'	I-NEGATION
s	I-NEGATION
disease	I-NEGATION
were	I-NEGATION
reduced	I-NEGATION
.	O

This	O
indicates	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
beneficial	I-SPECULATION
effects	I-SPECULATION
of	I-SPECULATION
ketoconazole	I-SPECULATION
in	I-SPECULATION
Cushing	I-SPECULATION
'	I-SPECULATION
s	I-SPECULATION
disease	I-SPECULATION
are	I-SPECULATION
due	I-SPECULATION
to	I-SPECULATION
adrenal	I-SPECULATION
cortisol	I-SPECULATION
suppression	I-SPECULATION
and	I-SPECULATION
not	B-NEGATION
to	I-NEGATION
interaction	I-NEGATION
with	I-NEGATION
GcR	I-NEGATION
of	I-NEGATION
target	I-NEGATION
cells	I-NEGATION
,	O
and	O
that	O
the	O
process	O
of	O
GcR	O
regulation	O
in	O
hMNL	O
is	O
a	O
complex	O
phenomenon	O
awaiting	O
further	O
elucidation	O
.	O

Glucocorticoid	O
receptors	O
in	O
lymphocytes	O
in	O
anorexia	O
nervosa	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
was	O
to	O
explore	O
the	O
down-regulation	O
of	O
the	O
glucocorticoid	O
receptors	O
during	O
hypercortisolaemia	O
in	O
anorexia	O
nervosa	O
.	O

DESIGN	O
:	O
Urine	O
and	O
plasma	O
samples	O
were	O
obtained	O
for	O
cortisol	O
determination	O
and	O
blood	O
lymphocytes	O
were	O
isolated	O
for	O
receptor	O
binding	O
studies	O
.	O

PATIENTS	O
:	O
Sixteen	O
anorexic	O
patients	O
,	O
aged	O
16-27	O
years	O
,	O
with	O
a	O
mean	O
	O
SEM	O
body	O
mass	O
index	O
of	O
14.2	O
	O
2.0	O
(	O
ranging	O
from	O
11.1	O
to	O
17.4	O
)	O
,	O
and	O
15	O
normal	O
women	O
were	O
studied	O
.	O

Six	O
patients	O
were	O
reinvestigated	O
after	O
a	O
significant	O
weight	O
gain	O
.	O

MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	O
receptors	O
were	O
measured	O
with	O
dexamethasone	O
as	O
ligand	O
on	O
lymphocytes	O
.	O

RESULTS	O
:	O
In	O
patients	O
,	O
both	O
total	O
and	O
free	O
plasma	O
cortisol	O
concentrations	O
were	O
higher	O
than	O
in	O
the	O
normal	O
women	O
,	O
as	O
was	O
their	O
urinary	O
free	O
cortisol	O
;	O

the	O
number	O
of	O
glucocorticoid	O
receptors	O
per	O
cell	O
(	O
Ro	O
)	O
and	O
the	O
binding	O
affinity	O
(	O
Kd	O
)	O
for	O
dexamethasone	O
were	O
,	O
however	O
,	O
not	O
significantly	O
different	O
(	O
Ro	O
:	O
7687	O
	O
1750	O
vs	O
7347	O
	O
1285	O
sites	O
/	O
cell	O
;	O
Kd	O
:	O
7.7	O
	O
2.4	O
vs	O
7.4	O
	O
1.7	O
nM	O
at	O
24	O
degrees	O
C	O
)	O
.	O

After	O
weight	O
gain	O
(	O
14	O
	O
2	O
to	O
16	O
	O
2	O
kg	O
/	O
m2	O
)	O
,	O
receptor	O
numbers	O
were	O
8421	O
	O
2126	O
(	O
pre	O
)	O
and	O
9011	O
	O
500	O
(	O
post	O
)	O
sites	O
/	O
cell	O
,	O
which	O
are	O
not	O
significantly	O
different	O
(	O
P	O
greater	O
than	O
0.2	O
)	O
;	O

the	O
Kd	O
was	O
unchanged	O
(	O
9.3	O
	O
2.6	O
vs	O
9.2	O
	O
2.4	O
nM	O
)	O
.	O

CONCLUSIONS	O
Hypercortisolaemia	O
does	O
not	B-NEGATION
down-regulate	I-NEGATION
the	I-NEGATION
lymphocyte	I-NEGATION
glucocorticoid	I-NEGATION
receptors	I-NEGATION
in	I-NEGATION
anorexia	I-NEGATION
nervosa	I-NEGATION
and	O
a	B-SPECULATION
post-receptor	I-SPECULATION
defect	I-SPECULATION
might	I-SPECULATION
be	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
peripheral	I-SPECULATION
tissue	I-SPECULATION
resistance	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
effects	I-SPECULATION
of	I-SPECULATION
glucocorticoid	I-SPECULATION
hormones	I-SPECULATION
in	I-SPECULATION
undernutrition	I-SPECULATION
.	O

Tumor	O
necrosis	O
factor-alpha	O
mRNA	O
accumulation	O
in	O
human	O
myelomonocytic	O
cell	O
lines	O
.	O

Role	O
of	O
transcriptional	O
regulation	O
by	O
DNA	O
sequence	O
motifs	O
and	O
mRNA	O
stabilization	O
.	O

The	O
cytokine	O
TNF	O
mediates	O
many	O
of	O
the	O
pathologic	O
signs	O
of	O
cachexia	O
,	O
inflammation	O
,	O
and	O
sepsis	O
.	O

The	O
current	O
work	O
describes	O
the	O
regulation	O
of	O
TNF	O
in	O
human	O
myelomonocytic	O
cell	O
lines	O
after	O
PMA	O
stimulation	O
.	O

The	O
cell	O
lines	O
exhibit	O
a	O
low	O
level	O
of	O
constitutive	O
TNF	O
mRNA	O
expression	O
.	O

Within	O
2	O
to	O
4	O
h	O
of	O
PMA	O
exposure	O
,	O
steady	O
state	O
levels	O
of	O
TNF	O
mRNA	O
are	O
markedly	O
elevated	O
in	O
all	O
myelomonocytic	O
cell	O
lines	O
studied	O
.	O

This	O
rise	O
is	O
due	O
to	O
increased	O
mRNA	O
stability	O
,	O
which	O
increased	O
by	O
almost	O
twofold	O
,	O
and	O
to	O
an	O
overall	O
increase	O
in	O
transcription	O
,	O
which	O
rises	O
by	O
more	O
than	O
sixfold	O
.	O

At	O
the	O
level	O
of	O
the	O
genomic	O
TNF	O
gene	O
,	O
a	O
DNase	O
I	O
hypersensitive	O
site	O
is	O
detected	O
within	O
the	O
TNF	O
promoter	O
between	O
-	O
200	O
to	O
-	O
100	O
bp	O
relative	O
to	O
the	O
transcription	O
initiation	O
site	O
.	O

Although	O
absent	O
in	O
nonexpressing	O
erythroleukemia	O
cell	O
lines	O
,	O
the	O
DNase	O
I	O
site	O
is	O
present	O
in	O
uninduced	O
myelomonocytic	O
cell	O
lines	O
and	O
is	B-NEGATION
not	I-NEGATION
changed	I-NEGATION
after	I-NEGATION
PMA	I-NEGATION
induction	I-NEGATION
.	O

The	O
PMA	O
induction	O
of	O
c-fos	O
mRNA	O
correlated	O
well	O
with	O
TNF	O
gene	O
induction	O
;	O

expression	O
of	O
genes	O
encoding	O
other	O
proteins	O
in	O
the	O
AP-1	O
complex	O
(	O
junB	O
and	O
junD	O
)	O
were	O
also	O
induced	O
by	O
PMA	O
.	O

The	O
nuclear	O
extracts	O
from	O
resting	O
and	O
induced	O
ML-1	O
cells	O
contain	O
proteins	O
binding	O
specifically	O
to	O
the	O
AP-1	O
,	O
AP-2	O
,	O
and	O
NF	O
kappa	O
B	O
sequence	O
located	O
within	O
the	O
TNF	O
promoter	O
.	O

PMA	O
induction	O
increases	O
the	O
level	O
of	O
a	O
number	O
of	O
specific	O
binding	O
complexes	O
relative	O
to	O
the	O
resting	O
cells	O
.	O

The	O
regulatory	O
mechanisms	O
of	O
the	O
human	O
and	O
murine	O
TNF	O
genes	O
are	O
discussed	O
.	O

USF-related	O
transcription	O
factor	O
,	O
HIV-TF1	O
,	O
stimulates	O
transcription	O
of	O
human	O
immunodeficiency	O
virus-1	O
.	O

The	O
transcription	O
factor	O
HIV-TF1	O
,	O
which	O
binds	O
to	O
a	O
region	O
about	O
60	O
bp	O
upstream	O
from	O
the	O
enhancer	O
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
,	O
was	O
purified	O
from	O
human	O
B	O
cells	O
.	O

HIV-TF1	O
had	O
a	O
molecular	O
weight	O
of	O
39,000	O
.	O

Binding	O
of	O
HIV-TF1	O
to	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
activated	O
transcription	O
from	O
the	O
HIV	O
promoter	O
in	O
vitro	O
.	O

The	O
HIV-TF1-binding	O
site	O
in	O
HIV	O
LTR	O
was	O
similar	O
to	O
the	O
site	O
recognized	O
by	O
upstream	O
stimulatory	O
factor	O
(	O
USF	O
)	O
in	O
the	O
adenovirus	O
major	O
late	O
promoter	O
.	O

DNA-binding	O
properties	O
of	O
HIV-TF1	O
suggested	B-SPECULATION
that	I-SPECULATION
HIV-TF1	I-SPECULATION
might	B-SPECULATION
be	I-SPECULATION
identical	B-SPECULATION
or	I-SPECULATION
related	I-SPECULATION
to	O
USF	O
.	O

Interestingly	O
,	O
treatment	O
of	O
purified	O
HIV-TF1	O
by	O
phosphatase	O
greatly	O
reduced	O
its	O
DNA-binding	O
activity	O
,	O
suggesting	B-SPECULATION
that	I-SPECULATION
phosphorylation	I-SPECULATION
of	I-SPECULATION
HIV-TF1	I-SPECULATION
was	I-SPECULATION
essential	I-SPECULATION
for	I-SPECULATION
DNA	I-SPECULATION
binding	I-SPECULATION
.	O

The	O
disruption	O
of	O
HIV-TF1-binding	O
site	O
induced	O
a	O
60	O
%	O
decrease	O
in	O
the	O
level	O
of	O
transcription	O
from	O
the	O
HIV	O
promoter	O
in	O
vivo	O
.	O

These	O
results	O
suggest	B-SPECULATION
that	I-SPECULATION
HIV-TF1	I-SPECULATION
is	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
transcriptional	I-SPECULATION
regulation	I-SPECULATION
of	I-SPECULATION
HIV-1	I-SPECULATION
.	O

The	O
effect	O
of	O
toremifene	O
therapy	O
on	O
serum	O
immunoglobulin	O
levels	O
in	O
breast	O
cancer	O
.	O

Estrogens	O
and	O
anti-estrogens	O
enhance	O
the	O
number	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
-	O
secreting	O
cells	O
in	O
pokeweed	O
mitogen	O
(	O
PWM	O
)	O
-	O
stimulated	O
lymphocyte	O
cultures	O
.	O

Lymphocytes	O
from	O
patients	O
who	O
have	O
received	O
anti-estrogen	O
therapy	O
show	O
similar	O
enhancement	O
of	O
Ig-secreting	O
cells	O
after	O
PWM	O
stimulation	O
.	O

In	O
this	O
study	O
the	O
effect	O
of	O
anti-estrogen	O
(	O
toremifene	O
)	O
therapy	O
on	O
serum	O
immunoglobulin	O
(	O
IgA	O
,	O
IgM	O
,	O
IgG	O
)	O
levels	O
in	O
breast	O
cancer	O
patients	O
was	O
investigated	O
.	O

Serum	O
Ig	O
levels	O
were	O
followed	O
up	O
to	O
two	O
years	O
after	O
or	O
during	O
the	O
therapy	O
.	O

An	O
unexpected	O
finding	O
was	O
that	O
the	O
Ig	O
levels	O
decreased	O
during	O
the	O
follow-up	O
period	O
.	O

This	O
decrease	O
was	O
seen	O
in	O
patients	O
who	O
responded	O
to	O
the	O
therapy	O
as	O
well	O
as	O
in	O
those	O
who	O
did	O
not	B-NEGATION
.	O

HIV1	O
infection	O
of	O
human	O
monocytes	O
and	O
macrophages	O
promotes	O
induction	O
or	O
translocation	O
of	O
NF-KB-related	O
factors	O
.	O

In	O
1991	O
,	O
we	O
demonstrated	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
3	O
different	O
factors	O
(	O
termed	O
B1	O
,	O
B2	O
and	O
B3	O
)	O
with	O
affinity	O
for	O
the	O
KB-enhancer	O
target	O
sequence	O
were	O
specifically	O
detected	O
in	O
nuclear	O
extracts	O
from	O
HIV1-infected	O
monocytes	O
and	O
macrophages	O
.	O

The	O
B2	O
factor	O
was	O
induced	O
in	O
the	O
nuclei	O
of	O
these	O
cells	O
only	O
upon	O
HIV1	O
infection	O
.	O

The	O
B3	O
factor	O
was	O
only	O
slightly	O
evident	O
in	O
nuclei	O
of	O
uninfected	O
cells	O
but	O
was	O
readily	O
detectable	O
in	O
nuclei	O
of	O
infected	O
monocytes	O
.	O

Its	O
expression	O
remained	O
very	O
low	O
in	O
nuclei	O
of	O
HIV1-infected	O
macrophages	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
B2	O
factor	O
is	O
expressed	O
in	O
the	O
cytosol	O
of	O
monocytes	O
and	O
macrophages	O
as	O
a	O
DNA-binding	O
protein	O
,	O
indicating	B-SPECULATION
that	I-SPECULATION
it	I-SPECULATION
is	I-SPECULATION
not	B-NEGATION
associated	I-NEGATION
with	I-NEGATION
an	I-NEGATION
inhibitor	I-NEGATION
(	I-NEGATION
IKB	I-NEGATION
)	I-NEGATION
.	O

This	O
factor	O
remained	O
clustered	O
in	O
the	O
cytosol	O
and	O
was	O
translocated	O
to	O
the	O
nuclei	O
only	O
after	O
HIV1	O
infection	O
.	O

The	O
B3	O
factor	O
is	O
detected	O
in	O
the	O
cytosol	O
only	O
when	O
cells	O
are	O
HIV1-infected	O
.	O

The	O
role	O
of	O
HIV1	O
infection	O
in	O
the	O
expression	O
and	O
the	O
translocation	O
of	O
these	O
factors	O
is	O
discussed	O
.	O

Induction	O
of	O
NF-kappa	O
B	O
during	O
monocyte	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
HIV-gene	O
expression	O
.	O

Cells	O
of	O
the	O
monocyte-macrophage	O
lineage	O
are	O
important	O
targets	O
of	O
HIV	O
infection	O
.	O

We	O
report	O
here	O
that	O
the	O
phenotypic	O
differentiation	O
of	O
monocyte	O
cell	O
lines	O
induced	O
by	O
phorbol	O
esters	O
or	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
is	O
associated	O
with	O
expression	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
.	O

In	O
parallel	O
with	O
such	O
differentiation	O
,	O
HIV	O
transcription	O
,	O
monitored	O
using	O
an	O
HIV	O
long	O
terminal	O
repeat	O
reporter	O
gene	O
construct	O
,	O
is	O
activated	O
in	O
such	O
cells	O
under	O
the	O
influence	O
of	O
enhanced	O
NF-kappa	O
B	O
expression	O
.	O

Also	O
,	O
in	O
a	O
promonocyte	O
cell	O
line	O
chronically	O
infected	O
with	O
HIV	O
,	O
NF-kappa	O
B	O
expression	O
and	O
HIV	O
transcription	O
were	O
enhanced	O
on	O
stimulation	O
with	O
phorbol	O
ester	O
or	O
TNF	O
alpha	O
.	O

Thus	O
,	O
stimulation	O
of	O
monocyte	O
cell	O
lines	O
by	O
phorbol	O
esters	O
or	O
TNF	O
alpha	O
induces	O
cell	O
differentiation	O
and	O
activates	O
HIV	O
transcription	O
.	O

Such	O
a	O
process	O
may	B-SPECULATION
have	I-SPECULATION
fundamental	I-SPECULATION
implications	I-SPECULATION
in	I-SPECULATION
AIDS	I-SPECULATION
pathogenesis	I-SPECULATION
in	I-SPECULATION
vivo	I-SPECULATION
and	O
may	B-SPECULATION
be	I-SPECULATION
important	I-SPECULATION
in	I-SPECULATION
disease	I-SPECULATION
progression	I-SPECULATION
induced	I-SPECULATION
by	I-SPECULATION
opportunistic	I-SPECULATION
infections	I-SPECULATION
directly	B-SPECULATION
or	I-SPECULATION
indirectly	I-SPECULATION
involving	O
macrophages	O
.	O

A	O
nuclear	O
factor	O
NF-GM2	O
that	O
interacts	O
with	O
a	O
regulatory	O
region	O
of	O
the	O
GM-CSF	O
gene	O
essential	O
for	O
its	O
induction	O
in	O
responses	O
to	O
T-cell	O
activation	O
:	O
purification	O
from	O
human	O
T-cell	O
leukemia	O
line	O
Jurkat	O
cells	O
and	O
similarity	O
to	O
NF-kappa	O
B	O
.	O

Activation	O
of	O
T	O
cells	O
by	O
antigen	O
,	O
lectin	O
,	O
or	O
a	O
combination	O
of	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
leads	O
to	O
the	O
induction	O
of	O
genes	O
for	O
a	O
set	O
of	O
lymphokines	O
,	O
including	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
.	O

We	O
demonstrated	O
in	O
earlier	O
studies	O
that	O
the	O
upstream	O
region	O
of	O
the	O
mouse	O
GM-CSF	O
promoter	O
at	O
positions	O
between	O
-	O
95	O
and	O
-	O
73	O
is	O
essential	O
for	O
transcriptional	O
activation	O
in	O
response	O
to	O
PMA	O
/	O
A23187	O
.	O

This	O
region	O
contains	O
two	O
DNA-binding	O
motifs	O
,	O
GM2	O
and	O
GC-box	O
.	O

The	O
GM2	O
sequence	O
(	O
GGTAGTTCCC	O
)	O
is	O
recognized	O
by	O
an	O
inducible	O
factor	O
NF-GM2	O
;	O
the	O
other	O
(	O
CCGCCC	O
)	O
by	O
constitutive	O
factors	O
A1	O
,	O
A2	O
,	O
and	O
B	O
.	O

To	O
elucidate	O
the	O
mechanism	O
of	O
GM-CSF	O
gene	O
activation	O
,	O
we	O
have	O
purified	O
the	O
inducible	O
factor	O
NF-GM2	O
from	O
the	O
nuclear	O
extract	O
of	O
stimulated	O
Jurkat	O
cells	O
on	O
the	O
basis	O
of	O
specific	O
DNA-binding	O
activity	O
.	O

The	O
purified	O
NF-GM2	O
consists	O
of	O
50	O
(	O
p50	O
)	O
and	O
65	O
kDa	O
(	O
p65	O
)	O
polypeptides	O
and	O
has	O
a	O
binding	O
activity	O
specific	O
for	O
both	O
the	O
GM-CSF	O
and	O
immunoglobulin	O
kappa	O
(	O
GGAAAGTCCC	O
)	O
enhancers	O
.	O

Electrophoretically	O
purified	O
p50	O
alone	O
can	O
form	O
a	O
protein-DNA	O
complex	O
,	O
but	O
in	O
the	O
mixture	O
,	O
p50	O
associates	O
preferentially	O
with	O
p65	O
to	O
form	O
the	O
NF-GM2	O
complex	O
.	O

In	O
addition	O
,	O
p65	O
gave	O
per	O
se	O
,	O
with	O
low	O
affinity	O
,	O
a	O
protein-DNA	O
complex	O
that	O
migrated	O
more	O
slowly	O
than	O
native	O
NF-GM2	O
complex	O
.	O

Furthermore	O
,	O
an	O
antiserum	O
against	O
KBF1	O
(	O
identical	O
to	O
50	O
kDa	O
NF-kappa	O
B	O
protein	O
)	O
reacted	O
with	O
the	O
p50	O
of	O
NF-GM2	O
,	O
indicating	B-SPECULATION
that	I-SPECULATION
the	B-NEGATION
NF-GM2	I-NEGATION
polypeptide	I-NEGATION
can	I-NEGATION
not	I-NEGATION
be	I-NEGATION
immunologically	I-NEGATION
differentiated	I-NEGATION
from	I-NEGATION
the	I-NEGATION
50	I-NEGATION
kDa	I-NEGATION
subunit	I-NEGATION
of	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
.	O

The	O
purified	O
NF-GM2	O
activated	O
in	O
vitro	O
transcription	O
from	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
it	O
failed	B-NEGATION
to	I-NEGATION
stimulate	I-NEGATION
transcription	I-NEGATION
from	I-NEGATION
the	I-NEGATION
GM-CSF	I-NEGATION
promoter	I-NEGATION
harboring	I-NEGATION
the	I-NEGATION
GM2	I-NEGATION
sequence	I-NEGATION
.	O

This	O
suggests	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
activation	I-SPECULATION
mechanism	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
GM-CSF	I-SPECULATION
gene	I-SPECULATION
through	I-SPECULATION
the	I-SPECULATION
GM2	I-SPECULATION
/	I-SPECULATION
GC-box	I-SPECULATION
sequence	I-SPECULATION
is	I-SPECULATION
different	I-SPECULATION
from	I-SPECULATION
that	I-SPECULATION
of	I-SPECULATION
genes	I-SPECULATION
carrying	I-SPECULATION
the	I-SPECULATION
kappa	I-SPECULATION
B	I-SPECULATION
enhancer	I-SPECULATION
alone	I-SPECULATION
.	O

Glucocorticoid	O
receptors	O
in	O
normal	O
leukocytes	O
:	O
effects	O
of	O
age	O
,	O
gender	O
,	O
season	O
,	O
and	O
plasma	O
cortisol	O
concentrations	O
.	O

We	O
measured	O
glucocorticoid	O
receptors	O
(	O
GR	O
)	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
isolated	O
from	O
peripheral	O
blood	O
of	O
145	O
apparently	O
healthy	O
volunteers	O
(	O
86	O
men	O
and	O
59	O
women	O
)	O
.	O

An	B-SPECULATION
age-related	I-SPECULATION
decrease	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
number	I-SPECULATION
of	I-SPECULATION
GR	I-SPECULATION
was	I-SPECULATION
suggested	I-SPECULATION
between	I-SPECULATION
subjects	I-SPECULATION
younger	I-SPECULATION
than	I-SPECULATION
20	I-SPECULATION
years	I-SPECULATION
and	I-SPECULATION
elderly	I-SPECULATION
subjects	I-SPECULATION
;	O
.	O

there	O
was	O
no	B-NEGATION
apparent	I-NEGATION
seasonal	I-NEGATION
variation	I-NEGATION
in	I-NEGATION
GR	I-NEGATION
.	O

Gender	O
difference	O
in	O
the	O
number	O
of	O
GR	O
was	O
not	O
significant	O
,	O
although	O
women	O
showed	O
slightly	O
fewer	O
GR	O
.	O

Eight	O
patients	O
with	O
dermatomyositis	O
/	O
polymyositis	O
were	O
examined	O
to	O
determine	O
whether	B-SPECULATION
the	B-SPECULATION
number	I-SPECULATION
of	I-SPECULATION
GR	I-SPECULATION
in	I-SPECULATION
MNL	I-SPECULATION
could	I-SPECULATION
be	I-SPECULATION
down-regulated	I-SPECULATION
by	I-SPECULATION
their	I-SPECULATION
cognate	I-SPECULATION
ligands	I-SPECULATION
.	O

The	O
number	O
of	O
GR	O
in	O
MNL	O
from	O
these	O
patients	O
was	O
significantly	O
decreased	O
one	O
month	O
after	O
the	O
initiation	O
of	O
prednisolone	O
therapy	O
.	O

However	O
,	O
in	O
normal	O
subjects	O
,	O
the	O
GR	O
in	O
MNL	O
did	O
not	B-NEGATION
demonstrate	I-NEGATION
circadian	I-NEGATION
variation	I-NEGATION
,	O
in	O
contrast	O
to	O
concentrations	O
of	O
plasma	O
cortisol	O
.	O

Anti-CD2	O
receptor	O
antibodies	O
activate	O
the	O
HIV	O
long	O
terminal	O
repeat	O
in	O
T	O
lymphocytes	O
.	O

The	O
CD2	O
T	O
lymphocyte	O
glycoprotein	O
surface	O
molecule	O
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O

Treatment	O
of	O
chronically	O
HIV-infected	O
PBMC	O
with	O
anti-CD2	O
mAb	O
has	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
infectious	O
virus	O
from	O
these	O
cultures	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
mechanisms	O
whereby	O
anti-CD2	O
antibodies	O
stimulate	O
viral	O
production	O
.	O

We	O
demonstrate	O
that	O
treatment	O
of	O
transiently	O
transfected	O
T	O
lymphocytes	O
with	O
anti-CD2	O
antibodies	O
results	O
in	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

Furthermore	O
,	O
CAT	O
assays	O
using	O
mutated	O
HIV	O
long	O
terminal	O
repeat-CAT	O
constructs	O
and	O
gel	O
shift	O
assays	O
demonstrate	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
NF-kappa	O
B	O
enhancer	O
.	O

These	O
studies	O
suggest	B-SPECULATION
that	I-SPECULATION
interaction	I-SPECULATION
of	I-SPECULATION
CD2	I-SPECULATION
with	I-SPECULATION
its	I-SPECULATION
natural	I-SPECULATION
ligand	I-SPECULATION
,	I-SPECULATION
LFA-3	I-SPECULATION
,	I-SPECULATION
may	B-SPECULATION
play	I-SPECULATION
a	I-SPECULATION
role	I-SPECULATION
in	I-SPECULATION
regulation	I-SPECULATION
of	I-SPECULATION
HIV	I-SPECULATION
expression	I-SPECULATION
.	O

Nuclear	O
transcription	O
factors	O
that	O
bind	O
to	O
elements	O
of	O
the	O
IL-2	O
promoter	O
.	O

Induction	O
requirements	O
in	O
primary	O
human	O
T	O
cells	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
elements	O
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	O
promoter	O
in	O
the	O
stimulated	O
T	O
cell	O
line	O
,	O
Jurkat	O
.	O

The	O
sites	O
and	O
their	O
corresponding	O
nuclear	O
binding	O
factors	O
include	O
:	O
NF-kappa	O
B	O
,	O
AP-1	O
,	O
AP-3	O
,	O
OCT-1	O
,	O
and	O
NF-AT	O
.	O

The	O
latter	O
"	O
nuclear	O
factor	O
for	O
activated	O
T	O
cells	O
"	O
likely	B-SPECULATION
contributes	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
tissue	I-SPECULATION
specificity	I-SPECULATION
of	I-SPECULATION
IL-2	I-SPECULATION
gene	I-SPECULATION
expression	I-SPECULATION
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
have	O
studied	O
these	O
transcription	O
factors	O
in	O
primary	O
T	O
cells	O
from	O
human	O
blood	O
to	O
verify	O
their	O
presence	O
in	O
a	O
physiologic	O
setting	O
and	O
to	O
identify	O
the	O
signals	O
that	O
stimulate	O
factor	O
activity	O
.	O

All	O
factors	O
are	O
induced	O
in	O
the	O
nuclei	O
of	O
T	O
cells	O
upon	O
activation	O
with	O
mitogens	O
but	O
not	B-NEGATION
with	I-NEGATION
exogenous	I-NEGATION
IL-2	I-NEGATION
growth	I-NEGATION
factor	I-NEGATION
.	O

However	O
,	O
the	O
signaling	O
requirements	O
and	O
sensitivity	O
to	O
protein	O
synthesis	O
inhibitors	O
differ	O
considerably	O
.	O

Only	O
the	O
activities	O
for	O
NF-AT	O
and	O
AP-1	O
sites	O
require	O
two	O
signals	O
for	O
optimal	O
induction	O
,	O
i.e.	O
,	O
PMA	O
plus	O
either	B-SPECULATION
lectin	I-SPECULATION
.	O

Other	O
factors	O
are	O
induced	O
by	O
lectin	O
,	O
antibody	O
,	O
and	O
/	O
or	O
PMA	O
alone	O
.	O

After	O
appropriate	O
stimulation	O
,	O
both	O
NF-AT	O
and	O
AP-1	O
are	O
peculiarly	O
sensitive	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	O
.	O

Our	O
data	O
correlate	O
the	O
activity	O
of	O
NF-AT	O
and	O
AP-1	O
in	O
gel	O
shift	O
assays	O
with	O
the	O
two	O
signals	O
requirements	O
for	O
IL-2	O
gene	O
expression	O
.	O

An	O
erythroid	O
specific	O
enhancer	O
upstream	O
to	O
the	O
gene	O
encoding	O
the	O
cell-type	O
specific	O
transcription	O
factor	O
GATA-1	O
.	O

The	O
transcription	O
factor	O
GATA-1	O
is	O
expressed	O
in	O
a	O
subset	O
of	O
hemopoietic	O
cells	O
,	O
where	O
it	O
mediates	O
the	O
cell-type	O
specific	O
expression	O
of	O
several	O
genes	O
.	O

We	O
have	O
cloned	O
the	O
mouse	O
and	O
human	O
GATA-1	O
genes	O
.	O

A	O
region	O
upstream	O
to	O
the	O
first	O
exon	O
,	O
and	O
highly	O
conserved	O
between	O
mouse	O
and	O
man	O
,	O
acts	O
as	O
an	O
erythroid	O
specific	O
enhancer	O
in	O
transient	O
assays	O
,	O
if	O
linked	O
to	O
the	O
GATA-1	O
or	O
to	O
the	O
SV40	O
promoter	O
.	O

The	O
activity	O
of	O
the	O
enhancer	O
is	O
almost	O
completely	O
dependent	O
on	O
the	O
integrity	O
of	O
a	O
dimeric	O
GATA-1	O
binding	O
site	O
.	O

Demonstration	O
of	O
a	O
1,25-dihydroxyvitamin	O
D3-responsive	O
protein	O
in	O
human	O
lymphocytes	O
:	O
immunologic	O
crossreactivity	O
and	O
inverse	O
regulation	O
with	O
the	O
vitamin	O
D	O
receptor	O
.	O

Using	O
Western	O
blot	O
analysis	O
with	O
a	O
monoclonal	O
antibody	O
recognizing	O
a	O
17-amino	O
acid	O
epitope	O
of	O
the	O
1,25-dihydroxyvitamin	O
D3	O
[	O
1,25	O
(	O
OH	O
)	O
2D3	O
]	O
receptor	O
,	O
we	O
have	O
detected	O
two	O
crossreacting	O
proteins	O
in	O
activated	O
normal	O
human	O
lymphocytes	O
.	O

The	O
smaller	O
of	O
the	O
two	O
proteins	O
(	O
50	O
kDa	O
)	O
was	O
indistinguishable	O
from	O
the	O
classical	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
and	O
,	O
similar	O
to	O
the	O
classical	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
,	O
was	O
upregulated	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
1,25	O
(	O
OH	O
)	O
2D3	O
.	O

The	O
larger	O
crossreacting	O
protein	O
exhibited	O
an	O
electrophoretic	O
mobility	O
of	O
80	O
kDa	O
,	O
was	O
localized	O
in	O
the	O
cell	O
cytosol	O
,	O
and	O
appeared	B-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
specific	I-SPECULATION
for	I-SPECULATION
activated	I-SPECULATION
lymphocytes	I-SPECULATION
since	O
it	B-NEGATION
was	I-NEGATION
not	I-NEGATION
detected	I-NEGATION
in	I-NEGATION
several	I-NEGATION
other	I-NEGATION
human	I-NEGATION
cells	I-NEGATION
including	I-NEGATION
monocytes	I-NEGATION
.	O

More	O
strikingly	O
,	O
the	O
80-kDa	O
protein	O
was	O
downregulated	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
1,25	O
(	O
OH	O
)	O
2D3	O
;	O

this	O
effect	O
was	O
independent	O
of	O
the	O
mode	O
of	O
lymphocyte	O
activation	O
and	O
specific	O
for	O
the	O
1,25	O
(	O
OH	O
)	O
2D3	O
metabolite	O
of	O
vitamin	O
D3	O
.	O

However	O
,	O
two	O
potent	O
immunosuppressive	O
agents	O
,	O
glucocorticoids	O
and	O
cyclosporin	O
A	O
,	O
also	O
inhibited	O
the	O
80-kDa	O
protein	O
.	O

T-helper-cell	O
determinants	O
in	O
protein	O
antigens	O
are	O
preferentially	O
located	O
in	O
cysteine-rich	O
antigen	O
segments	O
resistant	O
to	O
proteolytic	O
cleavage	O
by	O
cathepsin	O
B	O
,	O
L	O
,	O
and	O
D	O
.	O

We	O
report	O
on	O
a	O
computer	O
algorithm	O
capable	O
of	O
predicting	O
the	O
location	O
of	O
T-helper-cell	O
epitopes	O
in	O
protein	O
antigen	O
(	O
Ag	O
)	O
by	O
analysing	O
the	O
Ag	O
amino	O
acid	O
sequence	O
.	O

The	O
algorithm	O
was	O
constructed	O
with	O
the	O
aim	O
of	O
identifying	O
segments	O
in	O
Ag	O
which	O
are	O
resistant	O
to	O
proteolytic	O
degradation	O
by	O
the	O
enzymes	O
cathepsin	O
B	O
,	O
L	O
,	O
and	O
D	O
.	O

These	O
are	O
prominent	O
enzymes	O
in	O
the	O
endocytic	O
pathway	O
through	O
which	O
soluble	O
protein	O
Ag	O
enter	O
APC	O
,	O
and	O
resistant	B-SPECULATION
segments	I-SPECULATION
in	I-SPECULATION
Ag	I-SPECULATION
may	I-SPECULATION
,	I-SPECULATION
therefore	I-SPECULATION
,	I-SPECULATION
be	I-SPECULATION
expected	I-SPECULATION
to	I-SPECULATION
contain	I-SPECULATION
more	I-SPECULATION
T-cell	I-SPECULATION
determinants	I-SPECULATION
than	I-SPECULATION
susceptible	I-SPECULATION
segments	I-SPECULATION
.	O

From	O
information	O
available	O
in	O
the	O
literature	O
on	O
the	O
substrate	O
specificity	O
of	O
the	O
three	O
enzymes	O
,	O
it	O
is	O
clear	O
that	O
a	B-NEGATION
cysteine	I-NEGATION
is	I-NEGATION
not	I-NEGATION
accepted	I-NEGATION
in	I-NEGATION
any	I-NEGATION
of	I-NEGATION
the	I-NEGATION
S2	I-NEGATION
,	I-NEGATION
S1	I-NEGATION
,	I-NEGATION
S1	I-NEGATION
'	I-NEGATION
,	O
and	O
S2	O
'	O
subsites	O
of	O
cathepsin	O
B	O
and	O
L	O
,	O
and	O
not	B-NEGATION
in	I-NEGATION
the	I-NEGATION
S1	I-NEGATION
and	I-NEGATION
S1	I-NEGATION
'	I-NEGATION
subsites	I-NEGATION
of	I-NEGATION
cathepsin	I-NEGATION
D	I-NEGATION
.	O

Moreover	O
,	O
we	O
have	O
noticed	O
that	O
cysteine-containing	O
T-cell	O
determinants	O
in	O
a	O
number	O
of	O
protein	O
Ag	O
are	O
particularly	O
rich	O
in	O
the	O
amino	O
acids	O
alanine	O
,	O
glycine	O
,	O
lysine	O
,	O
leucine	O
,	O
serine	O
,	O
threonine	O
,	O
and	O
valine	O
.	O

By	O
searching	O
protein	O
Ag	O
for	O
clusters	O
of	O
amino	O
acids	O
containing	O
cysteine	O
and	O
two	O
of	O
the	O
other	O
amino	O
acids	O
we	O
were	O
able	O
to	O
predict	O
17	O
out	O
of	O
23	O
empirically	O
known	O
T-cell	O
determinants	O
in	O
the	O
Ag	O
with	O
a	O
relatively	O
low	O
number	O
of	O
false	O
(	O
positive	O
)	O
predictions	O
.	O

Furthermore	O
,	O
we	O
present	O
a	O
new	O
principle	O
for	O
searching	O
Ag	O
for	O
potential	O
amphipatic	O
alpha-helical	O
protein	O
segments	O
.	O

Such	O
segments	O
accord	O
well	O
with	O
empirically	O
known	O
T-cell	O
determinants	O
and	O
our	O
algorithm	O
produces	O
a	O
lower	O
number	O
of	O
false	O
positive	O
predictions	O
than	O
the	O
principle	O
based	O
on	O
discrete	O
Fourier	O
transformations	O
previously	O
described	O
.	O

A	O
human	O
putative	B-SPECULATION
lymphocyte	I-SPECULATION
G0	I-SPECULATION
/	I-SPECULATION
G1	I-SPECULATION
switch	I-SPECULATION
gene	I-SPECULATION
containing	O
a	O
CpG-rich	O
island	O
encodes	O
a	O
small	O
basic	O
protein	O
with	O
the	O
potential	O
to	O
be	O
phosphorylated	O
.	O

Genes	B-SPECULATION
actively	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
G0	I-SPECULATION
/	I-SPECULATION
G1	I-SPECULATION
switch	I-SPECULATION
(	I-SPECULATION
G0S	I-SPECULATION
genes	I-SPECULATION
)	I-SPECULATION
may	I-SPECULATION
be	I-SPECULATION
differentially	I-SPECULATION
expressed	I-SPECULATION
during	I-SPECULATION
the	I-SPECULATION
lectin-induced	I-SPECULATION
switch	I-SPECULATION
of	I-SPECULATION
lymphocytes	I-SPECULATION
from	I-SPECULATION
the	I-SPECULATION
G0	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
G1	I-SPECULATION
phases	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
cell	I-SPECULATION
cycle	I-SPECULATION
.	O

This	O
paper	O
presents	O
studies	O
of	O
G0S2	O
,	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	B-SPECULATION
G0S	I-SPECULATION
genes	I-SPECULATION
,	O
for	O
which	O
cDNAs	O
were	O
cloned	O
and	O
selected	O
on	O
the	O
basis	O
of	O
differential	O
cDNA	O
hybridization	O
.	O

G0S2	O
mRNA	O
increases	O
transiently	O
within	O
1-2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	O
or	O
cycloheximide	O
to	O
cultured	O
blood	O
mononuclear	O
cells	O
.	O

Comparison	O
of	O
a	O
nearly	O
full-length	O
cDNA	O
sequence	O
with	O
the	O
corresponding	O
genomic	O
sequence	O
reveals	O
one	O
small	O
intron	O
and	O
an	O
open	O
reading	O
frame	O
in	O
the	O
second	O
exon	O
.	O

The	O
derived	O
103-amino-acid	O
basic	O
protein	O
has	O
two	O
potential	O
alpha-helical	O
domains	O
separated	O
by	O
a	O
hydrophobic	O
region	O
with	O
the	O
potential	O
to	O
generate	O
turns	O
and	O
assume	O
a	O
beta-sheet	O
conformation	O
.	O

Consistent	O
with	O
involvement	O
in	O
the	O
G0	O
/	O
G1	O
switch	O
,	O
the	O
protein	O
contains	O
potential	O
sites	O
for	O
phosphorylation	O
by	O
protein	O
kinase	O
C	O
and	O
casein	O
kinase	O
II	O
.	O

The	O
gene	O
contains	O
a	O
CpG-rich	O
island	O
suggesting	B-SPECULATION
expression	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
germ	I-SPECULATION
line	I-SPECULATION
.	O

An	O
upstream	O
segment	O
contains	O
tandem	O
dinucleotide	O
repeats	O
(	O
CT	O
)	O
19	O
/(	O
CA	O
)	O
16	O
.	O

There	O
is	O
a	O
suitably	O
located	O
TATA	O
box	O
,	O
but	O
potential	B-SPECULATION
sites	I-SPECULATION
for	I-SPECULATION
CCAAT-box	I-SPECULATION
binding	I-SPECULATION
factors	I-SPECULATION
are	O
far	O
upstream	O
,	O
embedded	O
in	O
a	O
42-nucleotide	O
repeat	O
element	O
.	O

Potential	B-SPECULATION
sites	I-SPECULATION
for	I-SPECULATION
transcription	I-SPECULATION
factors	I-SPECULATION
AP1	I-SPECULATION
,	I-SPECULATION
AP2	I-SPECULATION
,	I-SPECULATION
and	I-SPECULATION
AP3	I-SPECULATION
are	O
consistent	O
with	O
rapid	O
transcriptional	O
activation	O
in	O
response	O
to	O
inducing	O
agents	O
.	O

Synergism	O
between	O
two	O
distinct	O
elements	O
of	O
the	O
HTLV-I	O
enhancer	O
during	O
activation	O
by	O
the	O
trans-activator	O
of	O
HTLV-I	O
.	O

We	O
have	O
conducted	O
functional	O
studies	O
of	O
the	O
enhancer	O
elements	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
using	O
the	O
human	O
T-cell	O
lines	O
Jurkat	O
and	O
MOLT	O
4	O
,	O
which	O
are	O
negative	O
for	O
HTLV-I	O
,	O
and	O
MT-2	O
and	O
TL-Mor	O
,	O
which	O
carry	O
the	O
proviral	O
genome	O
of	O
HTLV-I	O
.	O

Two	O
distinct	O
elements	O
have	O
been	O
implicated	O
in	O
function	O
of	O
the	O
HTLV-I	O
enhancer	O
.	O

One	O
is	O
the	O
21-base-pair	O
(	O
bp	O
)	O
core	O
element	O
that	O
is	O
responsible	O
for	O
trans-activation	O
by	O
the	O
HTLV-I	O
trans-activator	O
p40tax	O
and	O
that	O
has	O
the	O
ability	O
to	O
bind	O
to	O
cyclic-AMP	O
responsive	O
element	O
binding	O
factor	O
(	O
CREB	O
)	O
-	O
like	O
factor	O
(	O
s	O
)	O
.	O

The	O
other	O
is	O
a	O
region	O
interposed	O
between	O
the	O
21-bp	O
elements	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
a	O
subfragment	O
(	O
C26	O
)	O
in	O
the	O
region	O
between	O
the	O
21-bp	O
elements	O
is	O
involved	O
in	O
trans-activation	O
by	O
p40tax	O
,	O
possibly	B-SPECULATION
through	I-SPECULATION
binding	I-SPECULATION
to	I-SPECULATION
an	I-SPECULATION
NF-kappa	I-SPECULATION
B-like	I-SPECULATION
nuclear	I-SPECULATION
factor	B-SPECULATION
or	I-SPECULATION
factors	I-SPECULATION
.	O

Formation	O
of	O
the	O
protein-DNA	O
complex	O
with	O
the	O
C26	O
subfragment	O
was	O
positively	O
affected	O
by	O
p40tax	O
.	O

The	O
C26	O
element	O
conferred	O
partial	O
responsiveness	O
to	O
p40tax	O
when	O
linked	O
to	O
one	O
copy	O
of	O
the	O
21-bp	O
element	O
that	O
,	O
by	O
itself	O
,	O
showed	O
little	O
activation	O
in	O
response	O
to	O
p40tax	O
.	O

However	B-NEGATION
,	I-NEGATION
the	I-NEGATION
C26	I-NEGATION
element	I-NEGATION
alone	I-NEGATION
,	I-NEGATION
even	I-NEGATION
when	I-NEGATION
repeated	I-NEGATION
,	I-NEGATION
could	I-NEGATION
not	I-NEGATION
be	I-NEGATION
activated	I-NEGATION
by	I-NEGATION
p40tax	I-NEGATION
,	O
unlike	O
other	O
NF-kappa	O
B-binding	O
elements	O
.	O

In	O
contrast	O
,	O
the	O
C26	O
element	O
itself	O
was	O
profoundly	O
activated	O
upon	O
stimulation	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
.	O

These	O
findings	O
therefore	O
suggest	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
HTLV-I	I-SPECULATION
enhancer	I-SPECULATION
contains	I-SPECULATION
multiple	I-SPECULATION
functional	I-SPECULATION
elements	I-SPECULATION
,	I-SPECULATION
including	I-SPECULATION
binding	I-SPECULATION
sites	I-SPECULATION
for	I-SPECULATION
at	I-SPECULATION
least	I-SPECULATION
CREB	I-SPECULATION
-	I-SPECULATION
and	I-SPECULATION
NF-kappa	I-SPECULATION
B-like	I-SPECULATION
factors	I-SPECULATION
,	O
which	O
synergistically	O
cooperate	O
in	O
activation	O
of	O
the	O
HTLV-I	O
enhancer	O
in	O
response	O
to	O
p40tax	O
.	O

Our	O
results	O
also	O
demonstrate	O
that	O
TPA-dependent	B-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
HTLV-I	I-SPECULATION
enhancer	I-SPECULATION
may	I-SPECULATION
be	I-SPECULATION
mediated	I-SPECULATION
through	I-SPECULATION
the	I-SPECULATION
C26	I-SPECULATION
element	I-SPECULATION
.	O

v-erbA	O
overexpression	O
is	O
required	O
to	O
extinguish	O
c-erbA	O
function	O
in	O
erythroid	O
cell	O
differentiation	O
and	O
regulation	O
of	O
the	O
erbA	O
target	O
gene	O
CAII	O
.	O

The	O
v-erbA	O
oncoprotein	O
represents	O
a	O
retrovirus-transduced	O
oncogenic	O
version	O
of	O
the	O
thyroid	O
hormone	O
(	O
T3	O
/	O
T4	O
)	O
receptor	O
c-erbA	O
(	O
type	O
alpha	O
)	O
.	O

It	O
contributes	O
to	O
virus-induced	O
erythroleukemia	O
by	O
efficiently	O
arresting	O
differentiation	O
of	O
red	O
cell	O
progenitors	O
and	O
by	O
suppressing	O
transcription	O
of	O
erythrocyte-specific	O
genes	O
.	O

Here	O
,	O
we	O
show	O
that	O
v-erbA	O
and	O
c-erbA	O
bind	O
directly	O
to	O
sequences	O
within	O
the	O
promoter	O
of	O
the	O
erythrocyte-specific	O
carbonic	O
anhydrase	O
II	O
(	O
CAII	O
)	O
,	O
a	O
gene	O
whose	O
transcription	O
is	O
efficiently	O
suppressed	O
by	O
v-erbA	O
.	O

This	O
erbA-binding	O
site	O
confers	O
thyroid	O
hormone	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
in	O
transient	O
expression	O
experiments	O
and	O
is	O
a	O
target	O
for	O
efficient	O
down-regulation	O
of	O
CAII	O
transcription	O
by	O
the	O
v-erbA	O
oncoprotein	O
.	O

In	O
stably	O
transformed	O
erythroblasts	O
coexpressing	O
the	O
v-erbA	O
oncoprotein	O
and	O
the	O
c-erbA	O
/	O
T3	O
receptor	O
at	O
an	O
approximately	O
equimolar	O
ratio	O
,	O
c-erbA	O
activity	O
is	O
dominant	O
over	O
v-erbA	O
.	O

T3	O
efficiently	O
induced	O
erythroid	O
differentiation	O
in	O
these	O
cells	O
,	O
thus	O
overcoming	O
the	O
v-erbA-mediated	O
differentiation	O
arrest	O
.	O

Likewise	O
,	O
T3	O
activated	O
CAII	O
transcription	O
as	O
well	O
as	O
transient	O
expression	O
of	O
a	O
T3-responsive	O
reporter	O
gene	O
containing	O
the	O
CAII-specific	O
erbA-binding	O
site	O
.	O

The	B-SPECULATION
c-erbA-dependent	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
this	I-SPECULATION
CAII	I-SPECULATION
reporter	I-SPECULATION
construct	I-SPECULATION
could	I-SPECULATION
only	I-SPECULATION
be	I-SPECULATION
suppressed	I-SPECULATION
by	I-SPECULATION
very	I-SPECULATION
high	I-SPECULATION
amounts	I-SPECULATION
of	I-SPECULATION
v-erbA	I-SPECULATION
.	O

Our	O
results	O
suggest	B-SPECULATION
that	I-SPECULATION
overexpression	I-SPECULATION
of	I-SPECULATION
v-erbA	I-SPECULATION
is	I-SPECULATION
required	I-SPECULATION
for	I-SPECULATION
its	I-SPECULATION
function	I-SPECULATION
as	I-SPECULATION
an	I-SPECULATION
oncoprotein	I-SPECULATION
.	O

Inhibition	O
of	O
phorbol	O
ester-induced	O
monocytic	O
differentiation	O
by	O
dexamethasone	O
is	O
associated	O
with	O
down-regulation	O
of	O
c-fos	O
and	O
c-jun	O
(	O
AP-1	O
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
treatment	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
is	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c-jun	O
and	O
c-fos	O
early	O
response	O
genes	O
.	O

The	O
present	O
work	O
demonstrates	O
that	O
the	O
glucocorticoid	O
dexamethasone	O
inhibits	O
TPA-induced	O
increases	O
in	O
c-jun	O
and	O
c-fos	O
mRNA	O
levels	O
in	O
U-937	O
leukemia	O
cells	O
.	O

These	O
findings	O
were	O
associated	O
with	O
a	O
block	O
in	O
appearance	O
of	O
the	O
monocytic	O
phenotype	O
,	O
including	O
inhibition	O
of	O
TPA-induced	O
increases	O
in	O
lamin	O
A	O
,	O
lamin	O
C	O
,	O
and	O
vimentin	O
transcripts	O
.	O

Other	O
studies	O
have	O
demonstrated	O
that	O
TPA-induced	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c-jun	O
and	O
c-fos	O
genes	O
in	O
myeloid	O
leukemia	O
cells	O
are	O
regulated	O
by	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

The	O
finding	O
that	O
dexamethasone	O
has	O
no	B-NEGATION
effect	I-NEGATION
on	I-NEGATION
TPA-induced	I-NEGATION
activation	I-NEGATION
of	I-NEGATION
PKC	I-NEGATION
suggests	B-SPECULATION
that	I-SPECULATION
this	I-SPECULATION
glucocorticoid	I-SPECULATION
inhibits	I-SPECULATION
signals	I-SPECULATION
downstream	B-SPECULATION
or	I-SPECULATION
parallel	I-SPECULATION
to	O
this	O
enzyme	O
.	O

Nuclear	O
run-on	O
assays	O
demonstrate	O
that	O
:	O
(	O
1	O
)	O
induction	O
of	O
c-jun	O
and	O
c-fos	O
expression	O
by	O
TPA	O
is	O
regulated	O
by	O
transcriptional	O
mechanisms	O
,	O
(	O
2	O
)	O
TPA-induced	O
expression	O
of	O
c-jun	O
and	O
c-fos	O
does	O
not	B-NEGATION
require	I-NEGATION
protein	I-NEGATION
synthesis	I-NEGATION
,	O
and	O
(	O
3	O
)	O
TPA-induced	O
expression	O
of	O
both	O
genes	O
is	O
inhibited	O
at	O
the	O
transcriptional	O
level	O
by	O
dexamethasone	O
.	O

To	O
further	O
define	O
the	O
effects	O
of	O
dexamethasone	O
at	O
the	O
molecular	O
level	O
,	O
we	O
prepared	O
a	O
series	O
of	O
deleted	O
c-jun	O
promoter	O
fragments	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
.	O

Increases	B-SPECULATION
in	I-SPECULATION
CAT	I-SPECULATION
activity	I-SPECULATION
during	I-SPECULATION
transient	I-SPECULATION
expression	I-SPECULATION
of	I-SPECULATION
these	I-SPECULATION
constructs	I-SPECULATION
in	I-SPECULATION
TPA-treated	I-SPECULATION
U-937	I-SPECULATION
cells	I-SPECULATION
could	I-SPECULATION
be	I-SPECULATION
assigned	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
region	I-SPECULATION
(-	I-SPECULATION
97	I-SPECULATION
to	I-SPECULATION
-	I-SPECULATION
20	I-SPECULATION
)	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
promoter	I-SPECULATION
that	I-SPECULATION
contains	I-SPECULATION
the	I-SPECULATION
AP-1	I-SPECULATION
binding	I-SPECULATION
site	I-SPECULATION
.	O

This	O
induction	O
of	O
CAT	O
activity	O
was	O
sensitive	O
to	O
dexamethasone	O
.	O

These	O
findings	O
suggest	B-SPECULATION
that	I-SPECULATION
dexamethasone	I-SPECULATION
down-regulates	I-SPECULATION
TPA-induced	I-SPECULATION
transcription	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
c-jun	I-SPECULATION
gene	I-SPECULATION
during	I-SPECULATION
monocytic	I-SPECULATION
differentiation	I-SPECULATION
by	I-SPECULATION
inhibiting	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
AP-1	I-SPECULATION
site	I-SPECULATION
.	O

Charybdotoxin-sensitive	O
,	O
Ca	O
(	O
2	O
+)-	O
dependent	O
membrane	O
potential	O
changes	O
are	O
not	B-NEGATION
involved	I-NEGATION
in	I-NEGATION
human	I-NEGATION
T	I-NEGATION
or	I-NEGATION
B	I-NEGATION
cell	I-NEGATION
activation	I-NEGATION
and	I-NEGATION
proliferation	I-NEGATION
.	O

The	B-SPECULATION
involvement	I-SPECULATION
of	I-SPECULATION
ion	I-SPECULATION
channels	I-SPECULATION
in	I-SPECULATION
B	I-SPECULATION
and	I-SPECULATION
T	I-SPECULATION
lymphocyte	I-SPECULATION
activation	I-SPECULATION
is	I-SPECULATION
supported	I-SPECULATION
by	I-SPECULATION
many	I-SPECULATION
reports	I-SPECULATION
of	I-SPECULATION
changes	I-SPECULATION
in	I-SPECULATION
ion	I-SPECULATION
fluxes	I-SPECULATION
and	I-SPECULATION
membrane	I-SPECULATION
potential	I-SPECULATION
after	I-SPECULATION
mitogen	I-SPECULATION
binding	I-SPECULATION
.	O

Human	O
T	O
and	O
B	O
lymphocytes	O
demonstrate	O
an	O
early	O
and	O
transient	O
hyperpolarization	O
after	O
ligand	O
binding	O
.	O

Inasmuch	O
as	O
the	O
change	O
in	O
membrane	O
potential	O
is	O
dependent	O
on	O
elevation	O
of	O
free	O
cytosolic	O
calcium	O
,	O
the	O
hyperpolarization	O
is	O
presumably	B-SPECULATION
through	I-SPECULATION
opening	I-SPECULATION
of	I-SPECULATION
Ca	I-SPECULATION
(	I-SPECULATION
2	I-SPECULATION
+)-	I-SPECULATION
stimulated	I-SPECULATION
K	I-SPECULATION
+	I-SPECULATION
channels	I-SPECULATION
.	O

We	O
have	O
used	O
charybdotoxin	O
,	O
a	O
known	O
inhibitor	O
of	O
Ca	O
(	O
2	O
+)-	O
dependent	O
K	O
+	O
channels	O
,	O
to	O
study	O
the	O
role	O
of	O
these	O
channels	O
in	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O

We	O
demonstrate	O
that	O
charybdotoxin	O
inhibits	O
the	O
ligand-induced	O
transient	O
membrane	O
hyperpolarization	O
in	O
B	O
and	O
T	O
cells	O
in	O
a	O
dose-dependent	O
fashion	O
,	O
without	B-NEGATION
affecting	I-NEGATION
changes	I-NEGATION
in	I-NEGATION
cytosolic	I-NEGATION
Ca2	I-NEGATION
+	I-NEGATION
.	O

However	O
,	O
blockade	O
of	O
the	O
Ca	O
(	O
2	O
+)-	O
activated	O
K	O
+	O
channel	O
is	O
not	B-NEGATION
associated	I-NEGATION
with	I-NEGATION
changes	I-NEGATION
in	I-NEGATION
cell-cycle	I-NEGATION
gene	I-NEGATION
activation	I-NEGATION
,	I-NEGATION
IL-2	I-NEGATION
production	I-NEGATION
,	I-NEGATION
IL-2R	I-NEGATION
expression	I-NEGATION
or	I-NEGATION
B	I-NEGATION
and	I-NEGATION
T	I-NEGATION
cell	I-NEGATION
mitogenesis	I-NEGATION
.	O

These	O
results	O
imply	B-SPECULATION
that	I-SPECULATION
membrane	B-NEGATION
potential	I-NEGATION
changes	I-NEGATION
secondary	I-NEGATION
to	I-NEGATION
the	I-NEGATION
ligand-dependent	I-NEGATION
opening	I-NEGATION
of	I-NEGATION
Ca	I-NEGATION
(	I-NEGATION
2	I-NEGATION
+)-	I-NEGATION
activated	I-NEGATION
K	I-NEGATION
+	I-NEGATION
channels	I-NEGATION
are	I-NEGATION
not	I-NEGATION
involved	I-NEGATION
in	I-NEGATION
B	I-NEGATION
and	I-NEGATION
T	I-NEGATION
lymphocyte	I-NEGATION
activation	I-NEGATION
and	I-NEGATION
mitogenesis	I-NEGATION
.	O

Evaluation	O
of	O
the	O
role	O
of	O
ligand	O
and	O
thermal	O
activation	O
of	O
specific	O
DNA	O
binding	O
by	O
in	O
vitro	O
synthesized	O
human	O
glucocorticoid	O
receptor	O
.	O

We	O
have	O
used	O
a	O
DNA-binding	O
/	O
immunoprecipitation	O
assay	O
to	O
analyze	O
the	O
capacity	O
of	O
human	O
glucocorticoid	O
receptor	O
(	O
hGR	O
)	O
,	O
generated	O
in	O
rabbit	O
reticulocyte	O
lysates	O
,	O
to	O
bind	O
DNA	O
.	O

In	O
vitro	O
translated	O
hGR	O
was	O
indistinguishable	O
from	O
native	O
hGR	O
,	O
as	O
determined	O
by	O
migration	O
on	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gels	O
,	O
sedimentation	O
on	O
sucrose	O
density	O
gradients	O
,	O
and	O
reactivity	O
with	O
antipeptide	O
antibodies	O
generated	O
against	O
hGR	O
.	O

In	O
addition	O
,	O
cell-free	O
synthesized	O
hGR	O
was	O
capable	O
of	O
specific	O
binding	O
to	O
glucocorticoid	O
response	O
element	O
(	O
GRE	O
)	O
-	O
containing	O
DNA	O
fragments	O
.	O

Using	O
this	O
assay	O
system	O
,	O
we	O
have	O
evaluated	O
the	O
contributions	O
of	O
ligand	O
binding	O
and	O
heat	O
activation	O
to	O
DNA	O
binding	O
by	O
these	O
glucocorticoid	O
receptors	O
.	O

In	O
vitro	O
translated	O
hGR	O
was	O
capable	O
of	O
selective	O
DNA	O
binding	O
even	O
in	O
the	O
absence	B-NEGATION
of	I-NEGATION
glucocorticoid	I-NEGATION
.	O

Treatment	O
with	O
dexamethasone	O
or	O
the	O
antiglucocorticoid	O
RU486	O
had	O
no	B-NEGATION
additional	I-NEGATION
effect	I-NEGATION
on	I-NEGATION
the	I-NEGATION
DNA-binding	I-NEGATION
capacity	I-NEGATION
when	O
receptor	O
preparations	O
were	O
maintained	O
at	O
0	O
C	O
(	O
no	B-NEGATION
activation	I-NEGATION
)	O
.	O

In	O
contrast	O
,	O
addition	O
of	O
either	O
ligand	O
or	O
antagonist	O
in	O
combination	O
with	O
a	O
heat	O
activation	O
step	O
promoted	O
DNA	O
binding	O
by	O
approximately	O
3-fold	O
over	O
that	O
of	O
heat-activated	O
unliganded	O
receptors	O
.	O

Agonist	O
(	O
dexamethasone	O
)	O
was	O
slightly	O
more	O
effective	O
in	O
supporting	O
specific	O
DNA	O
binding	O
than	O
antagonist	O
(	O
RU486	O
)	O
.	O

DNA	O
binding	O
by	O
in	O
vitro	O
synthesized	O
GR	O
was	O
blocked	O
by	O
the	O
addition	O
of	O
sodium	O
molybdate	O
to	O
the	O
receptor	O
preparations	O
before	O
steroid	O
addition	O
and	O
thermal	O
activation	O
.	O

Addition	O
of	O
KCl	O
resulted	O
in	O
less	O
DNA	O
binding	O
either	B-SPECULATION
due	I-SPECULATION
to	I-SPECULATION
blockage	I-SPECULATION
of	I-SPECULATION
DNA-receptor	I-SPECULATION
complex	I-SPECULATION
formation	I-SPECULATION
.	O

The	O
specificity	O
of	O
DNA	O
binding	O
by	O
cell-free	O
synthesized	O
hGR	O
was	O
analyzed	O
further	O
by	O
examining	O
the	O
abilities	O
of	O
various	O
DNAs	O
to	O
compete	O
for	O
binding	O
to	O
a	O
naturally	O
occurring	O
GRE	O
found	O
in	O
the	O
mouse	O
mammary	O
tumor	O
virus-long	O
terminal	O
repeat	O
.	O

Oligonucleotides	O
containing	O
the	O
consensus	O
GRE	O
were	O
the	O
most	O
efficient	O
competitors	O
,	O
and	O
fragments	O
containing	O
regulatory	O
sequences	O
from	O
glucocorticoid-repressible	O
genes	O
were	O
somewhat	O
competitive	O
,	O
whereas	O
single	O
stranded	O
oligonucleotides	O
were	O
unable	B-NEGATION
to	I-NEGATION
compete	I-NEGATION
for	I-NEGATION
mouse	I-NEGATION
mammary	I-NEGATION
tumor	I-NEGATION
virus-long	I-NEGATION
terminal	I-NEGATION
repeat	I-NEGATION
DNA	I-NEGATION
binding	I-NEGATION
,	O
except	O
when	O
competitor	O
was	O
present	O
at	O
extremely	O
high	O
concentrations	O
.	O

Together	O
these	O
studies	O
indicate	B-SPECULATION
that	I-SPECULATION
hGR	I-SPECULATION
synthesized	I-SPECULATION
in	I-SPECULATION
rabbit	I-SPECULATION
reticulocyte	I-SPECULATION
lysates	I-SPECULATION
displays	I-SPECULATION
many	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
same	I-SPECULATION
properties	I-SPECULATION
,	I-SPECULATION
including	I-SPECULATION
GRE-specific	I-SPECULATION
DNA	I-SPECULATION
binding	I-SPECULATION
,	I-SPECULATION
observed	I-SPECULATION
for	I-SPECULATION
glucocorticoid	I-SPECULATION
receptor	I-SPECULATION
present	I-SPECULATION
in	I-SPECULATION
cytosolic	I-SPECULATION
extracts	I-SPECULATION
of	I-SPECULATION
mammalian	I-SPECULATION
cells	I-SPECULATION
and	I-SPECULATION
tissues	I-SPECULATION
.	O

Similarities	O
between	O
the	O
effects	O
of	O
dexamethasone	O
and	O
RU486	O
suggest	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
antiglucocorticoid	I-SPECULATION
properties	I-SPECULATION
of	I-SPECULATION
RU486	I-SPECULATION
do	I-SPECULATION
not	B-NEGATION
occur	I-NEGATION
at	I-NEGATION
the	I-NEGATION
level	I-NEGATION
of	I-NEGATION
specific	I-NEGATION
DNA	I-NEGATION
binding	I-NEGATION
.	O

One	O
base	O
pair	O
change	O
abolishes	O
the	O
T	O
cell-restricted	O
activity	O
of	O
a	O
kB-like	O
proto-enhancer	O
element	O
from	O
the	O
interleukin	O
2	O
promoter	O
.	O

The	O
inducible	O
,	O
T	O
cell-specific	O
enhancers	O
of	O
murine	O
and	O
human	O
Interleukin	O
2	O
(	O
Il-2	O
)	O
genes	O
contain	O
the	O
kB-like	O
sequence	O
GGGATTTCACC	O
as	O
an	O
essential	O
cis-acting	O
enhancer	O
motif	O
.	O

When	O
cloned	O
in	O
multiple	O
copies	O
this	O
so-called	O
TCEd	O
(	O
distal	O
T	O
cell	O
element	O
)	O
acts	O
as	O
an	O
inducible	O
proto-enhancer	O
element	O
in	O
E14	O
T	O
lymphoma	O
cells	O
,	O
but	O
not	B-NEGATION
in	I-NEGATION
HeLa	I-NEGATION
cells	I-NEGATION
.	O

In	O
extracts	O
of	O
induced	O
,	O
Il-2	O
secreting	O
El4	O
cells	O
three	O
individual	O
protein	O
factors	O
bind	O
to	O
TCEd	O
DNA	O
.	O

The	O
binding	O
of	O
the	O
most	O
prominent	O
factor	O
,	O
named	O
TCF-1	O
(	O
T	O
cell	O
factor	O
1	O
)	O
,	O
is	O
correlated	O
with	O
the	O
proto-enhancer	O
activity	O
of	O
TCEd	O
.	O

TCF-1	O
consists	O
of	O
two	O
polypeptides	O
of	O
about	O
50	O
kD	O
and	O
105	O
kD	O
;	O

the	B-SPECULATION
former	I-SPECULATION
seems	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
related	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
50	I-SPECULATION
kD	I-SPECULATION
polypeptide	I-SPECULATION
of	I-SPECULATION
NF-kB	I-SPECULATION
.	O

Purified	O
NF-kB	O
is	O
also	O
able	O
to	O
bind	O
to	O
the	O
TCEd	O
,	O
but	O
TCF-1	O
binds	O
stronger	O
than	O
NF-kB	O
to	O
TCEd	O
DNA	O
.	O

The	O
conversion	O
of	O
the	O
TCEd	O
to	O
a	O
'	O
perfect	O
'	O
NF-kB	O
binding	O
site	O
leads	O
to	O
a	O
tighter	O
binding	O
of	O
NF-kB	O
to	O
TCEd	O
DNA	O
and	O
,	O
as	O
a	O
functional	O
consequence	O
,	O
to	O
the	O
activity	O
of	O
the	O
'	O
converted	O
'	O
TCEd	O
motifs	O
in	O
HeLa	O
cells	O
.	O

Thus	O
,	O
the	O
substitution	O
of	O
the	O
underlined	O
A	O
residue	O
to	O
a	O
C	O
within	O
the	O
GGGATTTCACC	O
motif	O
abolishes	O
its	O
T	O
cell-restricted	O
activity	O
and	O
leads	O
to	O
its	O
functioning	O
in	O
both	O
El4	O
cells	O
and	O
HeLa	O
cells	O
.	O

These	O
results	O
indicate	B-SPECULATION
that	I-SPECULATION
lymphocyte-specific	I-SPECULATION
factors	I-SPECULATION
binding	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
TCEd	I-SPECULATION
are	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
control	I-SPECULATION
of	I-SPECULATION
T	I-SPECULATION
cell	I-SPECULATION
specific-transcription	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
Il-2	I-SPECULATION
gene	I-SPECULATION
.	O

Negative	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytes	O
:	O
role	O
of	O
the	O
65-kDa	O
plus	O
50-kDa	O
NF-kappa	O
B	O
dimer	O
.	O

Although	O
monocytic	O
cells	O
can	O
provide	O
a	O
reservoir	O
for	O
viral	O
production	O
in	O
vivo	O
,	O
their	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
transcription	O
can	B-SPECULATION
be	I-SPECULATION
either	B-SPECULATION
latent	I-SPECULATION
,	I-SPECULATION
restricted	I-SPECULATION
,	I-SPECULATION
.	O

These	B-NEGATION
differences	I-NEGATION
in	I-NEGATION
gene	I-NEGATION
expression	I-NEGATION
have	I-NEGATION
not	I-NEGATION
been	I-NEGATION
molecularly	I-NEGATION
defined	I-NEGATION
.	O

In	O
THP-1	O
cells	O
with	O
restricted	O
HIV	O
expression	O
,	O
there	O
is	O
an	O
absence	O
of	O
DNA-protein	O
binding	O
complex	O
formation	O
with	O
the	O
HIV-1	O
promoter-enhancer	O
associated	O
with	O
markedly	O
less	O
viral	O
RNA	O
production	O
.	O

This	O
absence	B-NEGATION
of	I-NEGATION
binding	I-NEGATION
was	O
localized	O
to	O
the	O
NF-kappa	O
B	O
region	O
of	O
the	O
HIV-1	O
enhancer	O
;	O
.	O

the	O
65-kDa	O
plus	O
50-kDa	O
NF-kappa	O
B	O
heterodimer	O
was	O
preferentially	O
lost	O
.	O

Adding	O
purified	O
NF-kappa	O
B	O
protein	O
to	O
nuclear	O
extracts	O
from	O
cells	O
with	O
restricted	O
expression	O
overcomes	O
this	O
lack	B-NEGATION
of	I-NEGATION
binding	I-NEGATION
.	O

In	O
addition	O
,	O
treatment	O
of	O
these	O
nuclear	O
extracts	O
with	O
sodium	O
deoxycholate	O
restored	O
their	O
ability	O
to	O
form	O
the	O
heterodimer	O
,	O
suggesting	B-SPECULATION
the	I-SPECULATION
presence	I-SPECULATION
of	I-SPECULATION
an	I-SPECULATION
inhibitor	I-SPECULATION
of	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
activity	I-SPECULATION
.	O

Furthermore	O
,	O
treatment	O
of	O
nuclear	O
extracts	O
from	O
these	O
cells	O
that	O
had	O
restricted	O
expression	O
with	O
lipopolysaccharide	O
increased	O
viral	O
production	O
and	O
NF-kappa	O
B	O
activity	O
.	O

Antiserum	O
specific	O
for	O
NF-kappa	O
B	O
binding	O
proteins	O
,	O
but	O
not	B-NEGATION
c-rel-specific	I-NEGATION
antiserum	I-NEGATION
,	O
disrupted	O
heterodimer	O
complex	O
formation	O
.	O

Thus	O
,	O
both	O
NF-kappa	O
B-binding	O
complexes	O
are	O
needed	O
for	O
optimal	O
viral	O
transcription	O
.	O

Binding	O
of	O
the	O
65-kDa	O
plus	O
50-kDa	O
heterodimer	O
to	O
the	O
HIV-1	O
enhancer	O
can	B-SPECULATION
be	I-SPECULATION
negatively	I-SPECULATION
regulated	I-SPECULATION
in	I-SPECULATION
monocytes	I-SPECULATION
,	O
providing	O
one	O
mechanism	O
restricting	O
HIV-1	O
gene	O
expression	O
.	O

Isolation	O
of	O
a	O
candidate	O
repressor	O
/	O
activator	O
,	O
NF-E1	O
(	O
YY-1	O
,	O
delta	O
)	O
,	O
that	O
binds	O
to	O
the	O
immunoglobulin	O
kappa	O
3	O
'	O
enhancer	O
and	O
the	O
immunoglobulin	O
heavy-chain	O
mu	O
E1	O
site	O
.	O

We	O
have	O
determined	O
that	O
the	O
developmental	O
control	O
of	O
immunoglobulin	O
kappa	O
3	O
'	O
enhancer	O
(	O
kappa	O
E3	O
'	O
)	O
activity	O
is	O
the	O
result	O
of	O
the	O
combined	O
influence	O
of	O
positive	O
-	O
and	O
negative-acting	O
elements	O
.	O

We	O
show	O
that	O
a	O
central	O
core	O
in	O
the	O
kappa	O
E3	O
'	O
enhancer	O
is	O
active	O
at	O
the	O
pre-B-cell	O
stage	O
but	O
is	O
repressed	O
by	O
flanking	O
negative-acting	O
elements	O
.	O

The	O
negative-acting	O
sequences	O
repress	O
enhancer	O
activity	O
in	O
a	O
position	O
-	O
and	O
orientation-independent	O
manner	O
at	O
the	O
pre-B-cell	O
stage	O
.	O

We	O
have	O
isolated	O
a	O
human	O
cDNA	O
clone	O
encoding	O
a	O
zinc	O
finger	O
protein	O
(	O
NF-E1	O
)	O
that	O
binds	O
to	O
the	O
negative-acting	O
segment	O
of	O
the	O
kappa	O
E3	O
'	O
enhancer	O
.	O

This	O
protein	O
also	O
binds	O
to	O
the	O
immunoglobulin	O
heavy-chain	O
enhancer	O
mu	O
E1	O
site	O
.	O

NF-E1	O
is	O
encoded	O
by	O
the	O
same	O
gene	O
as	O
the	O
YY-1	O
protein	O
,	O
which	O
binds	O
to	O
the	O
adeno-associated	O
virus	O
P5	O
promoter	O
.	O

NF-E1	O
is	O
also	O
the	O
human	O
homologue	O
of	O
the	O
mouse	O
delta	O
protein	O
,	O
which	O
binds	O
to	O
ribosomal	O
protein	O
gene	O
promoters	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
contains	O
features	O
characteristic	O
of	O
transcriptional	O
activators	O
as	O
well	O
as	O
transcriptional	O
repressors	O
.	O

Cotransfection	O
studies	O
with	O
this	O
cDNA	O
indicate	B-SPECULATION
that	I-SPECULATION
it	I-SPECULATION
can	B-SPECULATION
repress	I-SPECULATION
basal	I-SPECULATION
promoter	I-SPECULATION
activity	I-SPECULATION
.	O

The	O
apparent	B-SPECULATION
dual	I-SPECULATION
function	I-SPECULATION
of	I-SPECULATION
this	I-SPECULATION
protein	I-SPECULATION
is	O
discussed	O
.	O

Clone	O
pAT	O
133	O
identifies	O
a	O
gene	O
that	O
encodes	O
another	O
human	O
member	O
of	O
a	O
class	O
of	O
growth	O
factor-induced	O
genes	O
with	O
almost	O
identical	O
zinc-finger	O
domains	O
.	O

We	O
report	O
the	O
structure	O
and	O
regulation	O
of	O
a	O
gene	O
represented	O
by	O
clone	O
pAT	O
133	O
,	O
which	O
is	O
induced	O
upon	O
transition	O
from	O
a	O
resting	O
state	O
(	O
G0	O
)	O
through	O
the	O
early	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
G1	O
)	O
.	O

The	O
pAT	O
133	O
gene	O
is	O
immediately	O
induced	O
,	O
with	O
FOS-like	O
kinetics	O
,	O
in	O
human	O
T	O
cells	O
and	O
in	O
fibroblasts	O
.	O

Primary	O
structure	O
analysis	O
showed	O
that	O
the	O
encoded	O
protein	O
contains	O
three	O
tandem	O
zinc-finger	O
sequences	O
of	O
the	O
type	O
Cys2-Xaa12-His2	O
.	O

This	O
zinc-finger	O
region	O
,	O
which	B-SPECULATION
is	I-SPECULATION
thought	I-SPECULATION
to	I-SPECULATION
bind	I-SPECULATION
DNA	I-SPECULATION
in	I-SPECULATION
a	I-SPECULATION
sequence-specific	I-SPECULATION
manner	I-SPECULATION
,	O
is	O
similar	O
(	O
greater	O
than	O
80	O
%	O
on	O
the	O
amino	O
acid	O
level	O
)	O
to	O
two	O
previously	O
described	O
transcription	O
factors	O
pAT	O
225	O
/	O
EGR1	O
and	O
pAT	O
591	O
/	O
EGR2	O
.	O

Except	O
for	O
the	O
conserved	O
zinc-finger	O
domains	O
,	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
three	O
proteins	O
are	O
distinct	O
.	O

This	O
structural	O
similarity	O
suggests	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
pAT	I-SPECULATION
133	I-SPECULATION
gene	I-SPECULATION
encodes	I-SPECULATION
a	I-SPECULATION
transcription	I-SPECULATION
factor	I-SPECULATION
with	I-SPECULATION
a	I-SPECULATION
specific	I-SPECULATION
biological	I-SPECULATION
function	I-SPECULATION
.	O

Comparing	O
the	O
regulation	O
of	O
these	O
related	O
zinc-finger-encoding	O
genes	O
showed	O
coordinate	O
induction	O
upon	O
mitogenic	O
stimulation	O
of	O
resting	O
T	O
lymphocytes	O
and	O
of	O
resting	O
fibroblasts	O
.	O

However	O
,	O
upon	O
transition	O
from	O
a	O
proliferating	O
(	O
G1	O
)	O
to	O
a	O
resting	O
state	O
of	O
the	O
cell	O
cycle	O
the	O
three	O
genes	O
were	O
differently	O
regulated	O
.	O

In	O
human	O
histiocytic	O
U937	O
cells	O
mRNA	O
of	O
clone	O
pAT	O
133	O
was	O
constitutively	O
expressed	O
,	O
whereas	O
mRNA	O
of	O
pAT	O
225	O
/	O
EGR1	O
was	O
induced	O
upon	O
induction	O
of	O
terminal	O
differentiation	O
.	O

In	O
contrast	O
mRNA	B-NEGATION
representing	I-NEGATION
pAT	I-NEGATION
591	I-NEGATION
/	I-NEGATION
EGR2	I-NEGATION
was	I-NEGATION
not	I-NEGATION
expressed	I-NEGATION
in	I-NEGATION
these	I-NEGATION
cells	I-NEGATION
.	O

This	O
difference	O
in	O
gene	O
regulation	O
suggests	B-SPECULATION
distinct	I-SPECULATION
biological	I-SPECULATION
roles	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
control	I-SPECULATION
of	I-SPECULATION
cell	I-SPECULATION
proliferation	I-SPECULATION
for	I-SPECULATION
the	I-SPECULATION
respective	I-SPECULATION
proteins	I-SPECULATION
.	O

cAMP-dependent	O
regulation	O
of	O
proenkephalin	O
by	O
JunD	O
and	O
JunB	O
:	O
positive	O
and	O
negative	O
effects	O
of	O
AP-1	O
proteins	O
.	O

We	O
demonstrate	O
that	O
JunD	O
,	O
a	O
component	O
of	O
the	O
AP-1	O
transcription	O
factor	O
complex	O
,	O
activates	O
transcription	O
of	O
the	O
human	O
proenkephalin	O
gene	O
in	O
a	O
fashion	O
that	O
is	O
completely	O
dependent	O
upon	O
the	O
cAMP-dependent	O
protein	O
kinase	O
,	O
protein	O
kinase	O
A	O
.	O

Activation	O
of	O
proenkephalin	O
transcription	O
by	O
JunD	O
is	O
dependent	O
upon	O
a	O
previously	O
characterized	O
cAMP	O
-	O
,	O
phorbol	O
ester	O
-	O
,	O
and	O
Ca	O
(	O
2	O
+)-	O
inducible	O
enhancer	O
,	O
and	O
JunD	O
is	O
shown	O
to	O
bind	O
the	O
enhancer	O
as	O
a	O
homodimer	O
.	O

Another	O
component	O
of	O
the	O
AP-1	O
transcription	O
complex	O
,	O
JunB	O
,	O
is	O
shown	O
to	O
inhibit	O
activation	O
mediated	O
by	O
JunD	O
.	O

As	O
a	O
homodimer	O
JunB	O
is	O
unable	B-NEGATION
to	I-NEGATION
bind	I-NEGATION
the	I-NEGATION
enhancer	I-NEGATION
;	O
however	O
in	O
the	O
presence	O
of	O
c-Fos	O
,	O
high-affinity	O
binding	O
is	O
observed	O
.	O

Furthermore	O
,	O
JunD	O
is	O
shown	O
to	O
activate	O
transcription	O
of	O
genes	O
linked	O
to	O
both	O
cAMP	O
and	O
phorbol	O
ester	O
response	O
elements	O
in	O
a	O
protein	O
kinase	O
A-dependent	O
fashion	O
,	O
further	O
blurring	O
the	O
distinction	O
between	O
these	O
response	O
elements	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
an	O
AP-1-related	O
protein	O
is	O
regulated	O
by	O
the	O
cAMP-dependent	O
second-messenger	O
pathway	O
and	O
suggest	B-SPECULATION
that	I-SPECULATION
JunD	I-SPECULATION
and	I-SPECULATION
other	I-SPECULATION
AP-1-related	I-SPECULATION
proteins	I-SPECULATION
may	B-SPECULATION
play	I-SPECULATION
an	I-SPECULATION
important	I-SPECULATION
role	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
regulation	I-SPECULATION
of	I-SPECULATION
gene	I-SPECULATION
expression	I-SPECULATION
by	I-SPECULATION
cAMP-dependent	I-SPECULATION
intracellular	I-SPECULATION
signaling	I-SPECULATION
pathways	I-SPECULATION
.	O

Glucocorticoid	O
resistance	O
in	O
chronic	O
asthma	O
.	O

Glucocorticoid	O
pharmacokinetics	O
,	O
glucocorticoid	O
receptor	O
characteristics	O
,	O
and	O
inhibition	O
of	O
peripheral	O
blood	O
T	O
cell	O
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
.	O

A	O
total	O
of	O
37	O
chronic	O
,	O
severe	O
,	O
nonsmoking	O
asthmatic	O
patients	O
with	O
documented	O
reversible	O
airways	O
obstruction	O
were	O
classified	O
as	O
glucocorticoid-sensitive	O
or	O
-	O
resistant	O
on	O
the	O
basis	O
of	O
changes	O
in	O
FEV1	O
,	O
FVC	O
,	O
and	O
peak	O
expiratory	O
flow	O
(	O
PEF	O
)	O
after	O
oral	O
prednisolone	O
.	O

The	O
resistant	O
patients	O
showed	O
no	B-NEGATION
significant	I-NEGATION
improvements	I-NEGATION
in	I-NEGATION
airflow	I-NEGATION
limitation	I-NEGATION
.	O

Phytohemagglutinin	O
(	O
PHA	O
)	O
-	O
induced	O
proliferation	O
of	O
peripheral	O
blood	O
T	O
lymphocytes	O
from	O
the	O
sensitive	O
but	O
not	B-NEGATION
the	I-NEGATION
resistant	I-NEGATION
asthmatic	O
patients	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0.01	O
)	O
inhibited	O
by	O
dexamethasone	O
(	O
10	O
(-	O
7	O
)	O
mol	O
/	O
L	O
)	O
,	O
reflecting	O
a	O
shift	O
of	O
the	O
dose-response	O
curve	O
.	O

When	O
all	O
the	O
asthmatic	O
patients	O
were	O
analyzed	O
together	O
,	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
degree	O
of	O
sensitivity	O
of	O
T	O
cells	O
to	O
dexamethasone	O
and	O
the	O
clinical	O
responsiveness	O
to	O
prednisolone	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

No	B-NEGATION
differences	I-NEGATION
were	I-NEGATION
observed	I-NEGATION
between	I-NEGATION
six	I-NEGATION
of	I-NEGATION
the	I-NEGATION
sensitive	I-NEGATION
and	I-NEGATION
resistant	I-NEGATION
patients	I-NEGATION
in	I-NEGATION
the	I-NEGATION
clearance	I-NEGATION
of	I-NEGATION
plasma	I-NEGATION
prednisolone	I-NEGATION
derived	I-NEGATION
from	I-NEGATION
orally	I-NEGATION
administered	I-NEGATION
prednisone	I-NEGATION
.	O

Peripheral	O
blood	O
mononuclear	O
cell	O
glucocorticoid	O
receptors	O
were	O
also	O
characterized	O
in	O
five	O
sensitive	O
and	O
seven	O
resistant	O
patients	O
.	O

The	O
numbers	O
and	O
binding	O
affinities	O
of	O
these	O
receptors	O
could	O
not	B-NEGATION
account	I-NEGATION
for	I-NEGATION
the	I-NEGATION
observed	I-NEGATION
difference	I-NEGATION
in	I-NEGATION
the	I-NEGATION
susceptibility	I-NEGATION
of	I-NEGATION
these	I-NEGATION
cells	I-NEGATION
to	I-NEGATION
functional	I-NEGATION
inhibition	I-NEGATION
by	I-NEGATION
dexamethasone	I-NEGATION
in	I-NEGATION
vitro	I-NEGATION
.	O

These	O
results	O
suggest	B-SPECULATION
that	I-SPECULATION
clinical	I-SPECULATION
glucocorticoid	I-SPECULATION
resistance	I-SPECULATION
in	I-SPECULATION
chronic	I-SPECULATION
asthma	I-SPECULATION
does	I-SPECULATION
not	B-NEGATION
reflect	I-NEGATION
abnormal	I-NEGATION
glucocorticoid	I-NEGATION
clearance	I-NEGATION
but	O
may	B-SPECULATION
be	I-SPECULATION
due	I-SPECULATION
at	I-SPECULATION
least	I-SPECULATION
partly	I-SPECULATION
to	I-SPECULATION
a	I-SPECULATION
relative	I-SPECULATION
insensitivity	I-SPECULATION
of	I-SPECULATION
T	I-SPECULATION
lymphocytes	I-SPECULATION
to	I-SPECULATION
glucocorticoids	I-SPECULATION
.	O

This	O
lack	B-NEGATION
of	I-NEGATION
sensitivity	I-NEGATION
is	O
unexplained	O
but	O
is	O
not	B-NEGATION
attributable	I-NEGATION
to	I-NEGATION
abnormalities	I-NEGATION
of	I-NEGATION
cellular	I-NEGATION
glucocorticoid	I-NEGATION
receptors	I-NEGATION
.	O

Regulation	O
of	O
interleukin-1	O
beta	O
production	O
by	O
glucocorticoids	O
in	O
human	O
monocytes	O
:	O
the	O
mechanism	O
of	O
action	O
depends	O
on	O
the	O
activation	O
signal	O
.	O

Glucocorticoids	O
are	O
known	O
to	O
downregulate	O
interleukin-1	O
beta	O
production	O
in	O
monocytic	O
cells	O
by	O
two	O
different	O
mechanims	O
:	O
direct	O
inhibition	O
of	O
the	O
gene	O
transcription	O
and	O
destabilization	O
of	O
the	O
preformed	O
interleukin-1	O
beta	O
mRNA	O
.	O

Now	O
we	O
have	O
examined	O
the	O
effect	O
of	O
the	O
nature	O
of	O
the	O
monocyte	O
activating	O
signal	O
on	O
these	O
two	O
inhibitory	O
mechanims	O
.	O

When	O
human	O
monocytes	O
were	O
preincubated	O
with	O
dexamethasone	O
for	O
1	O
hour	O
and	O
then	O
stimulated	O
either	O
with	O
bacterial	O
lipopolysaccharide	O
or	O
phorbol	O
myristate	O
,	O
it	O
was	O
found	O
that	O
dexamethasone	O
inhibited	O
the	O
lipopolysaccharide-induced	O
interleukin-1	O
beta	O
protein	O
production	O
,	O
but	O
the	O
phorbol	O
myristate-induced	O
production	O
was	O
increased	O
3-10	O
fold	O
.	O

This	O
difference	O
was	O
also	O
seen	O
at	O
the	O
mRNA	O
level	O
.	O

When	O
dexamethasone	O
was	O
added	O
to	O
the	O
cultures	O
3	O
hours	O
after	O
the	O
stimulators	O
,	O
it	O
clearly	O
decreased	O
the	O
interleukin-1	O
beta	O
mRNA	O
levels	O
regardless	O
of	O
the	O
stimulator	O
used	O
(	O
although	O
the	O
effect	O
was	O
clearly	O
weaker	O
on	O
the	O
PMA-induced	O
mRNA	O
)	O
.	O

Thus	O
these	O
data	O
suggest	B-SPECULATION
that	I-SPECULATION
the	B-NEGATION
phorbol	I-NEGATION
myristate-induced	I-NEGATION
signal	I-NEGATION
(	I-NEGATION
prolonged	I-NEGATION
protein	I-NEGATION
kinase	I-NEGATION
C	I-NEGATION
activation	I-NEGATION
?	I-NEGATION
)	I-NEGATION
can	I-NEGATION
not	I-NEGATION
be	I-NEGATION
inhibited	I-NEGATION
by	I-NEGATION
prior	I-NEGATION
incubation	I-NEGATION
with	I-NEGATION
dexamethasone	I-NEGATION
and	O
it	O
also	O
protects	O
the	O
induced	O
mRNA	O
for	O
the	O
degradative	O
action	O
of	O
dexamethasone	O
.	O

Identification	O
of	O
transcriptional	O
suppressor	O
proteins	O
that	O
bind	O
to	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Two	O
different	O
proteins	O
which	O
independently	O
bound	O
to	O
neighboring	O
sequences	O
within	O
the	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
were	O
detected	O
in	O
the	O
nuclear	O
extract	O
of	O
a	O
virus-infected	O
human	O
T	O
cell	O
line	O
.	O

One	O
of	O
the	O
factors	O
bound	O
to	O
a	O
novel	O
dyad	O
symmetrical	O
sequence	O
.	O

This	O
sequence	O
is	O
well	O
conserved	O
in	O
various	O
HIV-1	O
isolates	O
and	O
partial	O
homology	O
was	O
found	O
with	O
the	O
promoter	O
region	O
of	O
the	O
human	O
retinoblastoma	O
gene	O
.	O

Similar	O
DNA	O
binding	O
activity	O
was	O
detected	O
in	O
a	O
variety	O
of	O
virus-uninfected	O
human	O
T	O
cell	O
lines	O
and	O
HeLa	O
cells	O
by	O
means	O
of	O
a	O
gel	O
mobility	O
shift	O
assay	O
.	O

The	O
other	O
factor	O
bound	O
to	O
a	O
putative	B-SPECULATION
AP-1	I-SPECULATION
recognition	I-SPECULATION
sequence	I-SPECULATION
predicted	O
for	O
the	O
HIV-1	O
NRE	O
.	O

However	O
,	O
this	O
factor	O
did	O
not	B-NEGATION
bind	I-NEGATION
to	I-NEGATION
a	I-NEGATION
typical	I-NEGATION
AP-1	I-NEGATION
site	I-NEGATION
.	O

The	O
insertion	O
of	O
multiple	O
copies	O
of	O
the	O
binding	O
site	O
for	O
the	O
former	O
or	O
latter	O
factor	O
into	O
a	O
heterologous	O
promoter	O
reduced	O
the	O
promoter	O
activity	O
to	O
one-tenth	O
or	O
one-third	O
,	O
respectively	O
.	O

Thus	O
,	O
each	O
factor	O
may	B-SPECULATION
function	I-SPECULATION
as	I-SPECULATION
a	I-SPECULATION
novel	I-SPECULATION
negative	I-SPECULATION
regulator	I-SPECULATION
of	I-SPECULATION
transcription	I-SPECULATION
.	O

Constitutive	O
activation	O
of	O
NF-kB	O
in	O
human	O
thymocytes	O
.	O

NF-kB	O
is	O
a	O
eukaryotic	O
transcription	O
regulatory	O
factor	O
.	O

In	O
T	O
cells	O
and	O
T	O
cell	O
lines	O
,	O
NF-kB	O
is	O
bound	O
to	O
a	O
cytoplasmic	O
proteic	O
inhibitor	O
,	O
the	O
IkB	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
mitogens	O
(	O
phorbol	O
esters	O
)	O
or	O
cytokines	O
(	O
TNF	O
alpha	O
)	O
induces	O
NF-kB	O
nuclear	O
translocation	O
and	O
the	O
subsequent	O
expression	O
of	O
NF-kB	O
dependent	O
T	O
cell	O
genes	O
.	O

Here	O
we	O
examined	O
the	O
activation	O
of	O
NF-kB	O
in	O
human	O
T	O
cell	O
thymic	O
progenitors	O
.	O

We	O
report	O
differences	O
in	O
(	O
Ca2	O
+)	O
i	O
requirement	O
for	O
NF-kB	O
activation	O
in	O
thymocytes	O
as	O
compared	O
to	O
mature	O
T	O
cells	O
.	O

Furthermore	O
,	O
our	O
results	O
indicated	B-SPECULATION
that	I-SPECULATION
thymocytes	I-SPECULATION
have	I-SPECULATION
a	I-SPECULATION
constitutively	I-SPECULATION
active	I-SPECULATION
form	I-SPECULATION
of	I-SPECULATION
NF-kB	I-SPECULATION
,	O
suggesting	B-SPECULATION
that	I-SPECULATION
they	I-SPECULATION
are	I-SPECULATION
activated	I-SPECULATION
in	I-SPECULATION
vivo	I-SPECULATION
.	O

The	O
role	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
in	O
12-O-tetradecanoylphorbol-13-acetate	O
induced	O
hemopoietic	O
differentiation	O
.	O

Terminal	O
differentiation	O
of	O
the	O
leukemic	O
cell	O
lines	O
U-937	O
and	O
HL-60	O
by	O
12-O-tetradecanoylphorbol-13-acetate	O
is	O
accompanied	O
by	O
marked	O
changes	O
in	O
gene	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
is	O
induced	O
with	O
variable	O
kinetics	O
during	O
12-O-tetradecanoylphorbol-13-acetate	O
induced	O
differentiation	O
,	O
with	O
c-jun	O
expression	O
best	O
paralleling	O
differentiation	O
.	O

The	O
generation	O
of	O
AP-1	O
complexes	O
,	O
as	O
measured	O
by	O
DNA	O
binding	O
activity	O
,	O
closely	O
parallels	O
morphological	O
differentiation	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
these	O
complexes	O
to	O
regulate	O
gene	O
expression	O
is	O
demonstrated	O
by	O
increased	O
transcription	O
from	O
an	O
AP-1	O
driven	O
reporter	O
construct	O
and	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
endogenous	O
AP-1	O
regulated	O
genes	O
.	O

Differentiation	O
assays	O
using	O
water	O
soluble	O
phorbol	O
esters	O
reveal	O
that	O
differentiation	O
becomes	O
irreversible	O
soon	O
after	O
AP-1	O
appears	O
.	O

This	O
tight	O
correlation	O
between	O
c-jun	O
expression	O
,	O
the	O
generation	O
of	O
AP-1	O
activity	O
,	O
and	O
differentiation	O
suggests	B-SPECULATION
a	I-SPECULATION
critical	I-SPECULATION
role	I-SPECULATION
for	I-SPECULATION
this	I-SPECULATION
gene	I-SPECULATION
and	I-SPECULATION
transcriptional	I-SPECULATION
complex	I-SPECULATION
during	I-SPECULATION
this	I-SPECULATION
process	I-SPECULATION
.	O

TCF-1	O
,	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
of	O
the	O
HMG	O
box	O
family	O
,	O
interacts	O
with	O
sequence	O
motifs	O
in	O
the	O
TCR	O
beta	O
and	O
TCR	O
delta	O
enhancers	O
.	O

We	O
have	O
recently	O
identified	O
and	O
cloned	O
TCF-1	O
,	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
with	O
specificity	O
for	O
the	O
AACAAAG	O
motif	O
in	O
the	O
CD3	O
epsilon	O
enhancer	O
and	O
for	O
the	O
TTCAAAG	O
motif	O
in	O
the	O
TCR	O
alpha	O
enhancer	O
.	O

TCF-1	O
belongs	O
to	O
the	O
family	O
of	O
transcription-regulating	O
proteins	O
which	O
share	O
a	O
region	O
of	O
homology	O
termed	O
the	O
HMG-box	O
.	O

Here	O
,	O
we	O
show	O
by	O
gel	O
retardation	O
analysis	O
that	O
TCF-1	O
specifically	O
recognizes	O
the	O
T	O
beta	O
5	O
element	O
of	O
the	O
TCR	O
beta	O
enhancer	O
and	O
the	O
T	O
delta	O
7	O
element	O
of	O
the	O
TCR	O
delta	O
enhancer	O
.	O

Comparison	O
of	O
the	O
sequences	O
of	O
all	O
elements	O
recognized	O
by	O
TCF-1	O
defines	O
a	O
consensus	O
motif	O
A	O
/	O
T	O
A	O
/	O
T	O
C	O
A	O
A	O
/	O
G	O
A	O
G	O
.	O

These	O
observations	O
imply	B-SPECULATION
that	I-SPECULATION
TCF-1	I-SPECULATION
is	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
control	I-SPECULATION
of	I-SPECULATION
several	I-SPECULATION
T	I-SPECULATION
cell-specific	I-SPECULATION
genes	I-SPECULATION
and	I-SPECULATION
might	B-SPECULATION
thus	I-SPECULATION
play	I-SPECULATION
an	I-SPECULATION
important	I-SPECULATION
role	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
establishment	I-SPECULATION
and	I-SPECULATION
maintenance	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
mature	I-SPECULATION
T	I-SPECULATION
cell	I-SPECULATION
phenotype	I-SPECULATION
.	O

The	O
cellular	O
oncogene	O
c-myb	O
can	O
interact	O
synergistically	O
with	O
the	O
Epstein-Barr	O
virus	O
BZLF1	O
transactivator	O
in	O
lymphoid	O
cells	O
.	O

Regulation	O
of	O
replicative	O
functions	O
in	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
genome	O
is	O
mediated	O
through	O
activation	O
of	O
a	O
virally	O
encoded	O
transcription	O
factor	O
,	O
Z	O
(	O
BZLF1	O
)	O
.	O

We	O
have	O
shown	O
that	O
the	O
Z	O
gene	O
product	O
,	O
which	O
binds	O
to	O
AP-1	O
sites	O
as	O
a	O
homodimer	O
and	O
has	O
sequence	O
similarity	O
to	O
c-Fos	O
,	O
can	O
efficiently	O
activate	O
the	O
EBV	O
early	O
promoter	O
,	O
BMRF1	O
,	O
in	O
certain	O
cell	O
types	O
(	O
i.e.	O
,	O
HeLa	O
cells	O
)	O
but	O
not	B-NEGATION
others	I-NEGATION
(	I-NEGATION
i.e.	I-NEGATION
,	I-NEGATION
Jurkat	I-NEGATION
cells	I-NEGATION
)	I-NEGATION
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
c-myb	O
proto-oncogene	O
product	O
,	O
which	O
is	O
itself	O
a	O
DNA-binding	O
protein	O
and	O
transcriptional	O
transactivator	O
,	O
can	O
interact	O
synergistically	O
with	O
Z	O
in	O
activating	O
the	O
BMRF1	O
promoter	O
in	O
Jurkat	O
cells	O
(	O
a	O
T-cell	O
line	O
)	O
or	O
Raji	O
cells	O
(	O
an	O
EBV-positive	O
B-cell	O
)	O
,	O
whereas	O
the	O
c-myb	O
gene	O
product	O
by	O
itself	O
has	O
little	O
effect	O
.	O

The	O
simian	O
virus	O
40	O
early	O
promoter	O
is	O
also	O
synergistically	O
activated	O
by	O
the	O
Z	O
/	O
c-myb	O
combination	O
.	O

Synergistic	B-SPECULATION
transactivation	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
BMRF1	I-SPECULATION
promoter	I-SPECULATION
by	I-SPECULATION
the	I-SPECULATION
Z	I-SPECULATION
/	I-SPECULATION
c-myb	I-SPECULATION
combination	I-SPECULATION
appears	I-SPECULATION
to	I-SPECULATION
involve	I-SPECULATION
direct	I-SPECULATION
binding	I-SPECULATION
by	I-SPECULATION
the	I-SPECULATION
Z	I-SPECULATION
protein	I-SPECULATION
but	I-SPECULATION
not	B-NEGATION
the	I-NEGATION
c-myb	I-NEGATION
protein	I-NEGATION
.	O

A	O
30-bp	O
sequence	O
in	O
the	O
BMRF1	O
promoter	O
which	O
contains	O
a	O
Z	O
binding	O
site	O
(	O
a	O
consensus	O
AP-1	O
site	O
)	O
is	O
sufficient	O
to	O
transfer	O
high-level	O
lymphoid-specific	O
responsiveness	O
to	O
the	O
Z	O
/	O
c-myb	O
combination	O
to	O
a	O
heterologous	O
promoter	O
.	O

That	O
the	O
c-myb	O
oncogene	O
product	O
can	O
interact	O
synergistically	O
with	O
an	O
EBV-encoded	O
member	O
of	O
the	O
leucine	O
zipper	O
protein	O
family	O
suggests	B-SPECULATION
c-myb	B-SPECULATION
is	I-SPECULATION
likely	I-SPECULATION
to	I-SPECULATION
engage	I-SPECULATION
in	I-SPECULATION
similar	I-SPECULATION
interactions	I-SPECULATION
with	I-SPECULATION
cellularly	I-SPECULATION
encoded	I-SPECULATION
transcription	I-SPECULATION
factors	I-SPECULATION
.	O

The	O
29-kDa	O
proteins	O
phosphorylated	O
in	O
thrombin-activated	O
human	O
platelets	O
are	O
forms	O
of	O
the	O
estrogen	O
receptor-related	O
27-kDa	O
heat	O
shock	O
protein	O
.	O

Thrombin	O
plays	O
a	O
critical	O
role	O
in	O
platelet	O
activation	O
,	O
hemostasis	O
,	O
and	O
thrombosis	O
.	O

Cellular	O
activation	O
by	O
thrombin	O
leads	O
to	O
the	O
phosphorylation	O
of	O
multiple	O
proteins	O
,	O
most	O
of	O
which	O
are	O
unidentified	O
.	O

We	O
have	O
characterized	O
several	O
29-kDa	O
proteins	O
that	O
are	O
rapidly	O
phosphorylated	O
following	O
exposure	O
of	O
intact	O
human	O
platelets	O
to	O
thrombin	O
.	O

A	O
murine	O
monoclonal	O
antibody	O
raised	O
to	O
an	O
unidentified	O
estrogen	O
receptor-related	O
29-kDa	O
protein	O
selectively	O
recognized	O
these	O
proteins	O
as	O
well	O
as	O
a	O
more	O
basic	O
,	O
unphosphorylated	O
27-kDa	O
protein	O
.	O

Cellular	O
activation	O
by	O
thrombin	O
led	O
to	O
a	O
marked	O
shift	O
in	O
the	O
proportion	O
of	O
protein	O
from	O
the	O
27-kDa	O
unphosphorylated	O
form	O
to	O
the	O
29-kDa	O
phosphoprotein	O
species	O
.	O

Using	O
this	O
antibody	O
,	O
we	O
isolated	O
and	O
sequenced	O
a	O
human	O
cDNA	O
clone	O
encoding	O
a	O
protein	O
that	O
was	O
identical	O
to	O
the	O
mammalian	O
27-kDa	O
heat	O
shock	O
protein	O
(	O
HSP27	O
)	O
,	O
a	O
protein	O
of	O
uncertain	O
function	O
that	O
is	O
known	O
to	O
be	O
phosphorylated	O
to	O
several	O
forms	O
and	O
to	O
be	O
transcriptionally	O
induced	O
by	O
estrogen	O
.	O

The	O
29-kDa	O
proteins	O
were	O
confirmed	O
to	O
be	O
phosphorylated	O
forms	O
of	O
HSP27	O
by	O
immunoprecipitation	O
studies	O
.	O

Thus	O
,	O
the	O
"	O
estrogen	O
receptor-related	O
protein	O
"	O
is	O
HSP27	O
,	O
and	O
the	O
three	O
major	O
29-kDa	O
proteins	O
phosphorylated	O
in	O
thrombin-activated	O
platelets	O
are	O
forms	O
of	O
HSP27	O
.	O

These	O
data	O
suggest	B-SPECULATION
a	I-SPECULATION
role	I-SPECULATION
for	I-SPECULATION
HSP27	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
signal	I-SPECULATION
transduction	I-SPECULATION
events	I-SPECULATION
of	I-SPECULATION
platelet	I-SPECULATION
activation	I-SPECULATION
.	O

Characterization	O
of	O
a	O
cofactor	O
that	O
regulates	O
dimerization	O
of	O
a	O
mammalian	O
homeodomain	O
protein	O
.	O

Dimerization	O
among	O
transcription	O
factors	O
has	O
become	O
a	O
recurrent	O
theme	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

Hepatocyte	O
nuclear	O
factor-1	O
alpha	O
(	O
HNF-1	O
alpha	O
)	O
is	O
a	O
homeodomain-containing	O
protein	O
that	O
functions	O
as	O
a	O
dimer	O
.	O

A	O
dimerization	O
cofactor	O
of	O
HNF-1	O
alpha	O
(	O
DCoH	O
)	O
was	O
identified	O
that	O
displayed	O
a	O
restricted	O
tissue	O
distribution	O
and	O
did	O
not	B-NEGATION
bind	I-NEGATION
to	I-NEGATION
DNA	I-NEGATION
,	O
but	O
,	O
rather	O
,	O
selectively	O
stabilized	O
HNF-1	O
alpha	O
dimers	O
.	O

The	O
formation	O
of	O
a	O
stable	O
tetrameric	O
DCoH-HNF-1	O
alpha	O
complex	O
,	O
which	O
required	O
the	O
dimerization	O
domain	O
of	O
HNF-1	O
alpha	O
,	O
did	O
not	B-NEGATION
change	I-NEGATION
the	I-NEGATION
DNA	I-NEGATION
binding	I-NEGATION
characteristics	I-NEGATION
of	I-NEGATION
HNF-1	I-NEGATION
alpha	I-NEGATION
,	O
but	O
enhanced	O
its	O
transcriptional	O
activity	O
.	O

However	O
,	O
DCoH	O
did	O
not	B-NEGATION
confer	I-NEGATION
transcriptional	I-NEGATION
activation	I-NEGATION
to	I-NEGATION
the	I-NEGATION
GAL4	I-NEGATION
DNA	I-NEGATION
binding	I-NEGATION
domain	I-NEGATION
.	O

These	O
results	O
indicate	B-SPECULATION
that	I-SPECULATION
DCoH	I-SPECULATION
regulates	I-SPECULATION
formation	I-SPECULATION
of	I-SPECULATION
transcriptionally	I-SPECULATION
active	I-SPECULATION
tetrameric	I-SPECULATION
complexes	I-SPECULATION
and	I-SPECULATION
may	B-SPECULATION
contribute	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
developmental	I-SPECULATION
specificity	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
complex	I-SPECULATION
.	O

High	O
affinity	O
aldosterone	O
binding	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
from	O
mononuclear	O
leukocytes	O
:	O
is	O
there	O
a	O
membrane	O
receptor	O
for	O
mineralocorticoids	O
?	O

In	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
the	O
intracellular	O
concentrations	O
of	O
sodium	O
,	O
potassium	O
and	O
calcium	O
,	O
cell	O
volume	O
and	O
the	O
sodium-proton-antiport	O
have	O
been	O
described	O
in	O
intact	O
human	O
mononuclear	O
leukocytes	O
(	O
HML	O
)	O
.	O

In	O
the	O
present	O
paper	O
,	O
the	O
binding	O
of	O
a	O
[	O
125I	O
]-	O
labeled	O
aldosterone	O
derivative	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
of	O
HML	O
was	O
studied	O
.	O

High	O
affinity	O
binding	O
of	O
the	O
radioligand	O
with	O
an	O
apparent	B-SPECULATION
Kd	I-SPECULATION
of	I-SPECULATION
approximately	I-SPECULATION
0.1	I-SPECULATION
nM	I-SPECULATION
was	O
found	O
.	O

Aldosterone	O
displaced	O
the	O
tracer	O
at	O
a	O
similar	O
Kd	O
.	O

Both	O
canrenone	O
and	O
cortisol	O
were	O
inactive	O
as	O
ligands	O
up	O
to	O
concentrations	O
of	O
0.1	O
microM	O
.	O

The	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
sites	O
with	O
a	O
high	O
affinity	O
for	O
aldosterone	O
,	O
but	O
not	B-NEGATION
for	I-NEGATION
cortisol	I-NEGATION
.	O

These	O
data	O
are	O
perfectly	O
compatible	O
with	O
major	O
properties	O
of	O
steroidal	O
effects	O
on	O
the	O
sodium-proton-antiport	O
in	O
HML	O
and	O
thus	O
very	O
likely	B-SPECULATION
represent	I-SPECULATION
membrane	I-SPECULATION
receptors	I-SPECULATION
for	I-SPECULATION
aldosterone	I-SPECULATION
.	O

Transcription	O
factor	O
requirements	O
for	O
U2	O
snRNA-encoding	O
gene	O
activation	O
in	O
B	O
lymphoid	O
cells	O
.	O

Transcription	O
of	O
a	O
human	O
U2	O
small	O
nuclear	O
RNA	O
(	O
snRNA	O
)	O
-	O
encoding	O
gene	O
in	O
HeLa	O
cells	O
requires	O
a	O
distal	O
enhancer	O
element	O
,	O
which	O
is	O
composed	O
of	O
one	O
octamer	O
motif	O
(	O
Oct	O
)	O
and	O
three	O
Sp	O
1-binding	O
sites	O
.	O

To	O
study	O
the	O
transcription	O
factor	O
requirement	O
in	O
B-cells	O
,	O
different	O
U2	O
enhancer	O
constructions	O
were	O
transfected	O
into	O
the	O
lymphoid	O
cell	O
line	O
,	O
BJA-B	O
.	O

The	O
results	O
showed	O
that	O
the	O
activation	O
of	O
U2	O
snRNA	O
transcription	O
in	O
B-cells	O
also	O
requires	O
an	O
enhancer	O
comprising	O
both	O
the	O
Oct	O
and	O
at	O
least	O
one	O
Sp	O
1-binding	O
site	O
.	O

Deletion	O
of	O
all	O
the	O
Sp	O
1-binding	O
sites	O
from	O
the	O
enhancer	O
reduces	O
transcription	O
by	O
80-90	O
%	O
in	O
HeLa	O
,	O
as	O
well	O
as	O
in	O
BJA-B	O
cells	O
,	O
whereas	O
the	O
removal	O
of	O
the	O
octamer-binding	O
site	O
reduces	O
transcription	O
to	O
levels	O
below	O
detection	O
in	O
both	O
cell	O
types	O
.	O

Enhancers	O
containing	O
a	O
single	O
Oct	O
have	O
,	O
nevertheless	O
,	O
the	O
capacity	O
to	O
partially	O
activate	O
U2	O
snRNA	O
transcription	O
in	O
both	O
HeLa	O
cells	O
,	O
in	O
which	O
only	O
OTF-1	O
is	O
expressed	O
,	O
and	O
in	O
BJA-B	O
cells	O
in	O
which	O
OTF-2	O
is	O
the	O
predominantly	O
expressed	O
octamer-binding	O
factor	O
.	O

The	O
most	O
likely	B-SPECULATION
interpretation	I-SPECULATION
of	I-SPECULATION
our	I-SPECULATION
results	I-SPECULATION
is	I-SPECULATION
that	I-SPECULATION
both	I-SPECULATION
the	I-SPECULATION
ubiquitous	I-SPECULATION
transcription	I-SPECULATION
factor	I-SPECULATION
,	I-SPECULATION
OTF-1	I-SPECULATION
,	I-SPECULATION
and	I-SPECULATION
the	I-SPECULATION
B-cell-specific	I-SPECULATION
transcription	I-SPECULATION
factor	I-SPECULATION
,	I-SPECULATION
OTF-2	I-SPECULATION
,	I-SPECULATION
can	I-SPECULATION
activate	I-SPECULATION
U2	I-SPECULATION
snRNA	I-SPECULATION
transcription	I-SPECULATION
.	O

The	O
results	O
also	O
revealed	O
a	O
similar	O
functional	O
cooperation	O
between	O
the	O
transcription	O
factors	O
which	O
bind	O
to	O
the	O
Oct	O
and	O
the	O
adjacent	O
Sp	O
1-binding	O
site	O
in	O
BJA-B	O
cells	O
,	O
as	O
has	O
been	O
observed	O
in	O
HeLa	O
cells	O
,	O
since	O
a	O
template	O
which	O
contains	O
a	O
weak	O
binding	O
site	O
for	O
OTFs	O
expresses	O
wild-type	O
levels	O
of	O
U2	O
snRNA	O
in	O
both	O
cell	O
types	O
when	O
the	O
weak	O
octamer-binding	O
site	O
is	O
combined	O
with	O
a	O
Sp	O
1-binding	O
site	O
.	O

Cortisol	O
receptor	O
resistance	O
:	O
the	O
variability	O
of	O
its	O
clinical	O
presentation	O
and	O
response	O
to	O
treatment	O
.	O

Primary	O
(	O
partial	O
)	O
cortisol	O
receptor	O
resistance	O
was	O
previously	O
reported	O
in	O
a	O
total	O
of	O
7	O
patients	O
and	O
14	O
asymptomatic	O
family	O
members	O
.	O

Its	O
occurrence	O
is	O
considered	O
to	O
be	O
extremely	O
rare	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
on	O
6	O
patients	O
(	O
2	O
males	O
and	O
4	O
females	O
)	O
with	O
the	O
syndrome	O
.	O

The	O
first	O
male	O
patient	O
presented	O
with	O
mild	O
hypertension	O
.	O

Hydrochlorothiazide	O
therapy	O
resulted	O
in	O
life-threatening	O
hypokalemia	O
.	O

The	O
second	O
male	O
patient	O
had	O
slight	O
hypertension	O
without	B-NEGATION
hypokalemia	I-NEGATION
.	O

All	O
four	O
female	O
patients	O
presented	O
between	O
the	O
age	O
of	O
20-30	O
yr	O
with	O
acne	O
,	O
hirsutism	O
,	O
and	O
irregular	O
menstruations	O
.	O

Low	O
dose	O
dexamethasone	O
therapy	O
(	O
1-1.5	O
mg	O
/	O
day	O
)	O
was	O
of	O
clinical	O
benefit	O
in	O
these	O
patients	O
.	O

All	O
patients	O
showed	O
insufficient	O
suppression	O
of	O
serum	O
cortisol	O
concentrations	O
in	O
the	O
overnight	O
1-mg	O
dexamethasone	O
test	O
.	O

The	O
diurnal	O
rhythm	O
of	O
ACTH	O
and	O
cortisol	O
was	O
intact	O
,	O
albeit	O
at	O
an	O
elevated	O
level	O
.	O

There	O
was	O
a	O
normal	O
increase	O
in	O
ACTH	O
,	O
cortisol	O
,	O
and	O
GH	O
(	O
except	O
in	O
one	O
obese	O
patient	O
)	O
in	O
response	O
to	O
insulin-induced	O
hypoglycemia	O
,	O
while	O
cortisol	O
production	O
was	O
elevated	O
in	O
three	O
patients	O
.	O

Circulating	O
adrenal	O
androgen	O
levels	O
were	O
increased	O
in	O
all	O
patients	O
.	O

Glucocorticoid	O
receptors	O
were	O
investigated	O
in	O
a	O
whole	O
cell	O
dexamethasone	O
binding	O
assay	O
in	O
mononuclear	O
leukocytes	O
.	O

In	O
the	O
first	O
male	O
patient	O
,	O
the	O
number	O
of	O
receptors	O
was	O
very	O
low	O
,	O
while	O
the	O
affinity	O
was	O
lower	O
than	O
that	O
in	O
controls	O
.	O

A	O
lowered	O
affinity	O
to	O
dexamethasone	O
was	O
found	O
in	O
one	O
female	O
patient	O
,	O
while	O
a	O
lowered	O
number	O
of	O
receptors	O
was	O
found	O
in	O
three	O
patients	O
.	O

In	O
the	O
second	O
male	O
patient	O
,	O
no	B-NEGATION
abnormalities	I-NEGATION
were	I-NEGATION
found	I-NEGATION
.	O

As	O
a	O
bioassay	O
for	O
glucocorticoid	O
action	O
we	O
also	O
measured	O
dexamethasone	O
suppressibility	O
of	O
mitogen-stimulated	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
in	O
mononuclear	O
leukocytes	O
.	O

In	O
the	O
male	O
patient	O
with	O
normal	O
receptor	O
status	O
,	O
dexamethasone	O
suppressibility	O
of	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
with	O
respect	O
to	O
both	O
maximal	O
suppression	O
and	O
IC50	O
.	O

Partial	O
cortisol	O
receptor	O
resistance	O
might	B-SPECULATION
be	I-SPECULATION
less	I-SPECULATION
rare	I-SPECULATION
than	I-SPECULATION
previously	I-SPECULATION
thought	I-SPECULATION
.	O

In	O
the	O
six	O
patients	O
presented	O
,	O
at	O
least	O
three	O
different	O
forms	O
can	O
be	O
recognized	O
.	O

Therapy	O
with	O
dexamethasone	O
was	O
successful	O
in	O
female	O
patients	O
with	O
acne	O
and	O
hirsutism	O
,	O
as	O
the	O
secondary	O
increase	O
in	O
the	O
production	O
of	O
adrenal	O
androgens	O
was	O
effectively	O
controlled	O
.	O

Kappa	O
B-specific	O
DNA	O
binding	O
proteins	O
are	O
differentially	O
inhibited	O
by	O
enhancer	O
mutations	O
and	O
biological	O
oxidation	O
.	O

Kappa	O
B	O
(	O
kappa	O
B	O
)	O
enhancer	O
binding	O
proteins	O
isolated	O
from	O
the	O
nuclei	O
of	O
activated	O
human	O
T	O
cells	O
produce	O
two	O
distinct	O
nucleoprotein	O
complexes	O
when	O
incubated	O
with	O
the	O
kappa	O
B	O
element	O
from	O
the	O
interleukin-2	O
receptor-alpha	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
.	O

These	O
two	O
DNA-protein	O
complexes	O
are	O
composed	O
of	O
at	O
least	O
four	O
host	O
proteins	O
(	O
p50	O
,	O
p55	O
,	O
p75	O
,	O
p85	O
)	O
,	O
each	O
of	O
which	O
shares	O
structural	O
similarity	O
with	O
the	O
v-rel	O
oncogene	O
product	O
.	O

Nuclear	O
expression	O
of	O
these	O
proteins	O
is	O
induced	O
with	O
distinctly	O
biphasic	O
kinetics	O
following	O
phorbol	O
ester	O
activation	O
of	O
T	O
cells	O
(	O
p55	O
/	O
p75	O
early	O
and	O
p50	O
/	O
p85	O
late	O
)	O
.	O

DNA-protein	O
crosslinking	O
studies	O
have	O
revealed	O
that	O
the	O
more	O
rapidly	O
migrating	O
B2	O
complex	O
contains	O
both	O
p50	O
and	O
p55	O
while	O
the	O
more	O
slowly	O
migrating	O
B1	O
complex	O
is	O
composed	O
of	O
p50	O
,	O
p55	O
,	O
p75	O
,	O
and	O
p85	O
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
wild-type	O
IL-2R	O
alpha	O
kappa	O
B	O
enhancer	O
(	O
GGGGAATCTCCC	O
)	O
has	O
revealed	O
that	O
the	O
binding	O
of	O
p50	O
and	O
p55	O
(	O
B2	O
complex	O
)	O
is	O
particularly	O
sensitive	O
to	O
alteration	O
of	O
the	O
5	O
'	O
triplet	O
of	O
deoxyguanosine	O
residues	O
.	O

In	O
contrast	O
,	O
formation	O
of	O
the	O
B1	O
complex	O
,	O
reflecting	O
the	O
binding	O
of	O
p75	O
and	O
p85	O
,	O
critically	O
depends	O
upon	O
the	O
more	O
3	O
'	O
sequences	O
of	O
this	O
enhancer	O
element	O
.	O

DNA	O
binding	O
by	O
all	O
four	O
of	O
these	O
Rel-related	O
factors	O
is	O
blocked	O
by	O
selective	O
chemical	O
modification	O
of	O
lysine	O
and	O
arginine	O
residues	O
,	O
suggesting	B-SPECULATION
that	I-SPECULATION
both	I-SPECULATION
of	I-SPECULATION
these	I-SPECULATION
basic	I-SPECULATION
amino	I-SPECULATION
acids	I-SPECULATION
are	I-SPECULATION
required	I-SPECULATION
for	I-SPECULATION
binding	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
kappa	I-SPECULATION
B	I-SPECULATION
element	I-SPECULATION
.	O

Similarly	O
,	O
covalent	O
modification	O
of	O
free	O
sulfhydryl	O
groups	O
with	O
diamide	O
(	O
reversible	O
)	O
or	O
N-ethylmaleimide	O
(	O
irreversible	O
)	O
results	O
in	O
a	O
complete	O
loss	O
of	O
DNA	O
binding	O
activity	O
.	O

In	O
contrast	O
,	O
mild	O
oxidation	O
with	O
glucose	O
oxidase	O
selectively	O
inhibits	O
p75	O
and	O
p85	O
binding	O
while	O
not	B-NEGATION
blocking	I-NEGATION
p50	I-NEGATION
and	I-NEGATION
p55	I-NEGATION
interactions	I-NEGATION
.	O

These	O
findings	O
suggest	B-SPECULATION
that	I-SPECULATION
reduced	I-SPECULATION
cysteine	I-SPECULATION
thiols	I-SPECULATION
play	I-SPECULATION
an	I-SPECULATION
important	I-SPECULATION
role	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
DNA	I-SPECULATION
binding	I-SPECULATION
activity	I-SPECULATION
of	I-SPECULATION
this	I-SPECULATION
family	I-SPECULATION
of	I-SPECULATION
Rel-related	I-SPECULATION
transcription	I-SPECULATION
factors	I-SPECULATION
.	O

A	O
novel	O
mitogen-inducible	O
gene	O
product	O
related	O
to	O
p50	O
/	O
p105-NF-kappa	O
B	O
participates	O
in	O
transactivation	O
through	O
a	O
kappa	O
B	O
site	O
.	O

A	O
Rel-related	O
,	O
mitogen-inducible	O
,	O
kappa	O
B-binding	O
protein	O
has	O
been	O
cloned	O
as	O
an	O
immediate-early	O
activation	O
gene	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

The	O
cDNA	O
has	O
an	O
open	O
reading	O
frame	O
of	O
900	O
amino	O
acids	O
capable	O
of	O
encoding	O
a	O
97-kDa	O
protein	O
.	O

This	O
protein	O
is	O
most	O
similar	O
to	O
the	O
105-kDa	O
precursor	O
polypeptide	O
of	O
p50-NF-kappa	O
B	O
.	O

Like	O
the	O
105-kDa	O
precursor	O
,	O
it	O
contains	O
an	O
amino-terminal	O
Rel-related	O
domain	O
of	O
about	O
300	O
amino	O
acids	O
and	O
a	O
carboxy-terminal	O
domain	O
containing	O
six	B-SPECULATION
full	I-SPECULATION
cell	I-SPECULATION
cycle	I-SPECULATION
or	I-SPECULATION
ankyrin	I-SPECULATION
repeats	I-SPECULATION
.	O

In	O
vitro-translated	O
proteins	O
,	O
truncated	O
downstream	O
of	O
the	O
Rel	O
domain	O
and	O
excluding	O
the	O
repeats	O
,	O
bind	O
kappa	O
B	O
sites	O
.	O

We	O
refer	O
to	O
the	O
kappa	O
B-binding	O
,	O
truncated	O
protein	O
as	O
p50B	O
by	O
analogy	O
with	O
p50-NF-kappa	O
B	O
and	O
to	O
the	O
full-length	O
protein	O
as	O
p97	O
.	O

p50B	O
is	O
able	O
to	O
form	O
heteromeric	O
kappa	O
B-binding	O
complexes	O
with	O
RelB	O
,	O
as	O
well	O
as	O
with	O
p65	O
and	O
p50	O
,	O
the	O
two	O
subunits	O
of	O
NF-kappa	O
B	O
.	O

Transient-transfection	O
experiments	O
in	O
embryonal	O
carcinoma	O
cells	O
demonstrate	O
a	O
functional	O
cooperation	O
between	O
p50B	O
and	O
RelB	B-SPECULATION
or	I-SPECULATION
p65	I-SPECULATION
in	O
transactivation	O
of	O
a	O
reporter	O
plasmid	O
dependent	O
on	O
a	O
kappa	O
B	O
site	O
.	O

The	O
data	O
imply	B-SPECULATION
the	I-SPECULATION
existence	I-SPECULATION
of	I-SPECULATION
a	I-SPECULATION
complex	I-SPECULATION
family	I-SPECULATION
of	I-SPECULATION
NF-kappa	I-SPECULATION
B-like	I-SPECULATION
transcription	I-SPECULATION
factors	I-SPECULATION
.	O

[	O
Changes	O
in	O
leucocytic	O
estrogen	O
receptor	O
levels	O
in	O
patients	O
with	O
climacteric	O
syndrome	O
and	O
therapeutic	O
effect	O
of	O
liuwei	O
dihuang	O
pills	O
]	O

The	O
numbers	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
22	O
women	O
with	O
climacteric	O
syndrome	O
were	O
measured	O
by	O
radioligand	O
method	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
of	O
12	O
normal	O
child-bearing-age	O
women	O
.	O

It	O
wat	O
found	O
that	O
the	O
contents	O
of	O
leucocytic	O
ER	O
in	O
climacteric	O
syndrome	O
patients	O
were	O
significantly	O
lower	O
than	O
normal	O
child-bearing-age	O
women	O
.	O

The	O
authors	O
used	O
a	O
Chinese	O
prescription	O
--	O
Liuwei	O
Dihuang	O
Pills	O
(	O
LDP	O
)	O
to	O
treat	O
the	O
patients	O
for	O
2	O
months	O
.	O

The	O
numbers	O
of	O
leucocytic	O
ER	O
were	O
significantly	O
increased	O
after	O
treatment	O
.	O

The	O
data	O
indicate	B-SPECULATION
that	I-SPECULATION
decrease	I-SPECULATION
of	I-SPECULATION
ER	I-SPECULATION
levels	I-SPECULATION
in	I-SPECULATION
cell	I-SPECULATION
may	B-SPECULATION
involve	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
pathogenesis	I-SPECULATION
of	I-SPECULATION
climacteric	I-SPECULATION
syndrome	I-SPECULATION
.	O

LDP	O
not	O
only	O
increases	O
plasma	O
estradiol	O
levels	O
,	O
but	O
also	O
increases	O
the	O
leucocytic	O
ER	O
levels	O
.	O

This	O
may	B-SPECULATION
be	I-SPECULATION
the	I-SPECULATION
basis	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
therapeutic	I-SPECULATION
effect	I-SPECULATION
on	I-SPECULATION
the	I-SPECULATION
disease	I-SPECULATION
.	O

A	O
novel	O
primer	O
extension	O
method	O
to	O
detect	O
the	O
number	O
of	O
CAG	O
repeats	O
in	O
the	O
androgen	O
receptor	O
gene	O
in	O
families	O
with	O
X-linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
.	O

X-linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
(	O
SBMA	O
)	O
,	O
an	O
adult-onset	O
form	O
of	O
motor	O
neuron	O
disease	O
,	O
was	O
recently	O
reported	O
to	O
be	O
caused	O
by	O
amplification	O
of	O
the	O
CAG	O
repeats	O
in	O
the	O
androgen	O
receptor	O
gene	O
.	O

We	O
report	O
here	O
a	O
simple	O
and	O
rapid	O
strategy	O
to	O
detect	O
the	O
precise	O
number	O
of	O
the	O
CAGs	O
.	O

After	O
the	O
DNA	O
fragment	O
containing	O
the	O
CAG	O
repeats	O
is	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
,	O
a	O
primer	O
extension	O
is	O
carried	O
out	O
;	O

the	O
extension	O
of	O
the	O
end-labelled	O
reverse	O
primer	O
adjacent	O
to	O
3	O
'	O
end	O
of	O
CAG	O
repeats	O
stops	O
at	O
the	O
first	O
T	O
after	O
CAG	O
repeats	O
with	O
the	O
incorporation	O
of	O
dideoxy	O
ATP	O
in	O
the	O
reaction	O
mixture	O
.	O

The	O
resultant	O
primer	O
products	O
are	O
analysed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
autoradiography	O
.	O

This	O
method	O
could	B-SPECULATION
be	I-SPECULATION
quite	I-SPECULATION
useful	I-SPECULATION
to	I-SPECULATION
detect	I-SPECULATION
not	I-SPECULATION
only	I-SPECULATION
CAG	I-SPECULATION
repeats	I-SPECULATION
in	I-SPECULATION
SBMA	I-SPECULATION
but	I-SPECULATION
also	I-SPECULATION
other	I-SPECULATION
polymorphic	I-SPECULATION
dinucleotide	I-SPECULATION
and	I-SPECULATION
trinucleotide	I-SPECULATION
repeats	I-SPECULATION
.	O

Activity	O
of	O
the	O
kappa	O
B	O
enhancer	O
of	O
the	O
interleukin-2	O
receptor	O
alpha	O
chain	O
in	O
somatic	O
cell	O
hybrids	O
is	O
accompanied	O
by	O
the	O
nuclear	O
localization	O
of	O
NF-kappa	O
B	O
.	O

The	O
two	O
nuclear	O
proteins	O
NF-kappa	O
B	O
(	O
consisting	O
of	O
subunits	O
p50	O
andp65	O
)	O
and	O
the	O
DNA-binding	O
subunit	O
of	O
NF-kappa	O
B	O
(	O
p50	O
)	O
by	O
itself	O
,	O
also	O
called	O
KBF1	O
,	O
are	O
constitutively	O
expressed	O
and	O
localized	O
in	O
the	O
nucleus	O
of	O
the	O
human	O
T-cell	O
line	O
IARC	O
301.5	O
.	O

In	O
order	O
to	O
define	O
the	O
roles	O
of	O
these	O
two	O
factors	O
,	O
which	O
bind	O
to	O
the	O
same	O
kappa	O
B	O
enhancers	O
,	O
in	O
transcription	O
activation	O
we	O
have	O
prepared	O
somatic	O
cell	O
hybrids	O
between	O
IARC	O
301.5	O
and	O
a	O
murine	O
myeloma	O
.	O

Most	O
hybrids	O
express	O
both	O
KBF1	O
and	O
NF-kappa	O
B	O
in	O
their	O
nuclei	O
,	O
but	O
one	O
hybrid	O
expresses	O
only	O
KBF1	O
.	O

The	O
kappa	O
B	O
enhancer	O
of	O
the	O
gene	O
encoding	O
the	O
interleukin-2	O
(	O
IL-2	O
)	O
receptor	O
alpha	O
chain	O
(	O
IL-2R	O
alpha	O
)	O
is	O
functional	O
only	O
in	O
the	O
hybrids	O
expressing	O
nuclear	O
NF-kappa	O
B	O
.	O

These	O
findings	O
show	O
that	O
nuclear	O
NF-kappa	O
B	O
is	O
necessary	O
to	O
activate	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
KBF1	O
by	O
itself	O
is	O
not	B-NEGATION
sufficient	I-NEGATION
.	O

We	O
propose	O
that	O
KBF1	O
is	O
a	O
competitive	O
inhibitor	O
of	O
NF-kappa	O
B	O
and	O
discuss	O
how	O
these	B-SPECULATION
factors	I-SPECULATION
may	I-SPECULATION
be	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
transient	I-SPECULATION
expression	I-SPECULATION
of	I-SPECULATION
IL-2	I-SPECULATION
and	I-SPECULATION
IL-2R	I-SPECULATION
alpha	I-SPECULATION
genes	I-SPECULATION
during	I-SPECULATION
the	I-SPECULATION
immune	I-SPECULATION
response	I-SPECULATION
.	O

Influence	O
of	O
estradiol	O
and	O
tamoxifen	O
on	O
susceptibility	O
of	O
human	O
breast	O
cancer	O
cell	O
lines	O
to	O
lysis	O
by	O
lymphokine-activated	O
killer	O
cells	O
.	O

The	B-SPECULATION
design	I-SPECULATION
of	I-SPECULATION
combination	I-SPECULATION
hormonal	I-SPECULATION
and	I-SPECULATION
immunotherapeutic	I-SPECULATION
protocols	I-SPECULATION
for	I-SPECULATION
breast	I-SPECULATION
cancer	I-SPECULATION
patients	I-SPECULATION
may	I-SPECULATION
be	I-SPECULATION
facilitated	I-SPECULATION
by	I-SPECULATION
analysis	I-SPECULATION
of	I-SPECULATION
preclinical	I-SPECULATION
in	I-SPECULATION
vitro	I-SPECULATION
model	I-SPECULATION
systems	I-SPECULATION
.	O

Estrogen	O
receptor	O
positive	O
(	O
ER	O
+	O
:	O
MCF-7	O
)	O
and	O
negative	O
(	O
ER	O
-	O
:	O
MDA-MB-231	O
)	O
human	O
breast	O
cancer	O
cell	O
lines	O
were	O
utilized	O
to	O
evaluate	O
the	O
effects	O
of	O
tamoxifen	O
(	O
TAM	O
)	O
and	O
estradiol	O
(	O
E2	O
)	O
on	O
modulation	O
of	O
breast	O
cancer	O
target	O
susceptibility	O
to	O
lysis	O
by	O
lymphokine-activated	O
killer	O
(	O
LAK	O
)	O
cells	O
.	O

E2-stimulated	O
ER	O
+	O
cells	O
were	O
more	O
susceptible	O
to	O
lysis	O
by	O
LAK	O
cells	O
than	O
corresponding	O
TAM-treated	O
or	O
control	O
cells	O
,	O
while	O
treatment	O
of	O
ER	O
-	O
cells	O
with	O
either	O
E2	O
or	O
TAM	O
alone	O
did	O
not	B-NEGATION
alter	I-NEGATION
from	I-NEGATION
control	I-NEGATION
their	I-NEGATION
susceptibility	I-NEGATION
to	I-NEGATION
this	I-NEGATION
immune-mediated	I-NEGATION
lysis	I-NEGATION
.	O

All	O
ER	O
+	O
and	O
ER	O
-	O
cells	O
tested	O
remained	O
sensitive	O
after	O
treatment	O
with	O
TAM	O
to	O
lysis	O
by	O
LAK	O
cells	O
.	O

In	O
addition	O
,	O
an	O
adenocarcinoma	O
reactive	O
human-mouse	O
chimeric	O
monoclonal	O
antibody	O
(	O
ING-1	O
)	O
was	O
able	O
to	O
significantly	O
boost	O
in	O
vivo	O
generated	O
LAK	O
cell-mediated	O
lysis	O
of	O
control	O
,	O
E2-treated	O
,	O
and	O
TAM-treated	O
ER	O
+	O
and	O
ER	O
-	O
cells	O
.	O

These	O
in	O
vitro	O
results	O
provide	O
a	O
preclinical	O
rationale	O
for	O
in	O
vivo	O
testing	O
of	O
TAM	O
,	O
interleukin-2	O
(	O
IL-2	O
)	O
,	O
and	O
breast	O
cancer	O
reactive	O
antibody-dependent	O
cellular	O
cytotoxicity	O
facilitating	O
antibody	O
in	O
patients	O
with	O
refractory	O
or	O
high	O
risk	O
breast	O
cancer	O
.	O

Glucocorticoid	O
receptor	O
and	O
inhibition	O
of	O
3-O-methyl-D-glucose	O
uptake	O
by	O
glucocorticoids	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
normal	O
humans	O
:	O
correlation	O
between	O
receptor	O
level	O
and	O
hormone	O
effect	O
in	O
vitro	O
.	O

We	O
have	O
measured	O
the	O
glucocorticoid	O
receptor	O
concentration	O
in	O
mononuclear	O
and	O
polymorphonuclear	O
leukocytes	O
,	O
both	O
of	O
which	O
were	O
isolated	O
from	O
peripheral	O
blood	O
from	O
ten	O
healthy	O
male	O
volunteers	O
.	O

In	O
parallel	O
,	O
the	O
inhibitory	O
effect	O
of	O
dexamethasone	O
on	O
3-O-methyl-D-glucose	O
uptake	O
was	O
assayed	O
in	O
the	O
corresponding	O
mononuclear	O
leukocytes	O
.	O

The	O
glucocorticoid	O
receptor	O
levels	O
in	O
mononuclear	O
leukocytes	O
correlated	O
with	O
those	O
in	O
polymorphonuclear	O
leukocytes	O
,	O
and	O
there	O
was	O
a	O
linear	O
relationship	O
between	O
the	O
cellular	O
glucocorticoid	O
receptor	O
levels	O
and	O
glucocorticoid-mediated	O
inhibition	O
of	O
the	O
uptake	O
of	O
3-O-methyl-D-glucose	O
in	O
mononuclear	O
leukocytes	O
.	O

When	O
mononuclear	O
leukocytes	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
8-bromo-cAMP	O
,	O
cellular	O
glucocorticoid	O
receptor	O
levels	O
increased	O
and	O
a	O
more	O
pronounced	O
inhibitory	O
effect	O
of	O
dexamethasone	O
was	O
observed	O
on	O
the	O
transport	O
of	O
3-O-methyl-D-glucose	O
.	O

We	O
conclude	O
that	O
the	O
cellular	O
glucocorticoid	O
receptor	O
levels	O
in	O
peripheral	O
blood	O
leukocytes	O
reflect	O
in	O
vitro	O
responsiveness	O
to	O
glucocorticoids	O
in	O
mononuclear	O
leukocytes	O
from	O
healthy	O
males	O
,	O
and	O
that	O
the	O
individual	O
responsiveness	O
may	B-SPECULATION
alter	I-SPECULATION
upon	I-SPECULATION
changes	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
cellular	I-SPECULATION
levels	I-SPECULATION
of	I-SPECULATION
glucocorticoid	I-SPECULATION
receptor	I-SPECULATION
.	O

Stimulation	O
of	O
interferon	O
beta	O
gene	O
transcription	O
in	O
vitro	O
by	O
purified	O
NF-kappa	O
B	O
and	O
a	O
novel	O
TH	O
protein	O
.	O

The	O
human	O
interferon	O
beta	O
(	O
IFN-beta	O
)	O
regulatory	O
element	O
consists	O
of	O
multiple	O
enhanson	O
domains	O
which	O
are	O
targets	O
for	O
transcription	O
factors	O
involved	O
in	O
inducible	O
expression	O
of	O
the	O
promoter	O
.	O

To	O
further	O
characterize	O
the	O
protein-DNA	O
interactions	O
mediating	O
IFN-beta	O
induction	O
,	O
positive	O
regulatory	O
domain	O
(	O
PRD	O
)	O
II	O
binding	O
proteins	O
were	O
purified	O
from	O
phorbol	O
ester	O
induced	O
Jurkat	O
T-cells	O
and	O
from	O
IFN	O
primed	O
,	O
cycloheximide	O
/	O
polyinosinic-polycytidylic	O
acid	O
treated	O
HeLa	O
S3	O
cells	O
.	O

From	O
HeLa	O
cells	O
,	O
two	O
major	O
proteins	O
of	O
52	O
and	O
45	O
kilodaltons	O
(	O
kD	O
)	O
copurified	O
with	O
DNA	O
binding	O
activity	O
,	O
whereas	O
from	O
T-cells	O
,	O
four	O
proteins	O
--	O
a	O
major	O
protein	O
of	O
52	O
kD	O
and	O
three	O
minor	O
proteins	O
of	O
82	O
,	O
67	O
,	O
and	O
43-47	O
kD	O
--	O
were	O
purified	O
.	O

Also	O
,	O
an	O
induction	O
specific	O
DNA	O
binding	O
protein	O
was	O
purified	O
from	O
HeLa	O
cells	O
that	O
interacted	O
with	O
the	O
(	O
AAGTGA	O
)	O
4	O
tetrahexamer	O
sequence	O
and	O
the	O
PRDI	O
domain	O
.	O

This	O
protein	O
is	O
immunologically	O
distinct	O
from	O
IRF-1	O
/	O
ISGF2	O
.	O

Uninduced	O
or	O
Sendai	O
virus	O
induced	O
HeLa	O
extracts	O
were	O
used	O
to	O
examine	O
transcription	O
in	O
vitro	O
using	O
a	O
series	O
of	O
IFN	O
beta	O
promoter	O
deletions	O
.	O

Deletions	O
upstream	O
of	O
the	O
PRDII	O
element	O
increased	O
transcription	O
in	O
the	O
uninduced	O
extract	O
,	O
indicating	B-SPECULATION
predominantly	I-SPECULATION
negative	I-SPECULATION
regulation	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
promoter	I-SPECULATION
.	O

A	O
2-4-fold	O
increase	O
in	O
IFN-beta	O
promoter	O
transcription	O
was	O
observed	O
in	O
Sendai	O
virus	O
induced	O
extracts	O
,	O
and	O
deletion	O
of	O
PRDI	O
and	O
PRDII	O
elements	O
decreased	O
this	O
induced	O
level	O
of	O
transcription	O
.	O

When	O
purified	O
PRDII	O
and	O
tetrahexamer	O
binding	O
proteins	O
were	O
added	O
to	O
the	O
induced	O
extract	O
,	O
a	O
4-fold	O
increase	O
in	O
transcription	O
was	O
observed	O
.	O

These	O
experiments	O
demonstrate	O
that	O
it	B-SPECULATION
is	I-SPECULATION
possible	I-SPECULATION
to	I-SPECULATION
modulate	I-SPECULATION
IFN-beta	I-SPECULATION
transcription	I-SPECULATION
in	I-SPECULATION
vitro	I-SPECULATION
but	O
indicate	B-SPECULATION
that	I-SPECULATION
additional	B-SPECULATION
proteins	I-SPECULATION
may	I-SPECULATION
be	I-SPECULATION
required	I-SPECULATION
to	I-SPECULATION
fully	I-SPECULATION
activate	I-SPECULATION
IFN-beta	I-SPECULATION
transcription	I-SPECULATION
.	O

Structure	O
function	O
analysis	O
of	O
vitamin	O
D	O
analogs	O
with	O
C-ring	O
modifications	O
.	O

Analogs	O
of	O
1	O
alpha,25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha,25	O
-(	O
OH	O
)	O
2D3	O
)	O
with	O
substitutions	O
on	O
C-11	O
were	O
synthesized	O
.	O

Small	O
apolar	O
substitutions	O
(	O
11	O
alpha-methyl	O
,	O
11	O
alpha-fluoromethyl	O
)	O
did	O
not	O
markedly	O
decrease	O
the	O
affinity	O
for	O
the	O
vitamin	O
D	O
receptor	O
,	O
but	O
larger	O
(	O
11	O
alpha-chloromethyl	O
or	O
11	O
alpha	O
-	O
or	O
11	O
beta-phenyl	O
)	O
or	O
more	O
polar	O
substitutions	O
(	O
11	O
alpha-hydroxymethyl	O
,	O
11	O
alpha	O
-(	O
2-hydroxyethyl	O
]	O
decreased	O
the	O
affinity	O
to	O
less	O
than	O
5	O
%	O
of	O
that	O
of	O
1	O
alpha,25-OH	O
)	O
2D3	O
.	O

Their	O
affinity	O
for	O
the	O
vitamin	O
D-binding	O
protein	O
,	O
however	O
,	O
increased	O
up	O
to	O
4-fold	O
.	O

The	O
biological	O
activity	O
of	O
11	O
alpha-methyl-1	O
alpha,25	O
-(	O
OH	O
)	O
2D3	O
closely	O
resembled	O
that	O
of	O
the	O
natural	O
hormone	O
on	O
normal	O
and	O
leukemic	O
cell	O
proliferation	O
and	O
bone	O
resorption	O
,	O
whereas	O
its	O
in	O
vivo	O
effect	O
on	O
calcium	O
metabolism	O
of	O
the	O
rachitic	O
chick	O
was	O
about	O
50	O
%	O
of	O
that	O
of	O
1	O
alpha,25	O
-(	O
OH	O
)	O
2D3	O
.	O

The	O
11	O
beta-methyl	O
analog	O
had	O
a	O
greater	O
than	O
10-fold	O
lower	O
activity	O
.	O

The	O
differentiating	O
effects	O
of	O
the	O
other	O
C-11	O
analogs	O
on	O
human	O
promyeloid	O
leukemia	O
cells	O
(	O
HL-60	O
)	O
agreed	O
well	O
with	O
their	O
bone-resorbing	O
activity	O
and	O
receptor	O
affinity	O
,	O
but	O
they	O
demonstrated	O
lower	O
calcemic	O
effects	O
in	O
vivo	O
.	O

Large	O
or	O
polar	O
substitutions	O
on	O
C-11	O
of	O
1	O
alpha,25	O
-(	O
OH	O
)	O
2D3	O
thus	O
impair	O
the	O
binding	O
of	O
the	O
vitamin	O
D	O
receptor	O
but	O
increase	O
the	O
affinity	O
to	O
vitamin	O
D-binding	O
protein	O
.	O

The	O
effects	O
of	O
many	O
C-11-substituted	O
1	O
alpha,25	O
-(	O
OH	O
)	O
2D3	O
analogs	O
on	O
HL-60	O
cell	O
differentiation	O
exceeded	O
their	O
activity	O
on	O
calcium	O
metabolism	O
.	O

Transcriptional	O
regulation	O
during	O
T-cell	O
development	O
:	O
the	O
alpha	O
TCR	O
gene	O
as	O
a	O
molecular	O
model	O
.	O

The	O
regulation	O
of	O
gene	O
expression	O
during	O
lymphocyte	O
differentiation	O
is	O
a	O
complex	O
process	O
involving	O
interactions	O
between	O
multiple	O
positive	O
and	O
negative	O
transcriptional	O
regulatory	O
elements	O
.	O

In	O
this	O
article	O
,	O
transcriptional	O
regulation	O
of	O
the	O
archetypal	O
T-cell-specific	O
gene	O
,	O
alpha	O
TCR	O
,	O
is	O
discussed	O
.	O

Major	O
recent	O
developments	O
,	O
including	O
the	O
identification	O
of	O
novel	O
families	O
of	O
transcription	O
factors	O
that	O
regulate	O
multiple	O
T-cell	O
genes	O
during	O
thymocyte	O
ontogeny	O
and	O
T-cell	O
activation	O
,	O
are	O
described	O
.	O

Cortisol	O
resistance	O
in	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

This	O
study	O
concerns	O
9	O
iv	O
drug	O
abusers	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
who	O
developed	O
hypercortisolism	O
without	B-NEGATION
the	I-NEGATION
clinical	I-NEGATION
signs	I-NEGATION
or	I-NEGATION
metabolic	I-NEGATION
consequences	I-NEGATION
of	I-NEGATION
hypercortisolism	I-NEGATION
.	O

All	O
patients	O
were	O
characterized	O
by	O
an	O
Addisonian	O
picture	O
(	O
weakness	O
,	O
weight	O
loss	O
,	O
hypotension	O
,	O
hyponatremia	O
,	O
and	O
intense	O
mucocutaneous	O
melanosis	O
)	O
.	O

An	B-SPECULATION
acquired	I-SPECULATION
form	I-SPECULATION
of	I-SPECULATION
peripheral	I-SPECULATION
resistance	I-SPECULATION
to	I-SPECULATION
glucocorticoids	I-SPECULATION
was	I-SPECULATION
suspected	I-SPECULATION
.	O

We	O
,	O
therefore	O
,	O
examined	O
glucocorticoid	O
receptor	O
characteristics	O
on	O
mononuclear	O
leukocytes	O
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
is	O
one	O
of	O
the	O
effects	O
of	O
glucocorticoid	O
receptor	O
activation	O
.	O

Glucocorticoid	O
receptor	O
density	O
was	O
increased	O
in	O
AIDS	O
patients	O
with	O
an	O
Addisonian	O
picture	O
(	O
group	O
1	O
;	O
16.2	O
	O
9.4	O
fmol	O
/	O
million	O
cells	O
)	O
compared	O
to	O
values	O
in	O
12	O
AIDS	O
patients	O
without	B-NEGATION
an	I-NEGATION
Addisonian	I-NEGATION
picture	I-NEGATION
(	O
group	O
2	O
;	O
6.05	O
	O
2.6	O
fmol	O
/	O
million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
and	O
sex	O
-	O
and	O
age-matched	O
controls	O
(	O
3.15	O
	O
2.3	O
fmol	O
/	O
million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

The	O
affinity	O
of	O
glucocorticoid	O
receptors	O
(	O
Kd	O
)	O
was	O
strikingly	O
decreased	O
(	O
9.36	O
	O
3.44	O
nM	O
in	O
group	O
1	O
;	O
3.2	O
	O
1.5	O
nM	O
in	O
group	O
2	O
;	O
2.0	O
	O
0.8	O
nM	O
in	O
controls	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

[	O
3H	O
]	O
Thymidine	O
incorporation	O
was	O
decreased	O
dose-dependently	O
by	O
dexamethasone	O
in	O
controls	O
and	O
patients	O
;	O

the	O
effect	O
was	O
significantly	O
blunted	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
group	O
1	O
patients	O
,	O
which	O
suggests	B-SPECULATION
that	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
glucocorticoid	I-SPECULATION
receptor	I-SPECULATION
is	I-SPECULATION
impaired	I-SPECULATION
as	I-SPECULATION
a	I-SPECULATION
result	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
glucocorticoid	I-SPECULATION
receptor	I-SPECULATION
abnormality	I-SPECULATION
.	O

In	O
conclusion	O
,	O
AIDS	O
patients	O
with	O
hypercortisolism	O
and	O
clinical	O
features	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
are	O
characterized	O
by	O
abnormal	O
glucocorticoid	O
receptors	O
on	O
lymphocytes	O
.	O

Resistance	O
to	O
glucocorticoids	O
implies	B-SPECULATION
a	I-SPECULATION
complex	I-SPECULATION
change	I-SPECULATION
in	I-SPECULATION
immune-endocrine	I-SPECULATION
function	I-SPECULATION
,	I-SPECULATION
which	I-SPECULATION
may	B-SPECULATION
be	I-SPECULATION
important	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
course	I-SPECULATION
of	I-SPECULATION
immunodeficiency	I-SPECULATION
syndrome	I-SPECULATION
.	O

Induction	O
of	O
monocytic	O
differentiation	O
and	O
NF-kappa	O
B-like	O
activities	O
by	O
human	O
immunodeficiency	O
virus	O
1	O
infection	O
of	O
myelomonoblastic	O
cells	O
.	O

The	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
infection	O
on	O
cellular	O
differentiation	O
and	O
NF-kappa	O
B	O
DNA	O
binding	O
activity	O
have	O
been	O
investigated	O
in	O
a	O
new	O
model	O
of	O
myeloid	O
differentiation	O
.	O

PLB-985	O
cells	O
represent	O
a	O
bipotential	O
myelomonoblastic	O
cell	O
population	O
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O

By	O
virtue	O
of	O
the	O
presence	O
of	O
CD4	O
on	O
the	O
cell	O
surface	O
,	O
PLB-985	O
cells	O
were	O
chronically	O
infected	O
with	O
HIV-1	O
strain	O
IIIB	O
.	O

PLB-IIIB	O
cells	O
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	O
myeloblasts	O
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	O
expression	O
of	O
the	O
myeloid-specific	O
surface	O
markers	O
,	O
and	O
transcription	O
of	O
the	O
c-fms	O
proto-oncogene	O
.	O

NF-kappa	O
B	O
binding	O
activity	O
was	O
inducible	O
by	O
tumor	O
necrosis	O
factor	O
and	O
phorbol	O
myristate	O
acetate	O
in	O
PLB-985	O
.	O

However	O
,	O
in	O
PLB-IIIB	O
cells	O
,	O
constitutive	O
expression	O
of	O
a	O
novel	O
NF-kappa	O
B	O
complex	O
was	O
detected	O
,	O
composed	O
of	O
proteins	O
ranging	O
between	O
70	O
and	O
110	O
kD	O
.	O

These	O
proteins	O
interacted	O
specifically	O
with	O
the	O
symmetric	O
NF-kappa	O
B	O
site	O
from	O
the	O
interferon	O
beta	O
(	O
IFN-beta	O
)	O
promoter	O
.	O

Mutations	O
affecting	O
the	O
5	O
'	O
guanine	O
residues	O
of	O
the	O
kappa	O
B	O
site	O
were	O
unable	B-NEGATION
to	I-NEGATION
compete	I-NEGATION
for	I-NEGATION
these	I-NEGATION
NF-kappa	I-NEGATION
B-related	I-NEGATION
proteins	I-NEGATION
.	O

Inducibility	O
of	O
endogenous	O
IFN-beta	O
and	O
IFN-alpha	O
RNA	O
was	O
also	O
increased	O
in	O
PLB-IIIB	O
cells	O
.	O

These	O
studies	O
indicate	B-SPECULATION
that	I-SPECULATION
HIV-1	I-SPECULATION
infection	I-SPECULATION
of	I-SPECULATION
myelomonoblastic	I-SPECULATION
cells	I-SPECULATION
may	B-SPECULATION
select	I-SPECULATION
for	I-SPECULATION
a	I-SPECULATION
more	I-SPECULATION
mature	I-SPECULATION
monocytic	I-SPECULATION
phenotype	I-SPECULATION
and	O
that	O
unique	O
subunit	O
associations	O
of	O
NF-kappa	O
B	O
DNA	O
binding	O
proteins	O
may	B-SPECULATION
contribute	I-SPECULATION
to	I-SPECULATION
differential	I-SPECULATION
NF-kappa	I-SPECULATION
B-mediated	I-SPECULATION
gene	I-SPECULATION
expression	I-SPECULATION
.	O

The	B-SPECULATION
AP-1	I-SPECULATION
site	I-SPECULATION
at	I-SPECULATION
-	I-SPECULATION
150	I-SPECULATION
bp	I-SPECULATION
,	I-SPECULATION
but	I-SPECULATION
likely	I-SPECULATION
to	I-SPECULATION
represent	I-SPECULATION
the	I-SPECULATION
major	I-SPECULATION
target	I-SPECULATION
of	I-SPECULATION
protein	I-SPECULATION
kinase	I-SPECULATION
C	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
interleukin	I-SPECULATION
2	I-SPECULATION
promoter	I-SPECULATION
not	B-NEGATION
the	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
site	I-NEGATION
,	O
is	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
antigen	O
results	O
in	O
activation	O
of	O
several	O
kinases	O
,	O
including	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
that	O
may	B-SPECULATION
mediate	I-SPECULATION
the	I-SPECULATION
later	I-SPECULATION
induction	I-SPECULATION
of	I-SPECULATION
activation-related	I-SPECULATION
genes	I-SPECULATION
.	O

We	O
have	O
examined	O
the	O
potential	O
role	O
of	O
PKC	O
in	O
induction	O
of	O
the	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
in	O
T	O
cells	O
stimulated	O
through	O
the	O
T	O
cell	O
receptor	O
/	O
CD3	O
complex	O
.	O

We	O
have	O
previously	O
shown	O
that	O
prolonged	O
treatment	O
of	O
the	O
untransformed	O
T	O
cell	O
clone	O
Ar-5	O
with	O
phorbol	O
esters	O
results	O
in	O
downmodulation	O
of	O
the	O
alpha	O
and	O
beta	O
isozymes	O
of	O
PKC	O
,	O
and	O
abrogates	O
induction	O
of	O
IL-2	O
mRNA	O
and	O
protein	O
.	O

Here	O
we	O
show	O
that	O
phorbol	O
ester	O
treatment	O
also	O
abolishes	O
induction	O
of	O
chloramphenicol	O
acetyltransferase	O
activity	O
in	O
Ar-5	O
cells	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL-2	O
promoter	O
linked	O
to	O
this	O
reporter	O
gene	O
.	O

The	O
IL-2	O
promoter	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factors	O
including	O
NFAT-1	O
,	O
Oct	O
,	O
NF-kappa	O
B	O
,	O
and	O
AP-1	O
,	O
which	O
are	O
all	O
potentially	B-SPECULATION
sensitive	I-SPECULATION
to	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
PKC	I-SPECULATION
.	O

We	O
show	O
that	O
induction	O
of	O
a	O
trimer	O
of	O
the	O
NFAT	O
and	O
Oct	O
sites	O
is	O
not	B-NEGATION
sensitive	I-NEGATION
to	I-NEGATION
phorbol	I-NEGATION
ester	I-NEGATION
treatment	I-NEGATION
,	O
and	O
that	O
mutations	O
in	O
the	O
NF-kappa	O
B	O
site	O
have	O
no	B-NEGATION
effect	I-NEGATION
on	I-NEGATION
inducibility	I-NEGATION
of	I-NEGATION
the	I-NEGATION
IL-2	I-NEGATION
promoter	I-NEGATION
.	O

In	O
contrast	O
,	O
mutations	O
in	O
the	O
AP-1	O
site	O
located	O
at	O
-	O
150	O
bp	O
almost	O
completely	O
abrogate	O
induction	O
of	O
the	O
IL-2	O
promoter	O
,	O
and	O
appearance	O
of	O
an	O
inducible	O
nuclear	O
factor	O
binding	O
to	O
this	O
site	O
is	O
sensitive	O
to	O
PKC	O
depletion	O
.	O

Moreover	O
,	O
cotransfections	O
with	O
c-fos	O
and	O
c-jun	O
expression	O
plasmids	O
markedly	O
enhance	O
induction	O
of	O
the	O
IL-2	O
promoter	O
in	O
minimally	O
stimulated	O
T	O
cells	O
.	O

Our	O
results	O
indicate	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
AP-1	I-SPECULATION
site	I-SPECULATION
at	I-SPECULATION
-	I-SPECULATION
150	I-SPECULATION
bp	I-SPECULATION
represents	I-SPECULATION
a	I-SPECULATION
major	I-SPECULATION
,	I-SPECULATION
if	B-SPECULATION
not	I-SPECULATION
the	I-SPECULATION
only	I-SPECULATION
,	O
site	O
of	O
PKC	O
responsiveness	O
in	O
the	O
IL-2	O
promoter	O
.	O

Interleukin	O
6-induced	O
differentiation	O
of	O
a	O
human	O
B	O
cell	O
line	O
into	O
IgM-secreting	O
plasma	O
cells	O
is	O
mediated	O
by	O
c-fos	O
.	O

The	O
role	O
of	O
the	O
protooncogene	O
c-fos	O
in	O
interleukin	O
(	O
IL	O
)	O
6-induced	O
B	O
cell	O
differentiation	O
was	O
assessed	O
.	O

Treatment	O
of	O
SKW	O
6.4	O
cells	O
with	O
IL	O
6	O
induced	O
a	O
transient	O
and	O
early	O
stimulation	O
of	O
c-fos	O
sense	O
mRNA	O
expression	O
.	O

The	O
effect	O
appeared	O
within	O
30	O
min	O
and	O
returned	O
to	O
basal	O
levels	O
after	O
2	O
h	O
.	O

The	O
addition	O
of	O
antisense	O
oligonucleotides	O
to	O
c-fos	O
significantly	O
inhibited	O
IL	O
6-induced	O
IgM	O
production	O
by	O
SKW	O
6.4	O
cells	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
whereas	O
control	O
oligonucleotides	O
had	O
no	B-NEGATION
inhibitory	I-NEGATION
effect	I-NEGATION
.	O

These	O
results	O
indicate	B-SPECULATION
that	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
c-fos	I-SPECULATION
is	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
IL	I-SPECULATION
6-induced	I-SPECULATION
differentiation	I-SPECULATION
of	I-SPECULATION
SKW	I-SPECULATION
6.4	I-SPECULATION
cells	I-SPECULATION
into	I-SPECULATION
IgM-secreting	I-SPECULATION
cells	I-SPECULATION
.	O

Binding	O
of	O
erythroid	O
and	O
non-erythroid	O
nuclear	O
proteins	O
to	O
the	O
silencer	O
of	O
the	O
human	O
epsilon-globin-encoding	O
gene	O
.	O

To	O
clarify	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
developmental	O
control	O
of	O
hemoglobin-encoding	O
genes	O
we	O
have	O
been	O
studying	O
the	O
expression	O
of	O
these	O
genes	O
in	O
human	O
cells	O
in	O
continuous	O
culture	O
.	O

We	O
have	O
previously	O
reported	O
the	O
presence	O
of	O
a	O
transcriptional	O
control	O
element	O
with	O
the	O
properties	O
of	O
a	O
silencer	O
extending	O
from	O
-	O
392	O
to	O
-	O
177	O
bp	O
relative	O
to	O
the	O
cap	O
site	O
of	O
the	O
human	O
epsilon-globin-encoding	O
gene	O
[	O
Cao	O
et	O
al.	O
,	O
Proc.Natl.Acad.Sci.USA	O
86	O
(	O
1989	O
)	O
5306-5309	O
]	O
.	O

We	O
also	O
showed	O
that	O
this	O
silencer	O
has	O
stronger	O
inhibitory	O
activity	O
in	O
HeLa	O
cells	O
,	O
as	O
compared	O
to	O
K562	O
human	O
erythroleukemia	O
cells	O
.	O

Using	O
deletion	O
mutants	O
and	O
cis-cloned	O
synthetic	O
oligodeoxyribonucleotides	O
in	O
transient	O
expression	O
assays	O
,	O
nucleotide	O
sequences	O
responsible	O
for	O
this	O
effect	O
have	O
now	O
been	O
further	O
delimited	O
to	O
44	O
bp	O
located	O
from	O
-	O
294	O
to	O
-	O
251	O
bp	O
.	O

Gel	O
electrophoresis	O
mobility	O
shift	O
assays	O
and	O
DNaseI	O
footprinting	O
assays	O
demonstrate	O
that	O
these	O
negative	O
regulatory	O
sequences	O
are	O
recognized	O
differently	O
by	O
proteins	O
present	O
in	O
nuclear	O
extracts	O
obtained	O
from	O
HeLa	O
and	O
K562	O
cells	O
.	O

Two	O
binding	O
proteins	O
are	O
detected	O
in	O
K562	O
nuclear	O
extracts	O
,	O
while	O
only	O
one	O
is	O
found	O
in	O
extracts	O
from	O
HeLa	O
cells	O
.	O

Possible	B-SPECULATION
mechanisms	I-SPECULATION
by	I-SPECULATION
which	I-SPECULATION
these	I-SPECULATION
proteins	I-SPECULATION
are	O
discussed	O
.	O
may	B-SPECULATION
regulate	I-SPECULATION
transcription	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
epsilon-globin-encoding	I-SPECULATION
gene	I-SPECULATION
in	I-SPECULATION
erythroid	I-SPECULATION
and	I-SPECULATION
non-erythroid	I-SPECULATION
cells	I-SPECULATION
.	O

Gangliosides	O
suppress	O
tumor	O
necrosis	O
factor	O
production	O
in	O
human	O
monocytes	O
.	O

Both	O
normal	O
and	O
malignant	O
cells	O
contain	O
gangliosides	O
as	O
important	O
cell	O
membrane	O
constituents	O
that	O
,	O
after	O
being	O
shed	O
,	O
may	B-SPECULATION
influence	I-SPECULATION
cells	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
immune	I-SPECULATION
system	I-SPECULATION
.	O

We	O
have	O
studied	O
the	O
impact	O
of	O
gangliosides	O
on	O
the	O
expression	O
of	O
TNF	O
in	O
blood	O
monocytes	O
and	O
in	O
the	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
.	O

Although	O
under	O
standard	O
culture	O
conditions	O
,	O
bovine	O
brain	O
gangliosides	O
(	O
100	O
micrograms	O
/	O
ml	O
)	O
suppressed	O
LPS-stimulated	O
TNF	O
production	O
5-fold	O
in	O
PBMC	O
and	O
10-fold	O
in	O
Mono	O
Mac	O
6	O
cells	O
,	O
suppression	O
was	O
more	O
efficient	O
under	O
serum-free	O
conditions	O
.	O

Looking	O
at	O
highly	O
purified	O
gangliosides	O
,	O
GD3	O
,	O
GD1a	O
,	O
GM3	O
,	O
GM2	O
,	O
and	O
GM1	O
were	O
all	O
effective	O
in	O
reducing	O
TNF	O
production	O
in	O
PBMC	O
,	O
and	O
in	O
Mono	O
Mac	O
6	O
by	O
factor	O
10	O
to	O
50	O
.	O

The	O
suppressive	O
activity	O
was	O
lost	O
in	O
molecules	O
,	O
lacking	B-NEGATION
the	B-SPECULATION
sugar	I-SPECULATION
moiety	I-SPECULATION
or	I-SPECULATION
the	I-SPECULATION
lipid	I-SPECULATION
moiety	I-SPECULATION
.	O

Gangliosides	B-SPECULATION
appear	I-SPECULATION
to	I-SPECULATION
act	I-SPECULATION
at	I-SPECULATION
an	I-SPECULATION
early	I-SPECULATION
step	I-SPECULATION
of	I-SPECULATION
activation	I-SPECULATION
in	O
that	O
TNF	O
transcripts	O
were	O
reduced	O
and	O
the	O
mobilization	O
of	O
the	O
nuclear	O
factor	O
kappa	O
B	O
was	O
blocked	O
.	O

Furthermore	O
,	O
in	O
time	O
kinetics	O
,	O
gangliosides	O
were	O
effective	O
for	O
up	O
to	O
30	O
min	O
after	O
addition	O
of	O
LPS	O
,	O
but	O
not	B-NEGATION
thereafter	I-NEGATION
.	O

However	O
,	O
the	O
expression	O
of	O
the	O
CD14	O
Ag	O
,	O
a	O
receptor	O
molecule	O
for	O
LPS-LPS	O
binding	O
protein	O
complexes	O
,	O
was	O
unaffected	O
by	O
gangliosides	O
.	O

Finally	O
,	O
when	O
using	O
Staphylococcus	O
aureus	O
or	O
platelet	O
activating	O
factor	O
as	O
a	O
stimulus	O
,	O
gangliosides	O
were	O
able	O
to	O
suppress	O
TNF	O
production	O
in	O
Mono	O
Mac	O
6	O
cells	O
by	O
factor	O
5	O
to	O
10	O
,	O
as	O
well	O
.	O

On	O
the	O
other	O
hand	O
,	O
phorbol	O
ester-induced	O
production	O
of	O
O2	O
-	O
was	O
similar	O
in	O
cells	O
treated	O
with	O
and	O
without	B-NEGATION
gangliosides	I-NEGATION
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
TNF	O
gene	O
expression	O
in	O
monocytes	O
induced	O
by	O
different	O
types	O
of	O
stimuli	O
can	O
be	O
blocked	O
by	O
gangliosides	O
at	O
an	O
early	O
step	O
of	O
signal	O
transduction	O
.	O

T	O
cell-specific	O
negative	O
regulation	O
of	O
transcription	O
of	O
the	O
human	O
cytokine	O
IL-4	O
.	O

IL-4	O
secreted	O
by	O
activated	O
T	O
cells	O
is	O
a	O
pleiotropic	O
cytokine	O
affecting	O
growth	O
and	O
differentiation	O
of	O
diverse	O
cell	O
types	O
such	O
as	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
mast	O
cells	O
.	O

We	O
investigated	O
the	O
upstream	O
regulatory	O
elements	O
of	O
the	O
human	O
IL-4	O
promoter	O
.	O

A	O
novel	O
T	O
cell-specific	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
composed	O
of	O
two	O
protein-binding	O
sites	O
were	O
mapped	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
IL-4	O
gene	O
:	O
-	O
311CTCCCTTCT-303	O
(	O
NRE-I	O
)	O
and	O
-	O
288CTTTTTGCTT-TGC-300	O
(	O
NRE-II	O
)	O
.	O

A	O
T	O
cell-specific	O
protein	O
Neg-1	O
and	O
a	O
ubiquitous	O
protein	O
Neg-2	O
binding	O
to	O
NRE-I	O
and	O
NRE-II	O
,	O
respectively	O
,	O
were	O
identified	O
.	O

Furthermore	O
,	O
a	O
positive	O
regulatory	O
element	O
was	O
found	O
45	O
bp	O
downstream	O
of	O
the	O
NRE	O
.	O

The	O
enhancer	O
activity	O
of	O
the	O
PRE	O
was	O
completely	O
suppressed	O
when	O
the	O
NRE	O
was	O
present	O
.	O

These	O
data	O
suggest	B-SPECULATION
that	I-SPECULATION
IL-4	I-SPECULATION
promoter	I-SPECULATION
activity	I-SPECULATION
is	I-SPECULATION
normally	I-SPECULATION
down-regulated	I-SPECULATION
by	I-SPECULATION
an	I-SPECULATION
NRE	I-SPECULATION
via	I-SPECULATION
repression	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
enhancer	I-SPECULATION
positive	I-SPECULATION
regulatory	I-SPECULATION
element	I-SPECULATION
.	O

These	O
data	O
may	B-SPECULATION
have	I-SPECULATION
implications	I-SPECULATION
for	I-SPECULATION
the	I-SPECULATION
stringent	I-SPECULATION
control	I-SPECULATION
of	I-SPECULATION
IL-4	I-SPECULATION
expression	I-SPECULATION
in	I-SPECULATION
T	I-SPECULATION
cells	I-SPECULATION
.	O

[	O
Regulatory	O
effect	O
of	O
insulin	O
on	O
glucocorticoid	O
receptor	O
in	O
human	O
peripheral	O
leukocytes	O
]	O

The	O
regulatory	O
effect	O
of	O
insulin	O
on	O
the	O
specific	O
binding	O
power	O
of	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
of	O
human	O
leukocytes	O
was	O
assessed	O
by	O
the	O
unoccupied	O
receptor	O
sites	O
capable	O
of	O
combining	O
with	O
[	O
3H	O
]	O
labelled	O
dexamethasone	O
measured	O
at	O
3	O
and	O
24	O
h	O
after	O
incubation	O
with	O
various	O
concentrations	O
of	O
insulin	O
added	O
to	O
the	O
medium	O
.	O

After	O
3	O
h	O
incubation	O
the	O
specific	O
binding	O
power	O
with	O
[	O
3H	O
]	O
Dex	O
was	O
decreased	O
by	O
23.3	O
	O
10.0	O
,	O
32.2	O
	O
13.2	O
and	O
54.3	O
	O
9.2	O
%	O
(	O
P	O
greater	O
than	O
0.05	O
,	O
P	O
greater	O
than	O
0.05	O
and	O
P	O
less	O
than	O
0.01	O
as	O
compared	O
with	O
the	O
control	O
value	O
of	O
100	O
in	O
the	O
absence	O
of	O
insulin	O
)	O
respectively	O
in	O
the	O
presence	O
of	O
20	O
mU	O
/	O
L	O
(	O
physiological	O
testing	O
concentration	O
)	O
,	O
200	O
mU	O
/	O
L	O
(	O
physiological	O
upper	O
limit	O
)	O
and	O
2,000	O
mU	O
/	O
L	O
(	O
pharmacological	O
concentration	O
)	O
insulin	O
in	O
the	O
incubation	O
medium	O
.	O

After	O
24	O
h	O
incubation	O
the	O
decrease	O
of	O
these	O
values	O
increased	O
respectively	O
to	O
43.5	O
	O
19.0	O
,	O
56.1	O
	O
20.7	O
and	O
80.2	O
	O
15.5	O
(	O
P	O
less	O
than	O
0.05	O
,	O
P	O
less	O
than	O
0.01	O
and	O
P	O
less	O
than	O
0.01	O
compared	O
with	O
control	O
)	O
.	O

Thus	O
the	O
inhibitory	O
effect	O
of	O
insulin	O
on	O
the	O
GR	O
binding	O
power	O
is	O
both	O
dose	O
-	O
and	O
time-dependent	O
,	O
which	O
strongly	O
suggests	B-SPECULATION
that	I-SPECULATION
GR	I-SPECULATION
is	I-SPECULATION
tonically	I-SPECULATION
controlled	I-SPECULATION
by	I-SPECULATION
insulin	I-SPECULATION
concentration	I-SPECULATION
change	I-SPECULATION
under	I-SPECULATION
physiological	I-SPECULATION
conditions	I-SPECULATION
.	O

Human	O
T	O
cell	O
activation	O
through	O
the	O
activation-inducer	O
molecule	O
/	O
CD69	O
enhances	O
the	O
activity	O
of	O
transcription	O
factor	O
AP-1	O
.	O

The	O
induction	O
of	O
the	O
AP-1	O
transcription	O
factor	O
has	O
been	O
ascribed	O
to	O
the	O
early	O
events	O
leading	O
to	O
T	O
cell	O
differentiation	O
and	O
activation	O
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
AP-1	O
activity	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
stimulated	O
through	O
the	O
activation	O
inducer	O
molecule	O
(	O
AIM	O
)	O
/	O
CD69	O
activation	O
pathway	O
.	O

Phorbol	O
esters	O
are	O
required	O
to	O
induce	O
AIM	O
/	O
CD69	O
cell-surface	O
expression	O
as	O
well	O
as	O
for	O
triggering	O
the	O
proliferation	O
of	O
T	O
cells	O
in	O
conjunction	O
with	O
anti-AIM	O
mAb	O
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
addition	O
of	O
anti-AIM	O
mAb	O
to	O
PMA-treated	O
T	O
lymphocytes	O
markedly	O
enhanced	O
the	O
binding	O
activity	O
of	O
AP-1	O
to	O
its	O
cognate	O
sequence	O
,	O
the	O
phorbol	O
ester	O
response	O
element	O
.	O

In	O
contrast	O
,	O
anti-AIM	O
mAb	O
did	O
not	B-NEGATION
induce	I-NEGATION
any	I-NEGATION
change	I-NEGATION
in	I-NEGATION
the	I-NEGATION
binding	I-NEGATION
activity	I-NEGATION
of	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
,	I-NEGATION
a	I-NEGATION
transcription	I-NEGATION
factor	I-NEGATION
whose	I-NEGATION
activity	I-NEGATION
is	I-NEGATION
also	I-NEGATION
regulated	I-NEGATION
by	I-NEGATION
protein	I-NEGATION
kinase	I-NEGATION
C	I-NEGATION
.	O

The	O
increase	O
in	O
AP-1-binding	O
activity	O
was	O
accompanied	O
by	O
the	O
marked	O
stimulation	O
of	O
the	O
transcription	O
of	O
c-fos	O
but	O
not	B-NEGATION
that	I-NEGATION
of	I-NEGATION
c-jun	I-NEGATION
.	O

Blockade	O
of	O
the	O
DNA-binding	O
complexes	O
with	O
an	O
anti-Fos	O
mAb	O
demonstrated	O
a	O
direct	O
participation	O
of	O
c-Fos	O
in	O
the	O
AP-1	O
complexes	O
induced	O
by	O
anti-AIM	O
mAb	O
.	O

Most	O
of	O
the	O
AP-1	O
activity	O
could	O
be	O
eliminated	O
when	O
the	O
anti-AIM	O
mAb	O
was	O
added	O
to	O
the	O
culture	O
medium	O
in	O
the	O
presence	O
of	O
cycloheximide	O
,	O
suggesting	B-SPECULATION
that	I-SPECULATION
de	I-SPECULATION
novo	I-SPECULATION
protein	I-SPECULATION
synthesis	I-SPECULATION
is	I-SPECULATION
crucial	I-SPECULATION
for	I-SPECULATION
the	I-SPECULATION
induction	I-SPECULATION
of	I-SPECULATION
AP-1-binding	I-SPECULATION
activity	I-SPECULATION
.	O

These	O
data	O
provide	O
the	O
evidence	O
that	O
activation	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
through	O
the	O
AIM	O
activation	O
pathway	O
regulate	O
the	O
activity	O
of	O
AP-1	O
.	O

Therefore	O
,	O
this	O
pathway	O
appears	B-SPECULATION
as	I-SPECULATION
a	I-SPECULATION
crucial	I-SPECULATION
step	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
initiation	I-SPECULATION
of	I-SPECULATION
early	I-SPECULATION
T	I-SPECULATION
cell	I-SPECULATION
activation	I-SPECULATION
events	I-SPECULATION
.	O

cis-acting	O
sequences	O
required	O
for	O
inducible	O
interleukin-2	O
enhancer	O
function	O
bind	O
a	O
novel	O
Ets-related	O
protein	O
,	O
Elf-1	O
.	O

The	O
recent	O
definition	O
of	O
a	O
consensus	O
DNA	O
binding	O
sequence	O
for	O
the	O
Ets	O
family	O
of	O
transcription	O
factors	O
has	O
allowed	O
the	O
identification	O
of	O
potential	O
Ets	O
binding	O
sites	O
in	O
the	O
promoters	O
and	O
enhancers	O
of	O
many	O
inducible	O
T-cell	O
genes	O
.	O

In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
have	O
identified	O
two	O
potential	B-SPECULATION
Ets	I-SPECULATION
binding	I-SPECULATION
sites	I-SPECULATION
,	O
EBS1	O
and	O
EBS2	O
,	O
which	O
are	O
conserved	O
in	O
both	O
the	O
human	O
and	O
murine	O
interleukin-2	O
enhancers	O
.	O

Within	O
the	O
human	O
enhancer	O
,	O
these	O
two	O
sites	O
are	O
located	O
within	O
the	O
previously	O
defined	O
DNase	O
I	O
footprints	O
,	O
NFAT-1	O
and	O
NFIL-2B	O
,	O
respectively	O
.	O

Electrophoretic	O
mobility	O
shift	O
and	O
methylation	O
interference	O
analyses	O
demonstrated	O
that	O
EBS1	O
and	O
EBS2	O
are	O
essential	O
for	O
the	O
formation	O
of	O
the	O
NFAT-1	O
and	O
NFIL-2B	O
nuclear	O
protein	O
complexes	O
.	O

Furthermore	O
,	O
in	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
inducible	O
interleukin-2	O
enhancer	O
function	O
requires	O
the	O
presence	O
of	O
either	B-SPECULATION
EBS1	I-SPECULATION
.	O

Two	O
well-characterized	O
Ets	O
family	O
members	O
,	O
Ets-1	O
and	O
Ets-2	O
,	O
are	O
reciprocally	O
expressed	O
during	O
T-cell	O
activation	O
.	O

Surprisingly	O
,	O
however	O
,	O
neither	B-NEGATION
of	I-NEGATION
these	I-NEGATION
proteins	I-NEGATION
bound	I-NEGATION
in	I-NEGATION
vitro	I-NEGATION
to	I-NEGATION
EBS1	I-NEGATION
or	I-NEGATION
EBS2	I-NEGATION
.	O

We	O
therefore	O
screened	O
a	O
T-cell	O
cDNA	O
library	O
under	O
low-stringency	O
conditions	O
with	O
a	O
probe	O
from	O
the	O
DNA	O
binding	O
domain	O
of	O
Ets-1	O
and	O
isolated	O
a	O
novel	O
Ets	O
family	O
member	O
,	O
Elf-1	O
.	O

Elf-1	O
contains	O
a	O
DNA	O
binding	O
domain	O
that	O
is	O
nearly	O
identical	O
to	O
that	O
of	O
E74	O
,	O
the	O
ecdysone-inducible	O
Drosophila	O
transcription	O
factor	O
required	O
for	O
metamorphosis	O
(	O
hence	O
the	O
name	O
Elf-1	O
,	O
for	O
E74-like	O
factor	O
1	O
)	O
.	O

Elf-1	O
bound	O
specifically	O
to	O
both	O
EBS1	O
and	O
EBS2	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

It	O
also	O
bound	O
to	O
the	O
purine-rich	O
CD3R	O
element	O
from	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
long	O
terminal	O
repeat	O
,	O
which	O
is	O
required	O
for	O
inducible	O
virus	O
expression	O
in	O
response	O
to	O
signalling	O
through	O
the	O
T-cell	O
receptor	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
multiple	O
Ets	O
family	O
members	O
with	O
apparently	O
distinct	O
DNA	O
binding	O
specificities	O
regulate	O
differential	O
gene	O
expression	O
in	O
resting	O
and	O
activated	O
T	O
cells	O
.	O

Mineralocorticoids	O
and	O
mineralocorticoid	O
receptors	O
in	O
mononuclear	O
leukocytes	O
in	O
patients	O
with	O
pregnancy-induced	O
hypertension	O
.	O

To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	O
in	O
the	O
pathophysiology	O
of	O
pregnancy-induced	O
hypertension	O
(	O
PIH	O
)	O
,	O
we	O
studied	O
plasma	O
aldosterone	O
and	O
18-hydroxycorticosterone	O
levels	O
in	O
25	O
women	O
with	O
PIH	O
and	O
25	O
normal	O
pregnant	O
women	O
,	O
as	O
controls	O
.	O

Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	O
receptor	O
(	O
MR	O
)	O
status	O
in	O
mononuclear	O
leukocytes	O
in	O
the	O
2	O
groups	O
.	O

MR	O
count	O
was	O
significantly	O
(	O
P	O
less	O
than	O
0.0005	O
)	O
decreased	O
in	O
the	O
PIH	O
group	O
(	O
148	O
	O
9	O
binding	O
sites	O
/	O
cell	O
)	O
compared	O
with	O
the	O
control	O
group	O
(	O
300	O
	O
17	O
binding	O
sites	O
/	O
cell	O
;	O
mean	O
	O
SEM	O
)	O
.	O

Plasma	O
aldosterone	O
in	O
women	O
with	O
PIH	O
was	O
281	O
	O
61	O
pmol	O
/	O
L	O
;	O

in	O
normal	O
pregnant	O
women	O
it	O
was	O
697	O
	O
172	O
pmol	O
/	O
L	O
(	O
P	O
less	O
than	O
0.025	O
)	O
.	O

Plasma	O
18-hydroxycorticosterone	O
was	O
also	O
significantly	O
(	O
P	O
less	O
than	O
0.025	O
)	O
lower	O
(	O
PIH	O
,	O
1071	O
	O
149	O
pmol	O
/	O
L	O
;	O
controls	O
,	O
1907	O
	O
318	O
pmol	O
/	O
L	O
)	O
.	O

These	O
values	O
were	O
determined	O
at	O
the	O
onset	O
of	O
clinical	O
symptoms	O
of	O
PIH	O
.	O

These	B-NEGATION
results	I-NEGATION
can	I-NEGATION
not	I-NEGATION
be	I-NEGATION
explained	I-NEGATION
by	I-NEGATION
receptor	I-NEGATION
down-regulation	I-NEGATION
due	O
to	O
higher	O
levels	O
of	O
mineralocorticoids	O
in	O
PIH	O
;	O
.	O

a	O
hitherto	O
unknown	O
mineralocorticoid	O
may	B-SPECULATION
,	I-SPECULATION
thus	I-SPECULATION
,	I-SPECULATION
be	I-SPECULATION
responsible	I-SPECULATION
for	I-SPECULATION
the	I-SPECULATION
hypertension	I-SPECULATION
and	I-SPECULATION
altered	I-SPECULATION
MR	I-SPECULATION
status	I-SPECULATION
.	O

Mineralocorticoid	O
effector	O
mechanism	O
in	O
preeclampsia	O
.	O

Mineralocorticoid	O
effector	O
mechanisms	O
were	O
evaluated	O
in	O
29	O
patients	O
with	O
preeclampsia	O
and	O
in	O
25	O
uncomplicated	O
pregnancies	O
by	O
measurement	O
of	O
plasma	O
aldosterone	O
,	O
levels	O
of	O
mineralocorticoid	O
receptor	O
(	O
MR	O
)	O
in	O
mononuclear	O
leucocytes	O
,	O
and	O
subtraction	O
potential	O
difference	O
(	O
SPD	O
;	O
rectal	O
minus	O
oral	O
values	O
)	O
.	O

Mean	O
values	O
for	O
plasma	O
aldosterone	O
were	O
not	B-NEGATION
different	I-NEGATION
between	I-NEGATION
the	I-NEGATION
two	I-NEGATION
groups	I-NEGATION
,	O
but	O
significant	O
differences	O
were	O
observed	O
for	O
MR	O
(	O
preeclampsia	O
,	O
81	O
	O
44	O
receptors	O
/	O
cell	O
;	O
controls	O
,	O
306	O
	O
168	O
)	O
and	O
SPD	O
(	O
preeclampsia	O
,	O
65	O
	O
7	O
mV	O
;	O
controls	O
,	O
12	O
	O
5	O
mV	O
)	O
.	O

In	O
six	O
cases	O
we	O
determined	O
MR	O
,	O
plasma	O
aldosterone	O
,	O
and	O
SPD	O
in	O
patients	O
with	O
preeclampsia	O
before	O
and	O
3	O
months	O
after	O
delivery	O
.	O

MR	O
were	O
reduced	O
before	O
delivery	O
(	O
96	O
	O
27	O
receptors	O
/	O
cell	O
)	O
,	O
and	O
SPD	O
increased	O
(	O
64	O
	O
8	O
mV	O
)	O
,	O
with	O
both	O
parameters	O
normalizing	O
after	O
delivery	O
(	O
MR	O
,	O
242	O
	O
79	O
;	O
SPD	O
,	O
14.0	O
	O
4	O
mV	O
)	O
.	O

Aldosterone	O
levels	O
returned	O
to	O
normal	O
nonpregnant	O
values	O
after	O
delivery	O
.	O

These	O
data	O
suggest	B-SPECULATION
an	I-SPECULATION
important	I-SPECULATION
role	I-SPECULATION
for	I-SPECULATION
abnormalities	I-SPECULATION
in	I-SPECULATION
mineralocorticoid	I-SPECULATION
effector	I-SPECULATION
mechanisms	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
etiology	I-SPECULATION
of	I-SPECULATION
preeclampsia	I-SPECULATION
and	O
could	B-SPECULATION
be	I-SPECULATION
an	I-SPECULATION
useful	I-SPECULATION
marker	I-SPECULATION
for	I-SPECULATION
diagnosis	I-SPECULATION
.	O

A	O
lymphoid	O
cell-specific	O
nuclear	O
factor	O
containing	O
c-Rel-like	O
proteins	O
preferentially	O
interacts	O
with	O
interleukin-6	O
kappa	O
B-related	O
motifs	O
whose	O
activities	O
are	O
repressed	O
in	O
lymphoid	O
cells	O
.	O

The	O
proto-oncoprotein	O
c-Rel	O
is	O
a	O
member	O
of	O
the	O
nuclear	O
factor	O
kappa	O
B	O
transcription	O
factor	O
family	O
,	O
which	O
includes	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
nuclear	O
factor	O
kappa	O
B	O
.	O

We	O
show	O
here	O
that	O
c-Rel	O
binds	O
to	O
kappa	O
B	O
sites	O
as	O
homodimers	O
as	O
well	O
as	O
heterodimers	O
with	O
p50	O
.	O

These	O
homodimers	O
and	O
heterodimers	O
show	O
distinct	O
DNA-binding	O
specificities	O
and	O
affinities	O
for	O
various	O
kappa	O
B	O
motifs	O
.	O

In	O
particular	O
,	O
the	O
c-Rel	O
homodimer	O
has	O
a	O
high	O
affinity	O
for	O
interleukin-6	O
(	O
IL-6	O
)	O
and	O
beta	O
interferon	O
kappa	O
B	O
sites	O
.	O

In	O
spite	O
of	O
its	O
association	O
with	O
p50	O
in	O
vitro	O
,	O
however	O
,	O
we	O
found	O
a	O
lymphoid	O
cell-specific	O
nuclear	O
factor	O
in	O
vivo	O
that	O
contains	O
c-Rel	O
but	O
not	B-NEGATION
p50	I-NEGATION
epitopes	I-NEGATION
;	O
.	O

this	B-SPECULATION
factor	I-SPECULATION
,	I-SPECULATION
termed	I-SPECULATION
IL-6	I-SPECULATION
kappa	I-SPECULATION
B	I-SPECULATION
binding	I-SPECULATION
factor	I-SPECULATION
II	I-SPECULATION
,	I-SPECULATION
appears	I-SPECULATION
to	I-SPECULATION
contain	I-SPECULATION
the	I-SPECULATION
c-Rel	I-SPECULATION
homodimer	I-SPECULATION
and	O
preferentially	B-SPECULATION
recognizes	I-SPECULATION
several	I-SPECULATION
IL-6	I-SPECULATION
kappa	I-SPECULATION
B-related	I-SPECULATION
kappa	I-SPECULATION
B	I-SPECULATION
motifs	I-SPECULATION
.	O

Although	O
it	O
has	O
been	O
previously	O
shown	O
that	O
the	O
IL-6	O
kappa	O
B	O
motif	O
functions	O
as	O
a	O
potent	O
IL-1	O
/	O
tumor	O
necrosis	O
factor-responsive	O
element	O
in	O
nonlymphoid	O
cells	O
,	O
its	O
activity	O
was	O
found	O
to	O
be	O
repressed	O
in	O
lymphoid	O
cells	O
such	O
as	O
a	O
Jurkat	O
T-cell	O
line	O
.	O

We	O
also	O
present	O
evidence	O
that	O
IL-6	O
kappa	O
B	O
binding	O
factor	O
II	O
functions	O
as	O
a	O
repressor	O
specific	O
for	O
IL-6	O
kappa	O
B-related	O
kappa	O
B	O
motifs	O
in	O
lymphoid	O
cells	O
.	O

Modulation	O
of	O
normal	O
erythroid	O
differentiation	O
by	O
the	O
endogenous	O
thyroid	O
hormone	O
and	O
retinoic	O
acid	O
receptors	O
:	O
a	O
possible	B-SPECULATION
target	I-SPECULATION
for	I-SPECULATION
v-erbA	I-SPECULATION
oncogene	I-SPECULATION
action	I-SPECULATION
.	O

The	O
v-erbA	O
oncogene	O
,	O
a	O
mutated	O
version	O
of	O
the	O
thyroid	O
hormone	O
receptor	O
alpha	O
(	O
c-erbA	O
/	O
TR-alpha	O
)	O
,	O
inhibits	O
erythroid	O
differentiation	O
and	O
constitutively	O
represses	O
transcription	O
of	O
certain	O
erythrocyte	O
genes	O
,	O
suggesting	B-SPECULATION
a	I-SPECULATION
normal	I-SPECULATION
function	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
proto-oncogene	I-SPECULATION
c-erbA	I-SPECULATION
in	I-SPECULATION
erythropoiesis	I-SPECULATION
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
endogenous	O
thyroid	O
hormone	O
receptor	O
alpha	O
(	O
c-erbA	O
/	O
TR-alpha	O
)	O
and	O
the	O
closely	O
related	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR-alpha	O
)	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	O
erythroid	O
differentiation	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
distinctly	O
modulated	O
the	O
erythroid	O
differentiation	O
program	O
of	O
normal	O
erythroid	O
progenitors	O
and	O
erythroblasts	O
reversibly	O
transformed	O
by	O
a	O
conditional	O
tyrosine	O
kinase	O
oncogene	O
.	O

When	O
added	O
pulsewise	O
to	O
immature	O
cells	O
,	O
differentiation	O
was	O
accelerated	O
while	O
more	O
mature	O
cells	O
underwent	O
premature	O
cell	O
death	O
.	O

Thyroid	O
hormone	O
(	O
T3	O
)	O
alone	O
caused	O
similar	O
but	O
weaker	O
effects	O
.	O

Interestingly	O
,	O
T3	O
strongly	O
enhanced	O
the	O
action	O
of	O
RA	O
,	O
suggesting	B-SPECULATION
cooperative	I-SPECULATION
action	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
two	I-SPECULATION
receptors	I-SPECULATION
in	I-SPECULATION
modulating	I-SPECULATION
erythroid	I-SPECULATION
differentiation	I-SPECULATION
.	O

Expression	O
of	O
the	O
human	O
RAR-alpha	O
in	O
receptor-negative	O
erythroblasts	O
conferred	O
RA-induced	O
regulation	O
of	O
differentiation	O
to	O
the	O
otherwise	O
unresponsive	O
cells	O
,	O
thus	O
showing	O
that	O
the	O
RAR-alpha	O
is	O
essential	O
for	O
the	O
RA	O
effect	O
.	O

Likewise	O
,	O
enhanced	O
expression	O
of	O
exogenous	O
c-erbA	O
/	O
TR-alpha	O
in	O
erythroblasts	O
rendered	O
them	O
susceptible	O
to	O
modulation	O
of	O
differentiation	O
by	O
T3	O
,	O
suggesting	B-SPECULATION
a	I-SPECULATION
similar	I-SPECULATION
function	I-SPECULATION
of	I-SPECULATION
both	I-SPECULATION
receptors	I-SPECULATION
.	O

Leukotriene	O
B4	O
stimulates	O
c-fos	O
and	O
c-jun	O
gene	O
transcription	O
and	O
AP-1	O
binding	O
activity	O
in	O
human	O
monocytes	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
,	O
a	O
potent	O
lipid	O
proinflammatory	O
mediator	O
,	O
on	O
the	O
expression	O
of	O
the	O
proto-oncogenes	O
c-jun	O
and	O
c-fos	O
.	O

In	O
addition	O
,	O
we	O
looked	O
at	O
the	O
modulation	O
of	O
nuclear	O
factors	O
binding	O
specifically	O
to	O
the	O
AP-1	O
element	O
after	O
LTB4	O
stimulation	O
.	O

LTB4	O
increased	O
the	O
expression	O
of	O
the	O
c-fos	O
gene	O
in	O
a	O
time	O
-	O
and	O
concentration-dependent	O
manner	O
.	O

The	O
c-jun	O
mRNA	O
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
human	O
peripheral-blood	O
monocytes	O
at	O
relatively	O
high	O
levels	O
,	O
was	O
also	O
slightly	O
augmented	O
by	O
LTB4	O
,	O
although	O
to	O
a	O
much	O
lower	O
extent	O
than	O
c-fos	O
.	O

The	O
kinetics	O
of	O
expression	O
of	O
the	O
two	O
genes	O
were	O
also	O
slightly	O
different	O
,	O
with	O
c-fos	O
mRNA	O
reaching	O
a	O
peak	O
at	O
15	O
min	O
after	O
stimulation	O
and	O
c-jun	O
at	O
30	O
min	O
.	O

Both	O
messages	O
rapidly	O
declined	O
thereafter	O
.	O

Stability	B-NEGATION
of	I-NEGATION
the	I-NEGATION
c-fos	I-NEGATION
and	I-NEGATION
c-jun	I-NEGATION
mRNA	I-NEGATION
was	I-NEGATION
not	I-NEGATION
affected	I-NEGATION
by	I-NEGATION
LTB4	I-NEGATION
,	O
as	O
assessed	O
after	O
actinomycin	O
D	O
treatment	O
.	O

Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	O
increased	O
the	O
transcription	O
of	O
the	O
c-fos	O
gene	O
7-fold	O
and	O
the	O
c-jun	O
gene	O
1.4-fold	O
.	O

Resting	O
monocytes	O
contained	O
nuclear	O
factors	O
binding	O
to	O
the	O
AP-1	O
element	O
,	O
but	O
stimulation	O
of	O
monocytes	O
with	O
LTB4	O
induced	O
greater	O
AP-1-binding	O
activity	O
of	O
nuclear	O
proteins	O
.	O

These	O
results	O
indicate	B-SPECULATION
that	I-SPECULATION
LTB4	I-SPECULATION
may	B-SPECULATION
regulate	I-SPECULATION
the	I-SPECULATION
production	I-SPECULATION
of	I-SPECULATION
different	I-SPECULATION
cytokines	I-SPECULATION
by	I-SPECULATION
modulating	I-SPECULATION
the	B-SPECULATION
yield	I-SPECULATION
and	I-SPECULATION
/	I-SPECULATION
or	I-SPECULATION
the	I-SPECULATION
function	I-SPECULATION
of	O
transcription	O
factors	O
such	O
as	O
AP-1-binding	O
proto-oncogene	O
products	O
.	O

An	O
11-base-pair	O
DNA	O
sequence	O
motif	O
apparently	O
unique	O
to	O
the	O
human	O
interleukin	O
4	O
gene	O
confers	O
responsiveness	O
to	O
T-cell	O
activation	O
signals	O
.	O

We	O
have	O
identified	O
a	O
DNA	O
segment	O
that	O
confers	O
responsiveness	O
to	O
antigen	O
stimulation	O
signals	O
on	O
the	O
human	O
interleukin	O
(	O
IL	O
)	O
4	O
gene	O
in	O
Jurkat	O
cells	O
.	O

The	O
human	O
IL-4	O
gene	O
,	O
of	O
10	O
kilobases	O
,	O
is	O
composed	O
of	O
four	O
exons	O
and	O
three	O
introns	O
.	O

A	O
cis-acting	O
element	O
(	O
P	O
sequence	O
)	O
resides	O
in	O
the	O
5	O
'	O
upstream	O
region	O
;	O

no	B-NEGATION
additional	I-NEGATION
DNA	I-NEGATION
segments	I-NEGATION
with	I-NEGATION
enhancer	I-NEGATION
activity	I-NEGATION
were	I-NEGATION
identified	I-NEGATION
in	I-NEGATION
the	I-NEGATION
human	I-NEGATION
IL-4	I-NEGATION
gene	I-NEGATION
.	O

For	O
further	O
mapping	O
purposes	O
,	O
a	O
fusion	O
promoter	O
was	O
constructed	O
with	O
the	O
granulocyte	O
/	O
macrophage	O
colony-stimulating	O
factor	O
basic	O
promoter	O
containing	O
60	O
base	O
pairs	O
of	O
sequence	O
upstream	O
from	O
the	O
cap	O
site	O
of	O
the	O
mouse	O
granulocyte	O
/	O
macrophage	O
colony-stimulating	O
factor	O
gene	O
and	O
various	O
lengths	O
of	O
the	O
5	O
'	O
upstream	O
sequence	O
of	O
the	O
IL-4	O
gene	O
.	O

The	O
P	O
sequence	O
was	O
located	O
between	O
positions	O
-	O
79	O
and	O
-	O
69	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
of	O
the	O
human	O
IL-4	O
gene	O
,	O
and	O
this	O
location	O
was	O
confirmed	O
by	O
base-substitution	O
mutations	O
.	O

The	O
plasmids	O
carrying	O
multiple	O
copies	O
of	O
the	O
P	O
sequence	O
showed	O
higher	O
responsiveness	O
to	O
the	O
stimulation	O
.	O

The	O
binding	O
protein	O
(	O
s	O
)	O
that	O
recognize	O
the	O
P	O
sequence	O
of	O
the	O
IL-4	O
gene	O
were	O
identified	O
by	O
DNA-mobility-shift	O
assays	O
.	O

The	O
binding	O
of	O
NF	O
(	O
P	O
)	O
(	O
a	O
DNA	O
binding	O
protein	O
that	O
specifically	O
recognizes	O
the	O
P	O
sequence	O
)	O
to	O
the	O
P	O
sequence	O
was	O
abolished	O
when	O
oligonucleotides	O
carrying	O
base	O
substitutions	O
were	O
used	O
,	O
indicating	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
NF	I-SPECULATION
(	I-SPECULATION
P	I-SPECULATION
)	I-SPECULATION
interaction	I-SPECULATION
is	I-SPECULATION
sequence-specific	I-SPECULATION
and	I-SPECULATION
that	I-SPECULATION
binding	I-SPECULATION
specificity	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
protein	I-SPECULATION
paralleled	I-SPECULATION
the	I-SPECULATION
sequence	I-SPECULATION
requirements	I-SPECULATION
for	I-SPECULATION
IL-4	I-SPECULATION
expression	I-SPECULATION
in	I-SPECULATION
vivo	I-SPECULATION
.	O

The	O
P	O
sequence	O
does	O
not	B-NEGATION
share	I-NEGATION
homology	I-NEGATION
with	I-NEGATION
the	I-NEGATION
5	I-NEGATION
'	I-NEGATION
upstream	I-NEGATION
sequence	I-NEGATION
of	I-NEGATION
the	I-NEGATION
IL-2	I-NEGATION
gene	I-NEGATION
,	O
even	O
though	O
surrounding	O
sequences	O
of	O
the	O
IL-4	O
gene	O
share	O
high	O
homology	O
with	O
the	O
IL-2	O
gene	O
.	O

We	O
conclude	O
that	O
a	O
different	O
set	O
of	O
proteins	O
recognize	O
IL-2	O
and	O
IL-4	O
genes	O
.	O

Glucocorticoid	O
receptor	O
binding	O
in	O
three	O
different	O
cell	O
types	O
in	O
major	O
depressive	O
disorder	O
:	O
lack	B-NEGATION
of	I-NEGATION
evidence	I-NEGATION
of	I-NEGATION
receptor	I-NEGATION
binding	I-NEGATION
defect	I-NEGATION
.	O

1	O
.	O
In	O
order	O
to	O
further	O
understand	O
the	O
apparent	O
glucocorticoid	O
resistance	O
in	O
major	O
depressive	O
disorder	O
,	O
circadian	O
variation	O
in	O
cortisol	O
concentration	O
,	O
dexamethasone	O
suppression	O
and	O
glucocorticoid	O
receptor	O
binding	O
in	O
mononuclear	O
leukocytes	O
,	O
polymorphonuclear	O
leukocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
were	O
measured	O
in	O
rigidly	O
defined	O
major	O
depressive	O
disorder	O
patients	O
and	O
non-depressed	O
psychiatric	O
controls	O
.	O

2	O
.	O
Mononuclear	O
leukocytes	O
binding	O
to	O
glucocorticoid	O
correlated	O
significantly	O
with	O
polymorphonuclear	O
leukocytes	O
binding	O
to	O
glucocorticoid	O
,	O
but	O
both	O
determinations	O
failed	O
to	O
differentiate	O
major	O
depressive	O
disorder	O
and	O
control	O
subjects	O
.	O

3	O
.	O
Initial	O
and	O
post-dexamethasone	O
in	O
vitro	O
fibroblast	O
binding	O
to	O
glucocorticoid	O
was	O
not	B-NEGATION
different	I-NEGATION
between	I-NEGATION
major	I-NEGATION
depressive	I-NEGATION
disorder	I-NEGATION
and	I-NEGATION
non-depressed	I-NEGATION
control	I-NEGATION
subjects	I-NEGATION
.	O

4	O
.	O
The	O
phenomenon	O
of	O
glucocorticoid	O
resistance	O
in	O
major	O
depressive	O
disorder	O
remains	O
unexplained	O
.	O

Kinetics	O
of	O
nuclear	O
translocation	O
and	O
turnover	O
of	O
the	O
vitamin	O
D	O
receptor	O
in	O
human	O
HL60	O
leukemia	O
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
--	O
coincident	O
rise	O
of	O
DNA-relaxing	O
activity	O
in	O
nuclear	O
extracts	O
.	O

High	O
affinity	O
receptors	O
(	O
VDR	O
)	O
for	O
1,25-dihydroxycholecalciferol	O
(	O
calcitriol	O
)	O
are	O
expressed	O
in	O
HL60	O
human	O
leukemia	O
cells	O
and	O
in	O
low	O
numbers	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

HL60	O
cells	O
,	O
expressing	O
some	O
characteristics	O
of	O
promyelocytes	O
,	O
can	O
be	O
induced	O
to	O
monocytoid	O
differentiation	O
by	O
calcitriol	O
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	O
3H	O
]	O
calcitriol	O
/	O
VDR	O
was	O
examined	O
after	O
exposure	O
of	O
whole	O
cells	O
to	O
10	O
(-	O
9	O
)	O
M	O
/	O
l	O
calcitriol	O
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
500-fold	O
excess	O
of	O
unlabeled	O
ligand	O
and	O
subsequent	O
isolation	O
of	O
nuclei	O
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	O
3H	O
]	O
calcitriol	O
/	O
VDR	O
was	O
found	O
to	O
be	O
time	O
dependent	O
reaching	O
a	O
maximum	O
of	O
approximately	O
2100	O
binding	O
sites	O
/	O
nucleus	O
after	O
3	O
h	O
of	O
incubation	O
in	O
HL60	O
cells	O
,	O
whereas	O
a	O
maximum	O
of	O
approximately	O
310	O
binding	O
sites	O
/	O
nucleus	O
was	O
found	O
after	O
3	O
h	O
in	O
PBL	O
.	O

Pulse	O
exposure	O
of	O
HL60	O
to	O
radiolabeled	O
hormone	O
for	O
3	O
h	O
followed	O
by	O
culture	O
in	O
medium	O
without	B-NEGATION
serum	I-NEGATION
and	I-NEGATION
calcitriol	I-NEGATION
lead	O
to	O
nuclear	O
retention	O
of	O
approximately	O
1600	O
radiolabeled	O
VDR	O
by	O
8	O
h	O
and	O
approximately	O
1000	O
VDR	O
by	O
24	O
h	O
.	O

Radiolabeled	O
VDR	O
disappeared	O
from	O
the	O
nuclear	O
compartment	O
with	O
a	O
halflife	O
of	O
approximately	O
30	O
min	O
if	O
cells	O
were	O
cultured	O
with	O
identical	O
concentrations	O
of	O
unlabeled	O
hormone	O
after	O
the	O
pulse	O
(	O
pulse	O
/	O
chase-experiments	O
)	O
.	O

No	B-NEGATION
difference	I-NEGATION
of	I-NEGATION
VDR	I-NEGATION
retention	I-NEGATION
in	I-NEGATION
pulse	I-NEGATION
and	I-NEGATION
pulse	I-NEGATION
/	I-NEGATION
chase-experiments	I-NEGATION
was	I-NEGATION
seen	I-NEGATION
in	I-NEGATION
PBL	I-NEGATION
,	O
where	O
VDR	O
halflife	O
was	O
approximately	O
30	O
min	O
.	O

No	B-NEGATION
specific	I-NEGATION
translocation	I-NEGATION
into	I-NEGATION
the	I-NEGATION
nuclear	I-NEGATION
compartment	I-NEGATION
was	I-NEGATION
seen	I-NEGATION
when	I-NEGATION
isolated	I-NEGATION
nuclei	I-NEGATION
were	I-NEGATION
incubated	I-NEGATION
in	I-NEGATION
[	I-NEGATION
3H	I-NEGATION
]	I-NEGATION
calcitriol	I-NEGATION
.	O

Radiolabeled	O
hormone	O
/	O
receptor	O
complexes	O
of	O
nuclei	O
isolated	O
from	O
cells	O
exposed	O
for	O
3	O
h	O
to	O
radiolabeled	O
hormone	O
--	O
in	O
contrast	O
to	O
identical	O
experiments	O
with	O
intact	O
cells	O
--	O
did	O
not	B-NEGATION
disappear	I-NEGATION
from	I-NEGATION
the	I-NEGATION
nuclear	I-NEGATION
compartment	I-NEGATION
upon	I-NEGATION
incubation	I-NEGATION
of	I-NEGATION
nuclei	I-NEGATION
with	I-NEGATION
identical	I-NEGATION
concentrations	I-NEGATION
of	I-NEGATION
the	I-NEGATION
unlabeled	I-NEGATION
compound	I-NEGATION
.	O

The	O
activity	O
of	O
DNA	O
relaxing	O
enzymes	O
(	O
e.g	O
.	O

topoisomerases	O
I	O
and	O
II	O
)	O
in	O
nuclear	O
extracts	O
was	O
measured	O
using	O
a	O
PBR	O
322-relaxation-assay	O
.	O

Enhanced	O
overall	O
enzyme	O
activity	O
was	O
found	O
in	O
nuclear	O
extracts	O
by	O
1	O
h	O
after	O
incubation	O
with	O
calcitriol	O
(	O
final	O
ethanol	O
concentration	O
0.0001	O
%	O
v	O
/	O
v	O
)	O
in	O
HL60	O
and	O
PBL	O
.	O

The	O
enhanced	O
activity	O
disappeared	O
after	O
2	O
h	O
in	O
PBL	O
,	O
whereas	O
it	O
was	O
still	O
enhanced	O
by	O
4	O
h	O
in	O
HL60	O
.	O

No	B-NEGATION
effect	I-NEGATION
was	I-NEGATION
seen	I-NEGATION
in	I-NEGATION
ethanol	I-NEGATION
treated	I-NEGATION
controls	I-NEGATION
.	O

We	O
conclude	O
that	O
a	O
specific	O
nuclear	O
translocation	O
mechanism	O
exists	O
for	O
calcitriol	O
in	O
both	O
cell	O
types	O
examined	O
,	O
most	O
likely	B-SPECULATION
due	I-SPECULATION
to	I-SPECULATION
translocation	I-SPECULATION
of	I-SPECULATION
receptor	I-SPECULATION
proteins	I-SPECULATION
after	I-SPECULATION
hormone	I-SPECULATION
binding	I-SPECULATION
.	O

Translocated	O
hormone	O
/	O
receptor	O
complexes	O
compete	O
for	O
a	O
limited	O
number	O
of	O
specific	O
nuclear	O
binding	O
sites	O
.	O

Enhanced	O
activity	O
of	O
topoisomerases	O
in	O
nuclear	O
extracts	O
upon	O
translocation	O
of	O
VDR	O
might	B-SPECULATION
reflect	I-SPECULATION
interaction	I-SPECULATION
of	I-SPECULATION
both	I-SPECULATION
within	I-SPECULATION
the	I-SPECULATION
nuclear	I-SPECULATION
compartment	I-SPECULATION
,	I-SPECULATION
thus	I-SPECULATION
initiating	I-SPECULATION
DNA-unwinding	I-SPECULATION
,	I-SPECULATION
a	I-SPECULATION
prerequisite	I-SPECULATION
of	I-SPECULATION
transcription	I-SPECULATION
initiation	I-SPECULATION
.	O

The	O
B	O
cell-specific	O
nuclear	O
factor	O
OTF-2	O
positively	O
regulates	O
transcription	O
of	O
the	O
human	O
class	O
II	O
transplantation	O
gene	O
,	O
DRA	O
.	O

The	O
promoter	O
of	O
the	O
major	O
histocompatibility	O
class	O
II	O
gene	O
DRA	O
contains	O
an	O
octamer	O
element	O
(	O
ATTTGCAT	O
)	O
that	O
is	O
required	O
for	O
efficient	O
DRA	O
expression	O
in	O
B	O
cells	O
.	O

Several	O
DNA-binding	O
proteins	O
are	O
known	O
to	O
bind	O
this	O
sequence	O
.	O

The	O
best	O
characterized	O
are	O
the	O
B	O
cell-specific	O
OTF-2	O
and	O
the	O
ubiquitous	O
OTF-1	O
.	O

This	O
report	O
directly	O
demonstrates	O
that	O
OTF-2	O
but	O
not	B-NEGATION
OTF-1	I-NEGATION
regulates	O
the	O
DRA	O
gene	O
.	O

In	O
vitro	O
transcription	O
analysis	O
using	O
protein	O
fractions	O
enriched	O
for	O
the	O
octamer-binding	O
protein	O
OTF-2	O
demonstrate	O
a	O
positive	O
functional	O
role	O
for	O
OTF-2	O
in	O
DRA	O
gene	O
transcription	O
.	O

In	O
contrast	O
,	O
OTF-1-enriched	O
protein	O
fractions	O
did	O
not	B-NEGATION
affect	I-NEGATION
DRA	I-NEGATION
gene	I-NEGATION
transcription	I-NEGATION
although	O
it	O
functionally	O
enhanced	O
the	O
transcription	O
of	O
another	O
gene	O
.	O

Recombinant	O
OTF-2	O
protein	O
produced	O
by	O
in	O
vitro	O
transcription	O
/	O
translation	O
could	B-SPECULATION
also	I-SPECULATION
enhance	I-SPECULATION
DRA	I-SPECULATION
gene	I-SPECULATION
transcription	I-SPECULATION
in	I-SPECULATION
vitro	I-SPECULATION
.	O

In	O
vivo	O
transient	O
transfection	O
studies	O
utilizing	O
an	O
OTF-2	O
expression	O
vector	O
resulted	O
in	O
similar	O
findings	O
:	O
that	O
OTF-2	O
protein	O
enhanced	O
DRA	O
gene	O
transcription	O
,	O
and	O
that	O
this	O
effect	O
requires	O
an	O
intact	O
octamer	O
element	O
.	O

Together	O
these	O
results	O
constitute	O
the	O
first	O
direct	O
evidence	O
of	O
a	O
positive	O
role	O
for	O
the	O
lymphoid-specific	O
octamer-binding	O
factor	O
in	O
DRA	O
gene	O
transcription	O
.	O

[	O
Regulation	O
of	O
intracellular	O
cholesterol	O
synthesis	O
in	O
hypercholesterolemia	O
by	O
glucocorticoids	O
]	O

The	O
rate	O
of	O
endogenous	O
cholesterol	O
synthesis	O
in	O
blood	O
lymphocytes	O
and	O
skin	O
fibroblasts	O
from	O
patients	O
with	O
type	O
IIa	O
hyperlipidemia	O
was	O
found	O
to	O
be	O
increased	O
in	O
comparison	O
with	O
healthy	O
donors	O
.	O

The	O
cells	O
of	O
hyperlipidemic	O
patients	O
had	O
lowered	O
levels	O
of	O
glucocorticoid	O
receptors	O
concomitantly	O
with	O
a	O
partial	O
loss	O
of	O
their	O
sensitivity	O
to	O
glucocorticoids	O
.	O

In	O
fibroblasts	O
from	O
patients	O
with	O
hereditary	O
hypercholesteremia	O
of	O
homozygous	O
type	O
the	O
number	O
of	O
glucocorticoid	O
receptors	O
did	O
not	B-NEGATION
exceed	I-NEGATION
10	I-NEGATION
%	I-NEGATION
of	I-NEGATION
their	I-NEGATION
content	I-NEGATION
in	I-NEGATION
normal	I-NEGATION
cells	I-NEGATION
.	O

The	B-SPECULATION
decrease	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
number	I-SPECULATION
of	I-SPECULATION
glucocorticoid	I-SPECULATION
receptors	I-SPECULATION
in	I-SPECULATION
patients	I-SPECULATION
with	I-SPECULATION
type	I-SPECULATION
IIa	I-SPECULATION
hyperlipidemia	I-SPECULATION
seems	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
a	I-SPECULATION
compensatory	I-SPECULATION
response	I-SPECULATION
of	I-SPECULATION
cells	I-SPECULATION
culminating	I-SPECULATION
in	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
endogenous	I-SPECULATION
cholesterol	I-SPECULATION
synthesis	I-SPECULATION
.	O

Transcription	O
factor	O
activation	O
and	O
functional	O
stimulation	O
of	O
human	O
monocytes	O
.	O

Activation	O
of	O
expression	O
of	O
genes	O
encoding	O
transcription	O
factors	O
:	O
c-fos	O
and	O
c-jun	O
and	O
formation	O
of	O
AP1	O
transcriptional	O
complex	O
in	O
human	O
monocytes	O
was	O
investigated	O
.	O

It	O
was	O
found	O
that	O
lipopolysaccharide	O
induced	O
strongly	O
both	O
c-fos	O
and	O
c-jun	O
expression	O
as	O
well	O
as	O
AP1	O
formation	O
.	O

Interferon	O
gamma	O
activated	O
strongly	O
c-fos	O
and	O
weakly	O
c-jun	O
and	O
AP1	O
.	O

Tumor	O
necrosis	O
factor	O
induced	O
slightly	O
c-fos	O
and	O
had	O
almost	O
no	O
effect	O
on	O
c-jun	O
and	O
AP1	O
.	O

The	O
data	O
suggest	B-SPECULATION
that	I-SPECULATION
differences	I-SPECULATION
in	I-SPECULATION
functional	I-SPECULATION
responses	I-SPECULATION
elicited	I-SPECULATION
in	I-SPECULATION
monocytes	I-SPECULATION
by	I-SPECULATION
all	I-SPECULATION
three	I-SPECULATION
factors	I-SPECULATION
may	B-SPECULATION
be	I-SPECULATION
dependent	I-SPECULATION
on	I-SPECULATION
different	I-SPECULATION
routes	I-SPECULATION
on	I-SPECULATION
nuclear	I-SPECULATION
signalling	I-SPECULATION
employed	I-SPECULATION
by	I-SPECULATION
the	I-SPECULATION
factors	I-SPECULATION
.	O

Corticosteroid	O
receptors	O
and	O
lymphocyte	O
subsets	O
in	O
mononuclear	O
leukocytes	O
in	O
aging	O
.	O

Plasma	O
cortisol	O
and	O
aldosterone	O
levels	O
and	O
number	O
of	O
related	O
receptors	O
in	O
mononuclear	O
leukocytes	O
were	O
measured	O
in	O
49	O
healthy	O
aged	O
subjects	O
(	O
62-97	O
yr	O
)	O
and	O
in	O
21	O
adult	O
controls	O
(	O
21-50	O
yr	O
)	O
.	O

In	O
all	O
subjects	O
,	O
in	O
addition	O
,	O
lymphocyte	O
subsets	O
were	O
determined	O
as	O
an	O
index	O
of	O
corticosteroid	O
action	O
.	O

The	O
mean	O
number	O
of	O
type	O
I	O
and	O
type	O
II	O
receptors	O
was	O
significantly	O
lower	O
in	O
aged	O
subjects	O
than	O
in	O
controls	O
(	O
respectively	O
,	O
198	O
	O
96	O
and	O
272	O
	O
97	O
receptors	O
/	O
cell	O
for	O
type	O
I	O
,	O
and	O
1,794	O
	O
803	O
and	O
3,339	O
	O
918	O
for	O
type	O
II	O
receptors	O
)	O
.	O

Plasma	O
aldosterone	O
and	O
cortisol	O
and	O
lymphocyte	O
subsets	O
were	O
not	B-NEGATION
different	I-NEGATION
in	I-NEGATION
the	I-NEGATION
two	I-NEGATION
groups	I-NEGATION
.	O

All	O
of	O
the	O
parameters	O
were	O
also	O
tested	O
for	O
correlation	O
,	O
and	O
a	O
significant	O
inverse	O
correlation	O
was	O
found	O
between	O
age	O
and	O
type	O
I	O
and	O
type	O
II	O
receptors	O
when	O
all	O
subjects	O
were	O
plotted	O
and	O
between	O
aged	O
and	O
CD4	O
and	O
age	O
and	O
CD4	O
/	O
CD8	O
in	O
the	O
aged	O
group	O
.	O

These	O
data	O
show	O
that	O
aged	O
subjects	O
have	O
reductions	O
of	O
corticosteroid	O
receptors	O
that	O
are	O
not	B-NEGATION
associated	I-NEGATION
with	I-NEGATION
increase	I-NEGATION
of	I-NEGATION
related	I-NEGATION
steroids	I-NEGATION
and	O
that	O
this	O
situation	O
probably	B-SPECULATION
represents	I-SPECULATION
a	I-SPECULATION
concomitant	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
normal	I-SPECULATION
aging	I-SPECULATION
process	I-SPECULATION
.	O

Stable	O
expression	O
of	O
HB24	O
,	O
a	O
diverged	O
human	O
homeobox	O
gene	O
,	O
in	O
T	O
lymphocytes	O
induces	O
genes	O
involved	O
in	O
T	O
cell	O
activation	O
and	O
growth	O
.	O

A	O
diverged	O
homeobox	O
gene	O
,	O
HB24	O
,	O
which	O
is	O
known	O
to	O
be	O
induced	O
following	O
lymphocyte	O
activation	O
,	O
was	O
introduced	O
into	O
Jurkat	O
T	O
cells	O
under	O
the	O
control	O
of	O
a	O
constitutive	O
promoter	O
.	O

Stable	O
transfectants	O
of	O
HB24	O
were	O
established	O
that	O
expressed	O
high	O
levels	O
of	O
HB24	O
mRNA	O
and	O
possessed	O
an	O
altered	O
phenotype	O
suggestive	B-SPECULATION
of	I-SPECULATION
activated	I-SPECULATION
T	I-SPECULATION
cells	I-SPECULATION
.	O

A	O
number	O
of	O
genes	O
known	O
to	O
be	O
induced	O
following	O
T	O
cell	O
activation	O
and	O
associated	O
with	O
cell	O
growth	O
were	O
increased	O
in	O
the	O
transfectants	O
,	O
including	O
c-fos	O
,	O
c-myc	O
,	O
c-myb	O
,	O
HLA-DR	O
,	O
lck	O
,	O
NF-kappa	O
B	O
,	O
interleukin-2	O
and	O
interleukin-2	O
receptor	O
alpha	O
(	O
IL-2R	O
alpha	O
)	O
.	O

Analysis	O
of	O
IL-2R	O
alpha	O
expression	O
by	O
transient	O
transfection	O
of	O
IL-2R	O
alpha	O
promoter	O
constructs	O
into	O
the	O
HB24	O
transfectants	O
revealed	O
constitutive	O
expression	O
(	O
about	O
60	O
%	O
of	O
phytohemagglutinin	O
-	O
and	O
phorbol	O
ester-activated	O
Jurkat	O
cells	O
)	O
that	O
was	O
dependent	O
on	O
the	O
kappa	O
B	O
site	O
in	O
the	O
IL-2R	O
alpha	O
promoter	O
.	O

Furthermore	O
,	O
as	O
a	O
consequence	O
of	O
the	O
increased	O
HB24	O
mRNA	O
levels	O
,	O
the	O
Jurkat	O
HB24	O
transfectants	O
proliferated	O
more	O
rapidly	O
than	O
control	O
cell	O
lines	O
.	O

Thus	O
,	O
stable	O
expression	O
of	O
HB24	O
confers	O
an	O
activation	O
phenotype	O
on	O
a	O
human	O
T	O
cell	O
line	O
,	O
implicating	O
this	O
gene	O
as	O
an	O
important	O
transcriptional	O
factor	O
during	O
T	O
cell	O
activation	O
and	O
growth	O
.	O

Studies	O
on	O
the	O
biological	O
activity	O
of	O
triiodothyronine	O
sulfate	O
.	O

Hepatic	O
microsomes	O
and	O
isolated	O
hepatocytes	O
in	O
short	O
term	O
culture	O
desulfate	O
T3	O
sulfate	O
(	O
T3SO4	O
)	O
.	O

We	O
,	O
therefore	O
,	O
wished	O
to	O
determine	O
whether	B-SPECULATION
T3SO4	I-SPECULATION
could	B-SPECULATION
mimic	I-SPECULATION
the	I-SPECULATION
action	I-SPECULATION
of	I-SPECULATION
thyroid	I-SPECULATION
hormone	I-SPECULATION
in	I-SPECULATION
vitro	I-SPECULATION
.	O

T3SO4	O
had	O
no	B-NEGATION
thyromimetic	I-NEGATION
effect	I-NEGATION
on	O
the	O
activity	O
of	O
Ca	O
(	O
2	O
+)-	O
ATPase	O
in	O
human	O
erythrocyte	O
membranes	O
at	O
doses	O
up	O
to	O
10,000	O
times	O
the	O
maximally	O
effective	O
dose	O
of	O
T3	O
(	O
10	O
(-	O
10	O
)	O
mol	O
/	O
L	O
)	O
.	O

In	O
GH4C1	O
pituitary	O
cells	O
,	O
T3SO4	O
failed	O
to	O
displace	O
[	O
125I	O
]	O
T3	O
from	O
nuclear	O
receptors	O
in	O
intact	O
cells	O
or	O
soluble	O
preparations	O
.	O

Thus	O
,	O
T3SO4	O
was	O
not	B-NEGATION
directly	I-NEGATION
thyromimetic	I-NEGATION
in	I-NEGATION
either	I-NEGATION
an	I-NEGATION
isolated	I-NEGATION
human	I-NEGATION
membrane	I-NEGATION
system	I-NEGATION
or	I-NEGATION
a	I-NEGATION
pituitary	I-NEGATION
cell	I-NEGATION
system	I-NEGATION
in	O
which	O
nuclear	O
receptor	O
occupancy	O
correlates	O
with	O
GH	O
synthesis	O
.	O

Thyroid	O
hormones	O
inhibit	O
[	O
3H	O
]	O
glycosaminoglycan	O
synthesis	O
by	O
cultured	O
human	O
dermal	O
fibroblasts	O
,	O
and	O
T3SO4	O
displayed	O
about	O
0.5	O
%	O
the	O
activity	O
of	O
T3	O
at	O
72	O
h	O
.	O

Human	O
fibroblasts	O
contained	O
roughly	O
the	O
same	O
level	O
of	O
microsomal	O
p-nitrophenyl	O
sulfatase	O
activity	O
as	O
that	O
previously	O
observed	O
in	O
hepatic	O
microsomes	O
.	O

Propylthiouracil	O
(	O
50	O
mumol	O
/	O
L	O
)	O
did	O
not	B-NEGATION
affect	I-NEGATION
the	I-NEGATION
action	I-NEGATION
of	I-NEGATION
T3SO4	I-NEGATION
,	O
suggesting	B-SPECULATION
that	I-SPECULATION
deiodination	I-SPECULATION
was	I-SPECULATION
not	B-NEGATION
important	I-NEGATION
for	I-NEGATION
this	I-NEGATION
activity	I-NEGATION
of	I-NEGATION
T3SO4	I-NEGATION
.	O

Thus	O
,	O
it	O
appears	B-SPECULATION
T3SO4	I-SPECULATION
has	I-SPECULATION
no	B-NEGATION
intrinsic	I-NEGATION
biological	I-NEGATION
activity	I-NEGATION
,	O
but	O
,	O
under	O
certain	O
circumstances	O
,	O
may	B-SPECULATION
be	I-SPECULATION
reactivated	I-SPECULATION
by	I-SPECULATION
desulfation	I-SPECULATION
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
contains	O
Fos	O
and	O
Jun	O
.	O

The	O
nuclear	O
factor	O
NF-AT	O
(	O
ref.	O
1	O
)	O
is	O
induced	O
in	O
T	O
cells	O
stimulated	O
through	O
the	O
T-cell	O
receptor	O
/	O
CD3	O
complex	O
,	O
and	O
is	O
required	O
for	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
induction	O
.	O

Although	O
NF-AT	B-NEGATION
has	I-NEGATION
not	I-NEGATION
been	I-NEGATION
,	O
there	O
is	O
evidence	O
that	O
it	O
is	O
a	O
major	O
target	O
for	O
immunosuppression	O
by	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
(	O
refs	O
2-7	O
)	O
.	O
cloned	B-SPECULATION
or	I-SPECULATION
purified	I-SPECULATION
.	O

NF-AT	O
induction	O
may	B-SPECULATION
require	I-SPECULATION
two	I-SPECULATION
activation-dependent	I-SPECULATION
events	I-SPECULATION
:	I-SPECULATION
the	I-SPECULATION
CsA-sensitive	I-SPECULATION
translocation	I-SPECULATION
of	I-SPECULATION
a	I-SPECULATION
pre-existing	I-SPECULATION
component	I-SPECULATION
and	I-SPECULATION
the	I-SPECULATION
CsA-resistant	I-SPECULATION
synthesis	I-SPECULATION
of	I-SPECULATION
a	I-SPECULATION
nuclear	I-SPECULATION
component	I-SPECULATION
.	O

Here	O
we	O
report	O
that	O
the	O
newly	O
synthesized	O
nuclear	O
component	O
of	O
NF-AT	O
is	O
the	O
transcription	O
factor	O
AP-1	O
.	O

We	O
show	O
that	O
the	O
inducible	O
nuclear	O
form	O
of	O
NF-AT	O
contains	O
Fos	O
and	O
Jun	O
proteins	O
.	O

Furthermore	O
,	O
we	O
identify	O
a	O
pre-existing	O
NF-AT-binding	O
factor	O
that	O
is	O
present	O
in	O
hypotonic	O
extracts	O
of	O
unstimulated	O
T	O
cells	O
.	O

On	O
the	O
basis	O
of	O
binding	O
,	O
reconstitution	O
and	O
cotransfection	O
experiments	O
,	O
we	O
propose	B-SPECULATION
that	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
NF-AT	I-SPECULATION
occurs	I-SPECULATION
in	I-SPECULATION
at	I-SPECULATION
least	I-SPECULATION
two	I-SPECULATION
stages	I-SPECULATION
:	I-SPECULATION
a	I-SPECULATION
CsA-sensitive	I-SPECULATION
stage	I-SPECULATION
involving	I-SPECULATION
modification	B-SPECULATION
and	I-SPECULATION
/	I-SPECULATION
or	I-SPECULATION
translocation	I-SPECULATION
of	O
the	O
pre-existing	O
NF-AT	O
complex	O
,	O
and	O
a	O
CsA-insensitive	O
stage	O
involving	O
the	O
addition	O
of	O
newly	O
synthesized	O
Fos	B-SPECULATION
or	I-SPECULATION
Fos	I-SPECULATION
/	I-SPECULATION
Jun	I-SPECULATION
proteins	O
to	O
the	O
pre-existing	O
complex	O
.	O

Interferon-gamma	O
potentiates	O
the	O
antiviral	O
activity	O
and	O
the	O
expression	O
of	O
interferon-stimulated	O
genes	O
induced	O
by	O
interferon-alpha	O
in	O
U937	O
cells	O
.	O

Binding	O
of	O
type	O
I	O
interferon	O
(	O
IFN-alpha	O
/	O
beta	O
)	O
to	O
specific	O
receptors	O
results	O
in	O
the	O
rapid	O
transcriptional	O
activation	O
,	O
independent	O
of	O
protein	O
synthesis	O
,	O
of	O
IFN-alpha-stimulated	O
genes	O
(	O
ISGs	O
)	O
in	O
human	O
fibroblasts	O
and	O
HeLa	O
and	O
Daudi	O
cell	O
lines	O
.	O

The	O
binding	O
of	O
ISGF3	O
(	O
IFN-stimulated	O
gene	O
factor	O
3	O
)	O
to	O
the	O
conserved	O
IFN-stimulated	O
response	O
element	O
(	O
ISRE	O
)	O
results	O
in	O
transcriptional	O
activation	O
.	O

This	O
factor	O
is	O
composed	O
of	O
a	O
DNA-binding	O
protein	O
(	O
ISGF3	O
gamma	O
)	O
,	O
which	O
normally	O
is	O
present	O
in	O
the	O
cytoplasm	O
,	O
and	O
other	O
IFN-alpha-activated	O
proteins	O
which	O
preexist	O
as	O
latent	O
cytoplasmic	O
precursors	O
(	O
ISGF3	O
alpha	O
)	O
.	O

We	O
have	O
found	O
that	O
ISG	O
expression	O
in	O
the	O
monocytic	O
U937	O
cell	O
line	O
differs	O
from	O
most	O
cell	O
lines	O
previously	O
examined	O
.	O

U937	O
cells	O
express	O
both	O
type	O
I	O
and	O
type	O
II	O
IFN	O
receptors	O
,	O
but	O
only	O
IFN-alpha	O
is	O
capable	O
of	O
inducing	O
antiviral	O
protection	O
in	O
these	O
cells	O
.	O

Pretreatment	O
with	O
IFN-gamma	O
potentiates	O
the	O
IFN-alpha-induced	O
protection	O
,	O
but	O
IFN-gamma	O
alone	O
does	O
not	B-NEGATION
have	I-NEGATION
any	I-NEGATION
antiviral	I-NEGATION
activity	I-NEGATION
.	O

ISG15	O
mRNA	O
accumulation	O
in	O
U937	O
cells	O
is	O
not	B-NEGATION
detectable	I-NEGATION
before	I-NEGATION
6	I-NEGATION
h	I-NEGATION
of	I-NEGATION
IFN-alpha	I-NEGATION
treatment	I-NEGATION
,	O
peaks	O
at	O
24	O
h	O
,	O
and	O
requires	O
protein	O
synthesis	O
.	O

Although	O
IFN-gamma	O
alone	O
does	O
not	B-NEGATION
induce	I-NEGATION
ISG	I-NEGATION
expression	I-NEGATION
,	O
IFN-gamma	O
pretreatment	O
markedly	O
increases	O
and	O
hastens	O
ISG	O
expression	O
and	O
transcriptional	O
induction	O
.	O

Nuclear	O
extracts	O
assayed	O
for	O
the	O
presence	O
of	O
ISRE	O
binding	O
factors	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
ISGF3	O
is	O
induced	O
by	O
IFN-alpha	O
within	O
6	O
h	O
from	O
undetectable	O
basal	O
levels	O
in	O
untreated	O
U937	O
cells	O
.	O

Activation	O
of	O
ISGF3	O
alpha	O
,	O
the	O
latent	O
component	O
of	O
ISGF3	O
,	O
occurs	O
rapidly	O
.	O

However	O
,	O
the	O
increase	O
in	O
ISGF3	O
activity	O
ultimately	O
correlates	O
with	O
the	O
accumulation	O
of	O
ISGF3	O
gamma	O
induced	O
by	O
IFN-alpha	B-SPECULATION
or	I-SPECULATION
IFN-gamma	I-SPECULATION
.(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
.	O

CsA	O
and	O
FK506	O
are	O
powerful	O
suppressors	O
of	O
the	O
immune	O
system	O
,	O
most	O
notably	O
of	O
T	O
cells	O
.	O

They	O
act	O
at	O
a	O
point	O
in	O
activation	O
that	O
lies	O
between	O
receptor	O
ligation	O
and	O
the	O
transcription	O
of	O
early	O
genes	O
.	O

Here	O
,	O
Stuart	O
Schreiber	O
and	O
Gerald	O
Crabtree	O
review	O
recent	O
findings	O
that	O
indicate	B-SPECULATION
CsA	I-SPECULATION
and	I-SPECULATION
FK506	I-SPECULATION
operate	I-SPECULATION
as	I-SPECULATION
prodrugs	I-SPECULATION
:	O
.	O

they	O
bind	O
endogenous	O
intracellular	O
receptors	O
,	O
the	O
immunophilins	O
,	O
and	O
the	O
resulting	O
complex	O
targets	O
the	O
protein	O
phosphatase	O
,	O
calcineurin	O
,	O
to	O
exert	O
the	O
immunosuppressive	O
effect	O
.	O

[	O
Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	O
receptors	O
in	O
patients	O
with	O
deficiency-cold	O
vs	O
deficiency-heat	O
syndromes	O
]	O

Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	O
receptors	O
(	O
GCR	O
)	O
were	O
assayed	O
in	O
20	O
patients	O
with	O
deficiency	O
syndromes	O
,	O
10	O
cold	O
in	O
property	O
(	O
deficiency-cold	O
)	O
,	O
the	O
other	O
10	O
hot	O
in	O
property	O
(	O
deficiency-heat	O
)	O
,	O
and	O
also	O
in	O
10	O
healthy	O
individuals	O
as	O
normal	O
control	O
for	O
the	O
purpose	O
of	O
investigating	O
the	O
nature	O
of	O
cold	O
and	O
heat	O
syndromes	O
.	O

As	O
a	O
result	O
,	O
the	O
cases	O
of	O
deficiency-cold	O
syndrome	O
(	O
DCS	O
)	O
had	O
a	O
normal	O
concentration	O
of	O
plasma	O
cortisol	O
but	O
a	O
lowered	O
content	O
of	O
GCR	O
in	O
leukocytes	O
when	O
compared	O
with	O
the	O
normal	O
control	O
(	O
P	O
less	O
than	O
0.05	O
)	O
;	O

the	O
cases	O
of	O
deficiency-heat	O
syndrome	O
(	O
DHS	O
)	O
had	O
a	O
higher	O
concentration	O
of	O
plasma	O
cortisol	O
than	O
the	O
normal	O
control	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
a	O
slightly	O
higher	O
content	O
of	O
GCR	O
in	O
leukocytes	O
.	O

It	O
was	O
concluded	O
that	O
the	O
DCS	O
is	O
characterized	O
by	O
diminished	O
biological	O
effects	O
of	O
adrenocortical	O
activity	O
,	O
while	O
the	O
DHS	O
,	O
by	O
augmented	O
biological	O
effects	O
of	O
adrenocortical	O
activity	O
.	O

Specific	O
NF-kappa	O
B	O
subunits	O
act	O
in	O
concert	O
with	O
Tat	O
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
.	O

NF-kappa	O
B	O
is	O
a	O
protein	O
complex	O
which	O
functions	O
in	O
concert	O
with	O
the	O
tat-I	O
gene	O
product	O
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
transcription	O
.	O

To	O
determine	O
whether	B-SPECULATION
specific	I-SPECULATION
members	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
family	I-SPECULATION
contribute	I-SPECULATION
to	I-SPECULATION
this	I-SPECULATION
effect	I-SPECULATION
,	O
we	O
have	O
examined	O
the	O
abilities	O
of	O
different	O
NF-kappa	O
B	O
subunits	O
to	O
act	O
with	O
Tat-I	O
to	O
stimulate	O
transcription	O
of	O
HIV	O
in	O
Jurkat	O
T-leukemia	O
cells	O
.	O

We	O
have	O
found	O
that	O
the	O
p49	O
(	O
100	O
)	O
DNA	O
binding	O
subunit	O
,	O
together	O
with	O
p65	O
,	O
can	B-SPECULATION
act	I-SPECULATION
in	I-SPECULATION
concert	I-SPECULATION
with	I-SPECULATION
Tat-I	I-SPECULATION
to	I-SPECULATION
stimulate	I-SPECULATION
the	I-SPECULATION
expression	I-SPECULATION
of	I-SPECULATION
HIV-CAT	I-SPECULATION
plasmid	I-SPECULATION
.	O

Little	O
effect	O
was	O
observed	O
with	O
50-kDa	O
forms	O
of	O
p105	O
NF-kappa	O
B	O
or	O
rel	O
,	O
in	O
combination	O
with	O
p65	O
or	O
full-length	O
c-rel	O
,	O
which	O
do	O
not	B-NEGATION
stimulate	I-NEGATION
the	I-NEGATION
HIV	I-NEGATION
enhancer	I-NEGATION
in	I-NEGATION
these	I-NEGATION
cells	I-NEGATION
.	O

These	O
findings	O
suggest	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
combination	I-SPECULATION
of	I-SPECULATION
p49	I-SPECULATION
(	I-SPECULATION
100	I-SPECULATION
)	I-SPECULATION
and	I-SPECULATION
p65	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
can	B-SPECULATION
act	I-SPECULATION
in	I-SPECULATION
concert	I-SPECULATION
with	I-SPECULATION
the	I-SPECULATION
tat-I	I-SPECULATION
gene	I-SPECULATION
product	I-SPECULATION
to	I-SPECULATION
stimulate	I-SPECULATION
the	I-SPECULATION
synthesis	I-SPECULATION
of	I-SPECULATION
HIV	I-SPECULATION
RNA	I-SPECULATION
.	O

Activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
is	O
not	B-NEGATION
dependent	I-NEGATION
on	I-NEGATION
NFAT-1	I-NEGATION
.	O

The	O
function	O
of	O
a	O
putative	B-SPECULATION
NFAT-1	I-SPECULATION
site	I-SPECULATION
in	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
has	O
been	O
analyzed	O
.	O

Activation	O
by	O
the	O
T-cell	O
antigen	O
receptor	O
is	O
minimal	O
in	O
Jurkat	O
cells	O
and	O
is	O
mediated	O
by	O
the	O
kappa	O
B	O
sites	O
.	O

The	B-NEGATION
not	I-NEGATION
required	I-NEGATION
for	I-NEGATION
the	I-NEGATION
response	I-NEGATION
to	I-NEGATION
anti-CD3	I-NEGATION
or	I-NEGATION
to	I-NEGATION
mitogens	I-NEGATION
in	I-NEGATION
T-cell	I-NEGATION
,	I-NEGATION
B-cell	I-NEGATION
,	I-NEGATION
or	I-NEGATION
monocyte	I-NEGATION
/	I-NEGATION
macrophage	I-NEGATION
leukemia	I-NEGATION
lines	I-NEGATION
,	O
putative	B-SPECULATION
NFAT-1	I-SPECULATION
region	I-SPECULATION
is	O
nor	B-NEGATION
is	I-NEGATION
it	I-NEGATION
a	I-NEGATION
cis-acting	I-NEGATION
negative	I-NEGATION
regulatory	I-NEGATION
element	I-NEGATION
.	O

Protein	O
kinase	O
C	O
activation	O
and	O
protooncogene	O
expression	O
in	O
differentiation	O
/	O
retrodifferentiation	O
of	O
human	O
U-937	O
leukemia	O
cells	O
.	O

Human	O
U-937	O
leukemia	O
cells	O
differentiate	O
along	O
the	O
monocytic	O
lineage	O
following	O
3-day	O
exposures	O
to	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

This	O
induction	O
of	O
differentiation	O
is	O
accompanied	O
by	O
adherence	O
and	O
loss	O
of	O
proliferation	O
,	O
as	O
well	O
as	O
expression	O
/	O
repression	O
of	O
differentiation-associated	O
genes	O
.	O

Long	O
term	O
culture	O
of	O
TPA-differentiated	O
U-937	O
cells	O
in	O
the	O
absence	O
of	O
phorbol	O
ester	O
for	O
32-36	O
days	O
resulted	O
in	O
a	O
process	O
of	O
retrodifferentiation	O
.	O

The	O
retrodifferentiated	O
cells	O
detached	O
from	O
the	O
substrate	O
and	O
reinitiated	O
proliferation	O
.	O

Other	O
cellular	O
parameters	O
,	O
such	O
as	O
glycosidase	O
activities	O
,	O
cytokine	O
release	O
,	O
and	O
filament	O
expression	O
,	O
returned	O
to	O
levels	O
similar	O
to	O
that	O
observed	O
in	O
uninduced	O
cells	O
.	O

Treatment	O
of	O
U-937	O
cells	O
with	O
TPA	O
resulted	O
in	O
a	O
rapid	O
translocation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
from	O
the	O
cytosol	O
to	O
cell	O
membrane	O
fractions	O
within	O
2-8	O
min	O
.	O

Increased	O
levels	O
of	O
membrane-associated	O
PKC	O
activity	O
persisted	O
until	O
17-29	O
days	O
.	O

However	O
,	O
longer	O
periods	O
of	O
incubation	O
were	O
associated	O
with	O
a	O
return	O
to	O
the	O
distribution	O
of	O
PKC	O
in	O
control	O
cells	O
.	O

Activation	O
of	O
PKC	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
certain	O
immediate	O
early	O
response	O
genes	O
,	O
and	O
in	O
the	O
present	O
studies	O
,	O
TPA	O
rapidly	O
induced	O
c-fos	O
and	O
c-jun	O
gene	O
expression	O
.	O

Levels	O
of	O
c-fos	O
and	O
c-jun	O
transcripts	O
remained	O
elevated	O
during	O
periods	O
of	O
PKC	O
activation	O
and	O
also	O
returned	O
to	O
levels	O
observed	O
in	O
control	O
cells	O
by	O
30-36	O
days	O
,	O
when	O
the	O
cells	O
entered	O
retrodifferentiation	O
.	O

Staurosporine	O
,	O
a	O
nonspecific	O
inhibitor	O
of	O
PKC	O
,	O
partially	O
blocked	O
TPA-induced	O
adherence	O
and	O
growth	O
inhibition	O
and	O
concomitantly	O
prevented	O
TPA-induced	O
c-fos	O
and	O
c-jun	O
gene	O
expression.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
promoter	O
of	O
the	O
CD19	O
gene	O
is	O
a	O
target	O
for	O
the	O
B-cell-specific	O
transcription	O
factor	O
BSAP	O
.	O

The	O
CD19	O
protein	O
is	O
expressed	O
on	O
the	O
surface	O
of	O
all	O
B-lymphoid	O
cells	O
with	B-NEGATION
the	I-NEGATION
exception	I-NEGATION
of	I-NEGATION
terminally	I-NEGATION
differentiated	I-NEGATION
plasma	I-NEGATION
cells	I-NEGATION
and	O
has	O
been	O
implicated	O
as	O
a	O
signal-transducing	O
receptor	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
.	O

Here	O
we	O
demonstrate	O
complete	O
correlation	O
between	O
the	O
expression	O
pattern	O
of	O
the	O
CD19	O
gene	O
and	O
the	O
B-cell-specific	O
transcription	O
factor	O
BSAP	O
in	O
a	O
large	O
panel	O
of	O
B-lymphoid	O
cell	O
lines	O
.	O

The	O
human	O
CD19	O
gene	O
has	O
been	O
cloned	O
,	O
and	O
several	O
BSAP-binding	O
sites	O
have	O
been	O
mapped	O
by	O
in	O
vitro	O
protein-DNA	O
binding	O
studies	O
.	O

In	O
particular	O
,	O
a	O
high-affinity	O
BSAP-binding	O
site	O
instead	B-NEGATION
of	I-NEGATION
a	I-NEGATION
TATA	I-NEGATION
sequence	I-NEGATION
is	O
located	O
in	O
the	O
-	O
30	O
promoter	O
region	O
upstream	O
of	O
a	O
cluster	O
of	O
heterogeneous	O
transcription	O
start	O
sites	O
.	O

Moreover	O
,	O
this	O
site	O
is	O
occupied	O
by	O
BSAP	O
in	O
vivo	O
in	O
a	O
CD19-expressing	O
B-cell	O
line	O
but	O
not	B-NEGATION
in	I-NEGATION
plasma	I-NEGATION
or	I-NEGATION
HeLa	I-NEGATION
cells	I-NEGATION
.	O

This	O
high-affinity	O
site	O
has	O
been	O
conserved	O
in	O
the	O
promoters	O
of	O
both	O
human	O
and	O
mouse	O
CD19	O
genes	O
and	O
was	O
furthermore	O
shown	O
to	O
confer	O
B-cell	O
specificity	O
to	O
a	O
beta-globin	O
reporter	O
gene	O
in	O
transient	O
transfection	O
experiments	O
.	O

In	O
addition	O
,	O
BSAP	O
was	O
found	O
to	O
be	O
the	O
only	O
abundant	O
DNA-binding	O
activity	O
of	O
B-cell	O
nuclear	O
extracts	O
that	O
interacts	O
with	O
the	O
CD19	O
promoter	O
.	O

Together	O
,	O
this	O
evidence	O
strongly	O
implicates	B-SPECULATION
BSAP	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
regulation	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
CD19	I-SPECULATION
gene	I-SPECULATION
.	O

Reduced	O
susceptibility	O
to	O
HIV-1	O
infection	O
of	O
ethyl-methanesulfonate-treated	O
CEM	O
subclones	O
correlates	O
with	O
a	O
blockade	O
in	O
their	O
protein	O
kinase	O
C	O
signaling	O
pathway	O
.	O

We	O
have	O
described	O
the	O
isolation	O
of	O
chemically	O
induced	O
CEM	O
subclones	O
that	O
express	O
CD4	O
receptors	O
and	O
bind	O
soluble	O
gp120	O
,	O
yet	O
show	O
a	O
markedly	O
reduced	O
susceptibility	O
to	O
infection	O
with	O
HIV-1	O
.	O

Two	O
subclones	O
were	O
found	O
to	O
have	O
an	O
abnormal	O
response	O
to	O
the	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activator	O
PMA	O
.	O

PMA	O
treatment	O
induced	O
CD3	O
and	O
CD25	O
(	O
IL-2R	O
)	O
receptors	O
on	O
the	O
parental	O
line	O
and	O
on	O
other	O
ethyl-methanesulfonate-derived	O
subclones	O
,	O
but	O
not	B-NEGATION
on	I-NEGATION
these	I-NEGATION
two	I-NEGATION
mutants	I-NEGATION
.	O

Direct	O
assays	O
of	O
PKC	O
activity	O
were	O
conducted	O
.	O

Total	O
cellular	O
PKC	O
enzymatic	O
activity	O
was	O
found	O
to	O
be	O
normal	O
in	O
these	O
subclones	O
.	O

PMA-induced	O
CD4	O
down-modulation	O
occurred	O
normally	O
.	O

In	O
addition	O
,	O
activation	O
of	O
c-raf	O
kinase	O
was	O
normal	O
.	O

Since	O
HIV-1	O
long	O
terminal	O
repeat	O
contains	O
two	O
functional	O
nuclear	O
factor	O
kB	O
(	O
NF-kB	O
)	O
regulatory	O
elements	O
,	O
we	O
studied	O
the	O
ability	O
of	O
PMA	O
to	O
induce	O
NF-kB	O
binding	O
activity	O
by	O
different	O
assays	O
.	O

Chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
assays	O
using	O
the	O
HIV-1	O
(	O
-	O
139	O
)	O
long	O
terminal	O
repeat-CAT	O
construct	O
showed	O
no	B-NEGATION
PMA	I-NEGATION
induction	I-NEGATION
of	I-NEGATION
CAT	I-NEGATION
activity	I-NEGATION
in	I-NEGATION
these	I-NEGATION
subclones	I-NEGATION
(	O
unlike	O
the	O
parental	O
line	O
and	O
other	O
subclones	O
)	O
.	O

Okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	O
1	O
and	O
2A	O
,	O
did	O
not	B-NEGATION
overcome	I-NEGATION
the	I-NEGATION
defect	I-NEGATION
in	I-NEGATION
these	I-NEGATION
subclones	I-NEGATION
.	O

Gel	O
retardation	O
assays	O
,	O
using	O
a	O
32P-probe	O
containing	O
the	O
HIV-1	O
NF-kB	O
probe	O
and	O
nuclear	O
extracts	O
from	O
PMA-treated	O
cells	O
,	O
showed	O
significantly	O
reduced	O
induction	O
of	O
nuclear	O
NF-kB	O
binding	O
proteins	O
in	O
these	O
two	O
subclones	O
compared	O
with	O
wild	O
type	O
CEM	O
and	O
a	O
control	O
subclone	O
.	O

Deoxycholate	O
treatment	O
of	O
cytoplasmic	O
extracts	O
from	O
these	O
subclones	O
released	O
much	O
reduced	O
NF-kB	O
binding	O
proteins	O
from	O
their	O
cytoplasmic	O
pools	O
.	O

Thus	O
,	O
reduced	O
levels	O
of	O
PKC-induced	O
nuclear	O
NF-kB	O
activity	O
in	O
two	O
T	O
cell	O
subclones	O
did	O
not	B-NEGATION
affect	I-NEGATION
their	I-NEGATION
normal	I-NEGATION
cell	I-NEGATION
growth	I-NEGATION
,	O
but	O
correlated	O
with	O
a	O
pronounced	O
reduction	O
in	O
their	O
susceptibility	O
to	O
HIV-1	O
infection	O
.	O

Eicosanoids	O
in	O
breast	O
cancer	O
patients	O
before	O
and	O
after	O
mastectomy	O
.	O

In	O
19	O
patients	O
with	O
a	O
malignant	O
breast	O
tumor	O
,	O
tumor	O
tissue	O
and	O
blood	O
were	O
taken	O
to	O
determine	O
the	O
eicosanoid	O
profile	O
and	O
platelet	O
aggregation	O
.	O

Values	O
were	O
compared	O
with	O
those	O
of	O
patients	O
with	O
benign	O
tumors	O
(	O
n	O
=	O
4	O
)	O
,	O
or	O
undergoing	O
a	O
mammary	O
reduction	O
(	O
n	O
=	O
7	O
)	O
.	O

Postoperatively	O
,	O
blood	O
was	O
taken	O
as	O
well	O
in	O
order	O
to	O
compare	O
pre	O
-	O
and	O
postoperative	O
values	O
.	O

Eicosanoids	O
were	O
measured	O
in	O
peripheral	O
blood	O
monocytes	O
and	O
mammary	O
tissue	O
by	O
means	O
of	O
HPLC	O
;	O

furthermore	O
,	O
TXA2	O
,	O
6-keto-PGF1	O
alpha	O
,	O
and	O
PGE2	O
were	O
determined	O
by	O
RIA	O
.	O

Differences	O
in	O
pre	O
-	O
and	O
postoperative	O
values	O
of	O
cancer	O
patients	O
were	O
seen	O
in	O
plasma	O
RIA	O
values	O
:	O

PGE2	O
and	O
6-k-PGF1	O
alpha	O
were	O
significantly	O
higher	O
preoperatively	O
when	O
compared	O
with	O
postoperatively	O
,	O
however	O
,	O
such	O
differences	O
were	O
seen	O
in	O
the	O
control	O
groups	O
as	O
well	O
.	O

Compared	O
to	O
benign	O
tumor	O
or	O
mammary	O
reduction	O
test	O
material	O
the	O
eicosanoid	O
profile	O
of	O
tissue	O
obtained	O
from	O
malignant	O
mammary	O
tumors	O
showed	O
important	O
differences	O
.	O

Except	O
for	O
PGF2	O
alpha	O
,	O
HHT	O
and	O
15-HETE	O
no	B-NEGATION
detectable	I-NEGATION
quantities	I-NEGATION
of	I-NEGATION
eicosanoids	I-NEGATION
were	I-NEGATION
found	I-NEGATION
in	I-NEGATION
the	I-NEGATION
non-tumor	I-NEGATION
material	I-NEGATION
,	O
whereas	O
in	O
the	O
malignant	O
tumor	O
material	O
substantial	O
quantities	O
of	O
a	O
number	O
of	O
eicosanoid	O
metabolites	O
were	O
present	O
.	O

Statistically	B-SPECULATION
significant	I-SPECULATION
correlations	I-SPECULATION
could	I-SPECULATION
be	I-SPECULATION
established	I-SPECULATION
between	I-SPECULATION
patient	I-SPECULATION
/	I-SPECULATION
histopathology	I-SPECULATION
data	I-SPECULATION
and	I-SPECULATION
the	I-SPECULATION
results	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
platelet	I-SPECULATION
aggregation	I-SPECULATION
assays	I-SPECULATION
,	O
e.g	O
.	O

between	O
menopausal	O
status	O
and	O
ADP	O
aggregation	O
;	O
oestrogen	O
receptor	O
(+/-)	O
and	O
collagen	O
and	O
arachidonic	O
acid	O
aggregation	O
,	O
inflammatory	O
cell	O
infiltration	O
score	O
and	O
arachidonic	O
acid	O
aggregation	O
and	O
fibrosis	O
score	O
and	O
ADP	O
aggregation	O
.	O

The	O
results	O
show	O
that	O
eicosanoid	O
synthesis	O
in	O
material	O
from	O
mammary	O
cancer	O
patients	O
is	O
different	O
from	O
that	O
in	O
benign	O
mammary	O
tissue	O
.	O

The	O
implications	O
,	O
in	O
particular	O
,	O
in	O
relation	O
to	O
future	O
prognosis	O
of	O
the	O
patient	O
,	O
remain	O
obscure	O
.	O

c-myc	O
mRNA	O
expression	O
in	O
minor	O
salivary	O
glands	O
of	O
patients	O
with	O
Sjogren	O
'	O
s	O
syndrome	O
.	O

c-myc	O
protooncogene	O
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
B	O
cell	O
lymphoid	O
malignancies	O
and	O
high	O
levels	O
of	O
c-myc	O
mRNA	O
expression	O
are	O
observed	O
in	O
activated	O
blood	O
mononuclear	O
cells	O
.	O

Sjogren	O
'	O
s	O
syndrome	O
(	O
SS	O
)	O
is	O
characterized	O
by	O
lymphocytic	O
infiltrates	O
of	O
exocrine	O
glands	O
,	O
remarkable	O
B	O
cell	O
hyperreactivity	O
and	O
a	O
strong	O
predisposition	O
to	O
B	O
cell	O
neoplasia	O
.	O

In	O
this	O
study	O
,	O
c-myc	O
protooncogene	O
mRNA	O
expression	O
in	O
29	O
labial	O
minor	O
salivary	O
gland	O
biopsies	O
from	O
patients	O
with	O
primary	O
SS	O
and	O
15	O
controls	O
was	O
examined	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
.	O

Two	O
40mer	O
oligonucleotides	O
from	O
the	O
1st	O
and	O
the	O
2nd	O
exon	O
of	O
the	O
c-myc	O
gene	O
,	O
labeled	O
with	O
35S	O
,	O
were	O
used	O
as	O
probes	O
.	O

To	O
detect	O
the	O
origin	O
of	O
the	O
cell	O
hybridized	O
with	O
a	O
c-myc	O
probe	O
,	O
a	O
combined	O
immunochemistry	O
in	O
situ	O
hybridization	O
histochemistry	O
technique	O
was	O
used	O
.	O

High	O
c-myc	O
mRNA	O
expression	O
was	O
detected	O
on	O
acinar	O
epithelial	O
cells	O
.	O

c-myc	O
did	O
not	B-NEGATION
correlate	I-NEGATION
with	I-NEGATION
c-fos	I-NEGATION
and	I-NEGATION
c-jun	I-NEGATION
protein	I-NEGATION
expression	I-NEGATION
.	O

Stronger	O
c-myc	O
mRNA	O
expression	O
was	O
detected	O
in	O
labial	O
salivary	O
glands	O
of	O
patients	O
with	O
longer	O
disease	O
duration	O
(	O
p	O
less	O
than	O
or	O
equal	O
to	O
0.002	O
)	O
and	O
more	O
intense	O
T	O
lymphocyte	O
infiltrates	O
(	O
p	O
less	O
than	O
0.05	O
)	O
although	O
these	O
patients	O
revealed	O
no	B-NEGATION
hypergammaglobulinemia	I-NEGATION
.	O

No	B-NEGATION
correlation	I-NEGATION
was	I-NEGATION
observed	I-NEGATION
between	I-NEGATION
c-myc	I-NEGATION
mRNA	I-NEGATION
and	I-NEGATION
B	I-NEGATION
lymphocyte	I-NEGATION
monoclonicity	I-NEGATION
or	I-NEGATION
lymphoma	I-NEGATION
.	O

In	O
conclusion	O
,	O
strong	O
c-myc	O
mRNA	O
expression	O
was	O
observed	O
on	O
epithelial	O
cells	O
of	O
labial	O
salivary	O
glands	O
from	O
patients	O
with	O
primary	O
SS	O
.	O

Our	O
findings	O
may	B-SPECULATION
indicate	B-SPECULATION
the	I-SPECULATION
presence	I-SPECULATION
of	I-SPECULATION
a	I-SPECULATION
reactivated	I-SPECULATION
virus	I-SPECULATION
hosted	I-SPECULATION
in	I-SPECULATION
these	I-SPECULATION
cells	I-SPECULATION
.	O

Cytoplasmic	O
domain	O
heterogeneity	O
and	O
functions	O
of	O
IgG	O
Fc	O
receptors	O
in	O
B	O
lymphocytes	O
.	O

B	O
lymphocytes	O
and	O
macrophages	O
express	O
closely	O
related	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
Fc	O
receptors	O
(	O
Fc	O
gamma	O
RII	O
)	O
that	O
differ	O
only	O
in	O
the	O
structures	O
of	O
their	O
cytoplasmic	O
domains	O
.	O

Because	O
of	O
cell	O
type-specific	O
alternative	O
messenger	O
RNA	O
splicing	O
,	O
B-cell	O
Fc	O
gamma	O
RII	O
contains	O
an	O
insertion	O
of	O
47	O
amino	O
acids	O
that	O
participates	O
in	O
determining	O
receptor	O
function	O
in	O
these	O
cells	O
.	O

Transfection	O
of	O
an	O
Fc	O
gamma	O
RII-negative	O
B-cell	O
line	O
with	O
complementary	O
DNA	O
'	O
s	O
encoding	O
the	O
two	O
splice	O
products	O
and	O
various	O
receptor	O
mutants	O
indicated	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
insertion	I-SPECULATION
was	I-SPECULATION
responsible	I-SPECULATION
for	I-SPECULATION
preventing	I-SPECULATION
both	I-SPECULATION
Fc	I-SPECULATION
gamma	I-SPECULATION
RII-mediated	I-SPECULATION
endocytosis	I-SPECULATION
and	I-SPECULATION
Fc	I-SPECULATION
gamma	I-SPECULATION
RII-mediated	I-SPECULATION
antigen	I-SPECULATION
presentation	I-SPECULATION
.	O

The	O
insertion	O
was	O
not	B-NEGATION
required	I-NEGATION
for	I-NEGATION
Fc	I-NEGATION
gamma	I-NEGATION
RII	I-NEGATION
to	I-NEGATION
modulate	I-NEGATION
surface	I-NEGATION
immunoglobulin-triggered	I-NEGATION
B-cell	I-NEGATION
activation	I-NEGATION
.	O

Instead	O
,	O
regulation	O
of	O
activation	O
involved	O
a	O
region	O
of	O
the	O
cytoplasmic	O
domain	O
common	O
to	O
both	O
the	O
lymphocyte	O
and	O
macrophage	O
receptor	O
isoforms	O
.	O

In	O
contrast	O
,	O
the	O
insertion	O
did	O
contribute	O
to	O
the	O
formation	O
of	O
caps	O
in	O
response	O
to	O
receptor	O
cross-linking	O
,	O
consistent	O
with	O
suggestions	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
lymphocyte	I-SPECULATION
but	I-SPECULATION
not	B-NEGATION
macrophage	I-NEGATION
form	O
of	O
the	O
receptor	O
can	B-SPECULATION
associate	I-SPECULATION
with	I-SPECULATION
the	I-SPECULATION
detergent-insoluble	I-SPECULATION
cytoskeleton	I-SPECULATION
.	O

Every	O
enhancer	O
works	O
with	O
every	O
promoter	O
for	O
all	O
the	O
combinations	O
tested	O
:	O

could	B-SPECULATION
new	I-SPECULATION
regulatory	I-SPECULATION
pathways	I-SPECULATION
evolve	I-SPECULATION
by	I-SPECULATION
enhancer	I-SPECULATION
shuffling	I-SPECULATION
?	O
.	O

The	O
promoters	O
and	O
enhancers	O
of	O
cell	O
type-specific	O
genes	O
are	O
often	O
conserved	O
in	O
evolution	O
,	O
and	O
hence	O
one	O
might	B-SPECULATION
expect	B-SPECULATION
that	I-SPECULATION
a	I-SPECULATION
given	I-SPECULATION
enhancer	I-SPECULATION
has	I-SPECULATION
evolved	I-SPECULATION
to	I-SPECULATION
work	I-SPECULATION
best	I-SPECULATION
with	I-SPECULATION
its	I-SPECULATION
own	I-SPECULATION
promoter	I-SPECULATION
.	O

While	O
this	B-SPECULATION
expectation	I-SPECULATION
may	I-SPECULATION
be	I-SPECULATION
realized	I-SPECULATION
in	I-SPECULATION
some	I-SPECULATION
cases	I-SPECULATION
,	O
we	O
have	O
not	B-NEGATION
found	I-NEGATION
evidence	I-NEGATION
for	I-NEGATION
it	I-NEGATION
.	O

A	O
total	O
of	O
27	O
combinations	O
of	O
different	O
promoters	O
and	O
enhancers	O
were	O
tested	O
by	O
transfection	O
into	O
cultured	O
cells	O
.	O

We	O
found	O
that	O
the	O
relative	O
efficiency	O
of	O
the	O
enhancers	O
is	O
approximately	O
the	O
same	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
promoter	O
used	O
,	O
i.e.	O
,	O
there	O
was	O
no	B-NEGATION
strong	I-NEGATION
preference	I-NEGATION
for	I-NEGATION
any	I-NEGATION
given	I-NEGATION
enhancer	I-NEGATION
/	I-NEGATION
promoter	I-NEGATION
combination	I-NEGATION
.	O

Notably	O
,	O
we	O
do	O
not	B-NEGATION
see	I-NEGATION
particularly	I-NEGATION
strong	I-NEGATION
transcription	I-NEGATION
when	I-NEGATION
the	I-NEGATION
immunoglobulin	I-NEGATION
kappa	I-NEGATION
enhancer	I-NEGATION
(	I-NEGATION
or	I-NEGATION
the	I-NEGATION
immunoglobulin	I-NEGATION
heavy	I-NEGATION
chain	I-NEGATION
enhancer	I-NEGATION
)	I-NEGATION
is	I-NEGATION
used	I-NEGATION
to	I-NEGATION
activate	I-NEGATION
a	I-NEGATION
kappa	I-NEGATION
gene	I-NEGATION
promoter	I-NEGATION
.	O

We	O
propose	B-SPECULATION
that	I-SPECULATION
a	I-SPECULATION
generally	I-SPECULATION
permissive	I-SPECULATION
enhancer	I-SPECULATION
/	I-SPECULATION
promoter	I-SPECULATION
interaction	I-SPECULATION
is	I-SPECULATION
of	I-SPECULATION
evolutionary	I-SPECULATION
benefit	I-SPECULATION
for	I-SPECULATION
higher	I-SPECULATION
eukaryotes	I-SPECULATION
:	O
by	O
enhancer	O
shuffling	O
,	O
genes	O
could	B-SPECULATION
be	I-SPECULATION
easily	I-SPECULATION
brought	I-SPECULATION
under	I-SPECULATION
a	I-SPECULATION
new	I-SPECULATION
type	I-SPECULATION
of	I-SPECULATION
inducibility	I-SPECULATION
/	I-SPECULATION
cell	I-SPECULATION
type	I-SPECULATION
specificity	I-SPECULATION
.	O

Heterodimerization	O
and	O
transcriptional	O
activation	O
in	O
vitro	O
by	O
NF-kappa	O
B	O
proteins	O
.	O

The	O
NF-kappa	O
B	O
family	O
of	O
transcription	O
proteins	O
represents	O
multiple	O
DNA	O
binding	O
,	O
rel	O
related	O
polypeptides	O
that	O
contribute	O
to	O
regulation	O
of	O
genes	O
involved	O
in	O
immune	O
responsiveness	O
and	O
inflammation	O
,	O
as	O
well	O
as	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

In	O
this	O
study	O
multiple	O
NF-kappa	O
B	O
related	O
polypeptides	O
ranging	O
from	O
85	O
to	O
45	O
kDa	O
were	O
examined	B-SPECULATION
for	I-SPECULATION
their	I-SPECULATION
capacity	I-SPECULATION
to	I-SPECULATION
interact	I-SPECULATION
with	I-SPECULATION
the	I-SPECULATION
PRDII	I-SPECULATION
regulatory	I-SPECULATION
element	I-SPECULATION
of	I-SPECULATION
interferon	I-SPECULATION
beta	I-SPECULATION
and	O
were	O
shown	O
to	O
possess	O
distinct	O
intrinsic	O
DNA	O
binding	O
affinities	O
for	O
this	O
NF-kappa	O
B	O
site	O
and	O
form	O
multiple	O
DNA	O
binding	O
homo	O
-	O
and	O
heterodimer	O
complexes	O
in	O
co-renaturation	O
experiments	O
.	O

Furthermore	O
,	O
using	O
DNA	O
templates	O
containing	O
two	O
copies	O
of	O
the	O
PRDII	O
domain	O
linked	O
to	O
the	O
rabbit	O
beta	O
globin	O
gene	O
,	O
the	O
purified	O
polypeptides	O
specifically	O
stimulated	O
NF-kappa	O
B	O
dependent	O
transcription	O
in	O
an	O
in	O
vitro	O
reconstitution	O
assay	O
as	O
heterodimers	O
but	O
not	B-NEGATION
as	I-NEGATION
p50	I-NEGATION
homodimers	I-NEGATION
.	O

These	O
experiments	O
emphasize	O
the	O
role	O
of	O
NF-kappa	O
B	O
dimerization	O
as	O
a	O
distinct	O
level	O
of	O
transcriptional	O
control	O
that	O
may	B-SPECULATION
permit	I-SPECULATION
functional	I-SPECULATION
diversification	I-SPECULATION
of	I-SPECULATION
a	I-SPECULATION
limited	I-SPECULATION
number	I-SPECULATION
of	I-SPECULATION
regulatory	I-SPECULATION
proteins	I-SPECULATION
.	O

Oct2	O
transactivation	O
from	O
a	O
remote	O
enhancer	O
position	O
requires	O
a	O
B-cell-restricted	O
activity	O
.	O

Previous	O
cotransfection	O
experiments	O
had	O
demonstrated	O
that	O
ectopic	O
expression	O
of	O
the	O
lymphocyte-specific	O
transcription	O
factor	O
Oct2	O
could	B-SPECULATION
efficiently	I-SPECULATION
activate	I-SPECULATION
a	I-SPECULATION
promoter	I-SPECULATION
containing	I-SPECULATION
an	I-SPECULATION
octamer	I-SPECULATION
motif	I-SPECULATION
.	O

Oct2	O
expression	O
was	O
unable	B-NEGATION
to	I-NEGATION
stimulate	I-NEGATION
a	I-NEGATION
multimerized	I-NEGATION
octamer	I-NEGATION
enhancer	I-NEGATION
element	I-NEGATION
in	I-NEGATION
HeLa	I-NEGATION
cells	I-NEGATION
,	O
however	O
.	O

We	O
have	O
tested	O
a	O
variety	O
of	O
Oct2	O
isoforms	O
generated	O
by	O
alternative	O
splicing	O
for	O
the	O
capability	O
to	O
activate	O
an	O
octamer	O
enhancer	O
in	O
nonlymphoid	O
cells	O
and	O
a	O
B-cell	O
line	O
.	O

Our	O
analyses	O
show	O
that	O
several	O
Oct2	O
isoforms	O
can	O
stimulate	O
from	O
a	O
remote	O
position	O
but	O
that	O
this	O
stimulation	O
is	O
restricted	O
to	O
B	O
cells	O
.	O

This	O
result	O
indicates	B-SPECULATION
the	I-SPECULATION
involvement	I-SPECULATION
of	I-SPECULATION
either	B-SPECULATION
a	I-SPECULATION
B-cell-specific	I-SPECULATION
cofactor	I-SPECULATION
in	O
Oct2-mediated	O
enhancer	O
activation	O
.	O

Mutational	O
analyses	O
indicate	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
carboxy-terminal	I-SPECULATION
domain	I-SPECULATION
of	I-SPECULATION
Oct2	I-SPECULATION
is	I-SPECULATION
critical	I-SPECULATION
for	I-SPECULATION
enhancer	I-SPECULATION
activation	I-SPECULATION
.	O

Moreover	O
,	O
this	O
domain	O
conferred	O
enhancing	O
activity	O
when	O
fused	O
to	O
the	O
Oct1	O
protein	O
,	O
which	O
by	O
itself	O
was	O
unable	B-NEGATION
to	I-NEGATION
stimulate	I-NEGATION
from	I-NEGATION
a	I-NEGATION
remote	I-NEGATION
position	I-NEGATION
.	O

The	O
glutamine-rich	O
activation	O
domain	O
present	O
in	O
the	O
amino-terminal	O
portion	O
of	O
Oct2	O
and	O
the	O
POU	O
domain	O
contribute	O
only	O
marginally	O
to	O
the	O
transactivation	O
function	O
from	O
a	O
distal	O
position	O
.	O

Induction	O
of	O
the	O
POU	O
domain	O
transcription	O
factor	O
Oct-2	O
during	O
T-cell	O
activation	O
by	O
cognate	O
antigen	O
.	O

Oct-2	O
is	O
a	O
transcription	O
factor	O
that	O
binds	O
specifically	O
to	O
octamer	O
DNA	O
motifs	O
in	O
the	O
promoters	O
of	O
immunoglobulin	O
and	O
interleukin-2	O
genes	O
.	O

All	O
tumor	O
cell	O
lines	O
from	O
the	O
B-cell	O
lineage	O
and	O
a	O
few	O
from	O
the	O
T-cell	O
lineage	O
express	O
Oct-2	O
.	O

To	O
address	O
the	O
role	O
of	O
Oct-2	O
in	O
the	O
T-cell	O
lineage	O
,	O
we	O
studied	O
the	O
expression	O
of	O
Oct-2	O
mRNA	O
and	O
protein	O
in	O
nontransformed	O
human	O
and	O
mouse	O
T	O
cells	O
.	O

Oct-2	O
was	O
found	O
in	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
prepared	O
from	O
human	O
peripheral	O
blood	O
and	O
in	O
mouse	O
lymph	O
node	O
T	O
cells	O
.	O

In	O
a	O
T-cell	O
clone	O
specific	O
for	O
pigeon	O
cytochrome	O
c	O
in	O
the	O
context	O
of	O
I-Ek	O
,	O
Oct-2	O
was	O
induced	O
by	O
antigen	O
stimulation	O
,	O
with	O
the	O
increase	O
in	O
Oct-2	O
protein	O
seen	O
first	O
at	O
3	O
h	O
after	O
activation	O
and	O
continuing	O
for	O
at	O
least	O
24	O
h	O
.	O

Oct-2	O
mRNA	O
induction	O
during	O
antigen-driven	O
T-cell	O
activation	O
was	O
blocked	O
by	O
cyclosporin	O
A	O
,	O
as	O
well	O
as	O
by	O
protein	O
synthesis	O
inhibitors	O
.	O

These	O
results	O
suggest	B-SPECULATION
that	I-SPECULATION
Oct-2	I-SPECULATION
participates	I-SPECULATION
in	I-SPECULATION
transcriptional	I-SPECULATION
regulation	I-SPECULATION
during	I-SPECULATION
T-cell	I-SPECULATION
activation	I-SPECULATION
.	O

The	O
relatively	O
delayed	O
kinetics	O
of	O
Oct-2	O
induction	O
suggests	B-SPECULATION
that	I-SPECULATION
Oct-2	I-SPECULATION
mediates	I-SPECULATION
the	I-SPECULATION
changes	I-SPECULATION
in	I-SPECULATION
gene	I-SPECULATION
expression	I-SPECULATION
which	I-SPECULATION
occur	I-SPECULATION
many	I-SPECULATION
hours	I-SPECULATION
or	I-SPECULATION
days	I-SPECULATION
following	I-SPECULATION
antigen	I-SPECULATION
stimulation	I-SPECULATION
of	I-SPECULATION
T	I-SPECULATION
lymphocytes	I-SPECULATION
.	O

[	O
Changes	O
in	O
plasma	O
interleukin-1	O
and	O
their	O
possible	B-SPECULATION
relationship	I-SPECULATION
with	I-SPECULATION
the	I-SPECULATION
changes	I-SPECULATION
in	I-SPECULATION
glucocorticoid	I-SPECULATION
receptor	I-SPECULATION
in	I-SPECULATION
aged	I-SPECULATION
long-distance	I-SPECULATION
runner	I-SPECULATION
]	O
.	O

For	O
the	O
study	O
of	O
the	O
changes	O
in	O
plasma	O
interleukin-1	O
(	O
IL-1	O
)	O
and	O
their	O
possible	B-SPECULATION
relationship	I-SPECULATION
with	I-SPECULATION
the	I-SPECULATION
changes	I-SPECULATION
in	I-SPECULATION
glucocorticoid	I-SPECULATION
receptor	I-SPECULATION
(	I-SPECULATION
GR	I-SPECULATION
)	I-SPECULATION
,	I-SPECULATION
plasma	I-SPECULATION
IL-1	I-SPECULATION
and	I-SPECULATION
GR	I-SPECULATION
in	I-SPECULATION
peripheral	I-SPECULATION
blood	I-SPECULATION
leukocytes	I-SPECULATION
in	I-SPECULATION
aged	I-SPECULATION
long-distance	I-SPECULATION
runner	I-SPECULATION
were	O
measured	O
simultaneously	O
.	O

The	O
activity	O
of	O
IL-1	O
was	O
expressed	O
as	O
its	O
ability	O
to	O
stimulate	O
3H-TdR	O
incorporation	O
in	O
the	O
thymocytes	O
of	O
C57	O
mice	O
.	O

GR	O
was	O
determined	O
by	O
whole	O
cell	O
assay	O
with	O
3H-Dex	O
.	O

The	O
results	O
showed	O
that	O
the	O
activity	O
of	O
plasma	O
IL-1	O
in	O
aged	O
long-distance	O
runner	O
was	O
209	O
%	O
,	O
223	O
%	O
and	O
145	O
%	O
of	O
the	O
control	O
at	O
14.7-18.7	O
,	O
3.8-7.0	O
and	O
1.5-2.6	O
KD	O
fractions	O
.	O

The	O
GR	O
in	O
peripheral	O
blood	O
leukocytes	O
in	O
aged	O
runner	O
was	O
65	O
%	O
of	O
the	O
control	O
.	O

Possible	B-SPECULATION
relationship	I-SPECULATION
between	I-SPECULATION
the	I-SPECULATION
changes	I-SPECULATION
in	I-SPECULATION
IL-1	I-SPECULATION
and	I-SPECULATION
GR	I-SPECULATION
in	I-SPECULATION
aged	I-SPECULATION
long-distance	I-SPECULATION
runner	I-SPECULATION
and	O
its	O
physiological	O
significance	O
are	O
discussed	O
.	O

Transcription	O
factor	O
AP-2	O
activates	O
gene	O
expression	O
of	O
HTLV-I	O
.	O

The	O
HTLV-I	O
LTR	O
contains	O
three	O
conserved	O
regulatory	O
elements	O
known	O
as	O
21	O
base	O
pair	O
repeats	O
which	O
are	O
required	O
for	O
stimulation	O
of	O
gene	O
expression	O
by	O
the	O
transactivator	O
protein	O
tax	O
.	O

Mutagenesis	O
indicates	B-SPECULATION
that	I-SPECULATION
the	B-SPECULATION
21	I-SPECULATION
bp	I-SPECULATION
repeats	I-SPECULATION
can	I-SPECULATION
be	I-SPECULATION
subdivided	I-SPECULATION
into	I-SPECULATION
three	I-SPECULATION
motifs	I-SPECULATION
,	I-SPECULATION
A	I-SPECULATION
,	I-SPECULATION
B	I-SPECULATION
and	I-SPECULATION
C	I-SPECULATION
,	O
each	O
of	O
which	O
influences	O
the	O
level	O
of	O
tax	O
activation	O
.	O

The	O
A	O
site	O
in	O
the	O
21	O
bp	O
repeat	O
has	O
strong	O
homology	O
with	O
previously	O
described	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
AP-2	O
.	O

We	O
demonstrated	O
that	O
AP-2	O
mRNA	O
was	O
present	O
in	O
T-lymphocytes	O
and	O
that	O
cellular	O
factors	O
from	O
both	O
non-transformed	O
and	O
transformed	O
T-lymphocytes	O
specifically	O
bound	O
to	O
the	O
consensus	O
motif	O
for	O
AP-2	O
in	O
each	O
21	O
bp	O
.	O

To	O
determine	O
the	O
role	O
of	O
AP-2	O
in	O
the	O
regulation	O
of	O
the	O
HTLV-I	O
LTR	O
gene	O
expression	O
,	O
we	O
used	O
an	O
AP-2	O
cDNA	O
in	O
DNA	O
binding	O
and	O
transient	O
expression	O
assays	O
.	O

Gel	O
retardation	O
and	O
methylation	O
interference	O
studies	O
revealed	O
that	O
bacterially	O
produced	O
AP-2	O
bound	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
all	O
three	O
21	O
bp	O
repeats	O
,	O
and	O
that	O
it	O
required	O
the	O
core	O
sequence	O
AGGC	O
for	O
specific	O
binding	O
.	O

Binding	O
of	O
AP-2	O
prevented	O
the	O
subsequent	O
binding	O
of	O
members	O
of	O
the	O
CREB	O
/	O
ATF	O
family	O
to	O
an	O
adjacent	O
regulatory	O
motif	O
in	O
the	O
21	O
bp	O
repeat	O
.	O

Transfection	O
of	O
an	O
AP-2	O
expression	O
construct	O
into	O
T-lymphocytes	O
activated	O
gene	O
expression	O
from	O
the	O
HTLV-I	O
LTR	O
.	O

At	O
least	O
two	O
21	O
bp	O
repeats	O
were	O
required	O
for	O
high	O
levels	O
of	O
AP-2	O
activation	O
and	O
mutagenesis	O
of	O
the	O
AP-2	O
consensus	O
binding	O
sequences	O
in	O
the	O
21	O
bp	O
repeats	O
eliminate	O
this	O
activation.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Cell	O
cycle-dependent	O
initiation	O
and	O
lineage-dependent	O
abrogation	O
of	O
GATA-1	O
expression	O
in	O
pure	O
differentiating	O
hematopoietic	O
progenitors	O
.	O

The	B-NEGATION
programmed	I-NEGATION
activation	I-NEGATION
/	I-NEGATION
repression	I-NEGATION
of	I-NEGATION
transcription	I-NEGATION
factors	I-NEGATION
in	I-NEGATION
early	I-NEGATION
hematopoietic	I-NEGATION
differentiation	I-NEGATION
has	I-NEGATION
not	I-NEGATION
yet	I-NEGATION
been	I-NEGATION
explored	I-NEGATION
.	O

The	O
DNA-binding	O
protein	O
GATA-1	O
is	O
required	O
for	O
normal	O
erythroid	O
development	O
and	O
regulates	O
erythroid-expressed	O
genes	O
in	O
maturing	O
erythroblasts	O
.	O

We	O
analyzed	O
GATA-1	O
expression	O
in	O
early	O
human	O
adult	O
hematopoiesis	O
by	O
using	O
an	O
in	O
vitro	O
system	O
in	O
which	O
"	O
pure	O
"	O
early	O
hematopoietic	O
progenitors	O
are	O
induced	O
to	O
gradual	O
and	O
synchronized	O
differentiation	O
selectively	O
along	O
the	O
erythroid	O
or	O
granulocyte-macrophage	O
pathway	O
by	O
differential	O
treatment	O
with	O
hematopoietic	O
growth	O
factors	O
.	O

The	O
GATA-1	O
gene	O
,	O
though	O
virtually	O
silent	O
in	O
quiescent	O
progenitors	O
,	O
is	O
activated	O
after	O
entrance	O
into	O
the	O
cell	O
cycle	O
upon	O
stimulation	O
with	O
hematopoietic	O
growth	O
factors	O
.	O

Subsequently	O
,	O
increasing	O
expression	O
along	O
the	O
erythroid	O
pathway	O
contrasts	O
with	O
an	O
abrupt	O
downregulation	O
in	O
the	O
granulocyte-macrophage	O
lineage	O
.	O

These	O
results	O
suggest	B-SPECULATION
a	I-SPECULATION
microenvironment-directed	I-SPECULATION
,	I-SPECULATION
two-step	I-SPECULATION
model	I-SPECULATION
for	I-SPECULATION
GATA-1	I-SPECULATION
expression	I-SPECULATION
in	I-SPECULATION
differentiating	I-SPECULATION
hematopoietic	I-SPECULATION
progenitors	I-SPECULATION
that	I-SPECULATION
involves	I-SPECULATION
(	I-SPECULATION
i	I-SPECULATION
)	I-SPECULATION
cycle-dependent	I-SPECULATION
initiation	I-SPECULATION
and	I-SPECULATION
(	I-SPECULATION
ii	I-SPECULATION
)	I-SPECULATION
lineage-dependent	I-SPECULATION
maintenance	I-SPECULATION
or	I-SPECULATION
suppression	I-SPECULATION
.	O

Hypothetically	B-SPECULATION
,	I-SPECULATION
on	I-SPECULATION
/	I-SPECULATION
off	I-SPECULATION
switches	I-SPECULATION
of	I-SPECULATION
lineage-restricted	I-SPECULATION
transactivators	I-SPECULATION
may	B-SPECULATION
underlie	I-SPECULATION
the	I-SPECULATION
binary	I-SPECULATION
fate	I-SPECULATION
decisions	I-SPECULATION
of	I-SPECULATION
hematopoietic	I-SPECULATION
progenitors	I-SPECULATION
.	O

[	O
Age-related	O
changes	O
in	O
glucocorticoid	O
and	O
mineralocorticoid	O
receptors	O
in	O
lymphocytes	O
of	O
healthy	O
persons	O
and	O
patients	O
with	O
hypertension	O
]	O

It	O
has	O
been	O
found	O
that	O
the	O
number	O
of	O
glucocorticoid	O
receptors	O
in	O
lymphocytes	O
of	O
the	O
peripheral	O
blood	O
of	O
healthy	O
elderly	O
subjects	O
increases	O
,	O
while	O
the	O
number	O
of	O
mineralocorticoid	O
receptors	O
decreases	O
.	O

The	O
mechanisms	O
of	O
hormone-receptor	O
interactions	O
in	O
hypertension	O
are	O
activated	O
:	O

the	O
number	O
of	O
glucocorticoid	O
and	O
mineralocorticoid	O
binding	O
sites	O
grows	O
in	O
hypertensive	O
patients	O
.	O

Still	O
a	O
more	O
essential	O
rise	O
in	O
the	O
number	O
of	O
receptors	O
is	O
observed	O
in	O
mid-age	O
hypertensive	O
patients	O
than	O
in	O
elderly	O
ones	O
.	O

In	O
vivo	O
footprint	O
analysis	O
of	O
the	O
HLA-DRA	O
gene	O
promoter	O
:	O
cell-specific	O
interaction	O
at	O
the	O
octamer	O
site	O
and	O
up-regulation	O
of	O
X	O
box	O
binding	O
by	O
interferon	O
gamma	O
.	O

Analysis	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
II	O
gene	O
promoter	O
DRA	O
has	O
previously	O
identified	O
at	O
least	O
five	O
cis-acting	O
regions	O
required	O
for	O
maximal	O
expression	O
.	O

We	O
have	O
examined	O
the	O
DRA	O
promoter	O
for	O
protein-DNA	O
interactions	O
in	O
the	O
intact	O
cell	O
,	O
which	O
may	B-SPECULATION
mediate	I-SPECULATION
transcriptional	I-SPECULATION
activation	I-SPECULATION
.	O

Using	O
in	O
vivo	O
genomic	O
footprinting	O
we	O
identified	O
interactions	O
in	O
B-cell	O
lines	O
at	O
the	O
octamer	O
site	O
and	O
the	O
Y	O
,	O
X1	O
,	O
and	O
X2	O
boxes	O
.	O

Class	O
II	O
antigen	O
expressing	O
T-cell	O
lines	O
maintained	O
contacts	O
identical	O
to	O
B-cell	O
lines	O
,	O
while	O
class	O
II-negative	O
T-cell	O
lines	O
exhibited	O
no	B-NEGATION
interactions	I-NEGATION
.	O

In	O
lymphoid	O
cell	O
lines	O
,	O
the	O
octamer	O
site	O
is	O
occupied	O
and	O
required	O
for	O
maximal	O
expression	O
.	O

This	O
is	O
most	O
likely	B-SPECULATION
due	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
presence	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
lymphoid-specific	I-SPECULATION
OTF-2	I-SPECULATION
factor	I-SPECULATION
.	O

In	O
contrast	O
,	O
the	O
class	O
II-positive	O
nonlymphoid	O
glioblastoma	O
cell	O
line	O
does	O
not	B-NEGATION
exhibit	I-NEGATION
interactions	I-NEGATION
at	I-NEGATION
the	I-NEGATION
octamer	I-NEGATION
site	I-NEGATION
despite	O
the	O
presence	O
of	O
the	O
ubiquitous	O
OTF-1	O
factor	O
and	O
an	O
open	O
binding	O
site	O
.	O

Thus	O
,	O
the	O
DRA	O
promoter	O
discriminates	O
against	O
OTF-1	O
activation	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
in	O
the	O
glioblastoma	O
line	O
.	O

Interferon	O
gamma	O
induces	O
class	O
II	O
expression	O
in	O
this	O
glioblastoma	O
cell	O
line	O
and	O
,	O
in	O
parallel	O
,	O
up-regulates	O
X1	O
and	O
X2	O
box	O
protein-DNA	O
interactions	O
,	O
while	O
all	O
other	O
interactions	O
remain	O
unchanged	O
.	O

These	O
results	O
suggest	B-SPECULATION
that	I-SPECULATION
interferon	I-SPECULATION
gamma	I-SPECULATION
functions	I-SPECULATION
on	I-SPECULATION
a	I-SPECULATION
poised	I-SPECULATION
promoter	I-SPECULATION
by	I-SPECULATION
altering	I-SPECULATION
weak	I-SPECULATION
,	I-SPECULATION
nonproductive	I-SPECULATION
interactions	I-SPECULATION
at	I-SPECULATION
the	I-SPECULATION
X	I-SPECULATION
boxes	I-SPECULATION
to	I-SPECULATION
strong	I-SPECULATION
interactions	I-SPECULATION
.	O

These	O
findings	O
provide	O
direct	O
in	O
vivo	O
evidence	O
to	O
strongly	O
suggest	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
modulation	I-SPECULATION
of	I-SPECULATION
X1	I-SPECULATION
and	I-SPECULATION
X2	I-SPECULATION
interactions	I-SPECULATION
is	I-SPECULATION
an	I-SPECULATION
important	I-SPECULATION
constituent	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
interferon	I-SPECULATION
gamma	I-SPECULATION
induction	I-SPECULATION
pathway	I-SPECULATION
.	O

Simple	O
derivation	O
of	O
TFIID-dependent	O
RNA	O
polymerase	O
II	O
transcription	O
systems	O
from	O
Schizosaccharomyces	O
pombe	O
and	O
other	O
organisms	O
,	O
and	O
factors	O
required	O
for	O
transcriptional	O
activation	O
.	O

Resolution	O
of	O
whole	O
cell	O
extract	O
through	O
two	O
chromatographic	O
steps	O
yields	O
a	O
single	O
protein	O
fraction	O
requiring	O
only	O
the	O
addition	O
of	O
TFIID	O
for	O
the	O
initiation	O
of	O
transcription	O
at	O
RNA	O
polymerase	O
II	O
promoters	O
.	O

This	O
approach	O
allows	O
the	O
convenient	O
generation	O
of	O
RNA	O
polymerase	O
II	O
transcription	O
systems	O
from	O
Saccharomyces	O
cerevisiae	O
,	O
human	O
lymphocytes	O
,	O
and	O
Schizosaccharomyces	O
pombe	O
.	O

TFIIDs	O
from	O
all	O
three	O
organisms	O
are	O
interchangeable	O
among	O
all	O
three	O
systems	O
.	O

The	O
S.	O
cerevisiae	O
and	O
Sch.	O
pombe	O
systems	O
support	O
effects	O
of	O
acidic	O
activator	O
proteins	O
,	O
provided	O
a	O
further	O
protein	O
fraction	O
from	O
S.	O
cerevisiae	O
is	O
supplied	O
.	O

This	O
further	O
fraction	O
is	O
distinct	O
from	O
the	O
mediator	O
of	O
transcriptional	O
activation	O
described	O
previously	O
and	O
represents	O
a	O
second	O
component	O
in	O
addition	O
to	O
general	O
initiation	O
factors	O
that	O
may	B-SPECULATION
facilitate	I-SPECULATION
a	I-SPECULATION
response	I-SPECULATION
to	I-SPECULATION
acidic	I-SPECULATION
activators	I-SPECULATION
.	O

NF-kappa	O
B-dependent	O
induction	O
of	O
the	O
NF-kappa	O
B	O
p50	O
subunit	O
gene	O
promoter	O
underlies	O
self-perpetuation	O
of	O
human	O
immunodeficiency	O
virus	O
transcription	O
in	O
monocytic	O
cells	O
.	O

The	O
molecular	O
mechanisms	O
underlying	O
the	O
sustained	O
nuclear	O
translocation	O
of	O
NF-kappa	O
B	O
observed	O
in	O
U937	O
monocytic	O
cells	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
were	O
studied	O
.	O

The	O
activity	O
of	O
the	O
promoter	O
regulating	O
the	O
synthesis	O
of	O
the	O
p105	O
precursor	O
of	O
the	O
NF-kappa	O
B	O
p50	O
subunit	O
was	O
enhanced	O
in	O
these	O
cells	O
.	O

Deletions	O
in	O
this	O
promoter	O
indicated	B-SPECULATION
that	I-SPECULATION
this	I-SPECULATION
upregulation	I-SPECULATION
was	I-SPECULATION
mediated	I-SPECULATION
through	I-SPECULATION
the	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
-	I-SPECULATION
but	I-SPECULATION
not	B-NEGATION
the	I-NEGATION
AP-1-binding	I-NEGATION
motif	I-NEGATION
,	O
by	O
bona	O
fide	O
p50	O
/	O
p65	O
heterodimers	O
.	O

Analysis	O
of	O
cytosolic	O
extracts	O
indicated	B-SPECULATION
that	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
levels	I-SPECULATION
were	I-SPECULATION
increased	I-SPECULATION
in	I-SPECULATION
HIV-infected	I-SPECULATION
cells	I-SPECULATION
.	O

In	O
contrast	O
to	O
the	O
transient	O
NF-kappa	O
B	O
activation	O
induced	O
by	O
phorbol	O
ester	O
,	O
the	O
permanent	O
NF-kappa	O
B	O
translocation	O
induced	O
by	O
HIV	O
infection	O
was	O
not	B-NEGATION
dependent	I-NEGATION
on	I-NEGATION
PKC	I-NEGATION
isoenzymes	I-NEGATION
alpha	I-NEGATION
and	I-NEGATION
beta	I-NEGATION
as	O
shown	O
by	O
the	O
use	O
of	O
a	O
specific	O
inhibitor	O
(	O
GF	O
109203X	O
)	O
.	O

These	O
observations	O
indicate	B-SPECULATION
that	I-SPECULATION
during	I-SPECULATION
chronic	I-SPECULATION
HIV	I-SPECULATION
infection	I-SPECULATION
of	I-SPECULATION
U937	I-SPECULATION
cells	I-SPECULATION
,	I-SPECULATION
continuous	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
(	I-SPECULATION
p50	I-SPECULATION
/	I-SPECULATION
p65	I-SPECULATION
)	I-SPECULATION
translocation	I-SPECULATION
results	I-SPECULATION
in	I-SPECULATION
p105	I-SPECULATION
promoter	I-SPECULATION
upregulation	I-SPECULATION
with	I-SPECULATION
subsequent	I-SPECULATION
cytosolic	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
accumulation	I-SPECULATION
,	I-SPECULATION
ready	I-SPECULATION
for	I-SPECULATION
further	I-SPECULATION
translocation	I-SPECULATION
.	O

This	O
HIV-mediated	O
mechanism	O
results	O
in	O
a	O
self-perpetuating	O
loop	O
of	O
NF-kappa	O
B	O
production	O
.	O

The	O
development	O
of	O
functionally	O
responsive	O
T	O
cells	O
.	O

The	O
work	O
reviewed	O
in	O
this	O
article	O
separates	O
T	O
cell	O
development	O
into	O
four	O
phases	O
.	O

First	O
is	O
an	O
expansion	O
phase	O
prior	O
to	O
TCR	O
rearrangement	O
,	O
which	B-SPECULATION
appears	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
correlated	I-SPECULATION
with	I-SPECULATION
programming	I-SPECULATION
of	I-SPECULATION
at	I-SPECULATION
least	I-SPECULATION
some	I-SPECULATION
response	I-SPECULATION
genes	I-SPECULATION
for	I-SPECULATION
inducibility	I-SPECULATION
.	O

This	O
phase	O
can	B-SPECULATION
occur	I-SPECULATION
to	I-SPECULATION
some	I-SPECULATION
extent	I-SPECULATION
outside	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
thymus	I-SPECULATION
.	O

However	O
,	O
the	O
profound	O
T	O
cell	O
deficit	O
of	O
nude	O
mice	O
indicates	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
thymus	I-SPECULATION
is	I-SPECULATION
by	I-SPECULATION
far	I-SPECULATION
the	I-SPECULATION
most	I-SPECULATION
potent	I-SPECULATION
site	I-SPECULATION
for	I-SPECULATION
inducing	I-SPECULATION
the	I-SPECULATION
expansion	I-SPECULATION
per	I-SPECULATION
se	I-SPECULATION
,	O
even	O
if	O
other	O
sites	O
can	O
induce	O
some	O
response	O
acquisition	O
.	O

Second	O
is	O
a	O
controlled	O
phase	O
of	O
TCR	O
gene	O
rearrangement	O
.	O

The	O
details	O
of	O
the	O
regulatory	O
mechanism	O
that	O
selects	O
particular	O
loci	O
for	O
rearrangement	O
are	O
still	O
not	B-NEGATION
known	I-NEGATION
.	O

It	O
seems	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
rearrangement	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
TCR	I-SPECULATION
gamma	I-SPECULATION
loci	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
gamma	I-SPECULATION
delta	I-SPECULATION
lineage	I-SPECULATION
,	O
and	O
it	O
is	O
may	B-SPECULATION
not	I-SPECULATION
always	I-SPECULATION
take	I-SPECULATION
place	I-SPECULATION
at	I-SPECULATION
a	I-SPECULATION
developmental	I-SPECULATION
stage	I-SPECULATION
strictly	I-SPECULATION
equivalent	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
rearrangement	I-SPECULATION
of	I-SPECULATION
TCR	I-SPECULATION
beta	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
alpha	I-SPECULATION
beta	I-SPECULATION
lineage	I-SPECULATION
not	B-SPECULATION
clear	I-SPECULATION
just	I-SPECULATION
how	I-SPECULATION
early	I-SPECULATION
the	I-SPECULATION
two	I-SPECULATION
lineages	I-SPECULATION
diverge	I-SPECULATION
.	O

In	O
the	O
TCR	O
alpha	O
beta	O
lineage	O
,	O
however	O
,	O
the	O
final	O
gene	O
rearrangement	O
events	O
are	O
accompanied	O
by	O
rapid	O
proliferation	O
and	O
an	O
interruption	O
in	O
cellular	O
response	O
gene	O
inducibility	O
.	O

The	O
loss	O
of	O
conventional	O
responsiveness	O
is	O
probably	B-SPECULATION
caused	I-SPECULATION
by	I-SPECULATION
alterations	I-SPECULATION
at	I-SPECULATION
the	I-SPECULATION
level	I-SPECULATION
of	I-SPECULATION
signaling	I-SPECULATION
,	O
and	O
may	B-SPECULATION
be	I-SPECULATION
a	I-SPECULATION
manifestation	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
physiological	I-SPECULATION
state	I-SPECULATION
that	I-SPECULATION
is	I-SPECULATION
a	I-SPECULATION
precondition	I-SPECULATION
for	I-SPECULATION
selection	I-SPECULATION
.	O

Third	O
is	O
the	O
complex	O
process	O
of	O
selection	O
.	O

Whereas	O
peripheral	O
T	O
cells	O
can	O
undergo	O
forms	O
of	O
positive	O
selection	O
(	O
by	O
antigen-driven	O
clonal	O
expansion	O
)	O
and	O
negative	O
selection	O
(	O
by	O
abortive	O
stimulation	O
leading	O
to	O
anergy	O
or	O
death	O
)	O
,	O
neither	B-NEGATION
is	I-NEGATION
exactly	I-NEGATION
the	I-NEGATION
same	I-NEGATION
phenomenon	I-NEGATION
that	I-NEGATION
occurs	I-NEGATION
in	I-NEGATION
the	I-NEGATION
thymic	I-NEGATION
cortex	I-NEGATION
.	O

Negative	B-SPECULATION
selection	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
cortex	I-SPECULATION
appears	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
a	I-SPECULATION
suicidal	I-SPECULATION
inversion	I-SPECULATION
of	I-SPECULATION
antigen	I-SPECULATION
responsiveness	I-SPECULATION
:	O
instead	B-NEGATION
of	I-NEGATION
turning	I-NEGATION
on	I-NEGATION
IL-2	I-NEGATION
expression	I-NEGATION
,	O
the	O
activated	O
cell	O
destroys	O
its	O
own	O
chromatin	O
.	O

The	B-NEGATION
genes	I-NEGATION
that	I-NEGATION
need	I-NEGATION
to	I-NEGATION
be	I-NEGATION
induced	I-NEGATION
for	I-NEGATION
this	I-NEGATION
response	I-NEGATION
are	I-NEGATION
not	I-NEGATION
yet	I-NEGATION
identified	I-NEGATION
,	O
but	O
it	O
is	O
unquestionably	O
a	O
form	O
of	O
activation	O
.	O

It	O
is	O
interesting	O
that	O
in	O
humans	O
and	O
rats	O
,	O
cortical	O
thymocytes	O
undergoing	O
negative	O
selection	O
can	O
still	O
induce	O
IL-2R	O
alpha	O
expression	O
and	O
even	O
be	O
rescued	O
in	O
vitro	O
,	O
if	O
exogenous	O
IL-2	O
is	O
provided	O
.	O

Perhaps	B-SPECULATION
murine	I-SPECULATION
thymocytes	I-SPECULATION
are	I-SPECULATION
denied	I-SPECULATION
this	I-SPECULATION
form	I-SPECULATION
of	I-SPECULATION
rescue	I-SPECULATION
because	B-SPECULATION
they	I-SPECULATION
shut	I-SPECULATION
off	I-SPECULATION
IL-2R	I-SPECULATION
beta	I-SPECULATION
chain	I-SPECULATION
expression	I-SPECULATION
at	I-SPECULATION
an	I-SPECULATION
earlier	I-SPECULATION
stage	I-SPECULATION
or	I-SPECULATION
because	I-SPECULATION
they	I-SPECULATION
(	O
cf	O
.	O
may	B-SPECULATION
be	I-SPECULATION
uncommonly	I-SPECULATION
Bcl-2	I-SPECULATION
deficient	I-SPECULATION
.	O

Sentman	O
et	O
al.	O
,	O
1991	O
;	O
Strasser	O
et	O
al.	O
,	O
1991	O
)	O
.	O

Even	O
so	O
,	O
medullary	O
thymocytes	O
remain	O
at	O
least	O
partially	O
susceptible	O
to	O
negative	O
selection	O
even	O
as	O
they	O
continue	O
to	O
mature	O
.	O

SRC-related	O
proto-oncogenes	O
and	O
transcription	O
factors	O
in	O
primary	O
human	O
T	O
cells	O
:	O
modulation	O
by	O
cyclosporin	O
A	O
and	O
FK506	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
induces	O
transcription	O
of	O
genes	O
encoding	O
for	O
lymphokines	O
.	O

Interleukin-2	O
(	O
IL-2	O
)	O
gene	O
expression	O
is	O
controlled	O
transcriptionally	O
by	O
the	O
cooperative	O
activity	O
of	O
specific	O
trans-activating	O
factors	O
that	O
bind	O
to	O
the	O
IL-2	O
enhancer	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
inhibit	O
the	O
production	O
of	O
IL-2	O
in	O
T	O
lymphocytes	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

A	O
member	O
of	O
the	O
src	O
gene	O
family	O
,	O
the	O
lymphocyte-specific	O
protein	O
tyrosine	O
kinase	O
,	O
p56lck	O
,	O
has	O
been	O
implicated	O
in	O
IL-2	O
production	O
.	O

CsA	O
was	O
found	O
not	B-NEGATION
to	I-NEGATION
inhibit	I-NEGATION
lck	I-NEGATION
gene	I-NEGATION
expression	I-NEGATION
,	O
nor	B-NEGATION
the	I-NEGATION
activity	I-NEGATION
of	I-NEGATION
the	I-NEGATION
lck	I-NEGATION
gene	I-NEGATION
product	I-NEGATION
.	O

However	O
,	O
CsA	O
and	O
FK506	O
inhibit	O
the	O
appearance	O
of	O
DNA	O
binding	O
activity	O
of	O
factors	O
that	O
bind	O
to	O
the	O
NF-AT	O
and	O
AP-1	O
sites	O
in	O
the	O
IL-2	O
enhancer	O
.	O

Since	O
the	O
induction	O
of	O
NF-AT	O
and	O
AP-1	O
is	O
induced	O
by	O
the	O
same	O
stimuli	O
that	O
stimulate	O
IL-2	O
production	O
,	O
these	O
results	O
indicate	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
immunosuppressant	I-SPECULATION
action	I-SPECULATION
of	I-SPECULATION
CsA	I-SPECULATION
and	I-SPECULATION
FK506	I-SPECULATION
is	I-SPECULATION
exerted	I-SPECULATION
at	I-SPECULATION
the	I-SPECULATION
level	I-SPECULATION
of	I-SPECULATION
these	I-SPECULATION
trans-activating	I-SPECULATION
factors	I-SPECULATION
.	O

TAR-independent	O
transactivation	O
by	O
Tat	O
in	O
cells	O
derived	O
from	O
the	O
CNS	O
:	O
a	O
novel	O
mechanism	O
of	O
HIV-1	O
gene	O
regulation	O
.	O

The	O
Tat	O
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
essential	O
for	O
productive	O
infection	O
and	O
is	O
a	O
potential	O
target	O
for	O
antiviral	O
therapy	O
.	O

Tat	O
,	O
a	O
potent	O
activator	O
of	O
HIV-1	O
gene	O
expression	O
,	O
serves	O
to	O
greatly	O
increase	O
the	O
rate	O
of	O
transcription	O
directed	O
by	O
the	O
viral	O
promoter	O
.	O

This	O
induction	O
,	O
which	B-SPECULATION
seems	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
an	I-SPECULATION
important	I-SPECULATION
component	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
progression	I-SPECULATION
of	I-SPECULATION
acquired	I-SPECULATION
immune	I-SPECULATION
deficiency	I-SPECULATION
syndrome	I-SPECULATION
(	I-SPECULATION
AIDS	I-SPECULATION
)	I-SPECULATION
,	O
may	B-SPECULATION
be	I-SPECULATION
due	I-SPECULATION
to	I-SPECULATION
increased	B-SPECULATION
transcriptional	I-SPECULATION
initiation	I-SPECULATION
,	I-SPECULATION
increased	I-SPECULATION
transcriptional	I-SPECULATION
elongation	I-SPECULATION
,	I-SPECULATION
or	I-SPECULATION
a	I-SPECULATION
combination	I-SPECULATION
of	I-SPECULATION
these	I-SPECULATION
processes	I-SPECULATION
.	O

Much	O
attention	O
has	O
been	O
focused	O
on	O
the	O
interaction	O
of	O
Tat	O
with	O
a	O
specific	O
RNA	O
target	O
termed	O
TAR	O
(	O
transactivation	O
responsive	O
)	O
which	O
is	O
present	O
in	O
the	O
leader	O
sequence	O
of	O
all	O
HIV-1	O
mRNAs	O
.	O

This	B-SPECULATION
interaction	I-SPECULATION
is	I-SPECULATION
believed	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
an	I-SPECULATION
important	I-SPECULATION
component	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
mechanism	I-SPECULATION
of	I-SPECULATION
transactivation	I-SPECULATION
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
in	O
certain	O
CNS-derived	O
cells	O
Tat	O
is	O
capable	O
of	O
activating	O
HIV-1	O
through	O
a	O
TAR-independent	O
pathway	O
.	O

A	O
Tat-responsive	O
element	O
is	O
found	O
upstream	O
within	O
the	O
viral	O
promoter	O
that	O
in	O
glial-derived	O
cell	O
lines	O
allows	O
transactivation	O
in	O
the	O
absence	O
of	O
TAR	O
.	O

Deletion	O
mapping	O
and	O
hybrid	O
promoter	O
constructs	O
demonstrate	O
that	O
the	O
newly	O
identified	O
Tat-responsive	O
element	O
corresponds	O
to	O
a	O
sequence	O
within	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
previously	O
identified	O
as	O
the	O
HIV-1	O
enhancer	O
,	O
or	O
NF-kappa	O
B	O
domain	O
.	O

DNA	O
band-shift	O
analysis	O
reveals	O
NF-kappa	O
B	O
binding	O
activity	O
in	O
glial	O
cells	O
that	O
differs	O
from	O
that	O
present	O
in	O
T	O
lymphoid	O
cells	O
.	O

Further	O
,	O
we	O
observe	O
that	O
TAR-deleted	O
mutants	O
of	O
HIV-1	O
demonstrate	O
normal	O
late	O
gene	O
expression	O
in	O
glial	O
cells	O
as	O
evidenced	O
by	O
syncytia	O
formation	O
and	O
production	O
of	O
viral	O
p24	O
antigen.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Bcl-2	O
:	O
a	O
repressor	O
of	O
lymphocyte	O
death	O
.	O

The	O
genes	O
and	O
mechanisms	O
that	O
control	O
programmed	O
cell	O
death	O
are	O
currently	O
the	O
subject	O
of	O
intense	O
study	O
.	O

The	B-SPECULATION
bcl-2	I-SPECULATION
gene	I-SPECULATION
,	I-SPECULATION
a	I-SPECULATION
repressor	I-SPECULATION
of	I-SPECULATION
lymphocyte	I-SPECULATION
death	I-SPECULATION
,	I-SPECULATION
is	I-SPECULATION
perhaps	I-SPECULATION
the	I-SPECULATION
best	I-SPECULATION
understood	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
programmed	I-SPECULATION
cell	I-SPECULATION
death	I-SPECULATION
associated	I-SPECULATION
genes	I-SPECULATION
.	O

Here	O
,	O
Stanley	O
Korsmeyer	O
provides	O
a	O
brief	O
overview	O
of	O
bcl-2	O
,	O
concentrating	O
on	O
its	O
roles	O
in	O
B	O
-	O
and	O
T-cell	O
development	O
and	O
in	O
oncogenesis	O
.	O

Mitogen	O
stimulation	O
of	O
T-cells	O
increases	O
c-Fos	O
and	O
c-Jun	O
protein	O
levels	O
,	O
AP-1	O
binding	O
and	O
AP-1	O
transcriptional	O
activity	O
.	O

We	O
have	O
analysed	O
the	O
effect	O
of	O
mitogenic	O
lectins	O
on	O
c-Fos	O
and	O
c-Jun	O
protein	O
levels	O
as	O
well	O
as	O
on	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
binding	O
and	O
enhancer	O
activity	O
in	O
Jurkat	O
T-cells	O
.	O

Both	O
c-Fos	O
and	O
c-Jun	O
protein	O
levels	O
were	O
increased	O
after	O
Con	O
A	O
and	O
PHA	O
stimulation	O
.	O

Since	O
T-cell	O
stimulation	O
increases	O
both	O
intracellular	O
Ca2	O
+	O
and	O
cAMP	O
levels	O
and	O
activates	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
the	O
possible	B-SPECULATION
involvement	I-SPECULATION
of	I-SPECULATION
these	I-SPECULATION
intracellular	I-SPECULATION
messengers	I-SPECULATION
in	I-SPECULATION
c-Fos	I-SPECULATION
and	I-SPECULATION
c-Jun	I-SPECULATION
induction	I-SPECULATION
was	O
tested	O
.	O

PMA	O
,	O
which	O
directly	O
activates	O
PKC	O
,	O
mimicked	O
the	O
effect	O
of	O
the	O
lectins	O
on	O
c-Fos	O
and	O
c-Jun	O
,	O
but	O
elevation	O
of	O
either	O
intracellular	O
Ca2	O
+	O
or	O
cAMP	O
levels	O
had	O
little	O
or	O
no	B-NEGATION
effect	I-NEGATION
.	O

The	O
mitogen-induced	O
increase	O
of	O
c-Fos	O
and	O
c-Jun	O
immunoreactivity	O
was	O
inhibited	O
by	O
H-7	O
,	O
a	O
kinase	O
inhibitor	O
with	O
relatively	O
high	O
specificity	O
for	O
PKC	O
,	O
and	O
less	O
efficiently	O
by	O
H-8	O
,	O
a	O
structurally	O
related	O
kinase	O
inhibitor	O
less	O
active	O
on	O
PKC	O
,	O
but	O
more	O
active	O
on	O
cyclic	O
nucleotide-dependent	O
kinases	O
.	O

Con	O
A	O
stimulation	O
was	O
found	O
to	O
increase	O
both	O
binding	O
of	O
AP-1	O
to	O
the	O
AP-1	O
consensus	O
sequence	O
,	O
TRE	O
,	O
and	O
AP-1	O
enhancer	O
activity	O
,	O
in	O
Jurkat	O
cells	O
.	O

PMA	O
was	O
also	O
found	O
to	O
increase	O
the	O
AP-1	O
enhancer	O
activity	O
,	O
whereas	O
elevation	O
of	O
Ca2	O
+	O
or	O
cAMP	O
had	O
only	O
minor	O
effects	O
.	O

We	O
conclude	O
that	O
stimulation	O
with	O
mitogenic	O
lectins	O
is	O
sufficient	O
to	O
increase	O
both	O
c-Fos	O
and	O
c-Jun	O
protein	O
levels	O
,	O
AP-1	O
binding	O
and	O
AP-1	O
enhancer	O
activity	O
in	O
Jurkat	O
cells	O
and	O
that	O
they	O
act	O
via	O
mechanisms	O
that	O
could	B-SPECULATION
involve	I-SPECULATION
the	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
PKC	I-SPECULATION
.	O

Functional	O
interaction	O
between	O
the	O
two	O
zinc	O
finger	O
domains	O
of	O
the	O
v-erb	O
A	O
oncoprotein	O
.	O

The	O
v-erb	O
A	O
oncogene	O
of	O
avian	O
erythroblastosis	O
virus	O
is	O
a	O
mutated	O
and	O
virally	O
transduced	O
copy	O
of	O
a	O
host	O
cell	O
gene	O
encoding	O
a	O
thyroid	O
hormone	O
receptor	O
.	O

The	O
protein	O
expressed	O
by	O
the	O
v-erb	O
A	O
oncogene	O
binds	O
to	O
DNA	O
and	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
both	O
the	O
thyroid	O
hormone	O
receptor	O
and	O
the	O
closely	O
related	O
retinoic	O
acid	O
receptor	O
.	O

The	O
v-erb	O
A	O
protein	O
has	O
sustained	O
two	O
amino	O
acid	O
alterations	O
within	O
its	O
DNA-binding	O
domain	O
relative	O
to	O
that	O
of	O
c-erb	O
A	O
,	O
one	O
of	O
which	O
,	O
at	O
serine	O
61	O
,	O
is	O
known	O
to	O
be	O
important	O
for	O
v-erb	O
A	O
function	O
in	O
the	O
neoplastic	O
cell	O
.	O

We	O
report	O
here	O
that	O
the	O
second	O
alteration	O
,	O
at	O
threonine	O
78	O
,	O
also	O
plays	O
an	O
important	O
,	O
although	O
more	O
indirect	O
,	O
role	O
:	O

alteration	O
of	O
the	O
sequence	O
at	O
threonine	O
78	O
such	O
that	O
it	O
resembles	O
that	O
of	O
c-erb	O
A	O
can	O
act	O
as	O
an	O
intragenic	O
suppressor	O
and	O
can	O
partially	O
restore	O
function	O
to	O
a	O
v-erb	O
A	O
protein	O
rendered	O
defective	O
due	O
to	O
a	O
mutation	O
at	O
position	O
61	O
.	O

Threonine	O
78	O
lies	O
within	O
the	O
D-box	O
of	O
the	O
v-erb	O
A	O
protein	O
,	O
a	B-SPECULATION
region	I-SPECULATION
thought	I-SPECULATION
to	I-SPECULATION
mediate	I-SPECULATION
receptor-receptor	I-SPECULATION
dimerizations	I-SPECULATION
,	O
and	O
is	O
not	B-NEGATION
in	I-NEGATION
physical	I-NEGATION
proximity	I-NEGATION
to	I-NEGATION
the	I-NEGATION
serine	I-NEGATION
at	I-NEGATION
position	I-NEGATION
61	I-NEGATION
.	O

It	O
therefore	O
appears	B-SPECULATION
that	I-SPECULATION
an	I-SPECULATION
indirect	I-SPECULATION
interaction	I-SPECULATION
occurs	I-SPECULATION
between	I-SPECULATION
these	I-SPECULATION
two	I-SPECULATION
sites	I-SPECULATION
and	I-SPECULATION
that	I-SPECULATION
this	I-SPECULATION
interaction	I-SPECULATION
is	I-SPECULATION
crucial	I-SPECULATION
for	I-SPECULATION
v-erb	I-SPECULATION
A	I-SPECULATION
function	I-SPECULATION
.	O

Pax-5	O
encodes	O
the	O
transcription	O
factor	O
BSAP	O
and	O
is	O
expressed	O
in	O
B	O
lymphocytes	O
,	O
the	O
developing	O
CNS	O
,	O
and	O
adult	O
testis	O
.	O

BSAP	O
has	O
been	O
identified	O
previously	O
as	O
a	O
transcription	O
factor	O
that	O
is	O
expressed	O
at	O
early	O
,	O
but	O
not	B-NEGATION
late	I-NEGATION
,	O
stages	O
of	O
B-cell	O
differentiation	O
.	O

Biochemical	O
purification	O
and	O
cDNA	O
cloning	O
has	O
now	O
revealed	O
that	O
BSAP	O
belongs	O
to	O
the	O
family	O
of	O
paired	O
domain	O
proteins	O
.	O

BSAP	O
is	O
encoded	O
by	O
the	O
Pax-5	O
gene	O
and	O
has	O
been	O
highly	O
conserved	O
between	O
human	O
and	O
mouse	O
.	O

An	O
intact	O
paired	O
domain	O
was	O
shown	O
to	O
be	O
both	O
necessary	O
and	O
sufficient	O
for	O
DNA	O
binding	O
of	O
BSAP	O
.	O

Binding	O
studies	O
with	O
several	O
BSAP	O
recognition	O
sequences	O
demonstrated	O
that	O
the	O
sequence	O
specificity	O
of	O
BSAP	O
differs	O
from	O
that	O
of	O
the	O
distantly	O
related	O
paired	O
domain	O
protein	O
Pax-1	O
.	O

During	O
embryogenesis	O
,	O
the	O
BSAP	O
gene	O
is	O
transiently	O
expressed	O
in	O
the	O
mesencephalon	O
and	O
spinal	O
cord	O
with	O
a	O
spatial	O
and	O
temporal	O
expression	O
pattern	O
that	O
is	O
distinct	O
from	O
that	O
of	O
other	O
Pax	O
genes	O
in	O
the	O
developing	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Later	O
,	O
the	O
expression	O
of	O
the	O
BSAP	O
gene	O
shifts	O
to	O
the	O
fetal	O
liver	O
where	O
it	O
correlates	O
with	O
the	O
onset	O
of	O
B	O
lymphopoiesis	O
.	O

BSAP	O
expression	O
persists	O
in	O
B	O
lymphocytes	O
and	O
is	O
also	O
seen	O
in	O
the	O
testis	O
of	O
the	O
adult	O
mouse	O
.	O

All	O
of	O
this	O
evidence	O
indicates	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
transcription	I-SPECULATION
factor	I-SPECULATION
BSAP	I-SPECULATION
may	B-SPECULATION
not	I-SPECULATION
only	I-SPECULATION
play	I-SPECULATION
an	I-SPECULATION
important	I-SPECULATION
role	I-SPECULATION
in	I-SPECULATION
B-cell	I-SPECULATION
differentiation	I-SPECULATION
but	I-SPECULATION
also	I-SPECULATION
in	I-SPECULATION
neural	I-SPECULATION
development	I-SPECULATION
and	I-SPECULATION
spermatogenesis	I-SPECULATION
.	O

Okadaic	O
acid	O
is	O
a	O
potent	O
inducer	O
of	O
AP-1	O
,	O
NF-kappa	O
B	O
,	O
and	O
tumor	O
necrosis	O
factor-alpha	O
in	O
human	O
B	O
lymphocytes	O
.	O

Treatment	O
of	O
human	O
B	O
lymphocytes	O
with	O
an	O
optimal	O
concentration	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	O
1	O
and	O
2A	O
,	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factor	O
,	O
AP-1	O
and	O
a	O
marked	O
increase	O
in	O
NF-kappa	O
B	O
levels	O
.	O

In	O
contrast	O
,	O
no	B-NEGATION
effect	I-NEGATION
on	I-NEGATION
the	I-NEGATION
levels	I-NEGATION
of	I-NEGATION
the	I-NEGATION
octamer	I-NEGATION
binding	I-NEGATION
proteins	I-NEGATION
,	I-NEGATION
Oct-1	I-NEGATION
or	I-NEGATION
Oct-2	I-NEGATION
,	O
were	O
found	O
.	O

Since	O
both	O
AP-1	O
and	O
NF-kappa	O
B	O
have	O
been	O
reported	O
to	O
be	O
important	O
in	O
the	O
induction	O
of	O
the	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
gene	O
we	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
on	O
TNF-alpha	O
mRNA	O
levels	O
.	O

Treatment	O
with	O
okadaic	O
acid	O
resulted	O
in	O
a	O
striking	O
increase	O
in	O
TNF-alpha	O
mRNA	O
transcripts	O
within	O
1	O
h	O
of	O
stimulation	O
and	O
large	O
amounts	O
of	O
TNF-alpha	O
were	O
released	O
into	O
the	O
culture	O
media	O
.	O

Although	O
okadaic	O
acid	O
provides	O
a	O
potent	O
inductive	O
signal	O
for	O
AP-1	O
and	O
NF-kappa	O
B	O
it	O
did	O
not	B-NEGATION
induce	I-NEGATION
either	I-NEGATION
B	I-NEGATION
cell	I-NEGATION
proliferation	I-NEGATION
or	I-NEGATION
immunoglobulin	I-NEGATION
secretion	I-NEGATION
.	O

A	O
novel	O
Ets-related	O
transcription	O
factor	O
,	O
Elf-1	O
,	O
binds	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
regulatory	O
elements	O
that	O
are	O
required	O
for	O
inducible	O
trans	O
activation	O
in	O
T	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
HIV-2	O
are	O
structurally	O
related	O
retroviruses	O
which	O
both	O
cause	O
AIDS	O
in	O
humans	O
.	O

Although	O
both	O
viruses	O
establish	O
latency	O
in	O
quiescent	O
human-peripheral-blood	O
T	O
cells	O
,	O
the	O
asymptomatic	O
phase	O
of	O
HIV-2	O
infection	O
may	B-SPECULATION
be	I-SPECULATION
more	I-SPECULATION
prolonged	I-SPECULATION
than	I-SPECULATION
that	I-SPECULATION
of	I-SPECULATION
HIV-1	I-SPECULATION
.	O

The	O
latent	O
phases	O
of	O
both	O
HIV-1	O
and	O
HIV-2	O
infection	O
have	O
been	O
shown	O
to	O
be	O
disrupted	O
by	O
T-cell	O
activation	O
,	O
a	O
process	O
that	O
requires	O
host	O
cell	O
transcription	O
factors	O
.	O

In	O
the	O
case	O
of	O
HIV-1	O
,	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
is	O
sufficient	O
for	O
inducible	O
transcriptional	O
activation	O
.	O

In	O
contrast	O
,	O
factors	O
in	O
addition	O
to	O
NF-kappa	O
B	O
are	O
required	O
to	O
activate	O
HIV-2	O
transcription	O
in	O
infected	O
T	O
cells	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
a	O
novel	O
Ets-related	O
transcription	O
factor	O
,	O
Elf-1	O
,	O
binds	O
specifically	O
to	O
two	O
purine-rich	O
motifs	O
in	O
the	O
HIV-2	O
enhancer	O
.	O

Mutagenesis	O
experiments	O
demonstrated	O
that	O
these	O
Elf-1	O
binding	O
sites	O
are	O
required	O
for	O
induction	O
of	O
HIV-2	O
transcription	O
following	O
T-cell-receptor-mediated	O
T-cell	O
activation	O
.	O

Moreover	O
,	O
Elf-1	O
is	O
the	O
only	O
factor	O
present	O
in	O
activated	O
T-cell	O
nuclear	O
extracts	O
that	O
binds	O
to	O
these	O
sites	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Thus	O
,	O
Elf-1	O
is	O
a	O
novel	O
transcription	O
factor	O
that	B-SPECULATION
appears	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
required	I-SPECULATION
for	I-SPECULATION
the	I-SPECULATION
T-cell-receptor-mediated	I-SPECULATION
trans	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
HIV-2	I-SPECULATION
gene	I-SPECULATION
expression	I-SPECULATION
.	O

These	O
results	O
may	B-SPECULATION
explain	I-SPECULATION
differences	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
clinical	I-SPECULATION
spectra	I-SPECULATION
of	I-SPECULATION
diseases	I-SPECULATION
caused	I-SPECULATION
by	I-SPECULATION
HIV-1	I-SPECULATION
and	I-SPECULATION
HIV-2	I-SPECULATION
and	O
may	B-SPECULATION
also	I-SPECULATION
have	I-SPECULATION
implications	I-SPECULATION
for	I-SPECULATION
the	I-SPECULATION
design	I-SPECULATION
of	I-SPECULATION
therapeutic	I-SPECULATION
approaches	I-SPECULATION
to	I-SPECULATION
HIV-2	I-SPECULATION
infection	I-SPECULATION
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	O
protein	O
inhibits	O
NF-kappa	O
B	O
induction	O
in	O
human	O
T	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
can	O
establish	O
a	O
persistent	O
and	O
latent	O
infection	O
in	O
CD4	O
+	O
T	O
lymphocytes	O
(	O
W.C.Greene	O
,	O
N.Engl.J.	O
Med.324	O
:	O
308-317	O
,	O
1991	O
;	O
S.M.Schnittman	O
,	O
M.C.Psallidopoulos	O
,	O
H.C.	O
Lane	O
,	O
L.Thompson	O
,	O
M.Baseler	O
,	O
F.Massari	O
,	O
C.H.Fox	O
,	O
N.P.Salzman	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
245	O
:	O
305-308	O
,	O
1989	O
)	O
.	O

Production	O
of	O
HIV-1	O
from	O
latently	O
infected	O
cells	O
requires	O
host	O
cell	O
activation	O
by	O
T-cell	O
mitogens	O
(	O
T.Folks	O
,	O
D.M.Powell	O
,	O
M.M.Lightfoote	O
,	O
S.Benn	O
,	O
M.A.	O
Martin	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
231	O
:	O
600-602	O
,	O
1986	O
;	O
D.Zagury	O
,	O
J.	O
Bernard	O
,	O
R.Leonard	O
,	O
R.Cheynier	O
,	O
M.Feldman	O
,	O
P.S.Sarin	O
,	O
and	O
R.C.	O
Gallo	O
,	O
Science	O
231	O
:	O
850-853	O
,	O
1986	O
)	O
.	O

This	O
activation	O
is	O
mediated	O
by	O
the	O
host	O
transcription	O
factor	O
NF-kappa	O
B	O
[	O
G.Nabel	O
and	O
D.Baltimore	O
,	O
Nature	O
(	O
London	O
)	O
326	O
:	O
711-717	O
,	O
1987	O
]	O
.	O

We	O
report	O
here	O
that	O
the	O
HIV-1-encoded	O
Nef	O
protein	O
inhibits	O
the	O
induction	O
of	O
NF-kappa	O
B	O
DNA-binding	O
activity	O
by	O
T-cell	O
mitogens	O
.	O

However	O
,	O
Nef	O
does	O
not	B-NEGATION
affect	I-NEGATION
the	I-NEGATION
DNA-binding	I-NEGATION
activity	I-NEGATION
of	I-NEGATION
other	I-NEGATION
transcription	I-NEGATION
factors	I-NEGATION
implicated	I-NEGATION
in	I-NEGATION
HIV-1	I-NEGATION
regulation	I-NEGATION
,	I-NEGATION
including	I-NEGATION
SP-1	I-NEGATION
,	I-NEGATION
USF	I-NEGATION
,	I-NEGATION
URS	I-NEGATION
,	I-NEGATION
and	I-NEGATION
NF-AT	I-NEGATION
.	O

Additionally	O
,	O
Nef	O
inhibits	O
the	O
induction	O
of	O
HIV-1	O
-	O
and	O
interleukin	O
2-directed	O
gene	O
expression	O
,	O
and	O
the	O
effect	O
on	O
HIV-1	O
transcription	O
depends	O
on	O
an	O
intact	O
NF-kappa	O
B-binding	O
site	O
.	O

These	O
results	O
indicate	B-SPECULATION
that	I-SPECULATION
defective	I-SPECULATION
recruitment	I-SPECULATION
of	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
may	B-SPECULATION
underlie	I-SPECULATION
Nef	I-SPECULATION
'	I-SPECULATION
s	I-SPECULATION
negative	I-SPECULATION
transcriptional	I-SPECULATION
effects	I-SPECULATION
on	I-SPECULATION
the	I-SPECULATION
HIV-1	I-SPECULATION
and	I-SPECULATION
interleukin	I-SPECULATION
2	I-SPECULATION
promoters	I-SPECULATION
.	O

Further	O
evidence	O
suggests	B-SPECULATION
that	I-SPECULATION
Nef	I-SPECULATION
inhibits	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
induction	I-SPECULATION
by	I-SPECULATION
interfering	I-SPECULATION
with	I-SPECULATION
a	I-SPECULATION
signal	I-SPECULATION
derived	I-SPECULATION
from	I-SPECULATION
the	I-SPECULATION
T-cell	I-SPECULATION
receptor	I-SPECULATION
complex	I-SPECULATION
.	O

[	O
Effect	O
of	O
antihypertensive	O
therapy	O
with	O
captopril	O
on	O
gluco	O
-	O
and	O
mineralocorticoid	O
receptors	O
of	O
peripheral	O
blood	O
lymphocytes	O
in	O
hypertensive	O
patients	O
of	O
various	O
age	O
]	O

Binding	O
of	O
3H-dexamethasone	O
and	O
3H-aldosterone	O
by	O
peripheral	O
lymphocyte	O
receptors	O
was	O
investigated	O
in	O
healthy	O
persons	O
and	O
hypertensive	O
patients	O
before	O
and	O
after	O
2-week	O
captopril	O
treatment	O
.	O

The	O
number	O
of	O
glucocorticoid	O
and	O
mineralocorticoid	O
binding	O
sites	O
was	O
increased	O
in	O
hypertensives	O
vs	O
normotensives	O
.	O

The	O
treatment	O
with	O
the	O
ACE	O
inhibitor	O
captopril	O
led	O
to	O
activation	O
of	O
hormone-receptor	O
interactions	O
.	O

There	O
was	O
a	O
more	O
marked	O
rise	O
of	O
the	O
number	O
of	O
receptors	O
in	O
middle-aged	O
(	O
44-55	O
years	O
)	O
hypertensives	O
vs	O
elderly	O
(	O
61-80	O
years	O
)	O
subjects	O
after	O
captopril	O
treatment	O
.	O

Leukotriene	O
B4	O
transcriptionally	O
activates	O
interleukin-6	O
expression	O
involving	O
NK-chi	O
B	O
and	O
NF-IL6	O
.	O

Leukotriene	O
B4	O
(	O
LTB4	O
)	O
is	O
a	O
notable	O
participant	O
in	O
inflammation	O
and	O
chemotaxis	O
.	O

It	O
is	O
,	O
however	O
,	O
still	O
unclear	B-SPECULATION
whether	B-SPECULATION
LTB4	I-SPECULATION
acts	I-SPECULATION
in	I-SPECULATION
this	I-SPECULATION
regard	I-SPECULATION
directly	B-SPECULATION
or	I-SPECULATION
indirectly	I-SPECULATION
by	O
stimulating	O
the	O
release	O
of	O
chemotactic	O
and	O
inflammatory	O
cytokines	O
.	O

Here	O
we	O
report	O
that	O
LTB4	O
induces	O
synthesis	O
of	O
interleukin	O
(	O
IL	O
)-	O
6	O
by	O
human	O
blood	O
monocytes	O
through	O
transcriptional	O
activation	O
of	O
the	O
IL-6	O
gene	O
.	O

We	O
furthermore	O
demonstrate	O
that	O
this	O
process	O
involves	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-chi	O
B	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
of	O
NF-IL6	O
,	O
while	O
the	B-SPECULATION
activity	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
transcription	I-SPECULATION
factor	I-SPECULATION
AP-1	I-SPECULATION
,	I-SPECULATION
shown	I-SPECULATION
to	I-SPECULATION
otherwise	I-SPECULATION
confer	I-SPECULATION
IL-6	I-SPECULATION
inducibility	I-SPECULATION
,	I-SPECULATION
appeared	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
unaffected	I-SPECULATION
by	I-SPECULATION
LTB4	I-SPECULATION
.	O

Involvement	O
of	O
NF-chi	O
B	O
and	O
NF-IL6	O
in	O
induction	O
of	O
IL-6	O
transcription	O
by	O
monocytes	O
was	O
demonstrated	O
using	O
deleted	O
forms	O
of	O
the	O
IL-6	O
promoter	O
.	O

Activation	O
of	O
the	O
IL-6	O
promoter	O
by	O
LTB4	O
was	O
not	O
only	O
associated	O
with	O
accumulation	O
of	O
the	O
respective	O
transcripts	O
but	O
resulted	O
in	O
synthesis	O
of	O
functional	O
IL-6	O
protein	O
as	O
well	O
.	O

In	O
addition	O
,	O
LTB4	O
mediated	O
transactivation	O
of	O
a	O
heterologous	O
promoter	O
construct	O
containing	O
the	O
NF-chi	O
B	O
or	O
the	O
NF-IL6	O
enhancer	O
,	O
but	O
not	B-NEGATION
the	I-NEGATION
AP-1	I-NEGATION
enhancer	I-NEGATION
.	O

The	B-SPECULATION
signaling	I-SPECULATION
events	I-SPECULATION
mediating	I-SPECULATION
this	I-SPECULATION
effect	I-SPECULATION
appeared	I-SPECULATION
to	I-SPECULATION
involve	I-SPECULATION
the	I-SPECULATION
release	I-SPECULATION
of	I-SPECULATION
H2O2	I-SPECULATION
,	O
since	O
LTB4	O
failed	B-NEGATION
to	I-NEGATION
induce	I-NEGATION
NF-chi	I-NEGATION
B	I-NEGATION
or	I-NEGATION
NF-IL6	I-NEGATION
in	I-NEGATION
the	I-NEGATION
presence	I-NEGATION
of	I-NEGATION
the	I-NEGATION
scavenger	I-NEGATION
of	I-NEGATION
H2O2	I-NEGATION
,	I-NEGATION
N-acetyl-L-cysteine	I-NEGATION
.	O

Estrogen	O
binding	O
sites	O
in	O
peripheral	O
blood	O
monocytes	O
and	O
effects	O
of	O
danazol	O
on	O
their	O
sites	O
in	O
vitro	O
.	O

1	O
.	O
This	O
study	O
was	O
designed	O
to	O
investigate	B-SPECULATION
the	I-SPECULATION
presence	I-SPECULATION
of	I-SPECULATION
estrogen	I-SPECULATION
type	I-SPECULATION
I	I-SPECULATION
(	I-SPECULATION
high	I-SPECULATION
affinity	I-SPECULATION
,	I-SPECULATION
low	I-SPECULATION
capacity	I-SPECULATION
)	I-SPECULATION
and	I-SPECULATION
type	I-SPECULATION
II	I-SPECULATION
(	I-SPECULATION
low	I-SPECULATION
affinity	I-SPECULATION
,	I-SPECULATION
high	I-SPECULATION
capacity	I-SPECULATION
)	I-SPECULATION
binding	I-SPECULATION
sites	I-SPECULATION
in	I-SPECULATION
human	I-SPECULATION
peripheral	I-SPECULATION
blood	I-SPECULATION
monocytes	I-SPECULATION
and	I-SPECULATION
the	I-SPECULATION
effects	I-SPECULATION
of	I-SPECULATION
danazol	I-SPECULATION
on	I-SPECULATION
these	I-SPECULATION
sites	I-SPECULATION
.	O

2	O
.	O
These	O
two	O
types	O
of	O
estrogen	O
binding	O
sites	O
existed	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

3	O
.	O
Danazol	O
bound	O
to	O
these	O
sites	O
in	O
high	O
concentration	O
(	O
10	O
(-	O
6	O
)	O
M	O
,	O
clinical	O
serum	O
concentration	O
during	O
danazol	O
therapy	O
)	O
and	O
decreased	O
the	O
number	O
of	O
both	O
sites	O
.	O

4	O
.	O
It	O
is	O
suggested	B-SPECULATION
that	I-SPECULATION
danazol	I-SPECULATION
has	I-SPECULATION
an	I-SPECULATION
anti-estrogenic	I-SPECULATION
action	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
monocytes	I-SPECULATION
through	I-SPECULATION
the	I-SPECULATION
competition	I-SPECULATION
and	I-SPECULATION
suppression	I-SPECULATION
of	I-SPECULATION
estrogen	I-SPECULATION
binding	I-SPECULATION
sites	I-SPECULATION
as	O
seen	O
in	O
the	O
estrogen	O
target	O
organ	O
.	O

[	O
Mechanism	O
of	O
action	O
of	O
steroid	O
hormones	O
.	O
I	O
.	O
Estrogens	O
]	O

The	O
steroid	O
hormone	O
are	O
very	O
versatile	O
molecules	O
:	O

although	O
they	O
are	O
related	O
among	O
them	O
by	O
their	O
chemical	O
structure	O
,	O
they	O
have	O
very	O
diverse	O
functions	O
and	O
including	O
antagonic	O
.	O

Their	O
action	O
mechanism	O
is	O
not	B-NEGATION
completely	I-NEGATION
cleared	I-NEGATION
.	O

The	O
estrogens	O
participate	O
in	O
the	O
regulation	O
of	O
practically	O
all	O
the	O
reproductive	O
and	O
sexual	O
events	O
of	O
the	O
female	O
,	O
although	O
the	O
intracellular	O
actions	O
by	O
which	O
they	O
take	O
place	O
are	O
not	B-NEGATION
well	I-NEGATION
known	I-NEGATION
and	O
the	O
proposed	O
models	O
do	O
not	B-NEGATION
adequately	I-NEGATION
satisfy	I-NEGATION
the	I-NEGATION
questions	I-NEGATION
.	O

Currently	O
it	O
is	O
accepted	O
the	O
existence	O
of	O
a	O
cytoplasmic	O
and	O
/	O
or	O
nuclear	O
receptor	O
,	O
without	B-NEGATION
explaining	I-NEGATION
satisfactorily	I-NEGATION
how	I-NEGATION
the	I-NEGATION
hormones	I-NEGATION
come	I-NEGATION
to	I-NEGATION
the	I-NEGATION
nucleus	I-NEGATION
.	O

The	O
endocrine	O
events	O
that	O
are	O
rapidly	O
expressed	O
(	O
seconds	O
)	O
are	O
due	O
to	O
a	O
possible	B-SPECULATION
interaction	I-SPECULATION
with	I-SPECULATION
cellular	I-SPECULATION
membrane	I-SPECULATION
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
analyze	O
and	O
concilliate	O
the	O
reported	O
data	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
estrogens	O
.	O

Stable	O
expression	O
of	O
transdominant	O
Rev	O
protein	O
in	O
human	O
T	O
cells	O
inhibits	O
human	O
immunodeficiency	O
virus	O
replication	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
Rev	O
protein	O
is	O
essential	O
for	O
viral	O
structural	O
protein	O
expression	O
(	O
Gag	O
,	O
Pol	O
,	O
and	O
Env	O
)	O
and	O
,	O
hence	O
,	O
for	O
viral	O
replication	O
.	O

In	O
transient	O
transfection	O
assays	O
,	O
mutant	O
forms	O
of	O
Rev	O
have	O
been	O
identified	O
that	O
inhibit	O
wild-type	O
Rev	O
activity	O
and	O
therefore	O
suppress	O
viral	O
replication	O
.	O

To	O
determine	O
whether	B-SPECULATION
such	I-SPECULATION
transdominant	I-SPECULATION
Rev	I-SPECULATION
proteins	I-SPECULATION
,	O
T	O
leukemia	O
cell	O
lines	O
were	O
stably	O
transduced	O
with	O
a	O
retroviral	O
vector	O
encoding	O
a	O
transdominant	O
mutant	O
of	O
the	O
Rev	O
protein	O
,	O
M10	O
.	O
could	B-SPECULATION
provide	I-SPECULATION
long-term	I-SPECULATION
protection	I-SPECULATION
against	I-SPECULATION
HIV	I-SPECULATION
infection	I-SPECULATION
without	B-NEGATION
affecting	I-NEGATION
T	I-NEGATION
cell	I-NEGATION
function	I-NEGATION
.	O

While	O
all	O
the	O
M10-expressing	O
cell	O
lines	O
remained	O
infectable	O
by	O
HIV-1	O
,	O
these	O
same	O
cells	O
failed	B-NEGATION
to	I-NEGATION
support	I-NEGATION
a	I-NEGATION
productive	I-NEGATION
replication	I-NEGATION
cycle	I-NEGATION
when	I-NEGATION
infected	I-NEGATION
with	I-NEGATION
a	I-NEGATION
cloned	I-NEGATION
isolate	I-NEGATION
of	I-NEGATION
HIV-1	I-NEGATION
.	O

In	O
addition	O
,	O
two	O
out	O
of	O
three	O
M10-expressing	O
CEM	O
clones	O
were	O
also	O
resistant	O
to	O
highly	O
productive	O
infection	O
by	O
a	O
heterogeneous	O
HIV-1	O
pool	O
.	O

Expression	O
of	O
M10	O
did	O
not	B-NEGATION
affect	I-NEGATION
induction	I-NEGATION
of	I-NEGATION
HIV	I-NEGATION
transcription	I-NEGATION
mediated	I-NEGATION
by	I-NEGATION
the	I-NEGATION
kappa	I-NEGATION
B	I-NEGATION
regulatory	I-NEGATION
element	I-NEGATION
or	I-NEGATION
Tat	I-NEGATION
.	O

Importantly	O
,	O
constitutive	O
expression	O
of	O
Rev	O
M10	O
did	O
not	B-NEGATION
alter	I-NEGATION
the	I-NEGATION
secretion	I-NEGATION
of	I-NEGATION
interleukin	I-NEGATION
2	I-NEGATION
in	I-NEGATION
response	I-NEGATION
to	I-NEGATION
mitogen	I-NEGATION
stimulation	I-NEGATION
of	I-NEGATION
EL-4	I-NEGATION
and	I-NEGATION
Jurkat	I-NEGATION
cells	I-NEGATION
.	O

The	O
inhibition	O
of	O
HIV	O
infection	O
in	O
cells	O
stably	O
expressing	O
a	O
transdominant	O
Rev	O
protein	O
,	O
in	O
the	O
absence	O
of	O
any	O
deleterious	O
effect	O
on	O
T	O
cell	O
function	O
,	O
suggests	B-SPECULATION
that	I-SPECULATION
such	I-SPECULATION
a	I-SPECULATION
strategy	I-SPECULATION
could	B-SPECULATION
provide	I-SPECULATION
a	I-SPECULATION
therapeutic	I-SPECULATION
effect	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
T	I-SPECULATION
lymphocytes	I-SPECULATION
of	I-SPECULATION
acquired	I-SPECULATION
immunodeficiency	I-SPECULATION
syndrome	I-SPECULATION
patients	I-SPECULATION
.	O

Glucocorticoid	O
receptor	O
in	O
patients	O
with	O
lupus	O
nephritis	O
:	O
relationship	O
between	O
receptor	O
levels	O
in	O
mononuclear	O
leukocytes	O
and	O
effect	O
of	O
glucocorticoid	O
therapy	O
.	O

We	O
investigated	O
the	O
clinical	O
significance	O
of	O
glucocorticoid	O
receptor	O
determination	O
in	O
20	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
who	O
afterwards	O
developed	O
nephrotic	O
syndrome	O
.	O

Glucocorticoid	O
receptor	O
concentrations	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
in	O
these	O
patients	O
were	O
comparable	O
with	O
those	O
in	O
both	O
other	O
patients	O
with	O
SLE	O
and	O
healthy	O
persons	O
.	O

Improvement	O
in	O
urinary	O
protein	O
excretion	O
and	O
in	O
disease	O
activity	O
,	O
which	O
was	O
scored	O
according	O
to	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
system	O
of	O
the	O
University	O
of	O
Toronto	O
,	O
closely	O
related	O
to	O
the	O
glucocorticoid	O
receptor	O
concentrations	O
in	O
MNL	O
isolated	O
from	O
the	O
corresponding	O
patients	O
.	O

In	O
summary	O
,	O
glucocorticoid	O
receptor	O
determination	O
in	O
patients	O
with	O
lupus	O
nephritis	O
may	B-SPECULATION
be	I-SPECULATION
a	I-SPECULATION
predictive	I-SPECULATION
clue	I-SPECULATION
for	I-SPECULATION
assessing	I-SPECULATION
responsiveness	I-SPECULATION
to	I-SPECULATION
glucocorticoid	I-SPECULATION
therapy	I-SPECULATION
.	O

Selection	O
of	O
optimal	O
kappa	O
B	O
/	O
Rel	O
DNA-binding	O
motifs	O
:	O
interaction	O
of	O
both	O
subunits	O
of	O
NF-kappa	O
B	O
with	O
DNA	O
is	O
required	O
for	O
transcriptional	O
activation	O
.	O

Analysis	O
of	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
complex	O
has	O
revealed	O
that	O
both	O
proteins	O
can	O
interact	O
with	O
related	O
DNA	O
sequences	O
through	O
either	O
homo	O
-	O
or	O
heterodimer	O
formation	O
.	O

In	O
addition	O
,	O
the	O
product	O
of	O
the	O
proto-oncogene	O
c-rel	O
can	O
bind	O
to	O
similar	O
DNA	O
motifs	O
by	O
itself	O
or	O
as	O
a	O
heterodimer	O
with	O
p50	O
or	O
p65	O
.	O

However	O
,	O
these	O
studies	O
have	O
used	O
a	O
limited	O
number	O
of	O
known	O
kappa	O
B	O
DNA	O
motifs	O
,	O
and	O
the	B-NEGATION
question	I-NEGATION
of	I-NEGATION
the	I-NEGATION
optimal	I-NEGATION
DNA	I-NEGATION
sequences	I-NEGATION
preferred	I-NEGATION
by	I-NEGATION
each	I-NEGATION
homodimer	I-NEGATION
has	I-NEGATION
not	I-NEGATION
been	I-NEGATION
addressed	I-NEGATION
.	O

Using	O
purified	O
recombinant	O
p50	O
,	O
p65	O
,	O
and	O
c-Rel	O
proteins	O
,	O
optimal	O
DNA-binding	O
motifs	O
were	O
selected	O
from	O
a	O
pool	O
of	O
random	O
oligonucleotides	O
.	O

Alignment	O
of	O
the	O
selected	O
sequences	O
allowed	O
us	O
to	O
predict	O
a	O
consensus	O
sequence	O
for	O
binding	O
of	O
the	O
individual	O
homodimeric	O
Rel-related	O
proteins	O
,	O
and	O
DNA-protein	O
binding	O
analysis	O
of	O
the	O
selected	O
DNA	O
sequences	O
revealed	O
sequence	O
specificity	O
of	O
the	O
proteins	O
.	O

Contrary	O
to	O
previous	O
assumptions	O
,	O
we	O
observed	O
that	O
p65	O
homodimers	O
can	O
interact	O
with	O
a	O
subset	O
of	O
DNA	O
sequences	O
not	B-NEGATION
recognized	I-NEGATION
by	I-NEGATION
p50	I-NEGATION
homodimers	I-NEGATION
.	O

Differential	O
binding	O
affinities	O
were	O
also	O
obtained	O
with	O
p50	O
-	O
and	O
c-Rel-selected	O
sequences	O
.	O

Using	O
either	O
a	O
p50	O
-	O
or	O
p65-selected	O
kappa	O
B	O
motif	O
,	O
which	O
displayed	O
differential	O
binding	O
with	O
respect	O
to	O
the	O
other	O
protein	O
,	O
little	O
to	O
no	B-NEGATION
binding	I-NEGATION
was	O
observed	O
with	O
the	O
heterodimeric	O
NF-kappa	O
B	O
complex	O
.	O

Similarly	O
,	O
in	O
transfection	O
experiments	O
in	O
which	O
the	O
selective	O
kappa	O
B	O
binding	O
sites	O
were	O
used	O
to	O
drive	O
the	O
expression	O
of	O
a	O
chloramphenicol	O
acetyltransferase	O
reporter	O
construct	O
,	O
the	O
p65	O
-	O
and	O
p50-selected	O
motifs	O
were	O
activated	O
only	O
in	O
the	O
presence	O
of	O
p65	O
and	O
p50	O
/	O
65	O
(	O
a	O
chimeric	O
protein	O
with	O
the	O
p50	O
DNA	O
binding	O
domain	O
and	O
p65	O
activation	O
domain	O
)	O
expression	O
vectors	O
,	O
respectively	O
,	O
and	O
neither	B-NEGATION
demonstrated	I-NEGATION
a	I-NEGATION
significant	I-NEGATION
response	I-NEGATION
to	I-NEGATION
stimuli	I-NEGATION
that	I-NEGATION
induce	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
activity	I-NEGATION
.	O

These	O
findings	O
demonstrate	O
that	O
interaction	O
of	O
both	O
subunits	O
of	O
the	O
heterodimeric	O
NF-kappa	O
B	O
complex	O
with	O
DNA	O
is	O
required	O
for	O
DNA	O
binding	O
and	O
transcriptional	O
activation	O
and	O
suggest	B-SPECULATION
that	I-SPECULATION
transcriptional	I-SPECULATION
activation	I-SPECULATION
mediated	I-SPECULATION
by	I-SPECULATION
the	I-SPECULATION
individual	I-SPECULATION
rel-related	I-SPECULATION
proteins	I-SPECULATION
will	I-SPECULATION
differ	I-SPECULATION
dramatically	I-SPECULATION
,	I-SPECULATION
depending	I-SPECULATION
on	I-SPECULATION
the	I-SPECULATION
specific	I-SPECULATION
kappa	I-SPECULATION
B	I-SPECULATION
motifs	I-SPECULATION
present	I-SPECULATION
.	O

Characterization	O
of	O
a	O
new	O
tissue-specific	O
transcription	O
factor	O
binding	O
to	O
the	O
simian	O
virus	O
40	O
enhancer	O
TC-II	O
(	O
NF-kappa	O
B	O
)	O
element	O
.	O

We	O
have	O
biochemically	O
and	O
functionally	O
characterized	O
a	O
new	O
transcription	O
factor	O
,	O
NP-TCII	O
,	O
which	O
is	O
present	O
in	O
nuclei	O
from	O
unstimulated	O
T	O
and	O
B	O
lymphocytes	O
but	O
is	B-NEGATION
not	I-NEGATION
found	I-NEGATION
in	I-NEGATION
nonhematopoietic	I-NEGATION
cells	I-NEGATION
.	O

This	O
factor	O
has	O
a	O
DNA-binding	O
specificity	O
similar	O
to	O
that	O
of	O
NF-kappa	O
B	O
but	O
is	O
unrelated	O
to	O
this	O
or	O
other	O
Rel	O
proteins	O
by	O
functional	O
and	O
biochemical	O
criteria	O
.	O

It	O
can	O
also	O
be	O
distinguished	O
from	O
other	O
previously	O
described	O
lymphocyte-specific	O
DNA-binding	O
proteins	O
.	O

The	O
candidate	O
oncoprotein	O
Bcl-3	O
is	O
an	O
antagonist	O
of	O
p50	O
/	O
NF-kappa	O
B-mediated	O
inhibition	O
.	O

The	O
candidate	O
oncogene	O
bcl-3	O
was	O
discovered	O
as	O
a	O
translocation	O
into	O
the	O
immunoglobulin	O
alpha-locus	O
in	O
some	O
cases	O
of	O
B-cell	O
chronic	O
lymphocytic	O
leukaemias	O
.	O

The	O
protein	O
Bcl-3	O
contains	O
seven	O
so-called	O
ankyrin	O
repeats	O
.	O

Similar	O
repeat	O
motifs	O
are	O
found	O
in	O
a	O
number	O
of	O
diverse	O
regulatory	O
proteins	O
but	O
the	O
motifs	O
of	O
Bcl-3	O
are	O
most	O
closely	O
related	O
to	O
those	O
found	O
in	O
I	O
kappa	O
B	O
proteins	O
in	O
which	O
the	B-SPECULATION
ankyrin	I-SPECULATION
repeat	I-SPECULATION
domain	I-SPECULATION
is	I-SPECULATION
thought	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
directly	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
inhibition	I-SPECULATION
of	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
activity	I-SPECULATION
.	O

No	B-NEGATION
biological	I-NEGATION
function	I-NEGATION
has	I-NEGATION
yet	I-NEGATION
been	I-NEGATION
described	I-NEGATION
for	I-NEGATION
Bcl-3	I-NEGATION
,	O
but	O
it	O
was	O
noted	O
recently	O
that	O
Bcl-3	O
interferes	O
with	O
DNA-binding	O
of	O
the	O
p50	O
subunit	O
of	O
NF-kappa	O
B	O
in	O
vitro	O
.	O

Here	O
we	O
demonstrate	O
that	O
Bcl-3	O
can	O
aid	O
kappa	O
B	O
site-dependent	O
transcription	O
in	O
vivo	O
by	O
counteracting	O
the	O
inhibitory	O
effects	O
of	O
p50	O
/	O
NF-kappa	O
B	O
homodimers	O
.	O

Bcl-3	O
may	B-SPECULATION
therefore	I-SPECULATION
aid	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
select	I-SPECULATION
NF-kappa	I-SPECULATION
B-regulated	I-SPECULATION
genes	I-SPECULATION
,	I-SPECULATION
including	I-SPECULATION
those	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
human	I-SPECULATION
immunodeficiency	I-SPECULATION
virus	I-SPECULATION
.	O

A	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	O
receptors	O
:	O
decreased	O
receptor	O
concentration	O
in	O
myocardial	O
infarction	O
.	O

A	O
major	O
difficulty	O
in	O
determination	O
of	O
glucocorticoid	O
receptor	O
sites	O
is	O
the	O
very	O
complicated	O
assay	O
procedure	O
.	O

Therefore	O
,	O
we	O
describe	O
a	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	O
receptors	O
which	O
is	O
a	O
whole-cell	O
competitive	O
binding	O
radioassay	O
using	O
[	O
3H	O
]-	O
dexamethasone	O
as	O
radioligand	O
.	O

This	O
modification	O
of	O
a	O
previously	O
described	O
protocol	O
simplifies	O
and	O
reduces	O
laboratory	O
work	O
and	O
allows	O
assay	O
reproducibility	O
to	O
be	O
controlled	O
more	O
reliably	O
.	O

Thus	O
enabled	O
to	O
perform	O
the	O
test	O
on	O
multiple	O
blood	O
samples	O
in	O
parallel	O
,	O
we	O
investigated	O
cardiac	O
infarction	O
patients	O
over	O
a	O
12-day	O
period	O
to	O
test	O
if	B-SPECULATION
glucocorticoid	I-SPECULATION
receptor	I-SPECULATION
binding	I-SPECULATION
is	I-SPECULATION
altered	I-SPECULATION
in	I-SPECULATION
this	I-SPECULATION
'	I-SPECULATION
stressful	I-SPECULATION
'	I-SPECULATION
disease	I-SPECULATION
.	O

On	O
the	O
first	O
day	O
of	O
the	O
disease	O
,	O
glucocorticoid	O
receptor	O
capacity	O
was	O
significantly	O
decreased	O
without	B-NEGATION
alteration	I-NEGATION
of	I-NEGATION
the	I-NEGATION
receptor-ligand	I-NEGATION
affinity	I-NEGATION
,	O
whereas	O
on	O
days	O
4	O
and	O
12	O
the	O
number	O
of	O
receptor	O
sites	O
was	O
normal	O
again	O
.	O

This	O
result	O
fits	O
well	O
into	O
the	O
general	O
observation	O
of	O
stress-induced	O
down-regulation	O
of	O
immune	O
responses	O
.	O

Regulation	O
of	O
c-jun	O
expression	O
during	O
induction	O
of	O
monocytic	O
differentiation	O
by	O
okadaic	O
acid	O
.	O

The	O
present	O
work	O
has	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	O
1	O
and	O
2A	O
protein	O
phosphatases	O
,	O
on	O
the	O
regulation	O
of	O
c-jun	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	O
leukemia	O
cells	O
.	O

The	O
results	O
demonstrate	O
that	O
okadaic	O
acid	O
treatment	O
is	O
associated	O
with	O
induction	O
of	O
a	O
differentiated	O
monocyte	O
phenotype	O
characterized	O
by	O
:	O
(	O
a	O
)	O
growth	O
arrest	O
;	O
(	O
b	O
)	O
increases	O
in	O
Mac-1	O
cell	O
surface	O
antigen	O
expression	O
;	O
(	O
c	O
)	O
down-regulation	O
of	O
c-myc	O
transcripts	O
;	O
and	O
(	O
d	O
)	O
induction	O
of	O
tumor	O
necrosis	O
factor	O
gene	O
expression	O
.	O

This	O
induction	O
of	O
monocytic	O
differentiation	O
was	O
associated	O
with	O
transient	O
increases	O
in	O
c-jun	O
mRNA	O
levels	O
,	O
which	O
were	O
maximal	O
at	O
6	O
h	O
.	O

Similar	O
effects	O
were	O
obtained	O
for	O
the	O
c-fos	O
gene	O
.	O

Run-on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c-jun	O
transcription	O
in	O
U-937	O
cells	O
and	O
that	O
this	O
rate	O
is	O
increased	O
approximately	O
40-fold	O
following	O
okadaic	O
acid	O
exposure	O
.	O

c-jun	O
mRNA	O
levels	O
were	O
superinduced	O
in	O
cells	O
treated	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
,	O
whereas	O
inhibition	O
of	O
protein	O
synthesis	O
had	O
little	O
,	O
if	O
any	O
,	O
effect	O
on	O
okadaic	O
acid-induced	O
c-jun	O
transcription	O
.	O

The	O
half-life	O
of	O
c-jun	O
mRNA	O
was	O
similar	O
(	O
45-50	O
min	O
)	O
in	O
both	O
untreated	O
and	O
okadaic	O
acid-induced	O
cells	O
.	O

In	O
contrast	O
,	O
treatment	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
was	O
associated	O
with	O
stabilization	O
(	O
t	O
1	O
/	O
2	O
=	O
90	O
min	O
)	O
of	O
c-jun	O
transcripts	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
induction	I-SPECULATION
of	I-SPECULATION
c-jun	I-SPECULATION
transcription	I-SPECULATION
by	I-SPECULATION
okadaic	I-SPECULATION
acid	I-SPECULATION
is	I-SPECULATION
controlled	I-SPECULATION
primarily	I-SPECULATION
by	I-SPECULATION
a	I-SPECULATION
transcriptional	I-SPECULATION
mechanism	I-SPECULATION
.	O

Since	O
previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
c-jun	O
gene	O
is	O
autoinduced	O
by	O
Jun	O
/	O
AP-1	O
,	O
we	O
also	O
studied	O
transcription	O
of	O
c-jun	O
promoter	O
(	O
positions	O
-	O
132	O
/+	O
170	O
)-	O
reporter	O
gene	O
constructs	O
with	O
and	O
without	B-NEGATION
a	I-NEGATION
mutated	I-NEGATION
AP-1	I-NEGATION
element	I-NEGATION
.(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

Activation	O
of	O
NF-kappa	O
B	O
by	O
interleukin	O
2	O
in	O
human	O
blood	O
monocytes	O
.	O

We	O
report	O
here	O
that	O
interleukin	O
2	O
(	O
IL-2	O
)	O
acts	O
on	O
human	O
blood	O
monocytes	O
by	O
enhancing	O
binding	O
activity	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
IL-2	O
receptor	O
alpha	O
chain	O
(	O
p55	O
)	O
.	O

Similarly	O
,	O
IL-2	O
activates	O
NF-kappa	O
B	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
U	O
937	O
,	O
but	O
not	B-NEGATION
in	I-NEGATION
resting	I-NEGATION
human	I-NEGATION
T-cells	I-NEGATION
.	O

This	O
effect	O
is	O
detectable	O
within	O
15	O
min	O
and	O
peaks	O
1	O
h	O
after	O
exposure	O
to	O
IL-2	O
.	O

Enhanced	O
NF-kappa	O
B	O
binding	O
activity	O
is	O
followed	O
by	O
functional	O
activation	O
in	O
that	O
inducibility	O
of	O
the	O
IL-2	O
receptor	O
alpha	O
chain	O
is	O
mediated	O
by	O
enhanced	O
NF-kappa	O
B	O
binding	O
and	O
that	O
a	O
heterologous	O
promoter	O
containing	O
the	O
NF-kappa	O
B	O
consensus	O
sequence	O
(-	O
291	O
to	O
-	O
245	O
)	O
of	O
the	O
IL-2	O
receptor	O
alpha	O
chain	O
gene	O
is	O
activated	O
.	O

In	O
addition	O
,	O
IL-2	O
is	O
capable	O
of	O
increasing	O
transcript	O
levels	O
of	O
the	O
p50	O
gene	O
coding	O
for	O
the	O
p50	O
subunit	O
of	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
,	O
whereas	O
mRNA	O
levels	O
of	O
the	O
p65	O
NF-kappa	O
B	O
gene	O
remained	O
unchanged	O
.	O

Single	O
point	O
estimation	O
of	O
glucocorticoid	O
receptors	O
in	O
lymphocytes	O
of	O
normal	O
subjects	O
and	O
of	O
children	O
under	O
long	O
term	O
glucocorticoid	O
treatment	O
.	O

A	O
single	O
point	O
assay	O
of	O
glucocorticoid	O
receptors	O
(	O
GR	O
)	O
in	O
human	O
lymphocytes	O
based	O
on	O
the	O
measurement	O
of	O
specific	O
dexamethasone	O
binding	O
has	O
been	O
developed	O
and	O
compared	O
with	O
a	O
common	O
multi-point	O
Scatchard	O
analysis	O
.	O

The	O
assay	O
conditions-concentration	O
of	O
the	O
ligand	O
20	O
nmol	O
/	O
l	O
,	O
incubation	O
time	O
2	O
h	O
and	O
the	O
cell	O
count	O
2-6	O
mil.	O
cells	O
/	O
tube	O
in	O
the	O
assay	O
volume	O
0.25	O
ml	O
were	O
found	O
to	O
be	O
optimal	O
.	O

An	O
attempt	O
was	O
also	O
undertaken	O
to	O
use	O
a	O
cell	O
harvester	O
for	O
the	O
separation	O
of	O
cells	O
from	O
unbound	O
ligand	O
.	O

Though	O
specifically	O
bound	O
dexamethasone	O
measured	O
by	O
whole-cell	O
assay	O
and	O
that	O
using	O
cell	O
harvester	O
correlated	O
well	O
,	O
almost	O
by	O
one	O
order	O
lower	O
values	O
obtained	O
with	O
the	O
latter	O
method	O
render	O
it	O
non-applicable	O
for	O
receptor	O
quantitation	O
.	O

The	O
results	O
from	O
9	O
healthy	O
volunteers	O
(	O
average	O
GR	O
concentration	O
7131	O
	O
1256	O
sites	O
/	O
cell	O
)	O
correlated	O
excellently	O
with	O
those	O
obtained	O
by	O
the	O
Scatchard	O
analysis	O
.	O

The	O
single	O
point	O
assay	O
has	O
been	O
also	O
applied	O
for	O
determination	O
of	O
GH	O
in	O
10	O
children	O
treated	O
with	O
large	O
doses	O
of	O
prednisone	O
.	O

The	O
average	O
values	O
from	O
healthy	O
volunteers	O
did	O
not	B-NEGATION
differ	I-NEGATION
significantly	I-NEGATION
from	I-NEGATION
those	I-NEGATION
found	I-NEGATION
in	I-NEGATION
these	I-NEGATION
children	I-NEGATION
,	O
though	O
much	O
broader	O
range	O
was	O
found	O
in	O
patients	O
.	O

A	O
novel	O
B	O
cell-derived	O
coactivator	O
potentiates	O
the	O
activation	O
of	O
immunoglobulin	O
promoters	O
by	O
octamer-binding	O
transcription	O
factors	O
.	O

A	O
novel	O
B	O
cell-restricted	O
activity	O
,	O
required	O
for	O
high	O
levels	O
of	O
octamer	O
/	O
Oct-dependent	O
transcription	O
from	O
an	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
promoter	O
,	O
was	O
detected	O
in	O
an	O
in	O
vitro	O
system	O
consisting	O
of	O
HeLa	O
cell-derived	O
extracts	O
complemented	O
with	O
fractionated	O
B	O
cell	O
nuclear	O
proteins	O
.	O

The	O
factor	O
responsible	O
for	O
this	O
activity	O
was	O
designated	O
Oct	O
coactivator	O
from	O
B	O
cells	O
(	O
OCA-B	O
)	O
.	O

OCA-B	O
stimulates	O
the	O
transcription	O
from	O
an	O
IgH	O
promoter	O
in	O
conjunction	O
with	O
either	O
Oct-1	O
or	O
Oct-2	O
but	O
shows	O
no	B-NEGATION
significant	I-NEGATION
effect	I-NEGATION
on	I-NEGATION
the	I-NEGATION
octamer	I-NEGATION
/	I-NEGATION
Oct-dependent	I-NEGATION
transcription	I-NEGATION
of	I-NEGATION
the	I-NEGATION
ubiquitously	I-NEGATION
expressed	I-NEGATION
histone	I-NEGATION
H2B	I-NEGATION
promoter	I-NEGATION
and	I-NEGATION
the	I-NEGATION
transcription	I-NEGATION
of	I-NEGATION
USF	I-NEGATION
-	I-NEGATION
and	I-NEGATION
Sp1-regulated	I-NEGATION
promoters	I-NEGATION
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	B-SPECULATION
that	I-SPECULATION
OCA-B	I-SPECULATION
is	I-SPECULATION
a	I-SPECULATION
tissue	I-SPECULATION
-	I-SPECULATION
,	I-SPECULATION
promoter	I-SPECULATION
-	I-SPECULATION
,	I-SPECULATION
and	I-SPECULATION
factor-specific	I-SPECULATION
coactivator	I-SPECULATION
and	I-SPECULATION
that	I-SPECULATION
OCA-B	I-SPECULATION
may	B-SPECULATION
be	I-SPECULATION
a	I-SPECULATION
major	I-SPECULATION
determinant	I-SPECULATION
for	I-SPECULATION
B	I-SPECULATION
cell-specific	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
immunoglobulin	I-SPECULATION
promoters	I-SPECULATION
.	O

In	O
light	O
of	O
the	O
evidence	O
showing	O
physical	O
and	O
functional	O
interactions	O
between	O
Oct	O
factors	O
and	O
OCA-B	O
,	O
we	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
OCA-B	O
and	O
discuss	O
the	O
implications	O
of	O
OCA-B	O
for	O
the	O
transcriptional	O
regulation	O
of	O
other	O
tissue-specific	O
promoters	O
.	O

The	O
regulation	O
of	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
promoter	O
region	O
in	O
macrophage	O
,	O
T	O
cell	O
,	O
and	O
B	O
cell	O
lines	O
.	O

The	O
1311-base	O
pair	O
human	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
alpha	O
promoter	O
region	O
was	O
fused	O
to	O
the	O
luciferase	O
(	O
Luc	O
)	O
reporter	O
gene	O
and	O
studied	O
in	O
a	O
transient	O
transfection	O
system	O
in	O
three	O
TNF	O
producing	O
cell	O
lines	O
,	O
the	O
U937	O
macrophage	O
cell	O
line	O
,	O
the	O
MLA	O
144	O
T	O
cell	O
line	O
,	O
and	O
the	O
729-6	O
B	O
cell	O
line	O
.	O

This	O
full	O
length	O
promoter	O
construct	O
can	O
be	O
induced	O
by	O
phorbol	O
13-myristate	O
acetate	O
(	O
PMA	O
)	O
in	O
each	O
of	O
these	O
cell	O
types	O
.	O

Analysis	O
of	O
a	O
series	O
of	O
5	O
'-	O
truncations	O
showed	O
several	O
peaks	O
of	O
basal	O
and	O
PMA	O
induced	O
activity	O
suggesting	B-SPECULATION
the	I-SPECULATION
presence	I-SPECULATION
of	I-SPECULATION
several	I-SPECULATION
positive	I-SPECULATION
and	I-SPECULATION
negative	I-SPECULATION
regulatory	I-SPECULATION
elements	I-SPECULATION
.	O

A	O
PMA	O
responsive	O
element	O
was	O
localized	O
to	O
a	O
region	O
between	O
-	O
95	O
and	O
-	O
36	O
bp	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
.	O

Within	O
this	O
region	O
,	O
single	O
AP-2	O
-	O
and	O
AP-1-like	O
consensus	O
sequences	O
were	O
noted	O
.	O

These	O
AP-2	O
and	O
AP-1	O
sites	O
were	O
each	O
modified	O
with	O
a	O
double	O
point	O
mutation	O
.	O

A	O
modest	O
(	O
20-50	O
%)	O
reduction	O
in	O
TNF	O
promoter	O
activity	O
was	O
observed	O
with	O
the	O
AP-2	O
site	O
mutation	O
.	O

However	O
,	O
mutation	O
of	O
the	O
AP-1	O
site	O
markedly	O
diminished	O
both	O
the	O
basal	O
and	O
PMA-activated	O
promoter	O
activity	O
.	O

Also	O
co-transfections	O
of	O
the	O
wild-type	O
promoter	O
construct	O
with	O
an	O
AP-1	O
/	O
c-jun	O
expression	O
vector	O
resulted	O
in	O
augmented	O
basal	O
and	O
PMA-induced	O
promoter	O
activity	O
.	O

Redox	O
status	O
of	O
cells	O
influences	O
constitutive	O
or	O
induced	O
NF-kappa	O
B	O
translocation	O
and	O
HIV	O
long	O
terminal	O
repeat	O
activity	O
in	O
human	O
T	O
and	O
monocytic	O
cell	O
lines	O
.	O

We	O
have	O
tested	O
the	O
hypothesis	B-SPECULATION
that	I-SPECULATION
cellular	I-SPECULATION
activation	I-SPECULATION
events	I-SPECULATION
occurring	I-SPECULATION
in	I-SPECULATION
T	I-SPECULATION
lymphocytes	I-SPECULATION
and	I-SPECULATION
monocytes	I-SPECULATION
and	I-SPECULATION
mediated	I-SPECULATION
through	I-SPECULATION
translocation	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
transcription	I-SPECULATION
factor	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
are	I-SPECULATION
dependent	I-SPECULATION
upon	I-SPECULATION
the	I-SPECULATION
constitutive	I-SPECULATION
redox	I-SPECULATION
status	I-SPECULATION
of	I-SPECULATION
these	I-SPECULATION
cells	I-SPECULATION
.	O

We	O
used	O
phenolic	O
,	O
lipid-soluble	O
,	O
chain-breaking	O
antioxidants	O
(	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
nordihydroquairetic	O
acid	O
,	O
or	O
alpha-tocopherol	O
(	O
vitamin	O
E	O
)	O
to	O
show	O
that	O
peroxyl	O
radical	O
scavenging	O
in	O
unstimulated	O
and	O
PMA	O
-	O
or	O
TNF-stimulated	O
cells	O
blocks	O
the	O
functions	O
depending	O
on	O
NF-kappa	O
B	O
activation	O
.	O

BHA	O
was	O
found	O
to	O
suppress	O
not	O
only	O
PMA	O
-	O
or	O
TNF-induced	O
,	O
but	O
also	O
constitutive	O
,	O
HIV-enhancer	O
activity	O
concomitant	O
to	O
an	O
inhibition	O
of	O
NF-kappa	O
B	O
binding	O
activity	O
in	O
both	O
lymphoblastoid	O
T	O
(	O
J.Jhan	O
)	O
and	O
monocytic	O
(	O
U937	O
)	O
cell	O
lines	O
.	O

This	O
was	O
also	O
true	O
for	O
KBF	O
(	O
p50	O
homodimer	O
)	O
binding	O
activity	O
in	O
U937	O
cells	O
.	O

Secretion	O
of	O
TNF	O
,	O
the	O
product	O
of	O
another	O
NF-kappa	O
B-dependent	O
gene	O
,	O
was	O
abolished	O
by	O
BHA	O
in	O
PMA-stimulated	O
U937	O
cells	O
.	O

The	O
anti-oxidative	O
effect	O
of	O
BHA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
thiol	O
,	O
but	O
not	B-NEGATION
glutathione	I-NEGATION
,	O
content	O
in	O
stimulated	O
and	O
unstimulated	O
T	O
cell	O
,	O
whereas	O
TNF	O
stimulation	O
itself	O
barely	O
modified	O
the	O
cellular	O
thiol	O
level	O
.	O

Oxidative	O
stress	O
obtained	O
by	O
the	O
addition	O
of	O
H2O2	O
to	O
the	O
culture	O
medium	O
of	O
J.Jhan	O
or	O
U937	O
cells	O
could	B-SPECULATION
not	B-NEGATION
by	I-NEGATION
itself	I-NEGATION
induce	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
activation	I-NEGATION
.	O

These	O
observations	O
suggest	B-SPECULATION
that	I-SPECULATION
TNF	I-SPECULATION
and	I-SPECULATION
PMA	I-SPECULATION
do	I-SPECULATION
not	B-NEGATION
lead	I-NEGATION
to	I-NEGATION
NF-kappa	I-NEGATION
B	I-NEGATION
activation	I-NEGATION
through	I-NEGATION
induction	I-NEGATION
of	I-NEGATION
changes	I-NEGATION
in	I-NEGATION
the	I-NEGATION
cell	I-NEGATION
redox	I-NEGATION
status	I-NEGATION
.	O

Rather	O
,	O
TNF	O
and	O
PMA	O
can	O
exert	O
their	O
effect	O
only	O
if	O
cells	O
are	O
in	O
an	O
appropriate	O
redox	O
status	O
,	O
because	O
prior	O
modification	O
toward	O
reduction	O
with	O
BHA	O
treatment	O
prevents	O
this	O
activation	O
.	O

It	O
appears	B-SPECULATION
that	I-SPECULATION
a	I-SPECULATION
basal	I-SPECULATION
redox	I-SPECULATION
equilibrium	I-SPECULATION
tending	I-SPECULATION
toward	I-SPECULATION
oxidation	I-SPECULATION
is	I-SPECULATION
a	I-SPECULATION
prerequisite	I-SPECULATION
for	I-SPECULATION
full	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
transduction	I-SPECULATION
pathways	I-SPECULATION
regulating	I-SPECULATION
the	I-SPECULATION
activity	I-SPECULATION
of	I-SPECULATION
NF-kappa	I-SPECULATION
B-dependent	I-SPECULATION
genes	I-SPECULATION
.	O

Expression	O
of	O
c-fos	O
,	O
c-jun	O
and	O
jun	O
B	O
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
young	O
and	O
elderly	O
adults	O
.	O

The	O
expression	O
of	O
c-fos	O
,	O
c-jun	O
and	O
jun	O
B	O
proto-oncogenes	O
was	O
studied	O
in	O
phytohemagglutinin	O
(	O
PHA	O
)	O
activated	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
from	O
young	O
and	O
aged	O
humans	O
.	O

Specific	O
mRNAs	O
for	O
c-fos	O
and	O
c-jun	O
were	O
detectable	O
within	O
30	O
min	O
after	O
cell	O
activation	O
and	O
reached	O
maximal	O
levels	O
within	O
2	O
h	O
.	O

Both	O
c-fos	O
and	O
jun	O
B	O
mRNAs	O
decreased	O
to	O
pre-activation	O
levels	O
within	O
6	O
h	O
,	O
while	O
c-jun	O
mRNA	O
remained	O
elevated	O
.	O

In	B-NEGATION
PHA-activated	I-NEGATION
PBL	I-NEGATION
,	I-NEGATION
no	I-NEGATION
age-related	I-NEGATION
differences	I-NEGATION
were	I-NEGATION
observed	I-NEGATION
in	I-NEGATION
c-fos	I-NEGATION
or	I-NEGATION
jun	I-NEGATION
B	I-NEGATION
mRNA	I-NEGATION
expression	I-NEGATION
.	O

However	O
,	O
c-jun	O
mRNA	O
levels	O
decreased	O
significantly	O
(	O
1.73	O
	O
0.08	O
vs.	O
1.16	O
	O
0.09	O
arbitrary	O
units	O
,	O
P	O
<	O
0.01	O
,	O
young	O
vs.	O
old	O
)	O
in	O
PBL	O
from	O
elderly	O
individuals	O
activated	O
with	O
PHA	O
.	O

Because	O
previous	O
work	O
has	O
demonstrated	O
that	O
T	O
cells	O
from	O
elderly	O
individuals	O
may	B-SPECULATION
display	I-SPECULATION
normal	I-SPECULATION
proliferative	I-SPECULATION
responses	I-SPECULATION
when	I-SPECULATION
activated	I-SPECULATION
via	I-SPECULATION
the	I-SPECULATION
anti-CD2	I-SPECULATION
pathway	I-SPECULATION
,	O
c-jun	O
and	O
jun	O
B	O
mRNA	O
expression	O
was	O
also	O
studied	O
in	O
anti-CD2-activated	O
purified	O
T	O
cells	O
.	O

No	B-NEGATION
age-related	I-NEGATION
differences	I-NEGATION
were	I-NEGATION
found	I-NEGATION
in	I-NEGATION
the	I-NEGATION
expression	I-NEGATION
of	I-NEGATION
either	B-NEGATION
of	I-NEGATION
these	I-NEGATION
two	I-NEGATION
proto-oncogenes	I-NEGATION
by	O
anti-CD2	O
activated	O
T	O
cells	O
.	O

These	O
results	O
suggest	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
decreased	I-SPECULATION
IL-2	I-SPECULATION
production	I-SPECULATION
and	I-SPECULATION
proliferative	I-SPECULATION
response	I-SPECULATION
displayed	I-SPECULATION
by	I-SPECULATION
PHA-activated	I-SPECULATION
PBL	I-SPECULATION
from	I-SPECULATION
elderly	I-SPECULATION
adults	I-SPECULATION
may	B-SPECULATION
be	I-SPECULATION
related	I-SPECULATION
to	I-SPECULATION
age-related	I-SPECULATION
changes	I-SPECULATION
in	I-SPECULATION
c-jun	I-SPECULATION
mRNA	I-SPECULATION
expression	I-SPECULATION
and	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
ratio	I-SPECULATION
of	I-SPECULATION
c-fos	I-SPECULATION
to	I-SPECULATION
c-jun	I-SPECULATION
mRNA	I-SPECULATION
.	O

Characterization	O
of	O
a	O
novel	O
T	O
lymphocyte	O
protein	O
which	O
binds	O
to	O
a	O
site	O
related	O
to	O
steroid	O
/	O
thyroid	O
hormone	O
receptor	O
response	O
elements	O
in	O
the	O
negative	O
regulatory	O
sequence	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
.	O

We	O
have	O
previously	O
identified	O
a	O
T	O
lymphocyte	O
protein	O
which	O
binds	O
to	O
a	O
site	O
within	O
the	O
LTR	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
virus	O
gene	O
expression	O
.	O

The	O
palindromic	O
site	O
(	O
site	O
B	O
)	O
recognized	O
by	O
this	O
protein	O
is	O
related	O
to	O
the	O
palindromic	O
binding	O
sites	O
of	O
members	O
of	O
the	O
steroid	O
/	O
thyroid	O
hormone	O
receptor	O
family	O
.	O

Here	O
we	O
characterize	O
the	O
T	O
cell	O
protein	O
binding	O
to	O
this	O
site	O
as	O
a	O
100	O
kD	O
protein	O
which	O
is	O
most	O
abundant	O
in	O
T	O
cells	O
and	O
which	O
binds	O
to	O
site	O
B	O
as	O
a	O
200	O
kD	O
complex	O
.	O

This	O
protein	O
is	O
distinct	O
from	O
other	O
members	O
of	O
the	O
steroid	O
/	O
thyroid	O
hormone	O
receptor	O
family	O
including	O
the	O
COUP	O
protein	O
which	O
has	O
a	O
closely	O
related	O
DNA	O
binding	O
specificity	O
.	O

A	O
mechanism	O
for	O
the	O
antiinflammatory	O
effects	O
of	O
corticosteroids	O
:	O
the	O
glucocorticoid	O
receptor	O
regulates	O
leukocyte	O
adhesion	O
to	O
endothelial	O
cells	O
and	O
expression	O
of	O
endothelial-leukocyte	O
adhesion	O
molecule	O
1	O
and	O
intercellular	O
adhesion	O
molecule	O
1	O
.	O

Corticosteroids	O
are	O
the	O
preeminent	O
antiinflammatory	O
agents	O
although	O
the	B-NEGATION
molecular	I-NEGATION
mechanisms	I-NEGATION
that	I-NEGATION
impart	I-NEGATION
their	I-NEGATION
efficacy	I-NEGATION
have	I-NEGATION
not	I-NEGATION
been	I-NEGATION
defined	I-NEGATION
.	O

The	O
endothelium	O
plays	O
a	O
critical	O
role	O
in	O
inflammation	O
by	O
directing	O
circulating	O
leukocytes	O
into	O
extravascular	O
tissues	O
by	O
expressing	O
adhesive	O
molecules	O
for	O
leukocytes	O
[	O
e.g.	O
,	O
endothelial-leukocyte	O
adhesion	O
molecule	O
1	O
(	O
ELAM-1	O
)	O
and	O
intercellular	O
adhesion	O
molecule	O
1	O
(	O
ICAM-1	O
)]	O
.	O

We	O
therefore	O
determined	O
whether	B-SPECULATION
corticosteroids	I-SPECULATION
suppress	I-SPECULATION
inflammation	I-SPECULATION
by	I-SPECULATION
inhibiting	I-SPECULATION
endothelial	I-SPECULATION
expression	I-SPECULATION
of	I-SPECULATION
adhesion	I-SPECULATION
molecules	I-SPECULATION
for	I-SPECULATION
neutrophils	I-SPECULATION
(	I-SPECULATION
polymorphonuclear	I-SPECULATION
leukocytes	I-SPECULATION
)	I-SPECULATION
.	O

Preincubation	O
of	O
endothelial	O
cells	O
with	O
endotoxin	O
[	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
1	O
microgram	O
/	O
ml	O
]	O
led	O
to	O
a	O
4-fold	O
increase	O
in	O
subsequent	O
adherence	O
of	O
polymorphonuclear	O
leukocytes	O
(	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
10	O
)	O
to	O
endothelial	O
cells	O
,	O
an	O
increase	O
that	O
was	O
markedly	O
attenuated	O
when	O
endothelial	O
cells	O
were	O
treated	O
with	O
dexamethasone	O
(	O
IC50	O
<	O
1	O
nM	O
,	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
6	O
or	O
7	O
)	O
during	O
preincubation	O
with	O
LPS	O
.	O

Moreover	O
,	O
the	O
steroid	O
receptor	O
agonist	O
cortisol	O
(	O
10	O
microM	O
)	O
,	O
but	O
not	B-NEGATION
its	I-NEGATION
inactive	I-NEGATION
metabolite	I-NEGATION
tetrahydrocortisol	I-NEGATION
(	I-NEGATION
10	I-NEGATION
microM	I-NEGATION
)	I-NEGATION
,	O
diminished	O
LPS-induced	O
endothelial	O
cell	O
adhesiveness	O
.	O

Further	O
evidence	O
that	O
the	O
action	O
of	O
dexamethasone	O
was	O
mediated	O
through	O
ligation	O
of	O
corticosteroid	O
receptors	O
[	O
human	O
glucocorticoid	O
receptors	O
(	O
hGRs	O
)]	O
was	O
provided	O
by	O
experiments	O
utilizing	O
the	O
steroid	O
antagonist	O
RU-486	O
.	O

RU-486	O
(	O
10	O
microM	O
)	O
,	O
which	O
prevents	O
translocation	O
of	O
ligated	O
hGR	O
to	O
the	O
nucleus	O
by	O
inhibiting	O
dissociation	O
of	O
hGR	O
from	O
heat	O
shock	O
protein	O
90	O
,	O
completely	O
aborted	O
the	O
effect	O
of	O
dexamethasone	O
on	O
adhesiveness	O
of	O
endothelial	O
cells	O
(	O
P	O
<	O
0.0005	O
,	O
n	O
=	O
3	O
)	O
.	O

Treatment	O
of	O
endothelial	O
cells	O
with	O
LPS	O
(	O
1	O
microgram	O
/	O
ml	O
)	O
stimulated	O
transcription	O
of	O
ELAM-1	O
,	O
as	O
shown	O
by	O
Northern	O
blot	O
analysis	O
,	O
and	O
expression	O
of	O
membrane-associated	O
ELAM-1	O
and	O
ICAM-1	O
,	O
as	O
shown	O
by	O
quantitative	O
immunofluorescence	O
(	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
9	O
)	O
.	O

Dexamethasone	O
markedly	O
inhibited	O
LPS-stimulated	O
accumulation	O
of	O
mRNA	O
for	O
ELAM-1	O
and	O
expression	O
of	O
ELAM-1	O
and	O
ICAM-1	O
(	O
IC50	O
<	O
10	O
nM	O
,	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
4-9	O
)	O
;	O

inhibition	O
of	O
expression	O
by	O
dexamethasone	O
was	O
reversed	O
by	O
RU-486	O
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
4-6	O
)	O
.	O

As	O
in	O
the	O
adhesion	O
studies	O
,	O
cortisol	O
but	O
not	B-NEGATION
tetrahydrocortisol	I-NEGATION
inhibited	O
expression	O
of	O
ELAM-1	O
and	O
ICAM-1	O
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
3	O
or	O
4	O
)	O
9	O
.	O

In	O
contrast	O
,	O
sodium	O
salicylate	O
(	O
1	O
mM	O
)	O
inhibited	O
neither	B-NEGATION
adhesion	I-NEGATION
.	O

These	O
studies	O
suggest	B-SPECULATION
that	I-SPECULATION
antagonism	I-SPECULATION
by	I-SPECULATION
dexamethasone	I-SPECULATION
of	I-SPECULATION
endotoxin-induced	I-SPECULATION
inflammation	I-SPECULATION
is	I-SPECULATION
a	I-SPECULATION
specific	I-SPECULATION
instance	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
general	I-SPECULATION
biological	I-SPECULATION
principle	I-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
glucocorticoid	I-SPECULATION
receptor	I-SPECULATION
is	I-SPECULATION
a	I-SPECULATION
hormone-dependent	I-SPECULATION
regulator	I-SPECULATION
of	I-SPECULATION
transcription	I-SPECULATION
.	O

Membrane	O
receptors	O
for	O
aldosterone	O
:	O
a	O
novel	O
pathway	O
for	O
mineralocorticoid	O
action	O
.	O

Rapid	O
nongenomic	O
in	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
intracellular	O
electrolytes	O
,	O
cell	O
volume	O
,	O
and	O
Na	O
(+)-	O
H	O
+	O
antiport	O
have	O
been	O
found	O
in	O
human	O
mononuclear	O
leukocytes	O
(	O
HML	O
)	O
.	O

Binding	O
of	O
125I-labeled	O
aldosterone	O
to	O
plasma	O
membranes	O
of	O
HML	O
shares	O
important	O
features	O
with	O
these	O
functional	O
data	O
.	O

This	O
includes	O
a	O
very	O
low	O
apparent	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
0.1	O
nM	O
for	O
both	O
aldosterone	O
and	O
the	O
effect	O
on	O
the	O
Na	O
(+)-	O
H	O
(+)-	O
antiport	O
,	O
a	O
high	O
turnover	O
rate	O
,	O
and	O
the	O
almost	O
exclusive	O
binding	O
selectivity	O
for	O
aldosterone	O
.	O

Dexamethasone	O
,	O
RU	O
26988	O
,	O
corticosterone	O
,	O
ouabain	O
,	O
amiloride	O
,	O
and	O
18-hydroxyprogesterone	O
were	O
inactive	O
as	O
ligands	O
.	O

Deoxycorticosterone	O
acetate	O
had	O
an	O
intermediate	O
activity	O
with	O
an	O
apparent	O
Kd	O
of	O
100	O
nM	O
.	O

These	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
of	O
aldosterone	O
being	O
compatible	O
with	O
major	O
aspects	O
of	O
its	O
nongenomic	O
effects	O
.	O

Reticuloendotheliosis	O
virus	O
long	O
terminal	O
repeat	O
elements	O
are	O
efficient	O
promoters	O
in	O
cells	O
of	O
various	O
species	O
and	O
tissue	O
origin	O
,	O
including	O
human	O
lymphoid	O
cells	O
.	O

Promiscuous	O
transcriptional	O
activity	O
of	O
the	O
reticuloendotheliosis	O
virus	O
(	O
REV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
was	O
detected	O
in	O
transient	O
expression	O
assays	O
using	O
LTR-chloramphenicol	O
acetyltransferase-encoding	O
gene	O
chimeras	O
,	O
and	O
cells	O
of	O
diverse	O
species	O
and	O
tissue	O
type	O
;	O

levels	O
of	O
expression	O
from	O
two	O
different	O
REV	O
LTRs	O
correlate	O
with	O
reports	O
of	O
pathogenicity	O
of	O
the	O
respective	O
viruses	O
in	O
vivo	O
.	O

REVs	O
do	O
not	B-NEGATION
encode	I-NEGATION
a	I-NEGATION
transactivator	I-NEGATION
targeted	I-NEGATION
to	I-NEGATION
the	I-NEGATION
viral	I-NEGATION
LTR	I-NEGATION
,	O
and	O
cells	O
infected	O
with	O
Marek	O
'	O
s	O
disease	O
virus	O
,	O
a	O
herpesvirus	O
with	O
an	O
overlapping	O
host	O
range	O
,	O
do	O
not	B-NEGATION
express	I-NEGATION
factors	I-NEGATION
that	I-NEGATION
preferentially	I-NEGATION
enhance	I-NEGATION
expression	I-NEGATION
from	I-NEGATION
REV	I-NEGATION
or	I-NEGATION
avian	I-NEGATION
sarcoma	I-NEGATION
/	I-NEGATION
leukemia	I-NEGATION
virus	I-NEGATION
LTRs	I-NEGATION
.	O

REV	O
LTRs	O
work	O
efficiently	O
in	O
human	O
lymphoid	O
cells	O
,	O
and	O
are	O
viable	B-SPECULATION
alternatives	I-SPECULATION
to	I-SPECULATION
promoters	I-SPECULATION
commonly	I-SPECULATION
used	I-SPECULATION
for	I-SPECULATION
expression	I-SPECULATION
of	I-SPECULATION
cloned	I-SPECULATION
genes	I-SPECULATION
.	O

They	O
may	B-SPECULATION
also	I-SPECULATION
prove	I-SPECULATION
useful	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
identification	I-SPECULATION
of	I-SPECULATION
new	I-SPECULATION
,	I-SPECULATION
ubiquitous	I-SPECULATION
cellular	I-SPECULATION
transcription	I-SPECULATION
factors	I-SPECULATION
.	O

Natural	O
variants	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
:	O
analysis	O
of	O
promoters	O
with	O
duplicated	O
DNA	O
regulatory	O
motifs	O
.	O

Sequence	O
variation	O
in	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
region	O
of	O
HIV-1	O
was	O
analyzed	O
in	O
viral	O
isolates	O
of	O
17	O
infected	O
individuals	O
.	O

Two	O
classes	O
of	O
LTR	O
size	O
variants	O
were	O
found	O
.	O

One	O
HIV-1	O
variant	O
was	O
detected	O
containing	O
an	O
additional	O
binding	O
site	O
for	O
the	O
transcription	O
factor	O
Sp1	O
.	O

Another	O
LTR	O
size	O
variation	O
was	O
observed	O
in	O
four	O
patients	O
in	O
a	O
region	O
just	O
upstream	O
of	O
the	O
NF-kappa	O
B	O
enhancer	O
.	O

This	O
variation	O
was	O
the	O
result	O
of	O
a	O
duplication	O
of	O
a	O
short	O
DNA	O
sequence	O
(	O
CTG-motif	O
)	O
.	O

Cell	O
culture	O
experiments	O
demonstrated	O
that	O
the	O
natural	O
variant	O
with	O
four	O
Sp1	O
sites	O
had	O
a	O
slightly	O
higher	O
promoter	O
activity	O
and	O
viral	O
replication	O
rate	O
than	O
the	O
isogenic	O
control	O
LTR	O
with	O
three	O
Sp1	O
sites	O
.	O

No	B-NEGATION
positive	I-NEGATION
effect	I-NEGATION
of	I-NEGATION
the	I-NEGATION
duplicated	I-NEGATION
CTG-motif	I-NEGATION
could	I-NEGATION
be	I-NEGATION
detected	I-NEGATION
.	O

In	O
order	O
to	O
measure	O
small	O
differences	O
in	O
virus	O
production	O
more	O
accurately	O
,	O
equal	O
amounts	O
of	O
a	O
size	O
variant	O
and	O
the	O
wild-type	O
plasmid	O
were	O
cotransfected	O
into	O
T-cells	O
.	O

The	O
virus	O
with	O
four	O
Sp1	O
sites	O
did	O
outgrow	O
the	O
three	O
Sp1	O
virus	O
in	O
35	O
days	O
of	O
culture	O
and	O
CTG-monomer	O
virus	O
outcompeted	O
the	O
CTG-dimer	O
virus	O
in	O
42	O
days	O
.	O

Based	O
on	O
these	O
results	O
we	O
estimate	B-SPECULATION
a	I-SPECULATION
5-10	I-SPECULATION
%	I-SPECULATION
difference	I-SPECULATION
in	I-SPECULATION
virus	I-SPECULATION
production	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
LTR	I-SPECULATION
variants	I-SPECULATION
when	I-SPECULATION
compared	I-SPECULATION
to	I-SPECULATION
that	I-SPECULATION
of	I-SPECULATION
wild-type	I-SPECULATION
.	O

SCL	O
and	O
related	O
hemopoietic	O
helix-loop-helix	O
transcription	O
factors	O
.	O

The	O
helix-loop-helix	O
(	O
HLH	O
)	O
proteins	O
are	O
a	O
family	O
of	O
transcription	O
factors	O
that	O
include	O
proteins	O
critical	O
to	O
differentiation	O
and	O
development	O
in	O
species	O
ranging	O
from	O
plants	O
to	O
mammals	O
.	O

Five	O
members	O
of	O
this	O
family	O
(	O
MYC	O
,	O
SCL	O
,	O
TAL-2	O
,	O
LYL-1	O
and	O
E2A	O
)	O
are	O
implicated	O
in	O
oncogenic	O
events	O
in	O
human	O
lymphoid	O
tumors	O
because	O
of	O
their	O
consistent	O
involvement	O
in	O
chromosomal	O
translocations	O
.	O

Although	O
activated	O
in	O
T	O
cell	O
leukemias	O
,	O
expression	O
of	O
SCL	O
and	O
LYL-1	O
is	O
low	O
or	O
undetectable	O
in	O
normal	O
T	O
cell	O
populations	O
.	O

SCL	O
is	O
expressed	O
in	O
erythroid	O
,	O
megakaryocyte	O
and	O
mast	O
cell	O
populations	O
(	O
the	O
same	O
cell	O
lineages	O
as	O
GATA-1	O
,	O
a	O
zinc-finger	O
transcription	O
factor	O
)	O
.	O

In	O
addition	O
,	O
both	O
SCL	O
and	O
GATA-1	O
undergo	O
coordinate	O
modulation	O
during	O
chemically	O
induced	O
erythroid	O
differentiation	O
of	O
mouse	O
erythroleukemia	O
cells	O
and	O
are	O
down-modulated	O
during	O
myeloid	O
differentiation	O
of	O
human	O
K562	O
cells	O
,	O
thus	O
implying	B-SPECULATION
a	I-SPECULATION
role	I-SPECULATION
for	I-SPECULATION
SCL	I-SPECULATION
in	I-SPECULATION
erythroid	I-SPECULATION
differentiation	I-SPECULATION
events	I-SPECULATION
.	O

However	O
,	O
in	O
contrast	O
to	O
GATA-1	O
,	O
SCL	O
is	O
expressed	O
in	O
the	O
developing	O
brain	O
.	O

Studies	O
of	O
the	O
function	O
of	O
SCL	O
suggest	B-SPECULATION
it	I-SPECULATION
is	I-SPECULATION
also	I-SPECULATION
important	I-SPECULATION
in	I-SPECULATION
proliferation	I-SPECULATION
and	I-SPECULATION
self-renewal	I-SPECULATION
events	I-SPECULATION
in	I-SPECULATION
erythroid	I-SPECULATION
cells	I-SPECULATION
.	O

Transcription	O
of	O
the	O
hypersensitive	O
site	O
HS2	O
enhancer	O
in	O
erythroid	O
cells	O
.	O

In	O
the	O
human	O
genome	O
,	O
the	O
erythroid-specific	O
hypersensitive	O
site	O
HS2	O
enhancer	O
regulates	O
the	O
transcription	O
of	O
the	O
downstream	O
beta-like	O
globin	O
genes	O
10-50	O
kilobases	O
away	O
.	O

The	O
mechanism	O
of	O
HS2	O
enhancer	O
function	O
is	O
not	B-NEGATION
known	I-NEGATION
.	O

The	O
present	O
study	O
employs	O
RNA	O
protection	O
assays	O
to	O
analyze	O
the	O
transcriptional	O
status	O
of	O
the	O
HS2	O
enhancer	O
in	O
transfected	O
recombinant	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
plasmids	O
.	O

In	O
erythroid	O
K562	O
cells	O
in	O
which	O
the	O
HS2	O
enhancer	O
is	O
active	O
,	O
the	O
HS2	O
sequence	O
directs	O
the	O
synthesis	O
of	O
long	O
enhancer	O
transcripts	O
that	O
are	O
initiated	O
apparently	B-SPECULATION
from	I-SPECULATION
within	I-SPECULATION
the	I-SPECULATION
enhancer	I-SPECULATION
and	O
elongated	O
through	O
the	O
intervening	O
DNA	O
into	O
the	O
cis-linked	O
CAT	O
gene	O
.	O

In	O
nonerythroid	O
HL-60	O
cells	O
in	O
which	O
the	O
HS2	O
enhancer	O
is	O
inactive	O
,	O
long	O
enhancer	O
transcripts	O
are	O
not	B-NEGATION
detectable	I-NEGATION
.	O

Splitting	O
the	O
HS2	O
enhancer	O
between	O
two	O
tandem	O
Ap1	O
sites	O
abolishes	O
the	O
synthesis	O
of	O
a	O
group	O
of	O
long	O
enhancer	O
transcripts	O
and	O
results	O
in	O
loss	O
of	O
enhancer	O
function	O
and	O
transcriptional	O
silencing	O
of	O
the	O
cis-linked	O
CAT	O
gene	O
.	O

In	O
directing	O
the	O
synthesis	O
of	O
RNA	O
through	O
the	O
intervening	O
DNA	O
and	O
the	O
gene	O
by	O
a	O
tracking	O
and	O
transcription	O
mechanism	O
,	O
the	O
HS2	O
enhancer	O
may	B-SPECULATION
(	I-SPECULATION
i	I-SPECULATION
)	I-SPECULATION
open	I-SPECULATION
up	I-SPECULATION
the	I-SPECULATION
chromatin	I-SPECULATION
structure	I-SPECULATION
of	I-SPECULATION
a	I-SPECULATION
gene	I-SPECULATION
domain	I-SPECULATION
and	I-SPECULATION
(	I-SPECULATION
ii	I-SPECULATION
)	I-SPECULATION
deliver	I-SPECULATION
enhancer	I-SPECULATION
binding	I-SPECULATION
proteins	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
promoter	I-SPECULATION
sequence	I-SPECULATION
where	O
they	O
may	B-SPECULATION
stimulate	I-SPECULATION
the	I-SPECULATION
transcription	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
gene	I-SPECULATION
at	I-SPECULATION
the	I-SPECULATION
cap	I-SPECULATION
site	I-SPECULATION
.	O

Phorbol	O
ester	O
reduces	O
constitutive	O
nuclear	O
NF	O
kappa	O
B	O
and	O
inhibits	O
HIV-1	O
production	O
in	O
mature	O
human	O
monocytic	O
cells	O
.	O

NF	O
kappa	O
B	O
is	O
a	O
potent	O
mediator	O
of	O
specific	O
gene	O
expression	O
in	O
human	O
monocytes	O
and	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
transcription	O
of	O
the	O
HIV-1	O
genome	O
in	O
promonocytic	O
leukemias	O
.	O

There	O
is	O
little	O
information	O
available	O
on	O
the	O
response	O
of	O
NF	O
kappa	O
B	O
to	O
cytokines	O
in	O
normal	O
human	O
monocytes	O
.	O

We	O
have	O
used	O
a	O
32P-labeled	O
oligonucleotide	O
derived	O
from	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
long	O
terminal	O
repeat	O
,	O
which	O
contains	O
a	O
tandem	O
repeat	O
of	O
the	O
NF	O
kappa	O
B	O
binding	O
sequence	O
,	O
as	O
a	O
probe	O
in	O
a	O
gel	O
retardation	O
assay	O
to	O
study	O
this	O
transcription	O
factor	O
.	O

Using	O
this	O
assay	O
,	O
we	O
have	O
detected	O
NF	O
kappa	O
B	O
in	O
extracts	O
of	O
nuclei	O
from	O
normal	O
human	O
monocytes	O
.	O

Treatment	O
of	O
normal	O
monocytes	O
with	O
12-0-tetradecanoyl	O
phorbol-13-acetate	O
(	O
TPA	O
)	O
for	O
4-24	O
h	O
caused	O
the	O
complete	O
disappearance	O
of	O
NF	O
kappa	O
B	O
from	O
nuclear	O
extracts	O
of	O
monocytes	O
.	O

A	O
similar	O
result	O
was	O
obtained	O
with	O
the	O
mature	O
monocytic	O
leukemia	O
cell	O
line	O
THP-1	O
.	O

The	O
constitutive	O
transcription	O
factor	O
SP1	O
was	O
unaffected	O
by	O
addition	O
of	O
TPA	O
.	O

The	O
disappearance	O
of	O
NF	O
kappa	O
B	O
from	O
the	O
nucleus	O
was	O
concentration	O
dependent	O
between	O
10	O
and	O
50	O
ng	O
/	O
ml	O
of	O
phorbol	O
ester	O
.	O

In	O
THP-1	O
cells	O
,	O
TPA	O
also	O
induced	O
a	O
new	O
,	O
faster-migrating	O
NF	O
kappa	O
B	O
species	O
not	B-NEGATION
induced	I-NEGATION
in	I-NEGATION
monocytes	I-NEGATION
.	O

Protein	O
kinase	O
C	O
inhibitor	O
staurosporine	O
,	O
but	O
not	B-NEGATION
cyclic	I-NEGATION
nucleotide-dependent	I-NEGATION
protein	I-NEGATION
kinase	I-NEGATION
inhibitor	I-NEGATION
HA-1004	I-NEGATION
,	O
also	O
dramatically	O
reduced	O
constitutive	O
levels	O
of	O
nuclear	O
NF	O
kappa	O
B	O
.	O

Finally	O
,	O
TPA	O
addition	O
to	O
monocytes	O
infected	O
with	O
HIV-1	O
inhibited	O
HIV-1	O
replication	O
,	O
as	O
determined	O
by	O
reverse	O
transcriptase	O
assays	O
,	O
in	O
a	O
concentration-dependent	O
manner	O
.	O

These	O
results	O
are	O
in	O
striking	O
contrast	O
to	O
the	O
increase	O
in	O
nuclear	O
NF	O
kappa	O
B	O
and	O
HIV-1	O
replication	O
induced	O
by	O
phorbol	O
esters	O
in	O
promonocytic	O
leukemia	O
cells	O
U937	O
and	O
HL-60	O
,	O
and	O
emphasize	O
the	O
importance	O
of	O
studying	O
cytokine	O
regulation	O
of	O
HIV-1	O
in	O
normal	O
monocytes	O
.	O

Ablation	O
of	O
transplanted	O
HTLV-I	O
Tax-transformed	O
tumors	O
in	O
mice	O
by	O
antisense	O
inhibition	O
of	O
NF-kappa	O
B	O
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1993	O
Mar	O
12	O
;	O
259	O
(	O
5101	O
)	O
:	O
1523	O
]	O

Mice	O
transgenic	O
for	O
the	O
human	O
T	O
cell	O
leukemia	O
virus	O
(	O
HTLV-I	O
)	O
Tax	O
gene	O
develop	O
fibroblastic	O
tumors	O
that	O
express	O
NF-kappa	O
B-inducible	O
early	O
genes	O
.	O

In	O
vitro	O
inhibition	O
of	O
NF-kappa	O
B	O
expression	O
by	O
antisense	O
oligodeoxynucleotides	O
(	O
ODNs	O
)	O
inhibited	O
growth	O
of	O
these	O
culture-adapted	O
Tax-transformed	O
fibroblasts	O
as	O
well	O
as	O
an	O
HTLV-I-transformed	O
human	O
lymphocyte	O
line	O
.	O

In	O
contrast	O
,	O
antisense	O
inhibition	O
of	O
Tax	O
itself	O
had	O
no	B-NEGATION
apparent	I-NEGATION
effect	I-NEGATION
on	I-NEGATION
cell	I-NEGATION
growth	I-NEGATION
.	O

Mice	O
treated	O
with	O
antisense	O
to	O
NF-kappa	O
B	O
ODNs	O
showed	O
rapid	O
regression	O
of	O
transplanted	O
fibrosarcomas	O
.	O

This	O
suggests	B-SPECULATION
that	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
expression	I-SPECULATION
and	O
provides	O
a	O
therapeutic	O
approach	O
for	O
HTLV-I-associated	O
disease	O
.	O
may	B-SPECULATION
be	I-SPECULATION
necessary	I-SPECULATION
for	I-SPECULATION
the	I-SPECULATION
maintenance	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
malignant	I-SPECULATION
phenotype	I-SPECULATION
.	O

Inhibition	O
of	O
anti-CD3	O
monoclonal	O
antibody-induced	O
T-cell	O
proliferation	O
by	O
dexamethasone	O
,	O
isoproterenol	O
,	O
or	O
prostaglandin	O
E2	O
either	O
alone	O
or	O
in	O
combination	O
.	O

1	O
.	O
The	O
purpose	O
of	O
these	O
studies	O
was	O
to	O
investigate	O
the	O
modulation	O
of	O
the	O
proliferation	O
of	O
human	O
T	O
cells	O
obtained	O
from	O
peripheral	O
blood	O
by	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
isoproterenol	O
(	O
ISO	O
)	O
,	O
and	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
.	O

The	O
former	O
two	O
substances	O
interact	O
with	O
T	O
cells	O
via	O
the	O
glucocorticoid	O
and	O
beta-adrenergic	O
receptors	O
respectively	O
.	O

When	O
occupied	O
by	O
their	O
natural	O
ligands	O
,	O
glucocorticosteroids	O
and	O
catecholamines	O
,	O
these	O
receptors	O
have	O
a	O
role	O
in	O
modulating	O
T-cell	O
function	O
during	O
stress	O
.	O

During	O
the	O
inflammatory	O
response	O
increased	O
levels	O
of	O
PGE2	O
bind	O
to	O
their	O
receptors	O
on	O
T	O
cells	O
and	O
thus	O
alter	O
responsiveness	O
.	O

Proliferation	O
of	O
T	O
cells	O
was	O
induced	O
by	O
immobilized	O
anti-CD3	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
an	O
additional	O
costimulatory	O
signal	O
delivered	O
by	O
anti-CD28	O
mAb	O
.	O

2	O
.	O
Various	O
physiologic	O
concentrations	O
of	O
DEX	O
,	O
ISO	O
,	O
or	O
PGE2	O
were	O
added	O
at	O
the	O
time	O
of	O
initiation	O
of	O
the	O
cultures	O
and	O
subsequent	O
proliferation	O
of	O
the	O
unstimulated	O
T	O
cells	O
was	O
determined	O
.	O

The	O
results	O
demonstrate	O
that	O
physiologic	O
concentrations	O
of	O
all	O
three	O
of	O
these	O
agents	O
inhibit	O
the	O
anti-CD3	O
mAb-induced	O
proliferation	O
of	O
T	O
cells	O
.	O

3	O
.	O
Although	O
DEX	O
and	O
PGE2	O
were	O
equipotent	O
in	O
suppressing	O
T-cell	O
proliferation	O
,	O
ISO	O
was	O
much	O
less	O
effective	O
.	O

4	O
.	O
Because	O
concomitant	O
elevations	O
in	O
the	O
peripheral	O
levels	O
of	O
these	O
substances	O
may	B-SPECULATION
occur	I-SPECULATION
,	O
experiments	O
were	O
performed	O
to	O
determine	O
the	O
T-cell	O
inhibitory	O
effects	O
of	O
DEX	O
together	O
with	O
either	O
PGE2	O
or	O
ISO	O
.	O

Synergistic	O
suppression	O
of	O
T-cell	O
proliferation	O
was	O
observed	O
when	O
various	O
concentrations	O
of	O
DEX	O
and	O
PGE2	O
,	O
but	O
not	B-NEGATION
DEX	I-NEGATION
and	I-NEGATION
ISO	I-NEGATION
,	O
were	O
added	O
to	O
cultures	O
.	O

This	B-NEGATION
synergistic	I-NEGATION
suppression	I-NEGATION
could	I-NEGATION
not	I-NEGATION
be	I-NEGATION
explained	I-NEGATION
by	I-NEGATION
an	I-NEGATION
increase	I-NEGATION
in	I-NEGATION
cAMP	I-NEGATION
accumulation	I-NEGATION
in	I-NEGATION
T	I-NEGATION
cells	I-NEGATION
stimulated	I-NEGATION
with	I-NEGATION
DEX	I-NEGATION
and	I-NEGATION
PGE2	I-NEGATION
.	O

5	O
.	O
Finally	O
,	O
the	O
addition	O
of	O
anti-CD28	O
mAb	O
to	O
anti-CD3	O
mAb-stimulated	O
T	O
cells	O
overcame	O
much	O
of	O
the	O
suppression	O
of	O
proliferation	O
induced	O
by	O
PGE2	O
or	O
ISO	O
but	O
less	O
so	O
than	O
that	O
induced	O
by	O
DEX	O
.	O

Targeted	O
degradation	O
of	O
c-Fos	O
,	O
but	O
not	B-NEGATION
v-Fos	I-NEGATION
,	O
by	O
a	O
phosphorylation-dependent	O
signal	O
on	O
c-Jun	O
.	O

The	O
proto-oncogene	O
products	O
c-Fos	O
and	O
c-Jun	O
heterodimerize	O
through	O
their	O
leucine	O
zippers	O
to	O
form	O
the	O
AP-1	O
transcription	O
factor	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
heterodimer	O
is	O
regulated	O
by	O
signal-dependent	O
phosphorylation	O
and	O
dephosphorylation	O
events	O
.	O

The	O
stability	O
of	O
c-Fos	O
was	O
found	O
to	O
also	O
be	O
controlled	O
by	O
intracellular	O
signal	O
transduction	O
.	O

In	O
transient	O
expression	O
and	O
in	O
vitro	O
degradation	O
experiments	O
,	O
the	O
stability	O
of	O
c-Fos	O
was	O
decreased	O
when	O
the	O
protein	O
was	O
dimerized	O
with	O
phosphorylated	O
c-Jun	O
.	O

c-Jun	O
protein	O
isolated	O
from	O
phorbol	O
ester-induced	O
cells	O
did	O
not	B-NEGATION
target	I-NEGATION
c-Fos	I-NEGATION
for	I-NEGATION
degradation	I-NEGATION
,	O
which	O
suggests	B-SPECULATION
that	I-SPECULATION
c-Fos	I-SPECULATION
is	I-SPECULATION
transiently	I-SPECULATION
stabilized	I-SPECULATION
after	I-SPECULATION
stimulation	I-SPECULATION
of	I-SPECULATION
cell	I-SPECULATION
growth	I-SPECULATION
.	O

v-Fos	O
protein	O
,	O
the	O
retroviral	O
counterpart	O
of	O
c-Fos	O
,	O
was	O
not	B-NEGATION
susceptible	I-NEGATION
to	I-NEGATION
degradation	I-NEGATION
targeted	I-NEGATION
by	I-NEGATION
c-Jun	I-NEGATION
.	O

Mutations	O
in	O
the	O
Pit-1	O
gene	O
in	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
.	O

Pit-1	O
is	O
a	O
pituitary-specific	O
transcription	O
factor	O
that	O
binds	O
to	O
and	O
transactivates	O
promoters	O
of	O
growth	O
hormone	O
and	O
prolactin	O
genes	O
.	O

In	O
three	O
unrelated	O
Japanese	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
,	O
we	O
identified	O
three	O
point	O
mutations	O
in	O
the	O
Pit-1	O
gene	O
,	O
Pro24Leu	O
,	O
Arg143Gln	O
,	O
and	O
Arg271Trp	O
,	O
located	O
on	O
the	O
major	O
transactivation	O
region	O
,	O
POU-specific	O
domain	O
,	O
and	O
POU-homeodomain	O
,	O
respectively	O
.	O

Calcitriol	O
:	O
a	O
hematolymphopoietrope	O
?	O
[	O
editorial	O
]	O

A	O
MEDLINE	O
search	O
of	O
the	O
English-language	O
literature	O
was	O
conducted	O
using	O
the	O
indexing	O
terms	O
'	O
immunology	O
,	O
calcitriol	O
and	O
vitamin	O
D	O
'	O
to	O
identify	O
studies	O
indicating	B-SPECULATION
a	I-SPECULATION
role	I-SPECULATION
for	I-SPECULATION
calcitriol	I-SPECULATION
as	I-SPECULATION
a	I-SPECULATION
primary	I-SPECULATION
immunomodulator	I-SPECULATION
.	O

Sixty-six	O
papers	O
published	O
between	O
January	O
1956	O
and	O
June	O
1991	O
were	O
identified	O
.	O

Forty-five	O
of	O
these	O
reports	O
are	O
cited	O
in	O
this	O
review	O
.	O

The	O
data	O
strongly	O
suggest	B-SPECULATION
an	I-SPECULATION
endocrine	B-SPECULATION
,	I-SPECULATION
autocrine	I-SPECULATION
and	I-SPECULATION
/	I-SPECULATION
or	I-SPECULATION
paracrine	I-SPECULATION
role	O
for	O
calcitriol	O
in	O
immune	O
regulation	O
.	O

No	B-NEGATION
unifying	I-NEGATION
hypothesis	I-NEGATION
has	I-NEGATION
yet	I-NEGATION
emerged	I-NEGATION
explaining	I-NEGATION
this	I-NEGATION
collection	I-NEGATION
of	I-NEGATION
data	I-NEGATION
.	O

This	O
paper	O
provides	O
a	O
brief	O
review	O
of	O
immune	O
properties	O
currently	O
attributed	O
to	O
calcitriol	O
.	O

Activation	O
of	O
protein	O
kinase	O
C	O
and	O
elevation	O
of	O
cAMP	O
interact	O
synergistically	O
to	O
raise	O
c-Fos	O
and	O
AP-1	O
activity	O
in	O
Jurkat	O
cells	O
.	O

We	O
have	O
earlier	O
found	O
that	O
in	O
Jurkat	O
cells	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
enhances	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
accumulation	O
induced	O
by	O
adenosine	O
receptor	O
stimulation	O
or	O
activation	O
of	O
Gs	O
.	O

Here	O
we	O
have	O
therefore	O
examined	O
the	O
effect	O
of	O
the	O
phorbol	O
ester	O
PMA	O
(	O
phorbol	O
12-myristate	O
13-acetate	O
)	O
which	O
stimulates	O
PKC	O
and	O
a	O
combination	O
of	O
the	O
adenosine	O
receptor	O
agonist	O
NECA	O
(	O
5	O
'-(	O
N-ethyl	O
)-	O
carboxamido	O
adenosine	O
)	O
and	O
forskolin	O
to	O
raise	O
cAMP	O
,	O
on	O
the	O
levels	O
of	O
c-Fos	O
and	O
Jun	O
and	O
on	O
the	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
transcription	O
factor	O
,	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
.	O

PMA	O
treatment	O
caused	O
a	O
concentration	O
-	O
and	O
time-dependent	O
increase	O
in	O
both	O
c-Fos	O
and	O
Jun	O
immunoreactivity	O
in	O
contrast	O
to	O
cAMP	O
elevation	O
that	O
had	O
only	O
a	O
slight	O
effect	O
.	O

Both	O
PMA	O
and	O
the	O
combination	O
of	O
NECA	O
and	O
forskolin	O
acted	O
together	O
either	O
to	O
increase	O
(	O
c-Fos	O
)	O
or	O
decrease	O
(	O
Jun	O
)	O
protein	O
levels	O
as	O
well	O
as	O
increasing	O
AP-1	O
binding	O
,	O
as	O
judged	O
by	O
gel-shift	O
assay	O
,	O
and	O
AP-1	O
transcriptional	O
activity	O
.	O

Furthermore	O
there	O
was	O
a	O
clear-cut	O
synergy	O
between	O
the	O
PKC	O
stimulator	O
and	O
the	O
cAMP	O
elevating	O
agents	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
PKC	O
and	O
elevation	O
of	O
cAMP	O
leads	O
to	O
an	O
enhanced	O
AP-1	O
transcriptional	O
activity	O
in	O
a	O
T-leukemia	O
cell	O
line	O
,	O
suggesting	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
previously	I-SPECULATION
observed	I-SPECULATION
interaction	I-SPECULATION
between	I-SPECULATION
the	I-SPECULATION
parallel	I-SPECULATION
signal	I-SPECULATION
transduction	I-SPECULATION
pathways	I-SPECULATION
may	B-SPECULATION
have	I-SPECULATION
functional	I-SPECULATION
consequences	I-SPECULATION
at	I-SPECULATION
the	I-SPECULATION
level	I-SPECULATION
of	I-SPECULATION
gene	I-SPECULATION
transcription	I-SPECULATION
.	O

The	O
use	O
of	O
interferon-gamma-treated	O
U937	O
cells	O
in	O
chemiluminescence	O
assays	O
to	O
detect	O
red	O
cell	O
,	O
platelet	O
and	O
granulocyte	O
antibodies	O
of	O
potential	O
clinical	O
significance	O
.	O

The	O
chemiluminescent	O
(	O
CL	O
)	O
response	O
of	O
interferon-gamma-treated	O
U937	O
(	O
IFN-U937	O
)	O
cells	O
to	O
sensitized	O
target	O
cells	O
has	O
been	O
used	O
to	O
detect	O
red	O
cell	O
,	O
platelet	O
and	O
granulocyte	O
antibodies	O
.	O

A	O
clone	O
of	O
U937	O
cells	O
was	O
selected	O
which	O
expressed	O
Fc	O
receptor	O
I	O
(	O
Fc	O
gamma	O
RI	O
)	O
and	O
which	O
,	O
after	O
incubation	O
with	O
IFN-gamma	O
for	O
72	O
h	O
,	O
was	O
capable	O
of	O
generating	O
high	O
levels	O
of	O
lucigenin-enhanced	O
CL	O
.	O

The	O
CL	O
responses	O
of	O
IFN-U937	O
cells	O
and	O
peripheral	O
blood	O
human	O
monocytes	O
to	O
sensitized	O
red	O
cells	O
,	O
platelets	O
or	O
granulocytes	O
were	O
then	O
compared	O
.	O

Assays	O
using	O
monocytes	O
or	O
IFN-U937	O
cells	O
were	O
of	O
comparable	O
sensitivity	O
for	O
detection	O
of	O
antibodies	O
against	O
all	O
three	O
types	O
of	O
target	O
cell	O
.	O

In	O
addition	O
,	O
the	O
use	O
of	O
IFN-U937	O
cells	O
reduced	O
interassay	O
variation	O
and	O
simplified	O
assay	O
performance	O
.	O

The	B-SPECULATION
suggested	I-SPECULATION
by	I-SPECULATION
the	I-SPECULATION
ability	I-SPECULATION
of	I-SPECULATION
both	I-SPECULATION
monocytes	I-SPECULATION
and	I-SPECULATION
IFN-U937	I-SPECULATION
cells	I-SPECULATION
to	I-SPECULATION
respond	I-SPECULATION
to	I-SPECULATION
potential	B-SPECULATION
clinical	I-SPECULATION
usefulness	I-SPECULATION
of	I-SPECULATION
these	I-SPECULATION
CL	I-SPECULATION
assays	I-SPECULATION
was	O
red	B-SPECULATION
cells	I-SPECULATION
,	I-SPECULATION
platelets	I-SPECULATION
or	I-SPECULATION
granulocytes	I-SPECULATION
sensitized	O
with	O
sera	O
from	O
pregnant	O
women	O
whose	O
babies	O
had	O
either	B-SPECULATION
haemolytic	I-SPECULATION
disease	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
newborn	I-SPECULATION
(	I-SPECULATION
HDN	I-SPECULATION
)	I-SPECULATION
,	I-SPECULATION
alloimmune	I-SPECULATION
thrombocytopenia	I-SPECULATION
respectively	O
.	O

In	O
addition	O
,	O
monocytes	O
and	O
IFN-U937	O
cells	O
both	O
responded	O
to	O
red	O
cells	O
sensitized	O
with	O
antibodies	O
against	O
a	O
variety	O
of	O
specificities	O
of	O
assumed	B-SPECULATION
(	I-SPECULATION
although	I-SPECULATION
not	B-NEGATION
documented	I-NEGATION
)	O
clinical	O
significance	O
for	O
blood	O
transfusion	O
recipients	O
.	O

In	O
contrast	O
,	O
monocytes	O
and	O
IFN-U937	O
cells	O
responded	O
only	O
weakly	O
to	O
red	O
cells	O
sensitized	O
with	O
either	O
anti-D	O
in	O
sera	O
from	O
mothers	O
of	O
babies	O
unaffected	O
by	O
HDN	O
,	O
or	O
with	O
antisera	O
containing	O
high	O
titre	O
antibodies	O
with	O
specificities	O
not	B-NEGATION
normally	I-NEGATION
associated	I-NEGATION
with	I-NEGATION
significantly	I-NEGATION
reduced	I-NEGATION
red	I-NEGATION
cell	I-NEGATION
survival	I-NEGATION
.	O

Involvement	O
of	O
Alu	O
sequences	O
in	O
the	O
cell-specific	O
regulation	O
of	O
transcription	O
of	O
the	O
gamma	O
chain	O
of	O
Fc	O
and	O
T	O
cell	O
receptors	O
.	O

The	O
Fc	O
epsilon	O
RI-gamma	O
chains	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
hematopoietic	O
cells	O
where	O
they	O
play	O
a	O
critical	O
role	O
in	O
signal	O
transduction	O
.	O

They	O
are	O
part	O
of	O
the	O
high	O
affinity	O
IgE	O
receptor	O
in	O
mast	O
cells	O
,	O
basophils	O
,	O
Langerhans	O
cells	O
,	O
and	O
possibly	B-SPECULATION
other	I-SPECULATION
cells	I-SPECULATION
;	O
a	O
component	O
of	O
the	O
low	O
affinity	O
receptor	O
for	O
IgG	O
(	O
Fc	O
gamma	O
RIIIA	O
or	O
CD16	O
)	O
in	O
natural	O
killer	O
cells	O
and	O
macrophages	O
;	O
and	O
part	O
of	O
the	O
T	O
cell	O
antigen	O
receptor	O
in	O
subsets	O
of	O
T	O
cells	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
transcriptional	O
regulation	O
of	O
the	O
gamma	O
chain	O
gene	O
by	O
analyzing	O
the	O
2.5-kilobase	O
sequence	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

This	O
sequence	O
contains	O
a	O
promoter	O
specific	O
to	O
cells	O
of	O
hematopoietic	O
lineage	O
.	O

However	O
,	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	O
is	O
only	O
partial	O
because	O
it	O
is	O
active	O
in	O
all	O
of	O
the	O
hematopoietic	O
cells	O
tested	O
here	O
,	O
regardless	O
of	O
whether	B-SPECULATION
they	I-SPECULATION
constitutively	I-SPECULATION
express	I-SPECULATION
Fc	I-SPECULATION
epsilon	I-SPECULATION
RI-gamma	I-SPECULATION
chain	I-SPECULATION
transcripts	I-SPECULATION
.	O

We	O
have	O
identified	O
two	O
adjacent	O
cis-acting	O
regulatory	O
elements	O
,	O
both	O
of	O
which	O
are	O
part	O
of	O
an	O
Alu	O
repeat	O
.	O

The	O
first	O
(-	O
445	O
/-	O
366	O
)	O
is	O
a	O
positive	O
element	O
active	O
in	O
both	O
basophils	O
and	O
T	O
cells	O
.	O

The	O
second	O
(-	O
365	O
/-	O
264	O
)	O
binds	O
to	O
nuclear	O
factors	O
,	O
which	B-SPECULATION
appear	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
different	I-SPECULATION
in	I-SPECULATION
basophils	I-SPECULATION
and	I-SPECULATION
T	I-SPECULATION
cells	I-SPECULATION
,	O
and	O
acts	O
as	O
a	O
negative	O
element	O
in	O
basophils	O
and	O
as	O
a	O
positive	O
one	O
in	O
T	O
cells	O
.	O

Thus	O
,	O
this	O
Alu	O
repeat	O
(	O
90	O
%	O
identical	O
to	O
Alu	O
consensus	O
sequences	O
)	O
has	O
evolved	O
to	O
become	O
both	O
a	O
positive	O
and	O
negative	O
regulator	O
.	O

Human	O
immunodeficiency	O
viruses	O
containing	O
heterologous	O
enhancer	O
/	O
promoters	O
are	O
replication	O
competent	O
and	O
exhibit	O
different	O
lymphocyte	O
tropisms	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
and	O
the	O
constitutively	O
expressed	O
transcription	O
factor	O
Sp1	O
,	O
both	O
of	O
which	O
are	O
highly	O
conserved	O
in	O
HIV	O
and	O
simian	O
immunodeficiency	O
virus	O
isolates	O
.	O

To	O
delineate	O
the	O
effects	O
of	O
these	O
motifs	O
on	O
the	O
replicative	O
capacity	O
of	O
HIV	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
extending	O
the	O
virus	O
host	O
range	O
,	O
known	O
heterologous	O
enhancer	O
/	O
promoters	O
were	O
inserted	O
into	O
the	O
HIV-1	O
LTR	O
in	O
place	O
of	O
the	O
NF-kappa	O
B	O
and	O
Sp1	O
binding	O
sites	O
.	O

The	O
effects	O
of	O
these	O
substitutions	O
on	O
viral	O
replication	O
in	O
transfected	O
HeLa	O
cells	O
and	O
on	O
HIV	O
infection	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
or	O
continuous	O
T-leukemia	O
cell	O
lines	O
were	O
evaluated	O
.	O

HIVs	O
in	O
which	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Sp1	O
enhancer	O
plus	O
the	O
downstream	O
TATA	O
element	O
were	O
replaced	O
with	O
heterologous	O
enhancer	O
/	O
promoters	O
were	O
also	O
constructed	O
.	O

Viruses	O
containing	O
the	O
human	O
cytomegalovirus	O
immediate-early	O
enhancer	O
exhibited	O
infectious	O
kinetics	O
similar	O
to	O
that	O
of	O
wild-type	O
HIV	O
in	O
activated	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	O
AA2	O
cells	O
but	O
replicated	O
less	O
efficiently	O
in	O
H9	O
and	O
CEM	O
cells	O
.	O

These	O
studies	O
indicate	B-SPECULATION
that	I-SPECULATION
heterologous	I-SPECULATION
enhancer	I-SPECULATION
elements	I-SPECULATION
are	I-SPECULATION
capable	I-SPECULATION
of	I-SPECULATION
restoring	I-SPECULATION
Tat	I-SPECULATION
responsiveness	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
HIV	I-SPECULATION
LTR	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
context	I-SPECULATION
of	I-SPECULATION
directing	I-SPECULATION
reporter	I-SPECULATION
gene	I-SPECULATION
expression	I-SPECULATION
as	I-SPECULATION
well	I-SPECULATION
as	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
production	I-SPECULATION
of	I-SPECULATION
infectious	I-SPECULATION
progeny	I-SPECULATION
virions	I-SPECULATION
.	O

Tyrosine	O
phosphorylation	O
is	O
a	O
mandatory	O
proximal	O
step	O
in	O
radiation-induced	O
activation	O
of	O
the	O
protein	O
kinase	O
C	O
signaling	O
pathway	O
in	O
human	O
B	O
-	O
lymphocyte	O
precursors	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1993	O
Apr	O
15	O
;	O
90	O
(	O
8	O
)	O
:	O
3775	O
]	O

Ionizing	O
radiation	O
triggers	O
a	O
signal	O
in	O
human	O
B-lymphocyte	O
precursors	O
that	O
is	O
intimately	O
linked	O
to	O
an	O
active	O
protein-tyrosine	O
kinase	O
regulatory	O
pathway	O
.	O

We	O
show	O
that	O
in	O
B-lymphocyte	O
precursors	O
,	O
irradiation	O
with	O
gamma-rays	O
leads	O
to	O
(	O
i	O
)	O
stimulation	O
of	O
phosphatidylinositol	O
turnover	O
;	O
(	O
ii	O
)	O
downstream	O
activation	O
by	O
covalent	O
modification	O
of	O
multiple	O
serine-specific	O
protein	O
kinases	O
,	O
including	O
protein	O
kinase	O
C	O
;	O
and	O
(	O
iii	O
)	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
.	O

All	O
of	O
the	O
radiation-induced	O
signals	O
were	O
effectively	O
prevented	O
by	O
the	O
protein-tyrosine	O
kinase	O
inhibitors	O
genistein	O
and	O
herbimycin	O
A	O
.	O

Thus	O
,	O
tyrosine	O
phosphorylation	O
is	O
an	O
important	O
and	O
perhaps	B-SPECULATION
mandatory	I-SPECULATION
proximal	O
step	O
in	O
the	O
activation	O
of	O
the	O
protein	O
kinase	O
C	O
signaling	O
cascade	O
in	O
human	O
B-lymphocyte	O
precursors	O
.	O

Our	O
report	O
expands	O
current	O
knowledge	O
of	O
the	O
radiation-induced	O
signaling	O
cascade	O
by	O
clarifying	O
the	O
chronological	O
sequence	O
of	O
biochemical	O
events	O
that	O
follow	O
irradiation	O
.	O

Photoaffinity	O
labeling	O
of	O
plasma	O
membrane	O
receptors	O
for	O
aldosterone	O
from	O
human	O
mononuclear	O
leukocytes	O
.	O

Non-genomic	O
effects	O
of	O
aldosterone	O
on	O
the	O
sodium-proton-antiport	O
have	O
been	O
shown	O
in	O
human	O
mononuclear	O
leukocytes	O
which	B-SPECULATION
could	I-SPECULATION
be	I-SPECULATION
related	I-SPECULATION
to	I-SPECULATION
a	I-SPECULATION
new	I-SPECULATION
aldosterone	I-SPECULATION
membrane	I-SPECULATION
receptor	I-SPECULATION
.	O

In	O
the	O
present	O
paper	O
plasma	O
membranes	O
from	O
human	O
mononuclear	O
leukocytes	O
were	O
covalently	O
photolabeled	O
with	O
a	O
[	O
125I	O
]-	O
aldosterone	O
derivative	O
.	O

Sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
showed	O
significant	O
aldosterone	O
binding	O
at	O
a	O
molecular	O
weight	O
of	O
approximately	O
50000	O
Dalton	O
which	O
was	O
absent	O
with	O
1	O
microM	O
cold	O
aldosterone	O
,	O
but	O
not	B-NEGATION
cortisol	I-NEGATION
in	O
the	O
binding	O
media	O
.	O

The	O
presence	O
of	O
the	O
sulfhydryl	O
agent	O
dithiothreitol	O
did	O
not	B-NEGATION
affect	I-NEGATION
results	I-NEGATION
suggesting	B-SPECULATION
the	I-SPECULATION
absence	B-NEGATION
of	I-NEGATION
disulfide	I-NEGATION
bridges	I-NEGATION
in	I-NEGATION
the	I-NEGATION
steroid	I-NEGATION
binding	I-NEGATION
domain	I-NEGATION
of	I-NEGATION
the	I-NEGATION
receptor	I-NEGATION
.	O

These	O
data	O
are	O
the	O
first	O
to	O
define	O
the	O
molecular	O
weight	O
of	O
the	O
membrane	O
receptor	O
for	O
aldosterone	O
.	O

Alpha-lipoic	O
acid	O
is	O
a	O
potent	O
inhibitor	O
of	O
NF-kappa	O
B	O
activation	O
in	O
human	O
T	O
cells	O
.	O

Acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
results	O
from	O
infection	O
with	O
a	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

The	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
region	O
of	O
HIV	O
proviral	O
DNA	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
,	O
and	O
this	B-SPECULATION
transcriptional	I-SPECULATION
activator	I-SPECULATION
appears	I-SPECULATION
to	I-SPECULATION
regulate	I-SPECULATION
HIV	I-SPECULATION
activation	I-SPECULATION
.	O

Recent	O
findings	O
suggest	B-SPECULATION
an	I-SPECULATION
involvement	I-SPECULATION
of	I-SPECULATION
reactive	I-SPECULATION
oxygen	I-SPECULATION
species	I-SPECULATION
(	I-SPECULATION
ROS	I-SPECULATION
)	I-SPECULATION
in	I-SPECULATION
signal	I-SPECULATION
transduction	I-SPECULATION
pathways	I-SPECULATION
leading	I-SPECULATION
to	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
activation	I-SPECULATION
.	O

The	O
present	O
study	O
was	O
based	O
on	O
reports	O
that	O
antioxidants	O
which	O
eliminate	O
ROS	O
should	B-SPECULATION
block	I-SPECULATION
the	I-SPECULATION
activation	I-SPECULATION
of	I-SPECULATION
NF-kappa	I-SPECULATION
B	I-SPECULATION
and	I-SPECULATION
subsequently	I-SPECULATION
HIV	I-SPECULATION
transcription	I-SPECULATION
,	O
and	O
thus	O
antioxidants	B-SPECULATION
can	I-SPECULATION
be	I-SPECULATION
used	I-SPECULATION
as	I-SPECULATION
therapeutic	I-SPECULATION
agents	I-SPECULATION
for	I-SPECULATION
AIDS	I-SPECULATION
.	O

Incubation	O
of	O
Jurkat	O
T	O
cells	O
(	O
1	O
x	O
10	O
(	O
6	O
)	O
cells	O
/	O
ml	O
)	O
with	O
a	O
natural	O
thiol	O
antioxidant	O
,	O
alpha-lipoic	O
acid	O
,	O
prior	O
to	O
the	O
stimulation	O
of	O
cells	O
was	O
found	O
to	O
inhibit	O
NF-kappa	O
B	O
activation	O
induced	O
by	O
tumor	O
necrosis	O
factor-alpha	O
(	O
25	O
ng	O
/	O
ml	O
)	O
or	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
50	O
ng	O
/	O
ml	O
)	O
.	O

The	O
inhibitory	O
action	O
of	O
alpha-lipoic	O
acid	O
was	O
found	O
to	O
be	O
very	O
potent	O
as	O
only	O
4	O
mM	O
was	O
needed	O
for	O
a	O
complete	O
inhibition	O
,	O
whereas	O
20	O
mM	O
was	O
required	O
for	O
N-acetylcysteine	O
.	O

These	O
results	O
indicate	B-SPECULATION
that	I-SPECULATION
alpha-lipoic	I-SPECULATION
acid	I-SPECULATION
may	B-SPECULATION
be	I-SPECULATION
effective	I-SPECULATION
in	I-SPECULATION
AIDS	I-SPECULATION
therapeutics	I-SPECULATION
.	O

A	O
human	O
putative	B-SPECULATION
lymphocyte	I-SPECULATION
G0	I-SPECULATION
/	I-SPECULATION
G1	I-SPECULATION
switch	I-SPECULATION
gene	I-SPECULATION
homologous	O
to	O
a	O
rodent	O
gene	O
encoding	O
a	O
zinc-binding	O
potential	O
transcription	O
factor	O
.	O

G0S24	O
is	O
a	O
member	O
of	O
a	O
set	O
of	O
genes	O
(	O
putative	B-SPECULATION
G0	I-SPECULATION
/	I-SPECULATION
G1	I-SPECULATION
switch	I-SPECULATION
regulatory	I-SPECULATION
genes	I-SPECULATION
)	O
that	O
are	O
expressed	O
transiently	O
within	O
1-2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	O
or	O
cycloheximide	O
to	O
human	O
blood	O
mononuclear	O
cells	O
.	O

Comparison	O
of	O
a	O
full-length	O
cDNA	O
sequence	O
with	O
the	O
corresponding	O
genomic	O
sequence	O
reveals	O
an	O
open	O
reading	O
frame	O
of	O
326	O
amino	O
acids	O
,	O
distributed	O
across	O
two	O
exons	O
.	O

Potential	O
phosphorylation	O
sites	O
include	O
the	O
sequence	O
PSPTSPT	O
,	O
which	O
resembles	O
an	O
RNA	O
polymerase	O
II	O
repeat	O
reported	O
to	O
be	O
a	O
target	O
of	O
the	O
cell	O
cycle	O
control	O
kinase	O
cdc2	O
.	O

Comparison	O
of	O
the	O
derived	O
protein	O
sequence	O
with	O
those	O
of	O
rodent	O
homologs	O
allows	O
classification	O
into	O
three	O
groups	O
.	O

Group	O
1	O
contains	O
G0S24	O
and	O
the	O
rat	O
and	O
mouse	O
TIS11	O
genes	O
(	O
also	O
known	O
as	O
TTP	O
,	O
Nup475	O
,	O
and	O
Zfp36	O
)	O
.	O

Members	O
of	O
this	O
group	O
have	O
three	O
tetraproline	O
repeats	O
.	O

Groups	O
1	O
and	O
2	O
have	O
a	O
serine-rich	O
region	O
and	O
an	O
"	O
arginine	O
element	O
"	O
(	O
RRLPIF	O
)	O
at	O
the	O
carboxyl	O
terminus	O
.	O

All	O
groups	O
contain	O
cysteine	O
-	O
and	O
histidine-rich	O
putative	B-SPECULATION
zinc	I-SPECULATION
finger	I-SPECULATION
domains	I-SPECULATION
and	O
a	O
serine-phenylalanine	O
"	O
SFS	O
"	O
domain	O
similar	O
to	O
part	O
of	O
the	O
large	O
subunit	O
of	O
eukaryotic	O
RNA	O
polymerase	O
II	O
.	O

Comparison	O
of	O
group	O
1	O
human	O
and	O
mouse	O
genomic	O
sequences	O
shows	O
high	O
conservation	O
in	O
the	O
5	O
'	O
flank	O
and	O
exons	O
.	O

A	O
CpG	O
island	O
suggests	B-SPECULATION
expression	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
germ	I-SPECULATION
line	I-SPECULATION
.	O

G0S24	O
has	O
potential	O
sites	O
for	O
transcription	O
factors	O
in	O
the	O
5	O
'	O
flank	O
and	O
intron	O
;	O

these	O
include	O
a	O
serum	O
response	O
element	O
.	O

Protein	O
and	O
genomic	O
sequences	O
show	O
similarities	O
with	O
those	O
of	O
a	O
variety	O
of	O
proteins	O
involved	O
in	O
transcription	O
,	O
suggesting	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
G0S24	I-SPECULATION
product	I-SPECULATION
has	I-SPECULATION
a	I-SPECULATION
similar	I-SPECULATION
role	I-SPECULATION
.	O

Interleukin-4	O
inhibits	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
c-jun	O
and	O
c-fos	O
messenger	O
RNA	O
and	O
activator	O
protein-1	O
binding	O
activity	O
in	O
human	O
monocytes	O
.	O

We	O
studied	O
the	O
effect	O
of	O
interleukin-4	O
(	O
IL-4	O
)	O
on	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
two	O
immediate	O
early	O
genes	O
c-fos	O
and	O
c-jun	O
.	O

These	O
genes	O
encode	O
proteins	O
that	O
form	O
the	O
dimeric	O
complex	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
,	O
which	O
is	O
active	O
as	O
a	O
transcriptional	O
factor	O
.	O

Maximal	O
accumulation	O
of	O
either	O
c-fos	O
and	O
c-jun	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
occurred	O
30	O
minutes	O
after	O
LPS	O
addition	O
.	O

When	O
cells	O
were	O
treated	O
with	O
IL-4	O
for	O
5	O
hours	O
before	O
LPS	O
activation	O
,	O
both	O
the	O
c-fos	O
and	O
the	O
c-jun	O
mRNA	O
expression	O
was	O
decreased	O
.	O

The	O
inhibition	O
of	O
c-fos	O
and	O
c-jun	O
expression	O
by	O
IL-4	O
in	O
LPS-treated	O
cells	O
was	O
shown	O
to	O
be	O
due	O
to	O
a	O
lower	O
transcription	O
rate	O
of	O
the	O
c-fos	O
and	O
c-jun	O
genes	O
.	O

IL-4	O
did	O
not	B-NEGATION
affect	I-NEGATION
the	I-NEGATION
stability	I-NEGATION
of	I-NEGATION
the	I-NEGATION
c-fos	I-NEGATION
and	I-NEGATION
c-jun	I-NEGATION
transcripts	I-NEGATION
.	O

Finally	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
evidence	O
was	O
obtained	O
that	O
IL-4	O
inhibits	O
LPS-induced	O
expression	O
of	O
AP-1	O
protein	O
.	O

These	O
data	O
indicate	B-SPECULATION
that	I-SPECULATION
IL-4	I-SPECULATION
suppresses	I-SPECULATION
the	I-SPECULATION
induction	I-SPECULATION
of	I-SPECULATION
transcription	I-SPECULATION
factors	I-SPECULATION
in	I-SPECULATION
human	I-SPECULATION
activated	I-SPECULATION
monocytes	I-SPECULATION
.	O

Ras	O
oncogene	O
transformation	O
of	O
human	O
B	O
lymphoblasts	O
is	O
associated	O
with	O
lymphocyte	O
activation	O
and	O
with	O
a	O
block	O
of	O
differentiation	O
.	O

The	O
p21ras	O
small	O
GTP	O
binding	O
proteins	O
participate	O
in	O
signal	O
transduction	O
from	O
cell	O
surface	O
receptors	O
and	O
affect	O
neoplastic	O
transformation	O
and	O
development	O
in	O
many	O
different	O
cell	O
types	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
relationship	O
between	O
ras	O
transformation	O
and	O
differentiation	O
of	O
human	O
B	O
lymphocytes	O
.	O

We	O
show	O
that	O
the	O
constitutive	O
expression	O
of	O
the	O
T24	O
Ha-ras	O
oncogene	O
in	O
EBV-immortalized	O
B	O
lymphoblasts	O
was	O
associated	O
with	O
the	O
induction	O
of	O
the	O
interleukin	O
2	O
receptor	O
alpha	O
subunit	O
,	O
with	O
an	O
impaired	O
immunoglobulin	O
gene	O
expression	O
,	O
altered	O
adhesion	O
properties	O
and	O
increased	O
survival	O
in	O
serum-free	O
medium	O
.	O

Since	O
induction	O
of	O
the	O
IL-2	O
receptor	O
alpha	O
subunit	O
is	O
a	O
hallmark	O
of	O
lymphocyte	O
activation	O
,	O
we	O
suggest	B-SPECULATION
that	I-SPECULATION
p21ras	I-SPECULATION
naturally	I-SPECULATION
triggers	I-SPECULATION
B	I-SPECULATION
cell	I-SPECULATION
activation	I-SPECULATION
.	O

The	O
ras-transformed	O
lymphocytes	O
displayed	O
a	O
fully	O
functional	O
IL-2r	O
,	O
as	O
assessed	O
by	O
c-fos	O
induction	O
following	O
treatment	O
with	O
IL-2	O
;	O
nevertheless	O
,	O
they	B-NEGATION
were	I-NEGATION
not	I-NEGATION
growth	I-NEGATION
stimulated	I-NEGATION
by	I-NEGATION
this	I-NEGATION
lymphokine	I-NEGATION
.	O

The	O
decreased	O
expression	O
of	O
immunoglobulin	O
genes	O
indicates	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
ras	I-SPECULATION
oncogene	I-SPECULATION
blocks	I-SPECULATION
terminal	I-SPECULATION
differentiation	I-SPECULATION
to	I-SPECULATION
plasma	I-SPECULATION
cells	I-SPECULATION
,	I-SPECULATION
possibly	B-SPECULATION
by	I-SPECULATION
inhibiting	I-SPECULATION
the	I-SPECULATION
activity	I-SPECULATION
of	I-SPECULATION
lymphocyte-specific	I-SPECULATION
transcription	I-SPECULATION
factors	I-SPECULATION
.	O

Somewhat	O
unexpectedly	O
,	O
the	O
constitutive	O
p21ras	O
activity	O
did	O
not	B-NEGATION
cause	I-NEGATION
an	I-NEGATION
increased	I-NEGATION
DNA	I-NEGATION
binding	I-NEGATION
of	I-NEGATION
transcription	I-NEGATION
factors	I-NEGATION
PEA1	I-NEGATION
(	I-NEGATION
AP1	I-NEGATION
)	I-NEGATION
,	I-NEGATION
PEA3	I-NEGATION
,	I-NEGATION
Oct-2	I-NEGATION
or	I-NEGATION
NF-kB	I-NEGATION
.	O

Transcription	O
factor	O
GATA-1	O
and	O
erythroid	O
development	O
.	O

In	O
summary	O
,	O
we	O
derived	O
an	O
experimental	O
system	O
that	O
allows	O
us	O
to	O
dissect	O
the	O
function	O
of	O
GATA-1	O
in	O
red	O
cell	O
development	O
at	O
a	O
genetic	O
level	O
.	O

We	O
have	O
established	O
the	O
essential	O
nature	O
of	O
GATA-1	O
during	O
both	O
primitive	O
and	O
definitive	O
erythropoiesis	O
.	O

By	O
ablating	O
the	O
expression	O
of	O
the	O
endogenous	O
GATA-1	O
gene	O
,	O
we	O
are	O
in	O
a	O
position	O
to	O
introduce	O
a	O
variety	O
of	O
constructs	O
that	O
harbor	O
subtle	O
modifications	O
in	O
flanking	O
or	O
protein-coding	O
sequences	O
.	O

We	O
can	O
now	O
study	O
regulatory	O
regions	O
and	O
functional	O
domains	O
of	O
the	O
protein	O
in	O
the	O
context	O
of	O
a	O
true	O
erythroid	O
environment	O
,	O
experiments	O
that	O
have	O
not	B-NEGATION
been	I-NEGATION
possible	I-NEGATION
heretofore	I-NEGATION
.	O

Although	O
the	O
assay	O
involves	O
the	O
dramatic	O
loss	O
of	O
red	O
cell	O
production	O
,	O
it	O
should	B-SPECULATION
be	I-SPECULATION
possible	B-SPECULATION
to	I-SPECULATION
define	I-SPECULATION
important	I-SPECULATION
regulatory	I-SPECULATION
domains	I-SPECULATION
that	I-SPECULATION
can	I-SPECULATION
then	I-SPECULATION
be	I-SPECULATION
assayed	I-SPECULATION
using	I-SPECULATION
less	I-SPECULATION
stringent	I-SPECULATION
systems	I-SPECULATION
,	I-SPECULATION
such	I-SPECULATION
as	I-SPECULATION
cell-free	I-SPECULATION
extracts	I-SPECULATION
for	I-SPECULATION
in	I-SPECULATION
vitro	I-SPECULATION
transcription	I-SPECULATION
.	O

The	O
ideal	O
situation	O
would	B-SPECULATION
be	I-SPECULATION
analyses	I-SPECULATION
conducted	I-SPECULATION
in	I-SPECULATION
GATA-1	I-SPECULATION
-	I-SPECULATION
erythroid	I-SPECULATION
cells	I-SPECULATION
.	O

However	O
,	O
these	B-NEGATION
cells	I-NEGATION
have	I-NEGATION
been	I-NEGATION
impossible	I-NEGATION
to	I-NEGATION
generate	I-NEGATION
given	O
the	O
requirement	O
of	O
GATA-1	O
for	O
Epo	O
receptor	O
expression	O
and	O
red	O
cell	O
viability	O
(	O
C.	O
Simon	O
and	O
S.	O
Orkin	O
,	O
unpublished	O
observations	O
)	O
.	O

It	O
may	B-SPECULATION
be	I-SPECULATION
possible	B-SPECULATION
to	I-SPECULATION
produce	I-SPECULATION
such	I-SPECULATION
cells	I-SPECULATION
by	I-SPECULATION
first	I-SPECULATION
expressing	I-SPECULATION
the	I-SPECULATION
Epo	I-SPECULATION
receptor	I-SPECULATION
under	I-SPECULATION
the	I-SPECULATION
influence	I-SPECULATION
of	I-SPECULATION
a	I-SPECULATION
constitutive	I-SPECULATION
promoter	I-SPECULATION
and	I-SPECULATION
then	I-SPECULATION
targeting	I-SPECULATION
the	I-SPECULATION
GATA-1	I-SPECULATION
gene	I-SPECULATION
.	O

If	O
GATA-1	O
-	O
red	O
cells	O
were	O
available	O
,	O
the	O
analyses	O
would	B-SPECULATION
involve	I-SPECULATION
the	I-SPECULATION
actual	I-SPECULATION
transcription	I-SPECULATION
of	I-SPECULATION
or	I-SPECULATION
chromatin	I-SPECULATION
structure	I-SPECULATION
surrounding	I-SPECULATION
the	I-SPECULATION
globin	I-SPECULATION
genes	I-SPECULATION
.	O

Structure-function	B-SPECULATION
studies	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
GATA-1	I-SPECULATION
protein	I-SPECULATION
could	I-SPECULATION
be	I-SPECULATION
greatly	I-SPECULATION
simplified	I-SPECULATION
and	I-SPECULATION
a	I-SPECULATION
larger	I-SPECULATION
number	I-SPECULATION
of	I-SPECULATION
mutants	I-SPECULATION
studied	I-SPECULATION
.	O

However	O
,	O
the	B-SPECULATION
ES	I-SPECULATION
cell	I-SPECULATION
system	I-SPECULATION
can	I-SPECULATION
be	I-SPECULATION
used	I-SPECULATION
as	I-SPECULATION
an	I-SPECULATION
alternative	I-SPECULATION
until	I-SPECULATION
targeted	I-SPECULATION
erythroleukemia	I-SPECULATION
cells	I-SPECULATION
become	I-SPECULATION
available	I-SPECULATION
.	O

Other	O
applications	O
involve	O
the	O
introduction	O
of	O
other	O
GATA-binding	O
protein	O
family	O
members	O
to	O
determine	O
whether	B-SPECULATION
they	I-SPECULATION
rescue	I-SPECULATION
the	I-SPECULATION
mutation	I-SPECULATION
.	O

If	O
they	O
can	B-NEGATION
not	I-NEGATION
,	O
chimeric	O
proteins	O
can	O
be	O
tested	O
to	O
identify	O
which	O
amino	O
acids	O
distinguish	O
the	O
different	O
family	O
members	O
.	O

We	O
feel	B-SPECULATION
that	I-SPECULATION
these	I-SPECULATION
experiments	I-SPECULATION
are	I-SPECULATION
vital	I-SPECULATION
to	I-SPECULATION
understanding	I-SPECULATION
the	I-SPECULATION
function	I-SPECULATION
of	I-SPECULATION
GATA-1	I-SPECULATION
during	I-SPECULATION
erythroid	I-SPECULATION
ontogeny	I-SPECULATION
.	O

How	O
does	O
GATA-1	O
regulate	O
red	O
cell	O
genes	O
like	O
globin	O
or	O
the	O
Epo	O
receptor	O
?	O

Once	O
we	O
identify	O
the	O
functional	O
domains	O
of	O
the	O
GATA-binding	O
proteins	O
,	O
we	O
hope	B-SPECULATION
to	I-SPECULATION
learn	I-SPECULATION
what	I-SPECULATION
proteins	I-SPECULATION
GATA-1	I-SPECULATION
binds	I-SPECULATION
to	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
basic	I-SPECULATION
transcription	I-SPECULATION
machinery	I-SPECULATION
or	I-SPECULATION
in	I-SPECULATION
chromatin	I-SPECULATION
.	O

Is	O
GATA-1	O
necessary	O
for	O
globin	O
gene	O
switching	O
?	O

GATA-1	B-SPECULATION
may	I-SPECULATION
be	I-SPECULATION
modified	I-SPECULATION
differently	I-SPECULATION
during	I-SPECULATION
development	I-SPECULATION
so	I-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
locus	I-SPECULATION
control	I-SPECULATION
region	I-SPECULATION
can	I-SPECULATION
interact	I-SPECULATION
with	I-SPECULATION
different	I-SPECULATION
globin	I-SPECULATION
promoters	I-SPECULATION
.	O

We	O
may	B-SPECULATION
find	I-SPECULATION
that	I-SPECULATION
one	I-SPECULATION
region	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
protein	I-SPECULATION
is	I-SPECULATION
required	I-SPECULATION
for	I-SPECULATION
embryonic	I-SPECULATION
expression	I-SPECULATION
and	I-SPECULATION
another	I-SPECULATION
for	I-SPECULATION
adult	I-SPECULATION
globin	I-SPECULATION
gene	I-SPECULATION
expression	I-SPECULATION
.	O

The	O
zinc	O
finger	O
transcription	O
factor	O
Egr-1	O
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
along	O
the	O
macrophage	O
lineage	O
.	O

We	O
have	O
isolated	O
cDNA	O
clones	O
of	O
myeloid	O
differentiation	O
primary	O
response	O
(	O
MyD	O
)	O
genes	O
,	O
activated	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
following	O
induction	O
for	O
differentiation	O
along	O
either	O
the	O
macrophage	O
or	O
granulocyte	O
lineage	O
in	O
human	O
myeloblastic	O
leukemia	O
HL-60	O
cells	O
.	O

One	O
cDNA	O
clone	O
of	O
a	O
primary	O
response	O
gene	O
,	O
expressed	O
upon	O
macrophage	O
differentiation	O
,	O
encoded	O
for	O
Egr-1	O
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
.	O

The	O
Egr-1	O
gene	O
was	O
observed	O
to	O
be	O
transcriptionally	O
silent	O
in	O
HL-60	O
cells	O
,	O
but	O
active	O
in	O
U-937	O
and	O
M1	O
cells	O
,	O
the	O
latter	O
two	O
being	O
predetermined	O
for	O
macrophage	O
differentiation	O
.	O

Egr-1	O
antisense	O
oligomers	O
in	O
the	O
culture	O
media	O
blocked	O
macrophage	O
differentiation	O
in	O
both	O
myeloid	O
leukemia	O
cell	O
lines	O
and	O
normal	O
myeloblasts	O
.	O

HL-60	B-SPECULATION
cells	I-SPECULATION
constitutively	I-SPECULATION
expressing	I-SPECULATION
an	I-SPECULATION
Egr-1	I-SPECULATION
transgene	I-SPECULATION
(	I-SPECULATION
HL-60Egr-1	I-SPECULATION
)	I-SPECULATION
could	I-SPECULATION
be	I-SPECULATION
induced	I-SPECULATION
for	I-SPECULATION
macrophage	I-SPECULATION
,	I-SPECULATION
but	I-SPECULATION
not	B-NEGATION
granulocyte	I-NEGATION
,	O
differentiation	O
.	O

These	O
observations	O
indicate	B-SPECULATION
that	I-SPECULATION
expression	I-SPECULATION
of	I-SPECULATION
Egr-1	I-SPECULATION
is	I-SPECULATION
essential	I-SPECULATION
for	I-SPECULATION
and	I-SPECULATION
restricts	I-SPECULATION
differentiation	I-SPECULATION
of	I-SPECULATION
myeloblasts	I-SPECULATION
along	I-SPECULATION
the	I-SPECULATION
macrophage	I-SPECULATION
lineage	I-SPECULATION
.	O

Activation	O
of	O
lymphokine	O
genes	O
in	O
T	O
cells	O
:	O
role	O
of	O
cis-acting	O
DNA	O
elements	O
that	O
respond	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

Activation	O
of	O
T	O
cells	O
is	O
initiated	O
by	O
the	O
recognition	O
of	O
antigen	O
on	O
antigen	O
presenting	O
cells	O
to	O
exert	O
the	O
effector	O
functions	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Two	O
types	O
of	O
helper	O
T	O
cell	O
(	O
Th	O
)	O
clones	O
(	O
Th1	O
and	O
Th2	O
)	O
are	O
defined	O
on	O
the	O
basis	O
of	O
different	O
patterns	O
of	O
cytokine	O
(	O
lymphokine	O
)	O
secretion	O
.	O

They	O
determine	O
the	O
outcome	O
of	O
an	O
antigenic	O
response	O
toward	O
humoral	O
or	O
cell-mediated	O
immunity	O
.	O

Although	O
lymphokine	O
genes	O
are	O
coordinately	O
regulated	O
upon	O
antigen	O
stimulation	O
,	O
they	O
are	O
regulated	O
by	O
the	O
mechanisms	O
common	O
to	O
all	O
as	O
well	O
as	O
those	O
which	O
are	O
unique	O
to	O
each	O
gene	O
.	O

For	O
most	O
lymphokine	O
genes	O
,	O
a	O
combination	O
of	O
phorbol	O
esters	O
(	O
phorbol	O
12-myristate	O
13	O
acetate	O
,	O
PMA	O
)	O
and	O
calcium	O
ionophores	O
(	O
A23187	O
)	O
is	O
required	O
for	O
their	O
maximal	O
induction	O
.	O

Yet	O
phorbol	O
ester	O
alone	O
or	O
calcium	O
ionophore	O
alone	O
produce	O
several	O
lymphokines	O
.	O

The	O
production	O
of	O
the	O
granulocyte-macrophage	O
colony	O
stimulating	O
factor	O
(	O
GM-CSF	O
)	O
is	O
completely	O
dependent	O
on	O
the	O
two	O
signals	O
.	O

We	O
have	O
previously	O
found	O
a	O
cis-acting	O
region	O
spanning	O
the	O
GM-CSF	O
promoter	O
region	O
(	O
positions	O
-	O
95	O
to	O
+	O
27	O
)	O
that	O
confers	O
inducibility	O
to	O
reporter	O
genes	O
in	O
transient	O
transfection	O
assays	O
.	O

Further	O
analysis	O
identified	O
three	O
elements	O
required	O
for	O
efficient	O
induction	O
,	O
referred	O
to	O
as	O
GM2	O
,	O
GC-box	O
and	O
conserved	O
lymphokine	O
element	O
(	O
CLE0	O
)	O
.	O

GM2	O
defines	O
a	O
binding	O
site	O
for	O
protein	O
(	O
s	O
)	O
whose	O
binding	O
is	O
inducible	O
by	O
PMA	O
.	O

One	O
protein	O
,	O
NF-GM2	O
is	O
similar	O
to	O
the	O
transcription	O
factor	O
NF-kB	O
.	O

GC-box	O
is	O
a	O
binding	O
site	O
for	O
constitutively	O
bound	O
proteins	O
.	O

CLEO	O
defines	O
a	O
binding	O
site	O
for	O
protein	O
(	O
s	O
)	O
whose	O
optimum	O
binding	O
is	O
stimulated	O
by	O
PMA	O
and	O
A23187	O
.	O

Viral	O
trans-activators	O
such	O
as	O
Tax	O
(	O
human	O
T	O
cell	O
leukemia	O
virus-1	O
,	O
HTLV-1	O
)	O
and	O
E2	O
(	O
bovine	O
papilloma	O
virus	O
,	O
BPV	O
)	O
proteins	O
are	O
other	O
agents	O
which	O
activate	O
lymphokine	O
gene	O
expression	O
by	O
bypassing	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
mediated	O
signaling	O
.	O

The	O
trans-activation	O
domain	O
of	O
E2	O
and	O
Tax	O
is	O
interchangeable	O
although	O
they	O
have	O
no	B-NEGATION
obvious	I-NEGATION
sequence	I-NEGATION
homology	I-NEGATION
between	I-NEGATION
them	I-NEGATION
.	O

The	B-SPECULATION
viral	I-SPECULATION
trans-activators	I-SPECULATION
appear	I-SPECULATION
to	I-SPECULATION
target	I-SPECULATION
specific	I-SPECULATION
DNA	I-SPECULATION
binding	I-SPECULATION
protein	I-SPECULATION
such	I-SPECULATION
as	I-SPECULATION
NF-kB	I-SPECULATION
and	I-SPECULATION
Sp1	I-SPECULATION
to	I-SPECULATION
cis-acting	I-SPECULATION
DNA	I-SPECULATION
site	I-SPECULATION
and	I-SPECULATION
promote	I-SPECULATION
lymphokine	I-SPECULATION
gene	I-SPECULATION
expression	I-SPECULATION
without	B-NEGATION
TCR-mediated	I-NEGATION
stimulation	I-NEGATION
.	O

Expression	O
of	O
tal-1	O
and	O
GATA-binding	O
proteins	O
during	O
human	O
hematopoiesis	O
.	O

Tal-1	O
rearrangements	O
are	O
associated	O
with	O
nearly	O
30	O
%	O
of	O
human	O
T	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Tal-1	O
gene	O
encodes	O
a	O
putative	B-SPECULATION
transcription	I-SPECULATION
factor	I-SPECULATION
with	O
a	O
basic	O
helix-loop-helix	O
domain	O
and	O
is	O
known	O
to	O
be	O
predominantly	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O

We	O
investigated	O
the	O
pattern	O
of	O
tal-1	O
expression	O
in	O
purified	O
human	O
hematopoietic	O
cells	O
by	O
in	O
situ	O
hybridization	O
and	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Both	O
methods	O
demonstrated	O
that	O
the	O
tal-1	O
gene	O
is	O
expressed	O
in	O
megakaryocytes	O
and	O
erythroblasts	O
as	O
well	O
as	O
in	O
basophilic	O
granulocytes	O
.	O

In	O
addition	O
,	O
our	O
results	O
indicate	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
tal-1	I-SPECULATION
1A	I-SPECULATION
promoter	I-SPECULATION
,	I-SPECULATION
which	I-SPECULATION
contains	I-SPECULATION
two	I-SPECULATION
consensus	I-SPECULATION
GATA-binding	I-SPECULATION
sites	I-SPECULATION
,	I-SPECULATION
is	I-SPECULATION
active	I-SPECULATION
mainly	I-SPECULATION
in	I-SPECULATION
these	I-SPECULATION
lineages	I-SPECULATION
.	O

Because	O
the	O
GATA-1	O
gene	O
is	O
known	O
to	O
transactivate	O
several	O
genes	O
specific	O
for	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
mastocytic	O
/	O
basophilic	O
lineages	O
,	O
we	O
studied	O
GATA-1	O
expression	O
in	O
these	O
purified	O
hematopoietic	O
cells	O
.	O

We	O
found	O
that	O
GATA-1	O
and	O
tal-1	O
genes	O
are	O
coexpressed	O
in	O
these	O
three	O
lineages	O
.	O

Remarkably	O
,	O
the	O
expression	O
of	O
both	O
genes	O
is	O
downmodulated	O
during	O
erythroid	O
and	O
megakaryocytic	O
terminal	O
maturation	O
.	O

The	O
transitive	O
module	O
enhances	O
the	O
preliminary	O
likelihood	O
score	O
(	O
PS	O
)	O
(	O
calculated	O
using	O
the	O
group	O
A	O
modules	O
)	O
by	O
considering	O
the	O
local	O
topology	O
of	O
the	O
resulting	O
network	O
which	O
is	O
assessed	O
using	O
the	O
neighborhood	O
topology	O
score	O
as	O
detailed	O
in	O
the	O
Methods	O
section	O
.	O

The	O
likelihood	O
ratios	O
for	O
different	O
values	O
of	O
the	O
neighborhood	O
topology	O
score	O
are	O
shown	O
in	O
Figure	O
1B	O
.	O

The	O
Transitive	O
module	O
is	O
highly	O
predictive	O
of	O
interaction	O
and	O
achieves	O
likelihood	O
ratios	O
as	O
high	O
as	O
229	O
.	O

This	B-NEGATION
module	I-NEGATION
cannot	I-NEGATION
be	I-NEGATION
used	I-NEGATION
alone	I-NEGATION
as	O
it	O
requires	O
as	O
input	O
the	O
output	O
of	O
at	O
least	O
one	O
group	O
A	O
module	O
.	O

However	O
,	O
it	O
can	O
predict	B-SPECULATION
interacting	I-SPECULATION
protein	I-SPECULATION
pairs	I-SPECULATION
with	I-SPECULATION
a	I-SPECULATION
posterior	I-SPECULATION
odds	I-SPECULATION
ratio	I-SPECULATION
above	I-SPECULATION
1.0	I-SPECULATION
when	I-SPECULATION
used	I-SPECULATION
in	I-SPECULATION
combination	I-SPECULATION
with	I-SPECULATION
any	I-SPECULATION
single	I-SPECULATION
module	I-SPECULATION
in	I-SPECULATION
group	I-SPECULATION
A	I-SPECULATION
(	O
as	O
the	O
product	O
of	O
the	O
highest	O
likelihood	O
ratios	O
of	O
the	O
transitive	O
module	O
and	O
any	O
group	O
A	O
module	O
is	O
greater	O
than	O
400	O
as	O
can	O
be	O
seen	O
from	O
Figure	O
1	O
)	O
.	O

Independence	O
of	O
the	O
modules	O

The	O
final	O
likelihood	O
ratio	O
output	O
by	O
the	O
predictor	O
is	O
only	O
representative	O
of	O
the	O
true	O
likelihood	O
of	O
interaction	O
of	O
a	O
protein	O
pair	O
if	O
the	O
modules	O
considered	O
are	O
independent	O
.	O

If	O
the	O
modules	O
were	O
not	B-NEGATION
independent	I-NEGATION
,	O
some	B-SPECULATION
likelihood	I-SPECULATION
ratios	I-SPECULATION
would	I-SPECULATION
likely	I-SPECULATION
be	I-SPECULATION
overestimated	I-SPECULATION
,	I-SPECULATION
particularly	I-SPECULATION
for	I-SPECULATION
protein	I-SPECULATION
pairs	I-SPECULATION
that	I-SPECULATION
achieve	I-SPECULATION
simultaneously	I-SPECULATION
high	I-SPECULATION
likelihoods	I-SPECULATION
for	I-SPECULATION
non-independent	I-SPECULATION
features	I-SPECULATION
.	O

Conversely	O
,	O
some	B-SPECULATION
likelihood	I-SPECULATION
ratios	I-SPECULATION
would	I-SPECULATION
be	I-SPECULATION
underestimated	I-SPECULATION
for	I-SPECULATION
protein	I-SPECULATION
pairs	I-SPECULATION
achieving	I-SPECULATION
simultaneously	I-SPECULATION
low	I-SPECULATION
likelihoods	I-SPECULATION
for	I-SPECULATION
non-independent	I-SPECULATION
features	I-SPECULATION
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
some	O
of	O
the	O
features	O
considered	O
here	O
are	O
indeed	O
independent	O
43	O
.	O

Independence	O
of	O
all	O
modules	O
used	O
in	O
our	O
predictor	O
was	O
verified	O
by	O
calculating	O
Pearson	O
correlation	O
coefficients	O
for	O
all	O
pairs	O
of	O
modules	O
.	O

As	O
shown	O
in	O
Table	O
2	O
,	O
all	O
modules	O
considered	O
are	O
independent	O
,	O
since	O
the	O
highest	O
Pearson	O
correlation	O
coefficients	O
computed	O
are	O
well	O
below	O
any	O
value	O
considered	O
significant	O
.	O

Pairwise	O
Pearson	O
correlation	O
for	O
all	O
modules	O

Accuracy	O
of	O
the	O
predictors	O

All	O
combinations	O
of	O
modules	O
were	O
examined	O
to	O
determine	O
which	O
of	O
the	O
resulting	O
predictors	O
achieved	O
the	O
highest	O
prediction	O
accuracy	O
.	O

In	O
order	O
to	O
analyze	O
the	O
predictions	O
,	O
five-fold	O
cross	O
validation	O
experiments	O
were	O
performed	O
and	O
the	O
area	O
under	O
partial	O
ROC	O
(	O
receiver	O
operator	O
characteristic	O
)	O
curves	O
(	O
partial	O
AUCs	O
)	O
measured	O
.	O

ROC50	O
and	O
ROC100	O
curves	O
were	O
selected	O
as	O
they	O
consider	O
a	O
large	O
enough	O
number	O
of	O
positives	O
to	O
include	O
all	B-SPECULATION
protein	I-SPECULATION
pairs	I-SPECULATION
predicted	I-SPECULATION
to	I-SPECULATION
have	I-SPECULATION
a	I-SPECULATION
posterior	I-SPECULATION
odds	I-SPECULATION
ratio	I-SPECULATION
above	I-SPECULATION
1.0	I-SPECULATION
by	I-SPECULATION
all	I-SPECULATION
the	I-SPECULATION
predictors	I-SPECULATION
investigated	I-SPECULATION
.	O

Protein	O
pairs	O
predicted	O
to	O
have	O
a	O
posterior	O
odds	O
ratio	O
below	O
1.0	O
have	O
an	O
estimated	O
true	O
positive	O
rate	O
below	O
50	O
%	O
and	O
thus	O
are	B-SPECULATION
more	I-SPECULATION
likely	I-SPECULATION
not	B-NEGATION
to	I-NEGATION
interact	I-NEGATION
than	O
to	O
interact	O
.	O

These	O
protein	O
pairs	O
are	O
therefore	O
not	B-NEGATION
of	I-NEGATION
interest	I-NEGATION
in	I-NEGATION
this	I-NEGATION
context	I-NEGATION
.	O

The	O
area	O
under	O
all	O
ROCn	O
curves	O
considered	O
is	O
relatively	O
low	O
because	O
of	O
the	O
high	O
proportion	O
of	O
negatives	O
with	O
respect	O
to	O
positives	O
in	O
the	O
training	O
and	O
test	O
sets	O
(	O
100:1	O
)	O
.	O

Table	O
3	O
summarizes	O
the	O
characteristics	O
of	O
19	O
different	O
predictors	O
and	O
shows	O
accuracy	O
measures	O
.	O

Individual	O
modules	O
do	O
not	B-NEGATION
achieve	I-NEGATION
high	I-NEGATION
scores	I-NEGATION
for	I-NEGATION
the	I-NEGATION
areas	I-NEGATION
under	I-NEGATION
the	I-NEGATION
ROC50	I-NEGATION
and	I-NEGATION
ROC100	I-NEGATION
.	O

In	O
fact	O
,	O
all	O
ROC50	O
AUC	O
values	O
achieved	O
by	O
individual	O
modules	O
are	O
below	O
0.025	O
and	O
the	O
Expression	O
and	O
Disorder	O
modules	O
do	O
not	B-NEGATION
predict	I-NEGATION
any	I-NEGATION
protein	I-NEGATION
pairs	I-NEGATION
,	O
which	O
is	O
expected	O
as	O
the	O
highest	O
likelihood	O
ratios	O
they	O
achieve	O
are	O
lower	O
than	O
400	O
(	O
see	O
Figure	O
1A	O
)	O
.	O
(	B-SPECULATION
positive	I-SPECULATION
or	I-SPECULATION
negative	I-SPECULATION
)	I-SPECULATION
above	O
a	O
posterior	O
odds	O
ratio	O
of	O
1	O
.	O

As	O
more	O
Group	O
A	O
modules	O
are	O
considered	O
within	O
the	O
same	O
predictor	O
,	O
the	O
ROCn	O
AUC	O
scores	O
increase	O
significantly	O
,	O
as	O
would	B-SPECULATION
be	I-SPECULATION
expected	I-SPECULATION
since	O
these	O
features	O
are	O
independent	O
(	O
as	O
shown	O
in	O
Table	O
2	O
)	O
and	O
thus	O
contribute	O
different	O
information	O
to	O
the	O
prediction	O
.	O

For	O
example	O
,	O
the	O
predictor	O
that	O
considers	O
both	O
the	O
Expression	O
and	O
Combined	O
modules	O
achieves	O
a	O
ROC50	O
AUC	O
of	O
0.033	O
compared	O
to	O
0.003	O
and	O
0.022	O
respectively	O
for	O
the	O
individual	O
modules	O
.	O

However	O
,	O
the	O
Disorder	O
module	O
does	O
not	O
contribute	O
significantly	O
to	O
the	O
prediction	O
as	O
predictors	O
that	O
consider	O
it	O
do	O
not	B-NEGATION
,	I-NEGATION
in	I-NEGATION
general	I-NEGATION
,	I-NEGATION
do	I-NEGATION
better	I-NEGATION
than	I-NEGATION
their	I-NEGATION
counterparts	I-NEGATION
that	I-NEGATION
do	I-NEGATION
not	B-NEGATION
use	I-NEGATION
it	I-NEGATION
.	O

For	O
example	O
,	O
both	O
the	O
Expression-Orthology	O
predictor	O
and	O
the	O
Expression-Orthology-Disorder	O
predictor	O
achieve	O
a	O
ROC50	O
AUC	O
of	O
0.024	O
.	O

The	O
Disorder	O
module	O
offers	O
the	O
advantage	O
of	O
increasing	O
the	O
coverage	O
of	O
the	O
prediction	O
as	O
a	O
disorder	O
score	O
is	O
calculated	O
for	O
all	O
protein	O
pairs	O
.	O

However	O
,	O
this	B-SPECULATION
appears	I-SPECULATION
to	I-SPECULATION
add	I-SPECULATION
more	I-SPECULATION
noise	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
prediction	I-SPECULATION
without	B-NEGATION
increasing	I-NEGATION
the	I-NEGATION
accuracy	I-NEGATION
.	O

Prediction	O
accuracy	O
of	O
different	O
combinations	O
of	O
modules	O

As	O
the	O
scores	O
of	O
the	O
predictors	O
increase	O
,	O
so	O
do	O
the	O
number	O
of	O
interactions	O
predicted	O
above	O
different	O
posterior	O
odds	O
ratio	O
thresholds	O
(	O
see	O
lower	O
portion	O
of	O
Table	O
3	O
)	O
.	O

For	O
example	O
,	O
the	O
Expression-Orthology	O
predictor	O
achieves	O
a	O
ROC50	O
AUC	O
of	O
0.024	O
and	O
predicts	O
5670	O
interactions	O
at	O
a	O
posterior	O
odds	O
ratio	O
greater	O
than	O
1	O
whereas	O
the	O
Expression-Orthology-Combined	O
predictor	O
achieves	O
a	O
ROC50	O
AUC	O
of	O
0.044	O
and	O
predicts	O
over	O
15000	O
interactions	O
at	O
a	O
posterior	O
odds	O
ratio	O
above	O
1	O
.	O

The	O
best	O
combination	O
of	O
Group	O
A	O
modules	O
is	O
the	O
predictor	O
consisting	O
of	O
the	O
Expression	O
,	O
Orthology	O
and	O
Combined	O
modules	O
.	O

The	O
Transitive	O
module	O
,	O
which	O
can	O
only	O
be	O
used	O
in	O
combination	O
with	O
other	O
modules	O
,	O
increases	O
substantially	O
the	O
scores	O
and	O
number	O
of	O
interactions	O
predicted	O
.	O

The	O
right-hand	O
portion	O
of	O
Table	O
3	O
shows	O
the	O
accuracy	O
measures	O
for	O
the	O
highest	O
scoring	O
subset	O
of	O
predictors	O
that	O
consider	O
the	O
Transitive	O
module	O
.	O

The	O
Transitive	O
module	O
enhances	O
the	O
prediction	O
by	O
identifying	O
among	O
protein	O
pairs	O
with	O
a	O
relatively	O
high	O
preliminary	O
score	O
those	O
that	B-SPECULATION
are	I-SPECULATION
most	I-SPECULATION
likely	I-SPECULATION
to	I-SPECULATION
interact	I-SPECULATION
,	O
by	O
considering	O
the	O
local	O
topology	O
of	O
the	O
network	O
around	O
them	O
.	O

For	O
example	O
,	O
the	O
ROC50	O
AUC	O
rises	O
from	O
0.044	O
to	O
0.075	O
when	O
the	O
Transitive	O
module	O
is	O
added	O
to	O
the	O
Expression-Orthology-Combined	O
predictor	O
,	O
and	O
the	O
number	O
of	O
predictions	O
above	O
a	O
posterior	O
odds	O
ratio	O
of	O
1	O
doubles	O
from	O
15330	O
to	O
34780	O
.	O

Once	O
again	O
,	O
the	O
Disorder	O
module	O
does	O
not	B-NEGATION
contribute	I-NEGATION
positively	I-NEGATION
to	I-NEGATION
the	I-NEGATION
prediction	I-NEGATION
.	O

Its	O
inclusion	O
does	O
not	B-NEGATION
increase	I-NEGATION
any	I-NEGATION
of	I-NEGATION
the	I-NEGATION
measures	I-NEGATION
of	I-NEGATION
accuracy	I-NEGATION
considered	I-NEGATION
.	O

The	O
predictor	O
that	O
considers	O
the	O
Expression	O
,	O
Orthology	O
,	O
Combined	O
and	O
Transitive	O
modules	O
is	O
the	O
one	O
that	O
achieves	O
the	O
highest	O
accuracy	O
overall	O
.	O

It	O
is	O
this	O
predictor	O
that	O
is	O
further	O
analyzed	O
in	O
the	O
next	O
sections	O
.	O

Comparison	O
to	O
predictions	O
generated	O
using	O
alternative	O
training	O
sets	O

In	O
this	O
work	O
training	O
sets	O
were	O
used	O
that	O
comprised	O
100	O
times	O
more	O
negatives	O
than	O
positives	O
,	O
with	O
the	O
negatives	O
randomly	O
selected	O
and	O
filtered	O
to	O
remove	O
any	O
known	O
or	O
suspected	B-SPECULATION
positives	I-SPECULATION
(	O
see	O
Methods	O
)	O
.	O

Other	O
groups	O
have	O
used	O
negative	O
:	O
positive	O
ratios	O
ranging	O
from	O
1	O
to	O
more	O
than	O
600	O
(	O
see	O
for	O
example	O
374752	O
)	O
.	O

In	O
addition	O
,	O
several	O
groups	O
use	O
localization-derived	O
negatives	O
(	O
i.e.	O
protein	O
pairs	O
that	B-NEGATION
are	I-NEGATION
not	I-NEGATION
annotated	I-NEGATION
as	I-NEGATION
being	I-NEGATION
localized	I-NEGATION
to	I-NEGATION
the	I-NEGATION
same	I-NEGATION
cellular	I-NEGATION
compartment	I-NEGATION
)	O
rather	B-NEGATION
than	I-NEGATION
randomly	I-NEGATION
chosen	I-NEGATION
negatives	I-NEGATION
(	O
see	O
for	O
example	O
374346	O
)	O
.	O

These	O
issues	O
have	O
been	O
investigated	O
previously	O
53	O
.	O

Since	O
the	O
choice	O
of	O
negative	O
training	O
data	O
may	B-SPECULATION
influence	I-SPECULATION
the	I-SPECULATION
method	I-SPECULATION
,	O
the	O
choice	O
of	O
different	O
training	O
sets	O
in	O
the	O
context	O
of	O
the	O
probabilistic	O
predictor	O
presented	O
here	O
was	O
investigated	O
to	O
determine	O
which	O
type	O
of	O
training	O
set	O
offers	O
the	O
highest	O
accuracy	O
.	O

Table	O
4	O
compares	O
the	O
accuracy	O
of	O
predictors	O
trained	O
with	O
negative	O
:	O
positive	O
ratios	O
of	O
1:100	O
and	O
1:1	O
and	O
tested	O
by	O
five-fold	O
cross	O
validation	O
.	O

Ratios	B-NEGATION
greater	I-NEGATION
than	I-NEGATION
100	I-NEGATION
were	I-NEGATION
not	I-NEGATION
considered	I-NEGATION
because	O
they	O
are	O
computationally	O
infeasible	O
given	O
the	O
size	O
of	O
our	O
datasets	O
and	O
the	O
architecture	O
of	O
the	O
predictor	O
.	O

To	O
perform	O
such	O
a	O
comparison	O
,	O
the	O
EOCT	O
predictor	O
(	O
Expression	O
,	O
Orthology	O
,	O
Combined	O
and	O
Transitive	O
modules	O
)	O
was	O
trained	O
on	O
datasets	O
consisting	O
of	O
either	B-SPECULATION
equal	I-SPECULATION
numbers	I-SPECULATION
of	I-SPECULATION
positives	I-SPECULATION
and	I-SPECULATION
negatives	I-SPECULATION
and	O
then	O
tested	O
on	O
both	O
types	O
of	O
datasets	O
.	O

As	O
shown	O
in	O
Table	O
4	O
,	O
the	O
predictors	O
trained	O
on	O
datasets	O
containing	O
100	O
times	O
more	O
negatives	O
than	O
positives	O
perform	O
significantly	O
better	O
than	O
those	O
trained	O
on	O
datasets	O
containing	O
equal	O
numbers	O
of	O
positives	O
and	O
negatives	O
.	O

For	O
example	O
,	O
the	O
1:1	O
pos	O
:	O
neg	O
trained	O
predictor	O
achieves	O
a	O
ROC50	O
AUC	O
of	O
0.0645	O
whereas	O
its	O
1:100	O
pos	O
:	O
neg	O
trained	O
counterpart	O
achieves	O
a	O
0.0747	O
ROC50	O
AUC	O
.	O

This	O
could	B-SPECULATION
be	I-SPECULATION
due	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
fact	I-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
number	I-SPECULATION
of	I-SPECULATION
non-interacting	I-SPECULATION
protein	I-SPECULATION
pairs	I-SPECULATION
outweighs	I-SPECULATION
greatly	I-SPECULATION
the	I-SPECULATION
number	I-SPECULATION
of	I-SPECULATION
interacting	I-SPECULATION
protein	I-SPECULATION
pairs	I-SPECULATION
in	I-SPECULATION
cells	I-SPECULATION
.	O

When	O
equal	O
numbers	O
of	O
positives	O
and	O
negatives	O
are	O
used	O
in	O
training	O
,	O
the	B-SPECULATION
diversity	I-SPECULATION
that	I-SPECULATION
exists	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
non-interacting	I-SPECULATION
protein	I-SPECULATION
pair	I-SPECULATION
space	I-SPECULATION
may	I-SPECULATION
not	I-NEGATION
be	I-NEGATION
captured	I-NEGATION
,	O
thus	O
resulting	O
in	O
misleading	O
likelihood	O
ratios	O
for	O
the	O
predictive	O
modules	O
.	O

It	O
should	O
be	O
noted	O
that	O
predictors	O
tested	O
on	O
datasets	O
consisting	O
of	O
equal	O
numbers	O
of	O
positives	O
and	O
negatives	O
achieve	O
much	O
higher	O
accuracy	O
measures	O
than	O
those	O
tested	O
on	O
datasets	O
containing	O
100	O
times	O
more	O
negatives	O
than	O
positives	O
.	O

This	O
is	O
because	O
the	O
number	O
of	O
positives	O
scoring	O
higher	O
than	O
the	O
highest	O
scoring	O
n	O
negatives	O
,	O
for	O
a	O
given	O
value	O
of	O
n	O
and	O
a	O
given	O
predictor	O
,	O
will	O
be	O
greater	O
if	O
there	O
are	O
equal	O
numbers	O
of	O
positives	O
and	O
negatives	O
in	O
the	O
test	O
set	O
than	O
if	O
there	O
are	O
more	O
negatives	O
than	O
positives	O
.	O

Influence	O
of	O
the	O
negative	O
:	O
positive	O
training	O
set	O
ratio	O
on	O
the	O
prediction	O
accuracy	O

The	O
ROCn	O
AUCs	O
are	O
an	O
average	O
of	O
five	O
separate	O
experiments	O
(	O
each	O
of	O
which	O
is	O
itself	O
a	O
five-fold	O
cross	O
validation	O
experiment	O
)	O
.	O

Their	O
standard	O
deviation	O
is	O
shown	O
in	O
parenthesis	O
.	O

The	O
effect	O
of	O
localization-derived	O
negatives	O
rather	B-NEGATION
than	I-NEGATION
randomly	I-NEGATION
chosen	I-NEGATION
negatives	I-NEGATION
was	O
also	O
investigated	O
to	O
see	O
if	B-SPECULATION
it	I-SPECULATION
would	B-SPECULATION
increase	I-SPECULATION
the	I-SPECULATION
prediction	I-SPECULATION
accuracy	I-SPECULATION
.	O

A	O
criticism	O
of	O
randomly	O
chosen	O
negatives	O
is	O
that	O
they	O
will	O
contain	O
some	O
true	O
interactors	O
.	O

However	O
,	O
the	O
set	O
of	O
interacting	O
pairs	O
in	O
the	O
full	O
protein	O
pair	O
space	O
is	O
small	O
and	O
thus	O
the	O
contamination	O
rate	O
of	O
randomly	O
chosen	O
negative	O
datasets	O
will	O
in	O
fact	O
be	O
very	O
low	O
.	O

Contamination	O
is	O
probably	B-SPECULATION
below	I-SPECULATION
1	I-SPECULATION
%	I-SPECULATION
,	O
which	O
is	O
likely	B-SPECULATION
lower	I-SPECULATION
than	I-SPECULATION
the	I-SPECULATION
contamination	I-SPECULATION
rate	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
positive	I-SPECULATION
dataset	I-SPECULATION
as	O
discussed	O
in	O
47	O
.	O

Localization-derived	O
negatives	O
,	O
on	O
the	O
other	O
hand	O
,	O
should	B-SPECULATION
be	I-SPECULATION
free	I-SPECULATION
of	I-SPECULATION
contamination	I-SPECULATION
,	O
if	O
the	O
localization	O
annotations	O
are	O
complete	O
and	O
accurate	O
,	O
both	O
conditions	O
that	O
are	O
difficult	O
to	O
obtain	O
as	O
discussed	O
in	O
54	O
.	O

However	O
,	O
one	O
can	O
argue	O
that	O
localization-derived	O
negatives	O
might	B-SPECULATION
since	O
many	O
proteins	O
in	O
the	O
same	O
cellular	O
compartment	O
do	O
not	B-NEGATION
be	I-NEGATION
able	I-NEGATION
to	I-NEGATION
capture	I-NEGATION
the	I-NEGATION
full	I-NEGATION
diversity	I-NEGATION
of	I-NEGATION
the	I-NEGATION
non-interacting	I-NEGATION
protein	I-NEGATION
space	I-NEGATION
not	B-NEGATION
interact	I-NEGATION
.	O

In	O
addition	O
,	O
proteins	O
specific	O
to	O
a	O
cellular	O
compartment	O
may	B-SPECULATION
have	I-SPECULATION
different	I-SPECULATION
characteristics	I-SPECULATION
to	I-SPECULATION
proteins	I-SPECULATION
in	I-SPECULATION
other	I-SPECULATION
compartments	I-SPECULATION
.	O

Such	O
predictors	O
may	B-SPECULATION
when	O
predicting	O
on	O
cell-wide	O
protein	O
pairs	O
which	O
consist	O
not	O
only	O
of	O
non-colocalized	O
non-interacting	O
pairs	O
but	O
also	O
numerous	O
protein	O
pairs	O
that	O
do	O
not	B-NEGATION
generalize	I-NEGATION
well	I-NEGATION
not	B-NEGATION
interact	I-NEGATION
but	O
are	O
present	O
in	O
the	O
same	O
cellular	O
compartment	O
.	O

These	O
issues	O
have	O
been	O
discussed	O
previously	O
52	O
.	O

In	O
order	O
to	O
see	O
if	B-SPECULATION
different	I-SPECULATION
types	I-SPECULATION
of	I-SPECULATION
negatives	I-SPECULATION
we	O
generated	O
negative	O
training	O
/	O
test	O
sets	O
as	O
in	O
46	O
by	O
identifying	O
all	O
pairs	O
of	O
human	O
proteins	O
for	O
which	O
one	O
protein	O
is	O
annotated	O
as	O
being	O
nuclear	O
and	O
the	O
other	O
is	O
annotated	O
as	O
being	O
localized	O
to	O
the	O
plasma	O
membrane	O
in	O
the	O
HPRD	O
database	O
15	O
.	O
could	B-SPECULATION
influence	I-SPECULATION
the	I-SPECULATION
accuracy	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
predictors	I-SPECULATION
developed	I-SPECULATION
here	I-SPECULATION
.	O

The	O
Combined	O
module	O
for	O
these	O
predictors	O
only	O
considers	O
domains	O
and	O
PTMs	O
but	O
not	B-NEGATION
subcellular	I-NEGATION
localization	I-NEGATION
as	O
this	O
would	B-SPECULATION
result	I-SPECULATION
in	I-SPECULATION
using	I-SPECULATION
this	I-SPECULATION
feature	I-SPECULATION
both	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
selection	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
training	I-SPECULATION
set	I-SPECULATION
and	I-SPECULATION
as	I-SPECULATION
a	I-SPECULATION
feature	I-SPECULATION
predictive	I-SPECULATION
of	I-SPECULATION
interaction	I-SPECULATION
.	O

The	O
localization-derived	O
negative	O
trained	O
predictor	O
tested	O
on	O
sets	O
containing	O
localization-derived	O
negatives	O
achieves	O
a	O
lower	O
accuracy	O
than	O
that	O
of	O
the	O
random	O
negative	O
trained	O
predictor	O
tested	O
on	O
a	O
test	O
set	O
containing	O
randomly-generated	O
negatives	O
(	O
0.0686	O
+/-	O
0.0010	O
vs	O
0.0747	O
+/-	O
0.0022	O
)	O
.	O

This	O
is	O
most	O
likely	B-SPECULATION
due	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
fact	I-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
localization-derived	I-SPECULATION
negative	I-SPECULATION
trained	I-SPECULATION
predictor	I-SPECULATION
,	O
since	O
the	O
network	O
resulting	O
from	O
the	O
predictions	O
of	O
the	O
Group	O
A	O
modules	O
cannot	B-NEGATION
take	I-NEGATION
full	I-NEGATION
advantage	I-NEGATION
of	I-NEGATION
the	I-NEGATION
Transitive	I-NEGATION
module	I-NEGATION
likely	B-SPECULATION
does	I-SPECULATION
not	B-NEGATION
sample	I-NEGATION
the	I-NEGATION
whole	I-NEGATION
protein	I-NEGATION
pair	I-NEGATION
space	I-NEGATION
well	I-NEGATION
.	O

Our	O
predictor	O
trained	O
with	O
randomly	O
generated	O
negatives	O
and	O
a	O
negative	O
:	O
positive	O
ratio	O
of	O
100	O
performs	O
the	O
best	O
out	O
of	O
all	O
the	O
combinations	O
of	O
training	O
sets	O
investigated	O
.	O

It	O
is	O
this	O
predictor	O
that	O
is	O
further	O
analyzed	O
in	O
subsequent	O
sections	O
.	O

Contribution	O
of	O
the	O
modules	O

The	O
relative	O
contribution	O
of	O
the	O
modules	O
to	O
the	O
prediction	O
of	O
interaction	O
was	O
investigated	O
in	O
order	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
predictive	O
power	O
and	O
areas	O
of	O
highest	O
usefulness	O
of	O
the	O
different	O
modules	O
.	O

To	O
do	O
this	O
,	O
all	O
protein	O
pairs	O
were	O
considered	O
that	O
achieve	O
an	O
estimated	O
posterior	O
odds	O
ratio	O
>	O
1	O
when	O
the	O
EOCT	O
predictor	O
was	O
trained	O
on	O
the	O
full	O
datasets	O
without	B-NEGATION
cross-validation	I-NEGATION
.	O

This	O
set	O
consists	O
of	O
37606	O
distinct	O
predicted	O
interactions	O
and	O
is	O
referred	O
to	O
as	O
the	O
LR400	O
dataset	O
(	O
all	O
these	O
interactions	O
are	O
listed	O
and	O
ranked	O
in	O
Additional	O
File	O
3	O
)	O
.	O

These	O
protein	O
pairs	O
represent	O
the	O
most	O
probable	B-SPECULATION
interactors	I-SPECULATION
with	O
respect	O
to	O
the	O
features	O
considered	O
,	O
among	O
all	O
protein	O
pairs	O
examined	O
by	O
the	O
predictor	O
.	O

To	O
investigate	O
the	O
individual	O
contribution	O
of	O
each	O
module	O
,	O
we	O
looked	O
at	O
the	O
number	O
of	O
interactions	O
predicted	O
out	O
of	O
all	O
LR400	O
pairs	O
as	O
a	O
function	O
of	O
the	O
minimum	O
likelihood	O
ratio	O
of	O
each	O
module	O
.	O

As	O
shown	O
in	O
Figure	O
4A	O
,	O
all	O
modules	O
contribute	O
positively	O
(	O
i.e.	O
contribute	O
a	O
likelihood	O
ratio	O
greater	O
than	O
1.0	O
)	O
to	O
the	O
prediction	O
of	O
a	O
certain	O
proportion	O
of	O
the	O
interactions	O
in	O
the	O
LR400	O
dataset	O
.	O

The	O
Transitive	O
module	O
and	O
to	O
an	O
even	O
greater	O
extent	O
,	O
the	O
Combined	O
module	O
contribute	O
positively	O
to	O
the	O
prediction	O
of	O
a	O
very	O
high	O
proportion	O
of	O
the	O
LR400	O
protein	O
pairs	O
(	O
73	O
%	O
and	O
91	O
%	O
of	O
the	O
LR400	O
interactions	O
have	O
likelihood	O
ratios	O
greater	O
than	O
1	O
for	O
the	O
Transitive	O
and	O
Combined	O
modules	O
respectively	O
)	O
.	O

The	O
Transitive	O
module	O
provides	O
a	O
likelihood	O
ratio	O
of	O
91	O
for	O
the	O
prediction	O
of	O
over	O
70	O
%	O
of	O
the	O
LR400	O
interactions	O
.	O

The	O
Combined	O
module	O
provides	O
positive	O
evidence	O
for	O
the	O
highest	O
number	O
of	O
interactions	O
of	O
the	O
LR400	O
dataset	O
.	O

However	O
,	O
the	O
value	O
of	O
the	O
likelihood	O
ratio	O
it	O
contributes	O
is	O
below	O
20	O
for	O
over	O
50	O
%	O
of	O
protein	O
pairs	O
in	O
the	O
LR400	O
dataset	O
(	O
which	O
means	O
that	O
for	O
these	O
protein	O
pairs	O
,	O
the	O
Combined	O
module	O
must	O
be	O
used	O
in	O
combination	O
with	O
other	O
modules	O
to	O
achieve	O
a	O
total	O
likelihood	O
ratio	O
above	O
400	O
)	O
.	O

The	O
Combined	O
module	O
does	O
,	O
however	O
,	O
achieve	O
likelihood	O
ratios	O
high	O
enough	O
to	O
predict	O
over	O
two	O
thousand	O
interactions	O
of	O
the	O
LR400	O
dataset	O
on	O
its	O
own	O
,	O
less	O
than	O
15	O
%	O
of	O
which	O
are	O
present	O
in	O
the	O
training	O
set	O
.	O

The	O
Orthology	O
module	O
contributes	O
to	O
the	O
prediction	O
of	O
only	O
8474	O
protein	O
pairs	O
in	O
the	O
LR400	O
dataset	O
(	O
23	O
%)	O
.	O

However	O
,	O
a	O
large	O
majority	O
(>	O
75	O
%)	O
of	O
these	O
8474	O
predicted	O
interactions	O
achieve	O
likelihood	O
ratios	O
above	O
200	O
from	O
this	O
module	O
.	O

In	O
fact	O
,	O
almost	O
40	O
%	O
of	O
these	O
LR400	O
interactions	O
achieve	O
a	O
likelihood	O
ratio	O
above	O
400	O
from	O
the	O
Orthology	O
module	O
.	O

This	O
indicates	B-SPECULATION
that	I-SPECULATION
most	I-SPECULATION
interactions	I-SPECULATION
predicted	I-SPECULATION
by	I-SPECULATION
the	I-SPECULATION
Orthology	I-SPECULATION
module	I-SPECULATION
(	I-SPECULATION
alone	I-SPECULATION
or	I-SPECULATION
in	I-SPECULATION
combination	I-SPECULATION
with	I-SPECULATION
other	I-SPECULATION
modules	I-SPECULATION
)	I-SPECULATION
are	I-SPECULATION
based	I-SPECULATION
on	I-SPECULATION
the	I-SPECULATION
highest	I-SPECULATION
scoring	I-SPECULATION
Orthology	I-SPECULATION
bins	I-SPECULATION
(	I-SPECULATION
see	I-SPECULATION
Figure	I-SPECULATION
1A	I-SPECULATION
)	I-SPECULATION
which	I-SPECULATION
are	I-SPECULATION
the	I-SPECULATION
most	I-SPECULATION
conserved	I-SPECULATION
yeast	I-SPECULATION
interactions	I-SPECULATION
(	I-SPECULATION
whose	I-SPECULATION
bin	I-SPECULATION
achieves	I-SPECULATION
a	I-SPECULATION
likelihood	I-SPECULATION
ratio	I-SPECULATION
of	I-SPECULATION
237	I-SPECULATION
)	I-SPECULATION
,	I-SPECULATION
as	I-SPECULATION
well	I-SPECULATION
as	I-SPECULATION
human	I-SPECULATION
paralogous	I-SPECULATION
interactions	I-SPECULATION
and	I-SPECULATION
interactions	I-SPECULATION
found	I-SPECULATION
in	I-SPECULATION
more	I-SPECULATION
than	I-SPECULATION
one	I-SPECULATION
model	I-SPECULATION
organism	I-SPECULATION
(	I-SPECULATION
both	I-SPECULATION
of	I-SPECULATION
which	I-SPECULATION
achieve	I-SPECULATION
a	I-SPECULATION
likelihood	I-SPECULATION
well	I-SPECULATION
above	I-SPECULATION
400	I-SPECULATION
)	I-SPECULATION
.	O

Few	O
interactions	O
in	O
the	O
LR400	O
dataset	O
are	O
predicted	O
on	O
the	O
basis	O
of	O
having	O
interacting	O
orthologs	O
in	O
worm	O
or	O
fly	O
alone	O
.	O

The	O
Expression	O
module	O
provides	O
positive	O
evidence	O
for	O
a	O
little	O
less	O
than	O
half	O
the	O
predictions	O
in	O
the	O
LR400	O
dataset	O
.	O

However	O
,	O
as	O
previously	O
noted	O
,	O
the	O
highest	O
likelihood	O
provided	O
by	O
this	O
module	O
is	O
33	O
and	O
thus	O
the	O
Expression	O
module	O
cannot	B-NEGATION
predict	I-NEGATION
interaction	I-NEGATION
on	I-NEGATION
its	I-NEGATION
own	I-NEGATION
.	O

Contribution	O
of	O
the	O
modules	O

Contribution	O
of	O
the	O
modules	O
.	O

To	O
examine	O
the	O
contribution	O
of	O
the	O
different	O
modules	O
,	O
we	O
plotted	O
the	O
number	O
of	O
interactions	O
predicted	O
among	O
all	O
LR400	O
interactions	O
(	O
all	O
interactions	O
predicted	O
using	O
the	O
full	O
predictor	O
that	O
obtain	O
a	O
likelihood	O
ratio	O
of	O
interaction	O
greater	O
than	O
400	O
)	O
as	O
a	O
function	O
of	O
the	O
minimum	O
likelihood	O
ratio	O
of	O
individual	O
modules	O
(	O
in	O
panel	O
A	O
)	O
or	O
of	O
combinations	O
of	O
modules	O
(	O
in	O
panel	O
B	O
)	O
.	O

In	O
the	O
case	O
of	O
combinations	O
of	O
modules	O
(	O
panel	O
B	O
)	O
,	O
the	O
minimum	O
likelihood	O
ratio	O
is	O
the	O
product	O
of	O
the	O
likelihood	O
ratios	O
of	O
the	O
modules	O
considered	O
.	O

Thus	O
for	O
example	O
,	O
the	O
product	O
of	O
the	O
expression	O
and	O
orthology	O
ratios	O
is	O
greater	O
than	O
1	O
for	O
almost	O
20000	O
LR400	O
interactions	O
and	O
greater	O
than	O
10	O
for	O
approximately	O
10000	O
LR400	O
interactions	O
(	O
dark	O
blue	O
diamonds	O
in	O
panel	O
B	O
)	O
.	O

E	O
:	O
Expression	O
module	O
,	O
O	O
:	O
Orthology	O
module	O
,	O
C	O
:	O
Combined	O
module	O
,	O
T	O
:	O
Transitive	O
module	O
.	O

Figure	O
4B	O
summarizes	O
the	O
contributions	O
of	O
different	O
combinations	O
of	O
modules	O
.	O

The	O
Combined	O
and	O
Transitive	O
modules	O
contribute	O
the	O
most	O
to	O
the	O
prediction	O
of	O
interactions	O
.	O

They	O
alone	O
can	O
predict	O
approximately	O
27000	O
of	O
the	O
37606	O
interactions	O
of	O
the	O
LR400	O
dataset	O
.	O

When	O
they	O
are	O
both	O
present	O
,	O
regardless	O
of	O
which	O
other	O
modules	O
are	O
also	O
present	O
,	O
they	O
predict	O
over	O
70	O
%	O
of	O
the	O
LR400	O
interactions	O
.	O

When	O
either	B-NEGATION
of	I-NEGATION
these	I-NEGATION
two	I-NEGATION
modules	I-NEGATION
is	I-NEGATION
absent	I-NEGATION
,	O
fewer	O
than	O
12500	O
interactions	O
are	O
predicted	O
.	O

In	O
contrast	O
,	O
the	O
two	O
remaining	O
modules	O
(	O
Expression	O
and	O
Orthology	O
)	O
can	O
predict	O
approximately	O
5000	O
interactions	O
together	O
.	O

This	O
is	O
interesting	O
as	O
many	O
of	O
the	O
publicly	O
available	O
predicted	O
interaction	O
datasets	O
mentioned	O
in	O
the	O
Background	O
section	O
use	O
mainly	O
orthology	O
transfer	O
from	O
model	O
organisms	O
to	O
identify	O
interactions	O
.	O

As	O
the	O
majority	O
of	O
the	O
LR400	O
interactions	O
are	O
derived	O
from	O
the	O
Combined	O
and	O
Transitive	O
modules	O
,	O
it	O
is	O
possible	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
method	I-SPECULATION
is	I-SPECULATION
identifying	I-SPECULATION
a	I-SPECULATION
large	I-SPECULATION
subset	I-SPECULATION
of	I-SPECULATION
interactions	I-SPECULATION
that	I-SPECULATION
are	I-SPECULATION
not	B-NEGATION
common	I-NEGATION
to	I-NEGATION
previous	I-NEGATION
human	I-NEGATION
protein	I-NEGATION
interaction	I-NEGATION
datasets	I-NEGATION
.	O

This	O
is	O
discussed	O
further	O
in	O
the	O
next	O
section	O
.	O

The	O
curve	O
representing	O
the	O
full	O
predictor	O
(	O
consisting	O
of	O
the	O
Expression	O
,	O
Orthology	O
,	O
Combined	O
and	O
Transitive	O
modules	O
)	O
is	O
also	O
represented	O
in	O
Figure	O
4B	O
(	O
the	O
dark	O
green	O
squares	O
)	O
.	O

By	O
definition	O
,	O
it	O
predicts	O
all	O
proteins	O
in	O
the	O
LR400	O
dataset	O
at	O
likelihood	O
ratios	O
equal	O
to	O
or	O
above	O
400	O
(	O
this	O
is	O
how	O
the	O
LR400	O
dataset	O
was	O
generated	O
)	O
.	O

The	O
right	O
side	O
of	O
the	O
curve	O
illustrates	O
the	O
number	O
of	O
interactions	O
that	O
are	O
predicted	O
above	O
likelihood	O
ratios	O
of	O
400	O
and	O
more	O
.	O

As	O
shown	O
in	O
Figure	O
4B	O
,	O
the	O
full	O
predictor	O
predicts	O
approximately	O
20000	O
interactions	O
at	O
a	O
total	O
likelihood	O
ratio	O
of	O
1600	O
(	O
which	O
is	O
equivalent	O
to	O
an	O
estimated	O
posterior	O
odds	O
ratio	O
of	O
4	O
)	O
.	O

At	O
a	O
likelihood	O
ratio	O
of	O
4000	O
,	O
approximately	O
11000	O
interactions	O
are	O
predicted	O
and	O
at	O
a	O
likelihood	O
ratio	O
of	O
8000	O
,	O
approximately	O
6500	O
interactions	O
are	O
predicted	O
.	O

We	O
verified	O
that	O
the	O
increasing	O
estimated	O
posterior	O
odds	O
ratios	O
translated	O
into	O
better	O
predictive	O
value	O
.	O

Figure	O
5	O
shows	O
the	O
true	O
positive	O
rate	O
versus	O
false	O
positive	O
rate	O
for	O
different	O
posterior	O
odds	O
ratios	O
as	O
measured	O
by	O
five-fold	O
cross	O
validation	O
.	O

As	O
the	O
posterior	O
odds	O
ratio	O
increases	O
,	O
the	O
false	O
positive	O
rate	O
decreases	O
and	O
the	O
relative	O
proportion	O
of	O
true	O
positives	O
increases	O
when	O
compared	O
to	O
the	O
proportion	O
of	O
false	O
positives	O
.	O

Accordingly	O
,	O
subsets	B-SPECULATION
of	I-SPECULATION
very	I-SPECULATION
high	I-SPECULATION
quality	I-SPECULATION
predictions	I-SPECULATION
may	I-SPECULATION
be	I-SPECULATION
generated	I-SPECULATION
by	I-SPECULATION
choosing	I-SPECULATION
a	I-SPECULATION
suitably	I-SPECULATION
high	I-SPECULATION
posterior	I-SPECULATION
odds	I-SPECULATION
ratio	I-SPECULATION
threshold	I-SPECULATION
.	O

True	O
positive	O
rate	O
versus	O
false	O
positive	O
rate	O
for	O
different	O
estimated	O
posterior	O
odds	O
ratios	O

True	O
positive	O
rate	O
versus	O
false	O
positive	O
rate	O
for	O
different	O
estimated	O
posterior	O
odds	O
ratios	O
.	O

The	O
true	O
positive	O
rate	O
(	O
TPR	O
)	O
versus	O
false	O
positive	O
rate	O
(	O
FPR	O
)	O
is	O
plotted	O
for	O
different	O
values	O
of	O
the	O
posterior	O
odds	O
ratio	O
estimated	O
for	O
the	O
dataset	O
by	O
five-fold	O
cross-validation	O
.	O

As	O
the	O
posterior	O
odds	O
ratio	O
increases	O
,	O
the	O
false	O
positive	O
rate	O
decreases	O
and	O
the	O
ratio	O
of	O
the	O
true	O
positive	O
rate	O
divided	O
by	O
the	O
false	O
positive	O
ratio	O
increases	O
.	O

Thus	O
,	O
higher	O
quality	O
datasets	O
can	O
be	O
generated	O
by	O
requiring	O
higher	O
posterior	O
odds	O
ratios	O
.	O

The	O
TPR	O
is	O
calculated	O
as	O
the	O
number	O
of	O
true	O
positives	O
predicted	O
divided	O
by	O
the	O
total	O
number	O
of	O
positives	O
in	O
the	O
test	O
set	O
.	O

The	O
FPR	O
is	O
calculated	O
as	O
the	O
number	O
of	O
false	O
positives	O
predicted	O
divided	O
by	O
the	O
total	O
number	O
of	O
negatives	O
in	O
the	O
test	O
set	O
.	O

Comparison	O
to	O
other	O
interaction	O
datasets	O

The	O
false	O
positive	O
rate	O
(	O
FPR	O
)	O
of	O
our	O
predictor	O
was	O
estimated	O
by	O
the	O
method	O
of	O
D'Haeseleer	O
and	O
Church	O
1855	O
and	O
used	O
to	O
compare	O
it	O
to	O
other	O
prediction	O
datasets	O
.	O

The	O
Ramani	O
interaction	O
dataset	O
that	O
was	O
automatically	O
extracted	O
from	O
the	O
literature	O
16	O
as	O
well	O
as	O
all	O
new	O
interactions	O
present	O
in	O
the	O
October	O
2006	O
version	O
of	O
the	O
manually	O
curated	O
HPRD	O
database	O
15	O
(	O
but	O
none	B-NEGATION
of	I-NEGATION
the	I-NEGATION
interactions	I-NEGATION
also	I-NEGATION
present	I-NEGATION
in	I-NEGATION
earlier	I-NEGATION
versions	I-NEGATION
of	I-NEGATION
the	I-NEGATION
HPRD	I-NEGATION
which	I-NEGATION
were	I-NEGATION
used	I-NEGATION
to	I-NEGATION
train	I-NEGATION
our	I-NEGATION
predictor	I-NEGATION
)	I-NEGATION
were	I-NEGATION
taken	I-NEGATION
as	I-NEGATION
reference	I-NEGATION
datasets	I-NEGATION
.	O

The	O
D'Haeseleer	O
and	O
Church	O
method	O
compares	O
two	O
experimental	O
datasets	O
to	O
a	O
reference	O
set	O
and	O
assumes	B-SPECULATION
that	I-SPECULATION
all	I-SPECULATION
intersections	I-SPECULATION
between	I-SPECULATION
the	I-SPECULATION
three	I-SPECULATION
datasets	I-SPECULATION
contain	I-SPECULATION
true	I-SPECULATION
positives	I-SPECULATION
.	O

It	O
is	O
thus	O
possible	B-SPECULATION
to	I-SPECULATION
estimate	I-SPECULATION
the	I-SPECULATION
number	I-SPECULATION
of	I-SPECULATION
true	I-SPECULATION
positives	I-SPECULATION
predicted	I-SPECULATION
by	I-SPECULATION
an	I-SPECULATION
experimental	I-SPECULATION
dataset	I-SPECULATION
by	I-SPECULATION
comparing	I-SPECULATION
the	I-SPECULATION
number	I-SPECULATION
of	I-SPECULATION
interactions	I-SPECULATION
present	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
different	I-SPECULATION
intersections	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
two	I-SPECULATION
experimental	I-SPECULATION
methods	I-SPECULATION
and	I-SPECULATION
the	I-SPECULATION
reference	I-SPECULATION
dataset	I-SPECULATION
(	O
for	O
details	O
,	O
see	O
1855	O
)	O
.	O

Here	O
,	O
we	O
compare	O
three	O
human	O
interaction	O
prediction	O
datasets	O
:	O
the	O
Rhodes	O
probabilistic	O
dataset	O
46	O
,	O
the	O
Lehner	O
orthology-derived	O
dataset	O
36	O
and	O
the	O
most	O
accurate	O
of	O
our	O
predictors	O
(	O
the	O
LR400	O
subset	O
of	O
the	O
predictor	O
considering	O
the	O
Expression	O
,	O
Orthology	O
,	O
Combined	O
and	O
Transitive	O
modules	O
)	O
.	O

We	O
estimated	O
false	O
positive	O
rates	O
for	O
each	O
of	O
the	O
datasets	O
by	O
comparing	O
them	O
two	O
by	O
two	O
to	O
one	O
of	O
the	O
reference	O
datasets	O
,	O
thus	O
generating	O
4	O
to	O
6	O
different	O
estimates	O
of	O
false	O
positive	O
rates	O
for	O
each	O
computational	O
dataset	O
,	O
as	O
shown	O
in	O
Figure	O
6A	O
(	B-NEGATION
the	I-NEGATION
two	I-NEGATION
Lehner	I-NEGATION
datasets	I-NEGATION
were	I-NEGATION
not	I-NEGATION
compared	I-NEGATION
to	I-NEGATION
each	I-NEGATION
other	I-NEGATION
,	O
which	O
is	O
why	O
they	O
have	O
fewer	O
FPR	O
estimates	O
)	O
.	O

The	O
rates	O
estimated	O
for	O
the	O
Rhodes	O
and	O
Lehner	O
datasets	O
are	O
similar	O
to	O
previous	O
estimates	O
18	O
.	O

The	O
estimated	O
false	O
positive	O
rates	O
for	O
the	O
LR400	O
,	O
Rhodes	O
and	O
core	O
Lehner	O
are	O
quite	O
similar	O
(	O
an	O
average	O
of	O
76	O
%	O
FPR	O
for	O
both	O
the	O
LR400	O
and	O
core	O
Lehner	O
datasets	O
and	O
78	O
%	O
for	O
the	O
Rhodes	O
dataset	O
)	O
and	O
well	O
below	O
the	O
overall	O
average	O
false-positive	O
rate	O
of	O
90	O
%	O
estimated	O
for	O
most	O
available	O
human	O
high-throughput	O
experimental	O
and	O
prediction	O
interaction	O
datasets	O
18	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
Rhodes	O
,	O
Lehner	O
and	O
Ramani	O
datasets	O
annotate	O
interactions	O
as	O
a	O
relationship	O
between	O
human	O
genes	O
and	O
not	B-NEGATION
their	I-NEGATION
protein	I-NEGATION
products	I-NEGATION
directly	I-NEGATION
.	O

However	O
,	O
not	O
all	O
proteins	O
encoded	O
by	O
a	O
single	O
gene	O
will	O
necessarily	O
interact	O
with	O
all	O
protein	O
products	O
encoded	O
by	O
a	O
second	O
gene	O
,	O
even	O
if	O
one	O
such	O
protein	O
pair	O
does	O
.	O

This	O
is	O
why	O
we	O
describe	O
interactions	O
as	O
a	O
relationship	O
between	O
two	O
proteins	O
,	O
allowing	O
for	O
a	O
more	O
precise	O
description	O
of	O
the	O
interaction	O
.	O

To	O
compare	O
our	O
predictions	O
to	O
these	O
datasets	O
,	O
we	O
consider	B-SPECULATION
that	I-SPECULATION
two	I-SPECULATION
genes	I-SPECULATION
interact	I-SPECULATION
if	I-SPECULATION
at	I-SPECULATION
least	I-SPECULATION
one	I-SPECULATION
of	I-SPECULATION
their	I-SPECULATION
respective	I-SPECULATION
protein	I-SPECULATION
products	I-SPECULATION
interact	I-SPECULATION
.	O

Comparison	O
to	O
other	O
interaction	O
datasets	O

Comparison	O
to	O
other	O
interaction	O
datasets	O
.	O

The	O
false	O
positive	O
rates	O
shown	O
in	O
panel	O
A	O
were	O
estimated	O
for	O
the	O
LR400	O
dataset	O
as	O
well	O
as	O
the	O
Rhodes	O
[	O
46	O
]	O
and	O
Lehner	O
[	O
36	O
]	O
predictions	O
using	O
the	O
method	O
described	O
in	O
[	O
18	O
,	O
55	O
]	O
by	O
comparing	O
them	O
two-by-two	O
to	O
a	O
reference	O
dataset	O
.	O

The	O
number	O
and	O
overlap	O
of	O
distinct	O
proteins	O
(	O
shown	O
in	O
B	O
)	O
and	O
distinct	O
interactions	O
(	O
shown	O
in	O
C	O
)	O
are	O
shown	O
for	O
the	O
LR400	O
dataset	O
,	O
the	O
Rhodes	O
prediction	O
dataset	O
and	O
the	O
June	O
2006	O
version	O
of	O
the	O
HPRD	O
.	O

In	O
Figure	O
6B	O
and	O
6C	O
,	O
we	O
compare	O
the	O
number	O
of	O
distinct	O
proteins	O
and	O
distinct	O
interactions	O
of	O
the	O
LR400	O
dataset	O
to	O
those	O
of	O
the	O
Rhodes	O
prediction	O
dataset	O
and	O
the	O
June	O
2006	O
version	O
of	O
the	O
HPRD	O
which	O
was	O
used	O
to	O
train	O
our	O
predictor	O
.	O

The	O
Rhodes	O
dataset	O
was	O
trained	O
using	O
an	O
earlier	O
version	O
of	O
the	O
HPRD	O
.	O

As	O
can	O
be	O
seen	O
in	O
Figure	O
6	O
,	O
the	O
intersections	O
between	O
the	O
three	O
datasets	O
considered	O
are	O
low	O
,	O
especially	O
when	O
comparing	O
the	O
interactions	O
.	O

Both	O
the	O
Rhodes	O
dataset	O
and	O
our	O
LR400	O
dataset	O
predict	O
interactions	O
involving	O
many	O
proteins	O
that	O
are	O
not	B-NEGATION
even	I-NEGATION
present	I-NEGATION
in	I-NEGATION
their	I-NEGATION
positive	I-NEGATION
training	I-NEGATION
set	I-NEGATION
(	I-NEGATION
the	I-NEGATION
HPRD	I-NEGATION
)	I-NEGATION
.	O

Many	O
of	O
the	O
predictions	O
in	O
these	O
two	O
datasets	O
concern	O
protein	O
pairs	O
and	O
proteins	O
that	O
are	O
not	B-NEGATION
present	I-NEGATION
in	I-NEGATION
other	I-NEGATION
datasets	I-NEGATION
,	O
suggesting	B-SPECULATION
that	I-SPECULATION
they	I-SPECULATION
cover	I-SPECULATION
different	I-SPECULATION
regions	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
human	I-SPECULATION
interaction	I-SPECULATION
space	I-SPECULATION
.	O

As	O
suggested	B-SPECULATION
in	I-SPECULATION
18	I-SPECULATION
,	I-SPECULATION
by	I-SPECULATION
making	I-SPECULATION
more	I-SPECULATION
such	I-SPECULATION
datasets	I-SPECULATION
available	I-SPECULATION
,	I-SPECULATION
it	I-SPECULATION
will	I-SPECULATION
be	I-SPECULATION
possible	B-SPECULATION
to	I-SPECULATION
increase	I-SPECULATION
our	I-SPECULATION
coverage	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
interaction	I-SPECULATION
space	I-SPECULATION
and	I-SPECULATION
determine	I-SPECULATION
the	I-SPECULATION
most	I-SPECULATION
likely	B-SPECULATION
human	I-SPECULATION
interactions	I-SPECULATION
.	O

Another	O
human	O
interaction	O
dataset	O
has	O
recently	O
become	O
available	O
:	O
the	O
IntNetDB	O
56	O
.	O

It	O
was	O
generated	O
by	O
integrating	O
seven	O
different	O
features	O
(	O
four	O
of	O
which	O
involve	O
transferring	O
interactions	O
or	O
characteristics	O
of	O
protein	O
pairs	O
from	O
model	O
organisms	O
to	O
human	O
)	O
in	O
a	O
probabilistic	O
framework	O
.	O

Interactions	O
were	O
predicted	O
above	O
a	O
TP	O
/	O
FP	O
ratio	O
(	O
number	O
of	O
true	O
positives	O
divided	O
by	O
the	O
number	O
of	O
false	O
positives	O
in	O
the	O
test	O
set	O
)	O
of	O
1	O
.	O

Using	O
such	O
a	O
threshold	O
,	O
the	O
authors	O
claim	O
to	O
predict	O
180	O
010	O
human	O
interactions	O
.	O

We	O
do	O
not	B-NEGATION
compare	I-NEGATION
our	I-NEGATION
predictions	I-NEGATION
to	I-NEGATION
this	I-NEGATION
dataset	I-NEGATION
because	O
such	O
a	O
threshold	O
of	O
TP	O
/	O
FP	O
>	O
1	O
does	O
not	B-NEGATION
correspond	I-NEGATION
to	I-NEGATION
a	I-NEGATION
posterior	I-NEGATION
odds	I-NEGATION
threshold	I-NEGATION
>	I-NEGATION
1	I-NEGATION
.	O

Depending	O
on	O
the	O
positive-to-negative	O
ratio	O
used	O
in	O
the	O
datasets	O
,	O
TP	O
/	O
FP	O
>	O
1	O
might	B-SPECULATION
correspond	I-SPECULATION
to	I-SPECULATION
an	I-SPECULATION
average	I-SPECULATION
posterior	I-SPECULATION
odds	I-SPECULATION
ratio	I-SPECULATION
of	I-SPECULATION
1	I-SPECULATION
.	O

In	O
contrast	O
,	O
the	O
average	O
posterior	O
odds	O
ratio	O
of	O
our	O
LR400	O
dataset	O
is	O
above	O
700	O
.	O

In	O
comparison	O
,	O
by	O
using	O
a	O
threshold	O
of	O
TP	O
/	O
FP	O
>	O
1	O
in	O
our	O
test	O
set	O
,	O
we	O
predict	B-SPECULATION
over	I-SPECULATION
1	I-SPECULATION
000	I-SPECULATION
000	I-SPECULATION
human	I-SPECULATION
interactions	I-SPECULATION
.	O

We	O
do	O
not	B-NEGATION
since	O
the	O
great	O
majority	O
of	O
these	O
protein	O
pairs	O
achieve	O
a	O
posterior	O
odds	O
ratio	O
below	O
1	O
.	O
believe	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
quality	I-SPECULATION
of	I-SPECULATION
this	I-SPECULATION
large	I-SPECULATION
number	I-SPECULATION
of	I-SPECULATION
predictions	I-SPECULATION
is	I-SPECULATION
high	I-SPECULATION
enough	I-SPECULATION
to	I-SPECULATION
warrant	I-SPECULATION
their	I-SPECULATION
publication	I-SPECULATION
.	O

Independent	O
validation	O

Although	O
the	O
overlap	O
between	O
the	O
LR400	O
dataset	O
and	O
the	O
HPRD-derived	O
positive	O
training	O
set	O
is	O
below	O
10	O
%	O
as	O
shown	O
in	O
Figure	O
6C	O
,	O
the	O
proportion	O
of	O
interactions	O
common	O
to	O
these	O
two	O
sets	O
is	O
not	B-NEGATION
equally	I-NEGATION
distributed	I-NEGATION
for	I-NEGATION
all	I-NEGATION
posterior	I-NEGATION
odds	I-NEGATION
ratios	I-NEGATION
of	I-NEGATION
interaction	I-NEGATION
values	I-NEGATION
.	O

As	O
shown	O
in	O
Figure	O
7	O
,	O
while	O
less	O
than	O
3	O
%	O
of	O
the	O
protein	O
pairs	O
predicted	O
to	O
interact	O
at	O
posterior	O
odds	O
ratios	O
between	O
1	O
and	O
2	O
overlap	O
with	O
the	O
HPRD	O
dataset	O
used	O
for	O
training	O
,	O
this	O
value	O
increases	O
to	O
over	O
50	O
%	O
for	O
the	O
highest	O
scoring	O
subsets	O
of	O
the	O
LR400	O
dataset	O
.	O

These	O
highest	O
scoring	O
predictions	O
receive	O
high	O
likelihood	O
ratios	O
of	O
interaction	O
from	O
all	O
four	O
predictive	O
modules	O
and	O
represent	O
the	O
strongest	O
examples	O
of	O
interaction	O
as	O
evaluated	O
by	O
our	O
predictor	O
.	O

Such	O
examples	O
include	O
interactions	O
that	O
allow	O
the	O
formation	O
of	O
well-known	O
protein	O
complexes	O
such	O
as	O
the	O
proteasome	O
,	O
the	O
MCM	O
protein	O
complex	O
involved	O
in	O
the	O
initiation	O
of	O
genome	O
replication	O
,	O
replication	O
factor	O
C	O
,	O
the	O
TBP	O
/	O
TAF	O
complex	O
(	O
TBP-associated	O
factors	O
)	O
and	O
the	O
EIF	O
complex	O
(	O
eukaryotic	O
translation	O
initiation	O
factors	O
)	O
.	O

The	O
highest	O
scoring	O
predictions	O
in	O
the	O
LR400	O
dataset	O
thus	O
mainly	O
represent	O
interactions	O
present	O
in	O
the	O
HPRD	O
dataset	O
as	O
well	O
as	O
interactions	O
between	O
proteins	O
that	O
have	O
strong	O
sequence	O
identity	O
to	O
these	O
known	O
interacting	O
pairs	O
.	O

However	O
,	O
as	O
the	O
posterior	O
odds	O
ratio	O
decreases	O
,	O
the	O
overlap	O
between	O
the	O
predictions	O
and	O
the	O
HPRD-derived	O
training	O
set	O
decreases	O
.	O

Some	O
subsets	O
of	O
quite	O
high	O
posterior	O
odds	O
have	O
much	O
smaller	O
overlaps	O
with	O
the	O
training	O
set	O
.	O

For	O
example	O
,	O
interactions	O
predicted	O
at	O
posterior	O
odds	O
ratios	O
between	O
128	O
and	O
2048	O
have	O
a	O
20	O
to	O
30	O
%	O
overlap	O
with	O
the	O
training	O
set	O
as	O
shown	O
in	O
Figure	O
7	O
.	O

Although	O
many	B-NEGATION
of	I-NEGATION
these	I-NEGATION
novel	I-NEGATION
predictions	I-NEGATION
have	I-NEGATION
not	I-NEGATION
been	I-NEGATION
previously	I-NEGATION
investigated	I-NEGATION
in	I-NEGATION
the	I-NEGATION
literature	I-NEGATION
,	O
there	O
exists	O
experimental	O
evidence	O
supporting	O
a	O
subset	O
of	O
these	O
predictions	O
which	O
is	O
not	B-NEGATION
present	I-NEGATION
in	I-NEGATION
the	I-NEGATION
June	I-NEGATION
2006	I-NEGATION
version	I-NEGATION
of	I-NEGATION
the	I-NEGATION
HPRD	I-NEGATION
used	I-NEGATION
to	I-NEGATION
train	I-NEGATION
our	I-NEGATION
predictor	I-NEGATION
,	O
thus	O
providing	O
independent	O
validation	O
of	O
our	O
method	O
.	O

Five	O
such	O
validated	O
predictions	O
are	O
reported	O
here	O
:	O

Overlap	O
of	O
different	O
subsets	O
of	O
the	O
LR400	O
dataset	O
with	O
the	O
HPRD-derived	O
training	O
set	O

Overlap	O
of	O
different	O
subsets	O
of	O
the	O
LR400	O
dataset	O
with	O
the	O
HPRD-derived	O
training	O
set	O
.	O

The	O
number	O
of	O
interactions	O
predicted	O
and	O
the	O
proportion	O
of	O
overlap	O
with	O
the	O
training	O
set	O
(	O
which	O
was	O
derived	O
from	O
the	O
HPRD	O
)	O
were	O
calculated	O
for	O
subsets	O
of	O
the	O
LR400	O
dataset	O
of	O
different	O
posterior	O
odds	O
ratios	O
.	O

-	O
TCPTP	O
was	O
predicted	O
to	O
interact	O
with	O
STAT6	O
at	O
a	O
posterior	O
odds	O
ratio	O
of	O
4300	O
.	O

It	O
has	O
been	O
recently	O
reported	O
that	O
TCPTP	O
,	O
the	O
only	O
protein	O
tyrosine	O
phosphatase	O
known	O
to	O
localize	O
to	O
the	O
nucleus	O
,	O
dephosphorylates	O
STAT6	O
in	O
this	O
cellular	O
compartment	O
,	O
which	O
may	B-SPECULATION
in	I-SPECULATION
turn	I-SPECULATION
lead	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
suppression	I-SPECULATION
of	I-SPECULATION
Interleukine-4	I-SPECULATION
(	I-SPECULATION
IL-4	I-SPECULATION
)	I-SPECULATION
induced	I-SPECULATION
signaling	I-SPECULATION
57	O
.	O

-	O
N-WASP	O
and	O
ARP3	O
achieve	O
a	O
predicted	O
posterior	O
odds	O
ratio	O
of	O
interaction	O
of	O
2700	O
.	O

A	O
recent	O
report	O
suggested	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
IQGAP1	I-SPECULATION
protein	I-SPECULATION
58	O
.	O
can	B-SPECULATION
activate	I-SPECULATION
N-WASP	I-SPECULATION
thus	O
changing	O
its	O
conformation	O
and	O
allowing	O
it	O
to	O
bind	O
the	O
ARP2	O
/	O
3	O
complex	O
,	O
which	O
in	O
turn	O
directs	O
the	O
generation	O
of	O
branched	O
actin	O
filaments	O
required	O
for	O
the	O
extension	O
of	O
a	O
lamellipodium	O
.	O

-	O
The	O
VAMP3-VTI1A	O
interaction	O
was	O
predicted	O
with	O
a	O
posterior	O
odds	O
ratio	O
of	O
1518	O
.	O

Both	B-SPECULATION
these	I-SPECULATION
proteins	I-SPECULATION
are	I-SPECULATION
believed	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
part	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
SNARE	I-SPECULATION
(	I-SPECULATION
soluble	I-SPECULATION
N-ethylmaleimide-sensitive	I-SPECULATION
factor	I-SPECULATION
attachment	I-SPECULATION
protein	I-SPECULATION
receptor	I-SPECULATION
)	I-SPECULATION
family	I-SPECULATION
of	I-SPECULATION
proteins	I-SPECULATION
which	I-SPECULATION
are	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
membrane	I-SPECULATION
fusion	I-SPECULATION
events	I-SPECULATION
.	O

VTI1A	O
is	O
a	O
trans-Golgi-network-localized	O
putative	B-SPECULATION
t-SNARE	I-SPECULATION
59	O
and	O
VAMP3	O
is	O
an	O
early	O
/	O
recycling	O
endosomal	O
v-SNARE	O
60	O
.	O

These	O
two	O
proteins	O
were	O
recently	O
shown	O
to	O
interact	O
,	O
leading	O
to	O
their	O
functional	O
implication	O
in	O
the	O
post-Golgi	O
retrograde	O
transport	O
step	O
61	O
.	O

-	O
CDK2	O
and	O
MCM4	O
were	O
predicted	O
to	O
interact	O
at	O
a	O
posterior	O
odds	O
ratio	O
of	O
62	O
.	O

CDK2	O
has	O
recently	O
been	O
shown	O
to	O
phosphorylate	O
MCM4	O
,	O
a	O
subunit	O
of	O
a	O
putative	B-SPECULATION
replicative	I-SPECULATION
helicase	I-SPECULATION
essential	O
for	O
DNA	O
replication	O
,	O
on	O
two	O
distinct	O
residues	O
,	O
leading	O
to	O
a	O
change	O
in	O
its	O
affinity	O
to	O
chromatin	O
and	O
its	O
enrichment	O
in	O
the	O
nucleolus	O
62	O
.	O

-	O
Sam68	O
and	O
Smad2	O
achieve	O
a	O
predicted	O
posterior	O
odds	O
ratio	O
of	O
32	O
.	O

This	O
interaction	O
has	O
been	O
experimentally	O
demonstrated	O
by	O
large-scale	O
yeast-two-hybrid	O
analysis	O
of	O
the	O
Smad	O
signaling	O
system	O
63	O
.	O

Our	O
probabilistic	O
predictor	O
therefore	O
not	O
only	O
reproduces	O
and	O
completes	O
well-known	O
protein	O
complexes	O
but	O
also	O
identifies	O
novel	O
interactions	O
,	O
a	O
subset	O
of	O
which	O
have	O
been	O
independently	O
validated	O
.	O

Conclusion	O

The	B-SPECULATION
current	I-SPECULATION
human	I-SPECULATION
protein	I-SPECULATION
interaction	I-SPECULATION
map	I-SPECULATION
is	I-SPECULATION
estimated	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
only	I-SPECULATION
10	I-SPECULATION
%	I-SPECULATION
complete	I-SPECULATION
18	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
prediction	O
of	O
human	O
protein-protein	O
interactions	O
in	O
an	O
effort	O
to	O
increase	O
the	O
coverage	O
of	O
the	O
human	O
interactome	O
while	O
simultaneously	O
providing	O
high	O
quality	O
predictions	O
.	O

By	O
considering	O
several	O
different	O
types	O
of	O
orthogonal	O
and	O
quite	O
distinct	O
features	O
including	O
expression	O
,	O
orthology	O
,	O
combined	O
protein	O
characteristics	O
and	O
local	O
network	O
topology	O
,	O
we	O
predicted	O
over	O
37000	O
human	O
protein	O
interactions	O
and	O
explored	O
a	O
subspace	O
of	O
the	O
human	O
interactome	O
that	B-NEGATION
has	I-NEGATION
not	I-NEGATION
been	I-NEGATION
investigated	I-NEGATION
by	I-NEGATION
previous	I-NEGATION
large	I-NEGATION
interaction	I-NEGATION
datasets	I-NEGATION
.	O

Our	O
investigation	O
led	O
us	O
to	O
compare	O
the	O
influence	O
of	O
different	O
training	O
sets	O
on	O
the	O
prediction	O
accuracy	O
.	O

The	O
use	O
of	O
randomly	O
generated	O
negative	O
training	O
examples	O
and	O
large	O
negative-to-positive	O
ratios	O
in	O
the	O
training	O
set	O
generated	O
the	O
most	O
accurate	O
predictors	O
in	O
the	O
context	O
of	O
our	O
model	O
.	O

A	O
comparison	O
to	O
other	O
large	O
human	O
interaction	O
datasets	O
revealed	O
the	O
average	O
false	O
positive	O
rate	O
of	O
our	O
dataset	O
to	O
be	O
76	O
%	O
,	O
which	O
is	O
much	O
lower	O
than	O
the	O
overall	O
average	O
for	O
most	O
large	O
scale	O
,	O
currently	O
available	O
,	O
human	O
interaction	O
datasets	O
(	O
experimental	O
and	O
computational	O
)	O
estimated	B-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
90	I-SPECULATION
%	I-SPECULATION
18	O
.	O

A	O
subset	O
of	O
our	O
novel	O
predictions	O
have	O
been	O
independently	O
validated	O
by	O
identifying	O
recent	O
reports	O
that	O
experimentally	O
investigated	O
and	O
confirmed	O
that	O
these	O
protein	O
pairs	O
do	O
interact	O
.	O

We	O
provide	O
all	O
our	O
predictions	O
ranked	O
according	O
to	O
the	O
posterior	O
odds	O
ratio	O
of	O
interaction	O
in	O
Additional	O
File	O
3	O
.	O

It	O
is	O
thus	O
possible	B-SPECULATION
to	I-SPECULATION
restrict	I-SPECULATION
the	I-SPECULATION
dataset	I-SPECULATION
to	I-SPECULATION
the	I-SPECULATION
highest	I-SPECULATION
scoring	I-SPECULATION
protein	I-SPECULATION
pairs	I-SPECULATION
(	I-SPECULATION
and	I-SPECULATION
only	I-SPECULATION
choose	I-SPECULATION
for	I-SPECULATION
example	I-SPECULATION
,	I-SPECULATION
protein	I-SPECULATION
pairs	I-SPECULATION
that	I-SPECULATION
have	I-SPECULATION
an	I-SPECULATION
estimated	B-SPECULATION
true	I-SPECULATION
positive	I-SPECULATION
rate	I-SPECULATION
of	I-SPECULATION
interaction	I-SPECULATION
above	I-SPECULATION
90	I-SPECULATION
%)	I-SPECULATION
.	O

By	O
making	O
this	O
human	O
interaction	O
prediction	O
dataset	O
publicly	O
available	O
,	O
it	O
is	O
our	O
hope	B-SPECULATION
that	I-SPECULATION
it	I-SPECULATION
will	I-SPECULATION
help	I-SPECULATION
to	I-SPECULATION
identify	I-SPECULATION
the	I-SPECULATION
most	I-SPECULATION
high-confidence	I-SPECULATION
interactions	I-SPECULATION
,	I-SPECULATION
leading	I-SPECULATION
to	I-SPECULATION
a	I-SPECULATION
more	I-SPECULATION
complete	I-SPECULATION
and	I-SPECULATION
accurate	I-SPECULATION
human	I-SPECULATION
interaction	I-SPECULATION
map	I-SPECULATION
.	O

Methods	O

Datasets	O

In	O
order	O
to	O
investigate	O
the	O
likelihood	O
of	O
interaction	O
of	O
human	O
proteins	O
,	O
62322	O
human	O
protein	O
sequences	O
were	O
downloaded	O
from	O
the	O
International	O
Protein	O
Index	O
(	O
IPI	O
)	O
database	O
(	O
version	O
3.16	O
)	O
64	O
.	O

Some	O
of	O
these	O
proteins	O
are	O
alternative	O
transcripts	O
of	O
the	O
same	O
gene	O
but	O
can	O
have	O
distinct	O
interaction	O
partners	O
.	O

Known	O
interactions	O
were	O
downloaded	O
from	O
the	O
Human	O
Protein	O
Reference	O
Database	O
(	O
HPRD	O
;	O
June	O
2006	O
version	O
)	O
15	O
.	O

Duplicate	B-NEGATION
interactions	I-NEGATION
and	I-NEGATION
self-interactions	I-NEGATION
were	I-NEGATION
not	I-NEGATION
considered	I-NEGATION
.	O

Additionally	O
,	O
some	B-NEGATION
proteins	I-NEGATION
were	I-NEGATION
not	I-NEGATION
recovered	I-NEGATION
in	I-NEGATION
the	I-NEGATION
conversion	I-NEGATION
between	I-NEGATION
different	I-NEGATION
identifiers	I-NEGATION
.	O

This	O
resulted	O
in	O
26896	O
distinct	O
human	O
protein	O
interactions	O
involving	O
7531	O
distinct	O
human	O
proteins	O
present	O
in	O
the	O
initial	O
IPI	O
dataset	O
.	O

The	O
26896	O
interactions	O
from	O
the	O
June	O
2006	O
version	O
of	O
the	O
HPRD	O
were	O
used	O
as	O
the	O
positive	O
dataset	O
in	O
the	O
training	O
/	O
testing	O
of	O
the	O
predictor	O
.	O

Two	O
different	O
sets	O
of	O
non-interacting	O
protein	O
pairs	O
were	O
investigated	O
:	O
the	O
main	O
analysis	O
employed	O
a	O
randomly-generated	O
negative	O
dataset	O
but	O
this	O
was	O
also	O
compared	O
to	O
a	O
localization-derived	O
negative	O
dataset	O
.	O

Both	O
non-interacting	O
protein	O
datasets	O
were	O
cleaned	O
by	O
removing	O
all	O
protein	O
pairs	O
that	O
came	O
from	O
the	O
positive	O
dataset	O
as	O
well	O
as	O
protein	O
pairs	O
that	O
were	O
annotated	O
as	O
interacting	O
in	O
other	O
databases	O
(	O
DIP	O
65	O
:	O
679	O
interactions	O
,	O
BIND	O
66	O
:	O
2650	O
interactions	O
)	O
,	O
or	O
predicted	O
to	O
interact	O
in	O
other	O
studies	O
(	O
OPHID	O
67	O
:	O
21815	O
interactions	O
)	O
.	O

Of	O
the	O
62322	O
human	O
proteins	O
from	O
the	O
initial	O
IPI	O
dataset	O
,	O
22889	O
were	O
characterized	O
by	O
at	O
least	O
one	O
of	O
the	O
features	O
that	O
we	O
considered	O
to	O
predict	O
interaction	O
(	O
see	O
the	O
Features	O
section	O
)	O
.	O

These	O
22889	O
human	O
proteins	O
are	O
encoded	O
by	O
16904	O
distinct	O
genes	O
and	O
are	O
referred	O
to	O
as	O
the	O
Informative	O
Protein	O
Set	O
.	O

The	O
randomly-generated	O
negative	O
dataset	O
used	O
for	O
the	O
training	O
and	O
testing	O
of	O
the	O
predictor	O
was	O
created	O
by	O
selecting	O
protein	O
pairs	O
at	O
random	O
from	O
the	O
Informative	O
Protein	O
Set	O
.	O

In	O
contrast	O
,	O
the	O
localization-derived	O
negative	O
dataset	O
was	O
created	O
by	O
selecting	O
protein	O
pairs	O
from	O
the	O
Informative	O
Protein	O
Set	O
for	O
which	O
the	O
HPRD	O
15	O
annotates	O
one	O
as	O
being	O
primarily	O
in	O
the	O
plasma	O
membrane	O
and	O
the	O
other	O
as	O
primarily	O
in	O
the	O
nucleus	O
.	O

Training	O
and	O
testing	O
was	O
performed	O
with	O
5-fold	O
cross-validation	O
.	O

In	O
addition	O
,	O
positive	O
to	O
negative	O
ratios	O
of	O
1:1	O
and	O
1:100	O
were	O
considered	O
.	O

The	O
predictions	O
were	O
compared	O
to	O
the	O
literature-mined	O
Ramani	O
dataset	O
16	O
,	O
the	O
orthology-derived	O
Lehner	O
prediction	O
dataset	O
36	O
and	O
the	O
probabilistic	O
Rhodes	O
prediction	O
dataset	O
46	O
.	O

All	O
three	O
datasets	O
identify	O
the	O
interactions	O
by	O
stating	O
the	O
names	O
and	O
/	O
or	O
gene	O
locus	O
IDs	O
of	O
the	O
genes	O
that	O
encode	O
the	O
interacting	O
proteins	O
.	O

In	O
contrast	O
,	O
we	O
work	O
directly	O
on	O
the	O
protein	O
sequences	O
and	O
so	O
related	O
the	O
gene	O
annotations	O
to	O
our	O
protein	O
identifiers	O
by	O
extracting	O
Entrez	O
Gene	O
IDs	O
corresponding	O
to	O
the	O
IPI	O
protein	O
entries	O
from	O
the	O
IPI	O
cross-reference	O
files	O
(	O
for	O
the	O
IPI	O
release	O
3.24	O
)	O
64	O
.	O

Ensembl	O
gene	O
identifiers	O
(	O
Ensembl	O
42	O
)	O
were	O
also	O
matched	O
to	O
Entrez	O
Locus	O
IDs	O
(	O
NCBI36	O
)	O
using	O
BioMart	O
68	O
.	O

Some	B-NEGATION
gene-gene	I-NEGATION
entries	I-NEGATION
were	I-NEGATION
not	I-NEGATION
recovered	I-NEGATION
in	I-NEGATION
the	I-NEGATION
conversion	I-NEGATION
between	I-NEGATION
different	I-NEGATION
identifiers	I-NEGATION
,	I-NEGATION
or	I-NEGATION
due	I-NEGATION
to	I-NEGATION
the	I-NEGATION
deletion	I-NEGATION
or	I-NEGATION
replacement	I-NEGATION
of	I-NEGATION
some	I-NEGATION
Entrez	I-NEGATION
Locus	I-NEGATION
IDs	I-NEGATION
.	O

Despite	O
this	O
,	O
37714	O
gene-gene	O
interactions	O
were	O
recovered	O
from	O
the	O
Rhodes	O
dataset	O
and	O
6132	O
interactions	O
from	O
the	O
Ramani	O
dataset	O
as	O
well	O
as	O
64306	O
and	O
10454	O
interactions	O
from	O
the	O
Lehner	O
full	O
and	O
core	O
datasets	O
respectively	O
.	O

Learning	O
method	O

Semi-nave	O
Bayes	O
classifiers	O
were	O
used	O
to	O
measure	O
the	O
likelihood	O
of	O
interaction	O
of	O
two	O
proteins	O
given	O
the	O
presence	O
of	O
the	O
features	O
considered	O
.	O

This	O
learning	O
method	O
was	O
chosen	O
because	O
it	O
allows	O
the	O
integration	O
of	O
highly	O
heterogeneous	O
data	O
in	O
a	O
model	O
that	O
is	O
easy	O
to	O
interpret	O
and	O
that	O
can	O
readily	O
accommodate	O
missing	O
data	O
.	O

The	O
transparency	O
of	O
the	O
method	O
allows	O
the	O
straightforward	O
determination	O
of	O
which	O
features	O
are	O
most	O
predictive	O
of	O
interaction	O
at	O
the	O
level	O
of	O
the	O
whole	O
proteome	O
as	O
well	O
as	O
for	O
individual	O
protein	O
pairs	O
.	O

The	O
prediction	O
of	O
protein	O
interaction	O
is	O
a	O
binary	O
problem	O
which	O
can	O
be	O
expressed	O
in	O
Bayesian	O
formalism	O
.	O

We	O
are	O
interested	O
in	O
determining	O
the	O
posterior	O
odds	O
ratio	O
of	O
interaction	O
of	O
two	O
proteins	O
,	O
given	O
the	O
presence	O
of	O
the	O
features	O
we	O
are	O
considering	O
.	O

This	O
posterior	O
odds	O
ratio	O
can	O
be	O
re-written	O
using	O
Bayes	O
rule	O
:	O
Opost	O
=	O
P	O
(	O
I	O
|	O
f1	O
,...	O
,	O
fn	O
)	O
P	O
(~	O
I	O
|	O
f1	O
,...	O
,	O
fn	O
)=	O
P	O
(	O
f1	O
,...	O
,	O
fn	O
|	O
I	O
)	O
P	O
(	O
I	O
)	O
P	O
(	O
f1	O
,...	O
,	O
fn	O
)	O
P	O
(	O
f1	O
,...	O
,	O
fn	O
|~	O
I	O
)	O
P	O
(~	O
I	O
)	O
P	O
(	O
f1	O
,...	O
,	O
fn	O
)=	O
P	O
(	O
f1	O
,...	O
,	O
fn	O
|	O
I	O
)	O
P	O
(	O
I	O
)	O
P	O
(	O
f	O
,...	O
,	O
fn	O
|~	O
I	O
	O
P	O
(~	O
I	O
)=	O
P	O
(	O
I	O
)	O
P	O
(~	O
I	O
	O
P	O
(	O
f1	O
,...	O
,	O
fn	O
|	O
I	O
)	O
P	O
(	O
f1	O
,...	O
,	O
fn	O
|~	O
I	O
)=	O
Oprior	O
	O
LR	O
(	O
1	O
,...	O
,	O
fn	O
)	O
where	O
I	O
is	O
a	O
binary	O
variable	O
representing	O
interaction	O
,	O
~	O
I	O
represents	O
non-interaction	O
,	O
f1	O
through	O
fn	O
are	O
the	O
features	O
we	O
are	O
considering	O
,	O
Oprior	O
is	O
the	O
prior	O
odds	O
ratio	O
and	O
LR	O
is	O
the	O
likelihood	O
ratio	O
.	O

If	O
the	O
features	O
considered	O
are	O
independent	O
,	O
the	O
likelihood	O
ratio	O
LR	O
can	O
be	O
calculated	O
as	O
the	O
product	O
of	O
the	O
individual	O
likelihood	O
ratios	O
with	O
respect	O
to	O
the	O
features	O
considered	O
separately	O
.	O

If	O
the	O
features	O
are	O
not	B-NEGATION
independent	I-NEGATION
,	O
all	O
possible	O
combinations	O
of	O
all	O
states	O
of	O
these	O
features	O
must	O
be	O
considered	O
,	O
which	O
can	B-SPECULATION
be	I-SPECULATION
computationally	I-SPECULATION
quite	I-SPECULATION
intensive	I-SPECULATION
.	O

In	O
the	O
independent	O
case	O
,	O
the	O
likelihood	O
ratio	O
can	O
be	O
calculated	O
as	O
:	O
LR	O
(	O
f1	O
,...	O
,	O
fn	O
)=[	O
P	O
(	O
f1	O
,...	O
,	O
fn	O
|	O
I	O
)	O
P	O
(	O
f1	O
,...	O
,	O
fn	O
|~	O
I	O
)]=	O
i	O
=	O
1n	O
[	O
P	O
(	O
fi	O
|	O
I	O
)	O
P	O
(	O
fi	O
~	O
I	O
)]	O

The	O
likelihood	O
ratios	O
for	O
the	O
different	O
features	O
considered	O
can	O
be	O
estimated	O
by	O
evaluating	O
the	O
ratio	O
of	O
the	O
proportion	O
of	O
interacting	O
and	O
non-interacting	O
proteins	O
for	O
which	O
a	O
particular	O
state	O
of	O
the	O
feature	O
is	O
true	O
in	O
the	O
training	O
set	O
(	O
i.e.	O
by	O
determining	O
to	O
which	O
bin	O
of	O
the	O
feature	O
the	O
protein	O
pair	O
belongs	O
,	O
for	O
every	O
protein	O
pair	O
in	O
the	O
positive	O
and	O
negative	O
training	O
sets	O
)	O
.	O

More	O
precisely	O
,	O
the	O
training	O
step	O
consisted	O
of	O
calculating	O
the	O
respective	O
proportions	O
of	O
positive	O
and	O
negative	O
examples	O
that	O
fall	O
into	O
each	O
bin	O
of	O
the	O
feature	O
(	O
s	O
)	O
considered	O
(	O
i.e.	O
that	O
have	O
a	O
particular	O
state	O
)	O
.	O

The	O
likelihood	O
ratio	O
of	O
interaction	O
for	O
a	O
given	O
state	O
is	O
simply	O
the	O
ratio	O
of	O
the	O
proportion	O
of	O
all	O
positives	O
that	O
have	O
that	O
state	O
divided	O
by	O
the	O
proportion	O
of	O
all	O
negatives	O
that	O
have	O
that	O
same	O
state	O
.	O

When	O
a	O
particular	O
state	O
of	O
a	O
feature	O
occurs	O
only	O
in	O
positive	O
examples	O
(	O
known	O
interacting	O
proteins	O
)	O
,	O
the	O
likelihoods	O
are	O
set	O
to	O
the	O
highest	O
non-infinite	O
value	O
of	O
any	O
state	O
for	O
that	O
feature	O
(	O
to	O
avoid	O
infinite	O
values	O
)	O
.	O

Additionally	O
,	O
when	O
no	B-NEGATION
data	I-NEGATION
are	I-NEGATION
available	I-NEGATION
for	I-NEGATION
a	I-NEGATION
specific	I-NEGATION
feature	I-NEGATION
(	I-NEGATION
for	I-NEGATION
a	I-NEGATION
given	I-NEGATION
pair	I-NEGATION
of	I-NEGATION
proteins	I-NEGATION
)	I-NEGATION
,	O
the	O
likelihood	O
of	O
the	O
feature	O
is	O
set	O
to	O
1.0	O
.	O

For	O
a	O
detailed	O
calculation	O
of	O
the	O
likelihoods	O
see	O
Additional	O
File	O
4	O
.	O

Prior	O
odds	O
ratio	O
estimate	O

The	O
prior	O
odds	O
ratio	O
(	O
Oprior	O
)	O
is	O
difficult	O
to	O
estimate	O
because	O
we	O
do	O
not	B-NEGATION
know	I-NEGATION
all	I-NEGATION
the	I-NEGATION
true	I-NEGATION
interactions	I-NEGATION
,	I-NEGATION
even	I-NEGATION
for	I-NEGATION
a	I-NEGATION
small	I-NEGATION
subset	I-NEGATION
of	I-NEGATION
proteins	I-NEGATION
.	O

The	O
prior	O
odds	O
ratio	O
of	O
interaction	O
for	O
yeast	O
was	O
estimated	O
by	O
combining	O
all	O
protein-protein	O
interactions	O
(	O
but	O
only	O
those	O
related	O
to	O
direct	O
physical	O
interactions	O
,	O
and	O
no	B-NEGATION
entries	I-NEGATION
derived	I-NEGATION
by	I-NEGATION
synthetic	I-NEGATION
lethal-type	I-NEGATION
experiments	I-NEGATION
)	I-NEGATION
from	I-NEGATION
the	I-NEGATION
BIND	I-NEGATION
,	I-NEGATION
DIP	I-NEGATION
and	I-NEGATION
GRID	I-NEGATION
databases	I-NEGATION
656669	O
.	O

This	O
subset	O
of	O
interactions	O
contains	O
36466	O
distinct	O
interactions	O
involving	O
5202	O
distinct	O
proteins	O
,	O
thus	O
resulting	O
in	O
a	O
prior	O
odds	O
ratio	O
of	O
1	O
/	O
370	O
.	O

This	O
is	O
most	O
likely	B-SPECULATION
a	I-SPECULATION
conservative	I-SPECULATION
estimate	I-SPECULATION
since	O
a	B-SPECULATION
certain	I-SPECULATION
proportion	I-SPECULATION
of	I-SPECULATION
interactions	I-SPECULATION
remain	I-SPECULATION
unknown	I-SPECULATION
and	O
so	O
when	O
more	O
data	O
become	O
available	O
,	O
the	O
prior	O
odds	O
ratio	O
will	O
increase	O
.	O

For	O
human	O
proteins	O
,	O
12191	O
distinct	O
interactions	O
were	O
recovered	O
,	O
involving	O
5164	O
human	O
proteins	O
from	O
the	O
September	O
2005	O
version	O
of	O
the	O
HPRD	O
15	O
and	O
26896	O
distinct	O
interactions	O
involving	O
7531	O
human	O
proteins	O
from	O
the	O
June	O
2006	O
version	O
,	O
leading	O
respectively	O
to	O
prior	O
odds	O
estimates	O
of	O
1	O
/	O
1093	O
and	O
1	O
/	O
1053	O
.	O

However	O
,	O
taking	O
the	O
subset	O
of	O
5164	O
proteins	O
from	O
the	O
September	O
2005	O
version	O
that	O
are	O
seen	O
in	O
the	O
June	O
2006	O
version	O
(	O
20842	O
distinct	O
interactions	O
)	O
,	O
gave	O
a	O
prior	O
odds	O
of	O
interaction	O
estimate	O
of	O
1	O
/	O
639	O
.	O

Thus	O
,	O
between	O
the	O
two	O
releases	O
of	O
the	O
HPRD	O
,	O
there	O
was	O
a	O
large	O
increase	O
in	O
the	O
number	O
of	O
interactions	O
for	O
this	O
subset	O
of	O
proteins	O
and	O
this	B-SPECULATION
is	I-SPECULATION
likely	I-SPECULATION
to	I-SPECULATION
continue	I-SPECULATION
for	I-SPECULATION
at	I-SPECULATION
least	I-SPECULATION
the	I-SPECULATION
next	I-SPECULATION
few	I-SPECULATION
releases	I-SPECULATION
.	O

Accordingly	O
,	O
it	O
is	O
reasonable	O
to	O
conclude	O
that	O
there	O
are	O
not	B-NEGATION
enough	I-NEGATION
known	I-NEGATION
human	I-NEGATION
interactions	I-NEGATION
to	I-NEGATION
calculate	I-NEGATION
a	I-NEGATION
realistic	I-NEGATION
and	I-NEGATION
stable	I-NEGATION
estimate	I-NEGATION
of	I-NEGATION
the	I-NEGATION
prior	I-NEGATION
odds	I-NEGATION
ratio	I-NEGATION
of	I-NEGATION
interactions	I-NEGATION
for	I-NEGATION
human	I-NEGATION
.	O

As	O
a	O
consequence	O
,	O
a	O
prior	O
odds	O
ratio	O
of	O
1	O
/	O
400	O
was	O
used	O
for	O
all	O
work	O
in	O
the	O
paper	O
,	O
which	O
is	O
similar	O
to	O
the	O
estimate	O
for	O
yeast	O
and	O
is	O
likely	B-SPECULATION
still	I-SPECULATION
an	I-SPECULATION
underestimate	I-SPECULATION
of	I-SPECULATION
the	I-SPECULATION
true	I-SPECULATION
value	I-SPECULATION
.	O

Features	O

Seven	O
distinct	O
features	O
combined	O
into	O
five	O
modules	O
were	O
investigated	O
as	O
summarized	O
in	O
Table	O
1	O
and	O
described	O
below	O
.	O

1	O
.	O

Expression	O
module	O

Expression	O
data	O
were	O
downloaded	O
from	O
the	O
Gene	O
Expression	O
Omnibus	O
70	O
.	O

The	O
GDS596	O
dataset	O
was	O
used	O
which	O
examines	O
gene	O
expression	O
profiles	O
from	O
79	O
physiologically	O
normal	O
tissues	O
obtained	O
from	O
various	O
sources	O
71	O
.	O

Expression	O
data	O
were	O
recovered	O
for	O
10642	O
distinct	O
transcripts	O
in	O
158	O
different	O
arrays	O
(	O
2	O
arrays	O
per	O
tissue	O
)	O
.	O

Pearson	O
correlations	O
were	O
calculated	O
for	O
all	O
56620761	O
transcript	O
pairs	O
and	O
correlation	O
values	O
were	O
grouped	O
into	O
20	O
bins	O
of	O
increasing	O
co-expression	O
.	O

2	O
.	O

Orthology	O
module	O

Orthology	O
maps	O
between	O
human	O
and	O
yeast	O
,	O
worm	O
and	O
fly	O
were	O
downloaded	O
from	O
the	O
InParanoid	O
database	O
72	O
.	O

Interaction	O
datasets	O
for	O
model	O
organisms	O
were	O
downloaded	O
from	O
the	O
BIND	O
66	O
,	O
DIP	O
65	O
and	O
GRID	O
69	O
databases	O
.	O

Orthology	O
interaction	O
data	O
were	O
classified	O
into	O
13	O
bins	O
.	O

High	O
,	O
medium	O
and	O
low	O
confidence	O
bins	O
were	O
defined	O
for	O
human	O
protein	O
pairs	O
that	O
have	O
interacting	O
orthologs	O
in	O
either	O
yeast	O
,	O
fly	O
or	O
worm	O
(	O
for	O
a	O
total	O
of	O
9	O
bins	O
)	O
.	O

The	O
high	O
confidence	O
bins	O
were	O
populated	O
by	O
human	O
protein	O
pairs	O
that	O
have	O
interacting	O
orthologs	O
that	O
both	O
achieve	O
an	O
InParanoid	O
score	O
of	O
1	O
(	O
i.e.	O
both	O
proteins	O
involved	O
in	O
an	O
interaction	O
in	O
another	O
organism	O
are	O
respectively	O
the	O
best	O
orthology	O
match	O
for	O
the	O
two	O
human	O
proteins	O
under	O
consideration	O
)	O
.	O

The	O
medium	O
confidence	O
bins	O
were	O
populated	O
by	O
human	O
protein	O
pairs	O
that	O
have	O
interacting	O
orthologs	O
but	O
only	O
one	O
of	O
the	O
interacting	O
orthologs	O
has	O
an	O
InParanoid	O
score	O
of	O
1	O
.	O

The	O
low	O
confidence	O
bins	O
were	O
filled	O
by	O
human	O
protein	O
pairs	O
that	O
have	O
interacting	O
orthologs	O
according	O
to	O
InParanoid	O
but	O
neither	B-NEGATION
achieves	I-NEGATION
a	I-NEGATION
score	I-NEGATION
of	I-NEGATION
1	I-NEGATION
(	O
i.e.	O
neither	O
is	O
the	O
best	O
match	O
for	O
the	O
two	O
human	O
proteins	O
under	O
consideration	O
)	O
.	O

The	O
orthology	O
module	O
has	O
four	O
additional	O
bins	O
:	O
two	O
bin	O
for	O
human	O
pairs	O
that	O
have	O
interacting	O
paralogs	O
in	O
human	O
(	O
a	O
medium	O
and	O
a	O
low	O
confidence	O
bin	O
which	O
use	O
the	O
same	O
definition	O
as	O
above	O
for	O
the	O
model	O
organisms	O
)	O
,	O
one	O
bin	O
for	O
human	O
pairs	O
that	O
have	O
interacting	O
homologs	O
in	O
more	O
than	O
one	O
organism	O
(	O
these	O
can	O
be	O
orthologs	O
in	O
yeast	O
,	O
worm	O
or	O
fly	O
,	O
or	O
paralogs	O
in	O
human	O
)	O
and	O
one	O
bin	O
for	O
human	O
pairs	O
that	O
have	O
only	O
non-interacting	O
orthologs	O
.	O

3	O
.	O

Combined	O
module	O

This	O
module	O
incorporates	O
three	O
distinct	O
features	O
in	O
a	O
non-nave	O
Bayesian	O
framework	O
:	O
subcellular	O
localization	O
,	O
domain	O
co-occurrence	O
and	O
post-translational	O
modification	O
co-occurrence	O
.	O

Subcellular	O
localization	O

PSLT	O
(	O
Protein	O
Subcellular	O
Localization	O
Tool	O
)	O
subcellular	O
localization	O
predictions	O
54	O
were	O
used	O
to	O
classify	O
protein	O
pairs	O
in	O
one	O
of	O
four	O
groups	O
:	O
:	O
pairs	O
of	O
proteins	O
predicted	O
to	O
be	O
in	O
the	O
same	O
compartment	O
,	O
pairs	O
of	O
proteins	O
predicted	O
to	O
be	O
in	O
neighboring	O
compartments	O
(	O
cytosol-nucleus	O
,	O
endoplasmic	O
reticulum-Golgi	O
,	O
Golgi-cytosol	O
,	O
cytosol-plasma	O
membrane	O
,	O
and	O
plasma	O
membrane-secreted	O
)	O
,	O
pairs	O
of	O
proteins	O
predicted	O
in	O
different	O
non-neighboring	O
compartments	O
and	O
pairs	O
of	O
proteins	O
for	O
which	O
there	O
were	O
no	B-NEGATION
localization	I-NEGATION
predictions	I-NEGATION
.	O

Neighboring	O
compartments	O
were	O
chosen	O
as	O
compartment	O
pairs	O
sharing	O
a	O
high	O
proportion	O
of	O
proteins	O
,	O
as	O
investigated	O
previously	O
54	O
.	O

Co-occurrence	O
of	O
domains	O

The	O
chi-square	O
test	O
was	O
used	O
as	O
a	O
measure	O
of	O
the	O
likelihood	O
of	O
co-occurrence	O
of	O
specific	O
InterPro	O
domains	O
and	O
motifs	O
73	O
in	O
protein	O
pairs	O
.	O

Chi-square	O
scores	O
were	O
calculated	O
for	O
all	O
pairs	O
of	O
domains	O
/	O
motifs	O
that	O
occurred	O
in	O
the	O
training	O
data	O
and	O
were	O
then	O
grouped	O
into	O
5	O
bins	O
of	O
increasing	O
value	O
.	O

Additionally	O
,	O
Pfam	O
74	O
domain	O
pairs	O
known	O
to	O
interact	O
from	O
three-dimensional	O
structures	O
75	O
were	O
included	O
in	O
the	O
highest	O
Chi-square	O
score	O
bin	O
.	O

When	O
protein	O
pairs	O
contained	O
more	O
than	O
one	O
domain	O
pair	O
,	O
the	O
domain	O
pair	O
assigned	O
to	O
the	O
highest	O
Chi-square	O
score	O
bin	O
was	O
used	O
to	O
assign	O
a	O
likelihood	O
of	O
interaction	O
.	O

Post-translational	O
modification	O
(	O
PTM	O
)	O
pair	O
co-occurrence	O

Likelihoods	O
were	O
assessed	O
using	O
a	O
PTM	O
pair	O
enrichment	O
score	O
calculated	O
as	O
the	O
probability	O
of	O
co-occurrence	O
of	O
two	O
specific	O
PTMs	O
in	O
all	O
pairs	O
of	O
interacting	O
protein	O
pairs	O
divided	O
by	O
the	O
probability	O
of	O
occurrence	O
of	O
both	O
of	O
these	O
PTMs	O
separately	O
:	O
PTM	O
_	O
score	O
=	O
P	O
(	O
PTM	O
[	O
i	O
]	O
,	O
PTM	O
[	O
j	O
]|	O
I	O
)	O
P	O
(	O
PTM	O
[	O
i	O
]|	O
I	O
)	O
P	O
(	O
PTM	O
[	O
j	O
]|	O
I	O
)	O
where	O
PTM	O
[	O
i	O
]	O
and	O
PTM	O
[	O
j	O
]	O
are	O
distinct	O
PTMs	O
and	O
I	O
is	O
the	O
set	O
of	O
all	O
interacting	O
proteins	O
that	O
were	O
used	O
to	O
train	O
the	O
predictor	O
.	O

The	O
annotations	O
of	O
PTMs	O
in	O
human	O
proteins	O
were	O
downloaded	O
from	O
UniProt	O
76	O
and	O
HPRD	O
15	O
.	O

PTM	O
instances	O
described	O
as	O
"	O
predicted	O
"	O
,	O
"	O
probable	O
"	O
or	O
"	O
possible	O
"	O
were	O
excluded	O
,	O
leaving	O
3439	O
distinct	O
proteins	O
with	O
PTM	O
annotations	O
in	O
the	O
training	O
set	O
.	O

The	O
PTM	O
pair	O
enrichment	O
scores	O
were	O
grouped	O
into	O
4	O
bins	O
of	O
increasing	O
value	O
.	O

The	O
localization	O
,	O
co-occurrence	O
of	O
domains	O
,	O
and	O
PTMs	O
were	O
considered	O
simultaneously	O
to	O
measure	O
their	O
predictive	O
power	O
in	O
assessing	O
the	O
likelihood	O
of	O
protein	O
interaction	O
.	O

To	O
do	O
this	O
,	O
all	O
possible	O
combinations	O
of	O
the	O
4	O
localization	O
bins	O
,	O
5	O
chi-square	O
domain-co-occurrence	O
bins	O
and	O
4	O
PTM	O
_	O
score	O
bins	O
were	O
investigated	O
and	O
are	O
referred	O
to	O
as	O
the	O
combined	O
module	O
.	O

4	O
.	O

Disorder	O
module	O

It	O
has	O
been	O
suggested	B-SPECULATION
that	I-SPECULATION
unstructured	I-SPECULATION
regions	I-SPECULATION
of	I-SPECULATION
proteins	I-SPECULATION
are	I-SPECULATION
often	I-SPECULATION
involved	I-SPECULATION
in	I-SPECULATION
binding	I-SPECULATION
interactions	I-SPECULATION
,	I-SPECULATION
particularly	I-SPECULATION
in	I-SPECULATION
the	I-SPECULATION
case	I-SPECULATION
of	I-SPECULATION
transient	I-SPECULATION
interactions	I-SPECULATION
77	O
.	O

Protein	O
intrinsic	O
disorder	O
was	O
predicted	O
for	O
all	O
proteins	O
considered	O
by	O
using	O
the	O
VSL2B	O
predictor	O
78	O
.	O

The	O
disorder	O
score	O
for	O
protein	O
pairs	O
was	O
then	O
calculated	O
as	O
the	O
sum	O
of	O
percent	O
disorder	O
for	O
each	O
protein	O
of	O
the	O
pair	O
.	O

Disorder	O
scores	O
were	O
grouped	O
into	O
6	O
bins	O
of	O
increasing	O
value	O
.	O

The	O
Expression	O
,	O
Orthology	O
,	O
Combined	O
and	O
Disorder	O
modules	O
are	O
referred	O
collectively	O
as	O
the	O
Group	O
A	O
modules	O
.	O

Likelihood	O
ratios	O
for	O
each	O
of	O
the	O
Group	O
A	O
modules	O
are	O
illustrated	O
in	O
Figure	O
1A	O
(	O
see	O
Additional	O
File	O
4	O
for	O
complete	O
likelihood	O
ratios	O
for	O
every	O
possible	O
state	O
of	O
these	O
modules	O
and	O
for	O
detailed	O
calculations	O
of	O
these	O
likelihood	O
ratios	O
)	O
.	O

5	O
.	O

Transitive	O
module	O

The	O
transitive	O
module	O
works	O
on	O
the	O
premise	O
that	O
a	B-SPECULATION
pair	I-SPECULATION
of	I-SPECULATION
proteins	I-SPECULATION
is	I-SPECULATION
more	I-SPECULATION
likely	I-SPECULATION
to	I-SPECULATION
interact	I-SPECULATION
if	I-SPECULATION
it	I-SPECULATION
shares	I-SPECULATION
interacting	I-SPECULATION
partners	I-SPECULATION
.	O

It	O
does	O
this	O
by	O
considering	O
the	O
local	O
topology	O
of	O
the	O
network	O
predicted	O
by	O
the	O
integration	O
of	O
the	O
Group	O
A	O
modules	O
as	O
depicted	O
in	O
Figure	O
2	O
.	O

Thus	O
,	O
the	O
transitive	O
module	O
takes	O
as	O
input	O
the	O
product	O
of	O
the	O
likelihood	O
ratios	O
of	O
all	O
other	O
modules	O
considered	O
by	O
the	O
predictor	O
(	O
as	O
illustrated	O
in	O
Figure	O
1B	O
)	O
.	O

For	O
each	O
pair	O
of	O
proteins	O
in	O
the	O
training	O
set	O
,	O
the	O
product	O
of	O
the	O
likelihood	O
ratios	O
from	O
all	O
other	O
modules	O
(	O
referred	O
to	O
as	O
the	O
preliminary	O
score	O
(	O
PS	O
)	O
in	O
Figure	O
1	O
)	O
was	O
calculated	O
for	O
all	O
protein	O
pairs	O
neighboring	O
the	O
pair	O
(	O
i.e.	O
all	O
protein	O
pairs	O
which	O
involve	O
one	O
protein	O
from	O
the	O
initial	O
protein	O
pair	O
under	O
study	O
and	O
for	O
which	O
it	O
is	O
possible	B-SPECULATION
to	I-SPECULATION
calculate	I-SPECULATION
such	I-SPECULATION
a	I-SPECULATION
score	I-SPECULATION
)	O
.	O

All	O
preliminary	O
scores	O
above	O
10	O
were	O
kept	O
.	O

This	O
parameter	O
was	O
determined	O
empirically	O
.	O

A	O
neighborhood	O
topology	O
score	O
T	O
was	O
then	O
calculated	O
as	O
follows	O
:	O

Transitive	O
module	O
hypothesis	O

Transitive	O
module	O
hypothesis	O
.	O

The	O
Transitive	O
module	O
investigates	O
whether	B-SPECULATION
two	B-SPECULATION
proteins	I-SPECULATION
(	I-SPECULATION
such	I-SPECULATION
as	I-SPECULATION
i	I-SPECULATION
and	I-SPECULATION
j	I-SPECULATION
)	I-SPECULATION
that	I-SPECULATION
share	I-SPECULATION
many	I-SPECULATION
common	I-SPECULATION
interactors	I-SPECULATION
and	I-SPECULATION
have	I-SPECULATION
few	I-SPECULATION
additional	I-SPECULATION
interactors	I-SPECULATION
that	I-SPECULATION
are	I-SPECULATION
likely	I-SPECULATION
to	I-SPECULATION
interact	I-SPECULATION
than	I-SPECULATION
two	I-SPECULATION
proteins	I-SPECULATION
(	I-SPECULATION
such	I-SPECULATION
as	I-SPECULATION
i	I-SPECULATION
'	I-SPECULATION
and	I-SPECULATION
j	I-SPECULATION
')	I-SPECULATION
that	I-SPECULATION
share	I-SPECULATION
few	I-SPECULATION
common	I-SPECULATION
interactors	I-SPECULATION
not	B-NEGATION
common	I-NEGATION
to	I-NEGATION
both	I-NEGATION
proteins	I-NEGATION
are	O
more	O
.	O

T	O
=	O
e	O
	O
Ecse1	O
+|	O
Ei	O
\	O
Ec	O
|+|	O
Ej	O
\	O
Ec	O
|	O
where	O
Ec	O
is	O
the	O
set	O
of	O
edges	O
that	O
connect	O
proteins	O
i	O
and	O
j	O
to	O
their	O
common	O
interactors	O
,	O
Ei	O
is	O
the	O
set	O
of	O
edges	O
that	O
involve	O
protein	O
i	O
,	O
se	O
is	O
the	O
score	O
(	O
likelihood	O
ratio	O
)	O
of	O
edge	O
e	O
and	O
Ei	O
\	O
Ec	O
refers	O
to	O
the	O
set	O
difference	O
of	O
Ei	O
and	O
Ec	O
.	O

For	O
a	O
given	O
set	O
of	O
neighbors	O
,	O
T	O
increases	O
as	O
the	O
interactions	O
with	O
these	O
neighbors	O
become	O
more	O
likely	O
(	O
as	O
the	O
sum	O
of	O
se	O
increases	O
)	O
.	O

Additionally	O
,	O
the	O
topology	O
score	O
T	O
of	O
a	O
pair	O
of	O
proteins	O
increases	O
as	O
the	O
proportion	O
of	O
likely	O
interactors	O
that	O
these	O
two	O
proteins	O
share	O
increases	O
.	O

The	O
topology	O
scores	O
were	O
grouped	O
into	O
5	O
bins	O
of	O
increasing	O
value	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
neighborhood	O
topology	O
score	O
calculated	O
for	O
a	O
given	O
protein	O
pair	O
does	O
not	B-NEGATION
consider	I-NEGATION
the	I-NEGATION
preliminary	I-NEGATION
score	I-NEGATION
assigned	I-NEGATION
to	I-NEGATION
that	I-NEGATION
protein	I-NEGATION
pair	I-NEGATION
.	O

It	O
only	O
considers	O
the	O
preliminary	O
scores	O
of	O
its	O
neighbors	O
and	O
so	O
is	O
truly	O
based	O
on	O
the	O
local	O
network	O
topology	O
around	O
that	O
protein	O
pair	O
.	O

Accordingly	O
,	O
the	O
likelihood	O
ratio	O
the	O
transitive	O
module	O
outputs	O
for	O
a	O
given	O
protein	O
pair	O
is	O
independent	O
of	O
the	O
likelihood	O
ratio	O
calculated	O
by	O
the	O
Group	O
A	O
modules	O
for	O
this	O
same	O
protein	O
pair	O
.	O

Correlation	O
analysis	O

The	O
Pearson	O
correlation	O
between	O
pairs	O
of	O
modules	O
was	O
estimated	O
by	O
taking	O
150	O
samples	O
of	O
10000	O
protein	O
pairs	O
each	O
and	O
calculating	O
the	O
Pearson	O
correlation	O
of	O
the	O
likelihood	O
ratios	O
for	O
the	O
two	O
modules	O
considered	O
,	O
for	O
each	O
sample	O
.	O

The	O
reported	O
correlation	O
values	O
are	O
the	O
average	O
of	O
the	O
150	O
experiments	O
.	O

Samples	O
of	O
the	O
protein	O
pair	O
space	O
were	O
taken	O
instead	B-NEGATION
of	I-NEGATION
considering	I-NEGATION
the	I-NEGATION
whole	I-NEGATION
space	I-NEGATION
as	O
this	O
was	O
more	O
computationally	O
tractable	O
.	O

Accuracy	O
measurements	O

The	O
accuracy	O
of	O
the	O
predictors	O
was	O
measured	O
by	O
performing	O
five-fold	O
cross	O
validation	O
experiments	O
in	O
which	O
the	O
datasets	O
were	O
randomly	O
divided	O
into	O
five	O
non-overlapping	O
sets	O
,	O
four	O
of	O
which	O
were	O
used	O
to	O
train	O
the	O
predictor	O
while	O
the	O
fifth	O
was	O
used	O
to	O
test	O
the	O
prediction	O
accuracy	O
.	O

The	O
accuracy	O
reported	O
is	O
the	O
average	O
measured	O
for	O
all	O
combinations	O
of	O
training	O
and	O
testing	O
sets	O
using	O
these	O
five	O
sets	O
.	O

Testing	O
was	O
done	O
by	O
predicting	O
the	O
total	O
likelihood	O
scores	O
for	O
all	O
protein	O
pairs	O
in	O
the	O
test	O
set	O
using	O
the	O
models	O
computed	O
in	O
the	O
training	O
phase	O
and	O
then	O
counting	O
the	O
number	O
of	O
pairs	O
that	O
were	O
well	O
predicted	O
.	O

We	O
used	O
the	O
area	O
under	O
partial	O
ROC	O
curves	O
as	O
a	O
measure	O
of	O
accuracy	O
.	O

Receiver	O
operator	O
characteristic	O
(	O
ROC	O
)	O
curves	O
plot	O
the	O
true	O
positive	O
rate	O
versus	O
the	O
false	O
positive	O
rate	O
over	O
their	O
full	O
range	O
of	O
possible	O
values	O
.	O

In	O
some	O
circumstances	O
,	O
it	O
is	O
more	O
informative	O
to	O
use	O
partial	O
ROC	O
curves	O
(	O
ROCn	O
curves	O
)	O
which	O
illustrate	O
the	O
number	O
of	O
true	O
positives	O
identified	O
by	O
the	O
predictor	O
that	O
score	O
higher	O
than	O
the	O
n	O
highest	O
scoring	O
negatives	O
,	O
plotted	O
for	O
all	O
values	O
from	O
0	O
to	O
n	O
.	O

There	O
are	O
many	O
more	O
negatives	O
than	O
positives	O
in	O
our	O
datasets	O
and	O
this	O
is	O
also	O
thought	B-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
true	I-SPECULATION
for	I-SPECULATION
the	I-SPECULATION
full	I-SPECULATION
protein	I-SPECULATION
interaction	I-SPECULATION
networks	I-SPECULATION
we	I-SPECULATION
are	I-SPECULATION
modeling	I-SPECULATION
.	O

Since	O
the	O
aim	O
is	O
to	O
identify	O
the	O
largest	O
number	O
of	O
true	O
interacting	O
pairs	O
while	O
leaving	O
out	O
as	O
many	O
non-interacting	O
pairs	O
as	O
possible	O
,	O
it	O
is	O
most	O
informative	O
to	O
measure	O
the	O
performance	O
of	O
the	O
predictor	O
under	O
conditions	O
of	O
very	O
low	O
false-positive	O
rates	O
.	O

Accordingly	O
,	O
ROC50	O
and	O
ROC100	O
curves	O
were	O
analyzed	O
because	O
given	O
the	O
size	O
of	O
the	O
datasets	O
,	O
these	O
curves	O
consider	O
all	O
the	O
protein	O
pairs	O
predicted	O
to	O
have	O
a	O
posterior	O
odds	O
ratio	O
above	O
1.0	O
,	O
for	O
all	O
the	O
predictors	O
investigated	O
.	O

The	O
area	O
under	O
ROC	O
curves	O
is	O
often	O
used	O
as	O
a	O
summary	O
measure	O
of	O
accuracy	O
.	O

For	O
ROCn	O
curves	O
,	O
it	O
can	O
be	O
calculated	O
as	O
AUC	O
ROCn	O
=	O
1nT	O
(	O
i	O
=	O
1nTi	O
)	O
where	O
i	O
takes	O
on	O
values	O
from	O
1	O
to	O
n	O
,	O
T	O
is	O
the	O
total	O
number	O
of	O
positives	O
in	O
the	O
test	O
set	O
and	O
Ti	O
is	O
the	O
number	O
of	O
positives	O
that	O
score	O
higher	O
than	O
the	O
ith	O
highest	O
scoring	O
negative	O
.	O

A	O
novel	O
ensemble	O
learning	O
method	O
for	O
de	O
novo	O
computational	O
identification	O
of	O
DNA	O
binding	O
sites	O

Abstract	O

Background	O

Despite	O
the	O
diversity	O
of	O
motif	O
representations	O
and	O
search	O
algorithms	O
,	O
the	O
de	O
novo	O
computational	O
identification	O
of	O
transcription	O
factor	O
binding	O
sites	O
remains	O
constrained	O
by	O
the	O
limited	O
accuracy	O
of	O
existing	O
algorithms	O
and	O
the	O
need	O
for	O
user-specified	O
input	O
parameters	O
that	O
describe	O
the	O
motif	O
being	O
sought	O
.	O

Results	O

We	O
present	O
a	O
novel	O
ensemble	O
learning	O
method	O
,	O
SCOPE	O
,	O
that	O
is	O
based	O
on	O
the	O
assumption	B-SPECULATION
that	I-SPECULATION
transcription	I-SPECULATION
factor	I-SPECULATION
binding	I-SPECULATION
sites	I-SPECULATION
belong	I-SPECULATION
to	I-SPECULATION
one	I-SPECULATION
of	I-SPECULATION
three	I-SPECULATION
broad	I-SPECULATION
classes	I-SPECULATION
of	I-SPECULATION
motifs	I-SPECULATION
:	I-SPECULATION
:	I-SPECULATION
non-degenerate	I-SPECULATION
,	I-SPECULATION
degenerate	I-SPECULATION
and	I-SPECULATION
gapped	I-SPECULATION
motifs	I-SPECULATION
.	O

SCOPE	O
employs	O
a	O
unified	O
scoring	O
metric	O
to	O
combine	O
the	O
results	O
from	O
three	O
motif	O
finding	O
algorithms	O
each	O
aimed	O
at	O
the	O
discovery	O
of	O
one	O
of	O
these	O
classes	O
of	O
motifs	O
.	O

We	O
found	O
that	O
SCOPE's	O
performance	O
on	O
78	O
experimentally	O
characterized	O
regulons	O
from	O
four	O
species	O
was	O
a	O
substantial	O
and	O
statistically	O
significant	O
improvement	O
over	O
that	O
of	O
its	O
component	O
algorithms	O
.	O

SCOPE	O
outperformed	O
a	O
broad	O
range	O
of	O
existing	O
motif	O
discovery	O
algorithms	O
on	O
the	O
same	O
dataset	O
by	O
a	O
statistically	O
significant	O
margin	O
.	O

Conclusion	O

SCOPE	O
demonstrates	O
that	O
combining	O
multiple	O
,	O
focused	O
motif	O
discovery	O
algorithms	O
can	O
provide	O
a	O
significant	O
gain	O
in	O
performance	O
.	O

By	O
building	O
on	O
components	O
that	O
efficiently	O
search	O
for	O
motifs	O
without	B-NEGATION
user-defined	I-NEGATION
parameters	I-NEGATION
,	O
SCOPE	O
requires	O
as	O
input	O
only	O
a	O
set	O
of	O
upstream	O
sequences	O
and	O
a	O
species	O
designation	O
,	O
making	O
it	O
a	O
practical	O
choice	O
for	O
non-expert	O
users	O
.	O

A	O
user-friendly	O
web	O
interface	O
,	O
Java	O
source	O
code	O
and	O
executables	O
are	O
available	O
at	O
http	O
://	O
genie.dartmouth.edu	O
/	O
scope	O
.	O

Backgound	O

The	O
computational	O
discovery	O
of	O
DNA	O
binding	O
sites	O
for	O
previously	O
uncharacterized	O
transcription	O
factors	O
in	O
groups	O
of	O
co-regulated	O
genes	O
is	O
a	O
well-studied	O
problem	O
with	O
a	O
great	O
deal	O
of	O
practical	O
relevance	O
to	O
the	O
biologist	O
,	O
since	O
such	O
binding	O
sites	O
provide	O
targets	O
for	O
mutational	O
analyses	O
(	O
for	O
reviews	O
see	O
123	O
)	O
.	O

The	O
position-specific	O
variability	O
of	O
transcription	O
factor	O
binding	O
sites	O
makes	O
their	O
de	O
novo	O
identification	O
challenging	O
.	O

Many	O
computational	O
motif	O
finding	O
methods	O
are	O
based	O
on	O
the	O
observation	O
that	O
transcription	O
factor	O
binding	O
sites	O
occur	O
more	O
often	O
than	O
expected	O
by	O
chance	O
in	O
the	O
upstream	O
regions	O
of	O
the	O
set	O
of	O
genes	O
regulated	O
by	O
the	O
same	O
transcription	O
factor	O
1	O
.	O

The	O
problem	O
thus	O
simplifies	O
to	O
the	O
identification	O
of	O
overrepresented	O
motifs	O
in	O
a	O
given	O
set	O
of	O
upstream	O
sequences	O
.	O

Motif	O
finding	O
programs	O
rely	O
on	O
a	O
search	O
algorithm	O
to	O
optimize	O
a	O
motif	O
model	O
(	O
an	O
abstract	O
representation	O
of	O
a	O
set	O
of	O
transcription	O
factor	O
binding	O
sites	O
)	O
.	O

Most	O
recent	O
programs	O
represent	O
motifs	O
as	O
position	O
weight	O
matrices	O
(	O
PWMs	O
)	O
,	O
which	O
record	O
the	O
frequency	O
of	O
each	O
base	O
at	O
every	O
position	O
in	O
the	O
motif	O
.	O

Other	O
motif	O
finding	O
programs	O
have	O
relied	O
on	O
the	O
use	O
of	O
consensus	O
motif	O
models	O
(	O
in	O
which	O
every	O
base	O
is	O
represented	O
by	O
a	O
letter	O
of	O
the	O
15-letter	O
IUPAC	O
code	O
,	O
which	O
accounts	O
for	O
degeneracies	O
as	O
well	O
as	O
single	O
bases	O
)	O
or	O
k-mismatch	O
motif	O
models	O
(	O
in	O
which	O
a	O
non-degenerate	O
word	O
with	O
at	O
most	O
k	O
allowed	O
mismatches	O
is	O
used	O
to	O
represent	O
the	O
word	O
)	O
.	O

Regardless	O
of	O
the	O
motif	O
model	O
used	O
,	O
a	O
search	O
for	O
all	O
overrepresented	O
motifs	O
of	O
any	O
length	O
and	O
degree	O
of	O
degeneracy	O
leads	O
to	O
a	O
dauntingly	O
large	O
search	O
space	O
.	O

Thus	O
,	O
motif	O
finding	O
algorithms	O
restrict	O
their	O
search	O
space	O
by	O
using	O
simplified	O
motif	O
representations	O
,	O
employing	O
heuristic	O
search	O
strategies	O
that	O
are	O
prone	O
to	O
local	O
optima	O
,	O
or	O
invoking	O
additional	O
parameters	O
to	O
limit	O
the	O
search	O
space	O
and	O
thereby	O
pass	O
some	O
of	O
the	O
optimization	O
process	O
off	O
to	O
the	O
user	O
3	O
.	O

Program	O
parameters	O
(	O
such	O
as	O
motif	O
length	O
,	O
number	O
of	O
occurrences	O
and	O
orientation	O
)	O
that	B-NEGATION
cannot	I-NEGATION
be	I-NEGATION
reasonably	I-NEGATION
specified	I-NEGATION
by	I-NEGATION
the	I-NEGATION
user	I-NEGATION
are	O
referred	O
to	O
as	O
nuisance	O
parameters	O
4	O
.	O
without	B-NEGATION
prior	I-NEGATION
knowledge	I-NEGATION
about	I-NEGATION
the	I-NEGATION
true	I-NEGATION
binding	I-NEGATION
sites	I-NEGATION
.	O

Selection	O
of	O
the	O
correct	O
settings	O
for	O
these	O
parameters	O
is	O
a	O
crucial	O
step	O
in	O
motif	O
finding	O
,	O
and	O
is	B-SPECULATION
often	I-SPECULATION
assumed	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
the	I-SPECULATION
domain	I-SPECULATION
of	I-SPECULATION
experts	I-SPECULATION
.	O

In	O
a	O
recent	O
evaluation	O
,	O
Hu	O
and	O
colleagues	O
4	O
compared	O
the	O
performance	O
of	O
five	O
motif	O
finders	O
on	O
a	O
single	O
prokaryotic	O
genome	O
,	O
systematically	O
exploring	O
the	O
effects	O
of	O
nuisance	O
parameters	O
,	O
including	O
expected	O
motif	O
length	O
and	O
number	O
of	O
occurrences	O
.	O

Every	O
motif	O
finder	O
they	O
tested	O
was	O
found	O
to	O
be	O
sensitive	O
to	O
values	O
used	O
for	O
these	O
parameters	O
.	O

Guidance	B-NEGATION
on	I-NEGATION
the	I-NEGATION
specific	I-NEGATION
parameter	I-NEGATION
settings	I-NEGATION
to	I-NEGATION
use	I-NEGATION
for	I-NEGATION
given	I-NEGATION
motif	I-NEGATION
finding	I-NEGATION
situations	I-NEGATION
is	I-NEGATION
not	I-NEGATION
provided	I-NEGATION
in	I-NEGATION
most	I-NEGATION
publications	I-NEGATION
presenting	I-NEGATION
motif	I-NEGATION
finders	I-NEGATION
.	O

Even	O
assuming	B-SPECULATION
that	I-SPECULATION
optimal	I-SPECULATION
parameter	I-SPECULATION
settings	I-SPECULATION
exist	I-SPECULATION
for	I-SPECULATION
a	I-SPECULATION
motif	I-SPECULATION
finding	I-SPECULATION
program	I-SPECULATION
for	I-SPECULATION
each	I-SPECULATION
specific	I-SPECULATION
situation	I-SPECULATION
,	O
for	O
the	O
typical	O
biologist	O
looking	O
to	O
identify	O
motifs	O
in	O
a	O
set	O
of	O
uncharacterized	O
sequences	O
,	O
acquiring	O
such	O
expertise	O
is	O
an	O
onerous	O
task	O
.	O

Nuisance	O
parameters	O
complicate	O
the	O
interpretation	O
of	O
performance	O
comparisons	O
as	O
well	O
.	O

A	O
recent	O
large-scale	O
performance	O
comparison	O
between	O
thirteen	O
different	O
motif	O
finding	O
tools	O
used	O
expert	O
knowledge	O
in	O
setting	O
the	O
parameters	O
for	O
every	O
program	O
5	O
.	O

Several	O
of	O
the	O
programs	O
contributing	O
to	O
the	O
performance	O
comparison	O
were	O
run	O
with	O
different	O
parameter	O
settings	O
for	O
each	O
regulon	O
,	O
and	O
in	O
some	O
cases	O
,	O
motifs	O
were	O
hand	O
filtered	O
as	O
a	O
post-processing	O
step	O
.	O

Such	O
performance	O
comparisons	O
evaluate	O
not	O
just	O
algorithms	O
but	O
also	O
the	O
expertise	O
of	O
the	O
users	O
,	O
making	O
it	O
difficult	O
for	O
a	O
first-time	O
user	O
to	O
select	O
a	O
motif	O
finder	O
on	O
a	O
principled	O
basis	O
.	O

A	O
key	O
result	O
of	O
the	O
Tompa	O
,	O
et	O
al.	O
study	O
was	O
the	O
finding	O
that	O
all	O
of	O
the	O
motif	O
finders	O
had	O
roughly	O
the	O
same	O
average	O
performance	O
under	O
a	O
wide	O
range	O
of	O
conditions	O
and	O
test	O
statistics	O
5	O
.	O

This	O
finding	O
was	O
particularly	O
notable	O
because	O
the	O
motif	O
finders	O
studied	O
employed	O
a	O
wide	O
range	O
of	O
motif	O
representations	O
,	O
scoring	O
functions	O
and	O
search	O
strategies	O
and	O
all	O
were	O
operated	O
under	O
the	O
most	O
favorable	O
conditions	O
possible	O
.	O

Although	O
the	O
average	O
performance	O
of	O
the	O
programs	O
did	O
not	O
differ	O
significantly	O
,	O
the	O
authors	O
found	O
that	O
,	O
for	O
each	O
pair	O
of	O
programs	O
,	O
each	O
program	O
performed	O
better	O
than	O
the	O
other	O
on	O
some	O
subset	O
of	O
the	O
data	O
5	O
.	O

Previous	O
studies	O
over	O
smaller	O
numbers	O
of	O
motif	O
finders	O
have	O
found	O
that	O
no	B-NEGATION
program	I-NEGATION
clearly	I-NEGATION
stands	I-NEGATION
out	I-NEGATION
as	I-NEGATION
superior	I-NEGATION
to	I-NEGATION
the	I-NEGATION
others	I-NEGATION
and	O
each	O
program	O
outperforms	O
all	O
others	O
on	O
some	O
subset	O
of	O
the	O
regulons	O
678	O
.	O

This	O
diversity	O
of	O
performance	O
has	O
led	O
a	O
number	O
of	O
authors	O
to	O
speculate	B-SPECULATION
that	I-SPECULATION
ensemble	I-SPECULATION
methods	I-SPECULATION
,	I-SPECULATION
comprising	I-SPECULATION
multiple	I-SPECULATION
motif	I-SPECULATION
finders	I-SPECULATION
,	I-SPECULATION
158	O
.	O
may	B-SPECULATION
lead	I-SPECULATION
to	I-SPECULATION
improvements	I-SPECULATION
in	I-SPECULATION
accuracy	I-SPECULATION
.	O

Ensemble	O
methods	O
,	O
well	O
known	O
in	O
the	O
machine	O
learning	O
community	O
9	O
,	O
are	O
typically	O
composed	O
of	O
multiple	O
methods	O
comprising	O
different	O
search	O
strategies	O
(	O
or	O
the	O
same	O
search	O
strategies	O
with	O
different	O
initiation	O
settings	O
or	O
random	O
restarts	O
)	O
with	O
a	O
unified	O
objective	O
function	O
.	O

The	O
final	O
predictions	O
are	O
chosen	O
from	O
the	O
ensemble	O
of	O
methods	O
by	O
a	O
learning	O
rule	O
,	O
which	O
may	B-SPECULATION
be	I-SPECULATION
as	I-SPECULATION
simple	I-SPECULATION
as	I-SPECULATION
finding	I-SPECULATION
the	I-SPECULATION
maximum	I-SPECULATION
score	I-SPECULATION
from	I-SPECULATION
all	I-SPECULATION
the	I-SPECULATION
methods	I-SPECULATION
,	I-SPECULATION
or	I-SPECULATION
as	I-SPECULATION
complex	I-SPECULATION
as	I-SPECULATION
optimizing	I-SPECULATION
a	I-SPECULATION
weighted	I-SPECULATION
scoring	I-SPECULATION
scheme	I-SPECULATION
from	I-SPECULATION
among	I-SPECULATION
the	I-SPECULATION
methods	I-SPECULATION
.	O

The	O
construction	O
of	O
this	O
learning	O
rule	O
is	O
key	O
to	O
the	O
performance	O
of	O
an	O
ensemble	O
learning	O
method	O
,	O
as	O
the	O
performance	O
of	O
an	O
ensemble	O
method	O
with	O
an	O
ineffective	O
learning	O
rule	O
will	O
be	O
the	O
average	O
of	O
the	O
performance	O
of	O
its	O
component	O
algorithms	O
.	O

In	O
this	O
context	O
,	O
we	O
note	O
that	O
Tompa	O
et	O
al.	O
5	O
found	O
that	O
,	O
although	O
every	O
motif	O
finding	O
program	O
tested	O
had	O
some	O
regulons	O
on	O
which	O
its	O
performance	O
was	O
clearly	O
superior	O
,	O
it	O
was	O
not	B-NEGATION
5	O
.	O
possible	B-SPECULATION
a	I-SPECULATION
priori	I-SPECULATION
to	I-SPECULATION
predict	I-SPECULATION
which	I-SPECULATION
motif	I-SPECULATION
finder	I-SPECULATION
represented	I-SPECULATION
the	I-SPECULATION
best	I-SPECULATION
choice	I-SPECULATION
under	I-SPECULATION
any	I-SPECULATION
given	I-SPECULATION
set	I-SPECULATION
of	I-SPECULATION
conditions	I-SPECULATION
.	O

This	O
observation	O
serves	O
to	O
illustrate	O
the	O
challenges	O
to	O
the	O
construction	O
of	O
an	O
effective	O
learning	O
rule	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
only	O
one	O
study	O
to	O
date	O
has	O
explored	O
ensemble	O
learning	O
in	O
motif	O
finding	O
.	O

Hu	O
,	O
Li	O
and	O
Kihara	O
4	O
described	O
a	O
simple	O
ensemble	O
method	O
wherein	O
the	O
component	O
programs	O
were	O
random	O
restarts	O
of	O
the	O
same	O
stochastic	O
algorithm	O
(	O
such	O
as	O
Gibbs	O
sampling	O
or	O
Expectation	O
Maximization	O
)	O
and	O
the	O
learning	O
rule	O
was	O
a	O
voting	O
scheme	O
in	O
which	O
the	O
results	O
of	O
each	O
random	O
restart	O
cast	O
a	O
"	O
vote	O
"	O
for	O
which	O
positions	O
in	O
the	O
DNA	O
sequence	O
should	O
be	O
part	O
of	O
the	O
final	O
reported	O
motif	O
(	O
hereafter	O
,	O
we	O
refer	O
to	O
this	O
as	O
the	O
HLK	O
method	O
)	O
.	O

Under	O
this	O
scheme	O
,	O
the	O
authors	O
found	O
that	O
ensemble	O
learning	O
resulted	O
in	O
an	O
increase	O
in	O
performance	O
ranging	O
from	O
6	O
to	O
45	O
%	O
.	O

The	O
HLK	O
voting	O
method	O
provides	O
a	O
framework	O
wherein	O
a	B-SPECULATION
number	I-SPECULATION
of	I-SPECULATION
different	I-SPECULATION
motifs	I-SPECULATION
finders	I-SPECULATION
can	I-SPECULATION
be	I-SPECULATION
combined	I-SPECULATION
under	I-SPECULATION
the	I-SPECULATION
heuristic	I-SPECULATION
that	I-SPECULATION
if	I-SPECULATION
several	I-SPECULATION
motif	I-SPECULATION
finders	I-SPECULATION
make	I-SPECULATION
the	I-SPECULATION
same	I-SPECULATION
(	I-SPECULATION
or	I-SPECULATION
overlapping	I-SPECULATION
)	I-SPECULATION
prediction	I-SPECULATION
,	I-SPECULATION
then	I-SPECULATION
that	I-SPECULATION
prediction	I-SPECULATION
is	I-SPECULATION
accurate	I-SPECULATION
.	O

Here	O
we	O
present	O
a	O
novel	O
ensemble	O
motif	O
finder	O
based	O
on	O
a	O
different	O
conceptual	O
approach	O
.	O

Rather	B-NEGATION
than	I-NEGATION
,	O
our	O
algorithm	O
randomly	B-SPECULATION
restarting	I-SPECULATION
the	I-SPECULATION
same	I-SPECULATION
search	I-SPECULATION
algorithm	I-SPECULATION
or	I-SPECULATION
comparing	I-SPECULATION
multiple	I-SPECULATION
search	I-SPECULATION
strategies	I-SPECULATION
that	I-SPECULATION
all	I-SPECULATION
search	I-SPECULATION
for	I-SPECULATION
the	I-SPECULATION
same	I-SPECULATION
global	I-SPECULATION
optimum	I-SPECULATION
(	I-SPECULATION
and	I-SPECULATION
are	I-SPECULATION
potentially	B-SPECULATION
vulnerable	I-SPECULATION
to	O
the	O
same	O
local	O
optima	O
)	O
assumes	B-SPECULATION
that	I-SPECULATION
the	I-SPECULATION
""	I-SPECULATION
biological	I-SPECULATION
significance	I-SPECULATION
surface	I-SPECULATION
""	I-SPECULATION
primarily	I-SPECULATION
consists	I-SPECULATION
of	I-SPECULATION
three	I-SPECULATION
local	I-SPECULATION
optima	I-SPECULATION
,	I-SPECULATION
and	I-SPECULATION
that	I-SPECULATION
one	I-SPECULATION
of	I-SPECULATION
these	I-SPECULATION
peaks	I-SPECULATION
represents	I-SPECULATION
the	I-SPECULATION
global	I-SPECULATION
optimum	I-SPECULATION
.	O

Thus	O
,	O
our	O
ensemble	O
uses	O
three	O
specialized	O
algorithms	O
whose	O
search	O
spaces	O
restrict	O
them	O
to	O
each	O
of	O
these	O
three	O
local	O
optima	O
(	O
BEAM	O
for	O
non-degenerate	O
motifs	O
,	O
PRISM	O
for	O
degenerate	O
motifs	O
and	O
SPACER	O
for	O
bipartite	O
motifs	O
)	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
the	O
greedy	O
search	O
strategies	O
employed	O
by	O
each	O
of	O
these	O
methods	O
allow	O
them	O
to	O
reliably	O
search	O
their	O
respective	O
motif	O
domains	O
without	B-NEGATION
the	I-NEGATION
use	I-NEGATION
of	I-NEGATION
nuisance	I-NEGATION
parameters	I-NEGATION
,	O
as	O
the	O
algorithms	O
themselves	O
efficiently	O
optimize	O
the	O
parameters	O
that	O
are	O
typically	O
forced	O
on	O
the	O
users	O
101112	O
.	O

The	O
results	O
of	O
these	O
component	O
algorithms	O
are	O
then	O
combined	O
using	O
a	O
learning	O
rule	O
that	O
is	O
simply	O
the	O
maximum	O
score	O
returned	O
by	O
each	O
component	O
algorithm	O
.	O

To	O
make	O
comparisons	O
possible	O
,	O
the	O
motif	O
scores	O
returned	O
by	O
each	O
algorithm	O
are	O
penalized	O
according	O
to	O
the	O
complexity	O
of	O
the	O
motif	O
.	O

The	O
resulting	O
ensemble	O
algorithm	O
,	O
SCOPE	O
,	O
has	O
no	B-NEGATION
nuisance	I-NEGATION
parameters	I-NEGATION
and	O
performs	O
significantly	O
better	O
than	O
its	O
component	O
algorithms	O
.	O

In	O
addition	O
,	O
we	O
find	O
that	O
SCOPE	O
performs	O
favorably	O
compared	O
to	O
a	O
diverse	O
range	O
of	O
existing	O
methods	O
and	O
is	O
robust	O
to	O
the	O
presence	O
of	O
extraneous	O
sequences	O
in	O
its	O
input	O
.	O

Results	O

Algorithm	O

SCOPE	O
takes	O
as	O
input	O
a	O
set	O
of	O
sequences	O
U	O
that	O
are	O
upstream	O
of	O
a	O
set	O
of	O
genes	O
G	O
that	B-SPECULATION
are	I-SPECULATION
thought	I-SPECULATION
to	I-SPECULATION
be	I-SPECULATION
coregulated	I-SPECULATION
.	O

The	O
ultimate	O
goal	O
of	O
a	O
motif	O
finder	O
is	O
to	O
identify	O
the	O
specific	O
subsequences	O
	O
in	O
U	O
that	O
act	O
as	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
(	O
s	O
)	O
that	O
regulate	O
G	O
.	O

In	O
practice	O
,	O
sets	O
of	O
binding	O
sites	O
are	O
represented	O
using	O
a	O
motif	O
.	O

We	O
have	O
found	O
that	O
simple	O
consensus	O
motifs	O
over	O
the	O
full	O
IUPAC	O
alphabet	O
(	O
a	O
15-letter	O
code	O
consisting	O
of	O
the	O
bases	O
A,T,C,G	O
and	O
all	O
possible	O
combinations	O
)	O
provide	O
enough	O
representational	O
power	O
to	O
adequately	O
describe	O
	O
,	O
while	O
still	O
allowing	O
for	O
an	O
efficient	O
search	O
34	O
.	O

While	O
alternative	O
representations	O
,	O
such	O
as	O
position	O
weight	O
matrices	O
(	O
PWMs	O
)	O
are	O
more	O
expressive	O
,	O
their	O
heuristic	O
searches	O
are	O
prone	B-SPECULATION
to	I-SPECULATION
local	I-SPECULATION
optima	I-SPECULATION
and	O
often	O
do	O
not	B-NEGATION
perform	I-NEGATION
well	I-NEGATION
in	I-NEGATION
practice	I-NEGATION
@	O
34111213	O
@	O
.	O

SCOPE	O
has	O
three	O
component	O
algorithms	O
,	O
BEAM	O
,	O
PRISM	O
and	O
SPACER	O
,	O
which	O
search	O
for	O
non-degenerate	O
,	O
short	O
degenerate	O
,	O
and	O
long	O
,	O
highly	O
degenerate	O
and	O
"	O
gapped	O
"	O
motifs	O
,	O
respectively	O
(	O
Figure	O
1	O
)	O
.	O

Each	O
motif	O
is	O
scored	O
considering	O
one	O
or	O
both	O
strands	O
and	O
the	O
motif	O
is	O
marked	O
to	O
indicate	O
which	O
calculation	O
scores	O
higher	O
.	O

The	O
results	O
of	O
the	O
three	O
algorithms	O
are	O
merged	O
and	O
sorted	O
.	O

Artifactual	O
motifs	O
,	O
whose	O
significance	O
can	O
be	O
accounted	O
for	O
by	O
higher	O
scoring	O
motifs	O
that	O
they	O
overlap	O
,	O
are	O
identified	O
and	O
removed	O
(	O
for	O
details	O
,	O
see	O
Additional	O
file	O
1	O
,	O
section	O
S1	O
)	O
.	O

Flow	O
diagram	O
for	O
SCOPE	O

Flow	O
diagram	O
for	O
SCOPE	O
.	O

BEAM	O
and	O
SPACER	O
are	O
run	O
independently	O
;	O
PRISM	O
runs	O
on	O
the	O
top	O
100	O
motifs	O
output	O
by	O
BEAM	O
.	O

For	O
yeast	O
(	O
whose	O
upstream	O
regions	O
are	O
standardized	O
to	O
800	O
bp	O
)	O
,	O
BEAM	O
and	O
PRISM	O
use	O
the	O
overrepresentation-KS	O
objective	O
function	O
(	O
so	O
/	O
ks	O
)	O
,	O
while	O
SPACER's	O
slower	O
running	O
time	O
requires	O
the	O
simpler	O
overrepresentation	O
objective	O
function	O
(	O
so	O
)	O
.	O

The	O
top	O
5	O
motifs	O
from	O
SPACER	O
are	O
rescored	O
using	O
the	O
combined	O
objective	O
function	O
.	O

For	O
bacteria	O
and	O
Drosophila	O
,	O
upstream	O
regions	O
are	O
defined	O
to	O
be	O
the	O
intergenic	O
region	O
upstream	O
of	O
each	O
gene	O
;	O
thus	O
,	O
the	B-NEGATION
KS	I-NEGATION
objective	I-NEGATION
function	I-NEGATION
is	I-NEGATION
not	I-NEGATION
used	I-NEGATION
.	O